{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Abstract\n",
    "\n",
    "**Author:** [Charles Tapley Hoyt](https://github.com/cthoyt)\n",
    "\n",
    "**Estimated Run Time:** 1 minute\n",
    "\n",
    "This notebook demonstrates the utilities in [PyBEL Tools](http://pybel-tools.readthedocs.io) that facilitate the exploration and expansion of subgraphs to allow for easier interpretation and contextualization of their underlying mechanisms. The data used in this notebook comes from the [AETIONOMY](http://www.aetionomy.eu/) Alzheimer's Disease (AD) knowledge assembly that has been annotated with the [NeuroMMSig Knowledge Base](http://neurommsig.scai.fraunhofer.de/pathways/introduction)."
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Notebook Setup"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": [
    "import logging\n",
    "import os\n",
    "import sys\n",
    "import time\n",
    "from collections import Counter, defaultdict\n",
    "from operator import itemgetter\n",
    "\n",
    "import matplotlib.pyplot as plt\n",
    "import networkx as nx\n",
    "\n",
    "import pybel\n",
    "import pybel_tools as pbt\n",
    "from pybel.constants import *\n",
    "from pybel_tools.visualization import to_jupyter\n",
    "from pybel_tools.utils import barh, barv"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": [
    "%config InlineBackend.figure_format = 'svg'\n",
    "%matplotlib inline"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Notebook Provenance\n",
    "\n",
    "The time of execution and the versions of the software packegs used are displayed explicitly."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'Mon Aug 14 14:45:31 2017'"
      ]
     },
     "execution_count": 3,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "time.asctime()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'0.7.2'"
      ]
     },
     "execution_count": 4,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "pybel.__version__"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'0.1.18-dev'"
      ]
     },
     "execution_count": 5,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "pbt.__version__"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Local Path Definitions\n",
    "\n",
    "To make this notebook interoperable across many machines, locations to the repositories that contain the data used in this notebook are referenced from the environment, set in `~/.bashrc` to point to the place where the repositories have been cloned. Assuming the repositories have been `git clone`'d into the `~/dev` folder, the entries in `~/.bashrc` should look like:\n",
    "\n",
    "```bash\n",
    "...\n",
    "export BMS_BASE=~/dev/bms\n",
    "...\n",
    "```\n",
    "\n",
    "#### BMS \n",
    "\n",
    "The biological model store (BMS) is the internal Fraunhofer SCAI repository for keeping BEL models under version control. It can be downloaded from https://tor-2.scai.fraunhofer.de/gf/project/bms/"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": [
    "bms_base = os.environ['BMS_BASE']"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Data\n",
    "\n",
    "The Alzheimer's Disease Knowledge Assembly has been precompiled with the following command line script, and will be loaded from this format for improved performance. In general, derived data, such as the gpickle representation of a BEL script, are not saved under version control to ensure that the most up-to-date data is always used.\n",
    "\n",
    "```sh\n",
    "pybel convert --path \"$BMS_BASE/aetionomy/alzheimers.bel\" --pickle \"$BMS_BASE/aetionomy/alzheimers.gpickle\"\n",
    "```\n",
    "\n",
    "The BEL script can also be compiled from inside this notebook with the following python code:\n",
    "\n",
    "```python\n",
    ">>> import os\n",
    ">>> import pybel\n",
    ">>> # Input from BEL script\n",
    ">>> bel_path = os.path.join(bms_base, 'aetionomy', 'alzheimers.bel')\n",
    ">>> graph = pybel.from_path(bel_path)\n",
    ">>> # Output to gpickle for fast loading later\n",
    ">>> pickle_path = os.path.join(bms_base, 'aetionomy', 'alzheimers.gpickle')\n",
    ">>> pybel.to_pickle(graph, pickle_path)\n",
    "```"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": [
    "pickle_path = os.path.join(bms_base, 'aetionomy', 'alzheimers', 'alzheimers.gpickle')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": [
    "graph = pybel.from_pickle(pickle_path)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'3.0.9'"
      ]
     },
     "execution_count": 9,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "graph.version"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": [
    "# Add all canonical names for later\n",
    "pbt.mutation.add_canonical_names(graph)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Connecting Components\n",
    "\n",
    "The GABA Subgraph is explored in this example. This subgraph contains a representative group of genes, RNAs, proteins, biological processes, and pathologies; and all of their relations. It is extracted with [pbt.selection.get_subgraph_by_annotation](http://pybel-tools.readthedocs.io/en/latest/selection.html#pybel_tools.selection.group_nodes_by_annotation_filtered)."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": [
    "example_subgraph_name = 'GABA subgraph'"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Nodes: 65\n",
      "Edges: 182\n",
      "Citations: 14\n",
      "Authors: 69\n",
      "Network density: 0.04375\n",
      "Components: 5\n",
      "Average degree: 2.8\n"
     ]
    }
   ],
   "source": [
    "subgraph = pbt.selection.get_subgraph_by_annotation_value(graph, annotation='Subgraph', value=example_subgraph_name)\n",
    "\n",
    "pbt.summary.print_summary(subgraph)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/javascript": [
       "function init_d3_force(d3, graph, chart, width, height, function_colors) {\n",
       "    var focus_node = null;\n",
       "    var highlight_node = null;\n",
       "\n",
       "    // Highlight color variables\n",
       "\n",
       "    // Highlight color of the node boundering\n",
       "    const highlight_node_boundering = \"#4EB2D4\";\n",
       "\n",
       "    // Highlight color of the edge\n",
       "    const highlighted_link_color = \"#4EB2D4\";\n",
       "\n",
       "    // Text highlight color\n",
       "    const highlight_text = \"#4EB2D4\";\n",
       "\n",
       "    // Size when zooming scale\n",
       "    var size = d3.scalePow().exponent(1)\n",
       "        .domain([1, 100])\n",
       "        .range([8, 24]);\n",
       "\n",
       "    // Simulation parameters\n",
       "    const linkDistance = 100;\n",
       "    const fCharge = -1000;\n",
       "    const linkStrength = 0.7;\n",
       "    const collideStrength = 1;\n",
       "\n",
       "    // Simulation defined with variables\n",
       "    var simulation = d3.forceSimulation()\n",
       "        .force(\"link\", d3.forceLink()\n",
       "            .distance(linkDistance)\n",
       "            .strength(linkStrength)\n",
       "        )\n",
       "        .force(\"collide\", d3.forceCollide()\n",
       "            .radius(function (d) {\n",
       "                return d.r + 10\n",
       "            })\n",
       "            .strength(collideStrength)\n",
       "        )\n",
       "        .force(\"charge\", d3.forceManyBody()\n",
       "            .strength(fCharge)\n",
       "        )\n",
       "        .force(\"center\", d3.forceCenter(width / 2, height / 2))\n",
       "        .force(\"y\", d3.forceY(0))\n",
       "        .force(\"x\", d3.forceX(0));\n",
       "\n",
       "    // Pin down functionality\n",
       "    var node_drag = d3.drag()\n",
       "        .on(\"start\", dragstarted)\n",
       "        .on(\"drag\", dragged)\n",
       "        .on(\"end\", dragended);\n",
       "\n",
       "    function dragstarted(d) {\n",
       "        if (!d3.event.active) simulation.alphaTarget(0.3).restart();\n",
       "        d.fx = d.x;\n",
       "        d.fy = d.y;\n",
       "    }\n",
       "\n",
       "    function dragged(d) {\n",
       "        d.fx = d3.event.x;\n",
       "        d.fy = d3.event.y;\n",
       "    }\n",
       "\n",
       "    function dragended(d) {\n",
       "        if (!d3.event.active) simulation.alphaTarget(0);\n",
       "    }\n",
       "\n",
       "    function releasenode(d) {\n",
       "        d.fx = null;\n",
       "        d.fy = null;\n",
       "    }\n",
       "\n",
       "    //END Pin down functionality\n",
       "\n",
       "    const color_circunferencia = \"black\";\n",
       "    const default_link_color = \"#AAAAAA\";\n",
       "    const nominal_base_node_size = 8;\n",
       "\n",
       "    // Normal and highlighted stroke of the links (double the width of the link when highlighted)\n",
       "    const nominal_stroke = 1.5;\n",
       "\n",
       "    // Zoom variables\n",
       "    const min_zoom = 0.1;\n",
       "    const max_zoom = 10;\n",
       "    const border = 1;\n",
       "    const bordercolor = 'black';\n",
       "\n",
       "    var svg = d3.select(chart).append(\"svg\")\n",
       "        .attr(\"width\", width)\n",
       "        .attr(\"height\", height);\n",
       "\n",
       "    // // Create definition for arrowhead.\n",
       "    svg.append(\"defs\").append(\"marker\")\n",
       "        .attr(\"id\", \"arrowhead\")\n",
       "        .attr(\"viewBox\", \"0 -5 10 10\")\n",
       "        .attr(\"refX\", 20)\n",
       "        .attr(\"refY\", 0)\n",
       "        .attr(\"markerUnits\", \"strokeWidth\")\n",
       "        .attr(\"markerWidth\", 6)\n",
       "        .attr(\"markerHeight\", 6)\n",
       "        .attr(\"orient\", \"auto\")\n",
       "        .append(\"path\")\n",
       "        .attr(\"d\", \"M0,-5L10,0L0,5\");\n",
       "\n",
       "    // // Create definition for stub.\n",
       "    svg.append(\"defs\").append(\"marker\")\n",
       "        .attr(\"id\", \"stub\")\n",
       "        .attr(\"viewBox\", \"-1 -5 2 10\")\n",
       "        .attr(\"refX\", 15)\n",
       "        .attr(\"refY\", 0)\n",
       "        .attr(\"markerUnits\", \"strokeWidth\")\n",
       "        .attr(\"markerWidth\", 6)\n",
       "        .attr(\"markerHeight\", 6)\n",
       "        .attr(\"orient\", \"auto\")\n",
       "        .append(\"path\")\n",
       "        .attr(\"d\", \"M 0,0 m -1,-5 L 1,-5 L 1,5 L -1,5 Z\");\n",
       "\n",
       "    // Background\n",
       "    svg.append(\"rect\")\n",
       "        .attr(\"width\", \"100%\")\n",
       "        .attr(\"height\", \"100%\")\n",
       "        .attr(\"fill\", \"#ffffff\")\n",
       "        .style(\"pointer-events\", \"all\")\n",
       "        // Zoom + panning functionality\n",
       "        .call(d3.zoom()\n",
       "            .scaleExtent([min_zoom, max_zoom])\n",
       "            .on(\"zoom\", zoomed))\n",
       "        .on(\"dblclick.zoom\", null);\n",
       "\n",
       "\n",
       "    function zoomed() {\n",
       "        g.attr(\"transform\", d3.event.transform);\n",
       "    }\n",
       "\n",
       "    // g = svg object where the graph will be appended\n",
       "    var g = svg.append(\"g\");\n",
       "\n",
       "    var linkedByIndex = {};\n",
       "    graph.links.forEach(function (d) {\n",
       "        linkedByIndex[d.source + \",\" + d.target] = true;\n",
       "    });\n",
       "\n",
       "    function isConnected(a, b) {\n",
       "        return linkedByIndex[a.index + \",\" + b.index] || linkedByIndex[b.index + \",\" + a.index] || a.index == b.index;\n",
       "    }\n",
       "\n",
       "    function ticked() {\n",
       "        link.attr(\"x1\", function (d) {\n",
       "            return d.source.x;\n",
       "        })\n",
       "            .attr(\"y1\", function (d) {\n",
       "                return d.source.y;\n",
       "            })\n",
       "            .attr(\"x2\", function (d) {\n",
       "                return d.target.x;\n",
       "            })\n",
       "            .attr(\"y2\", function (d) {\n",
       "                return d.target.y;\n",
       "            });\n",
       "\n",
       "        node\n",
       "            .attr(\"transform\", function (d) {\n",
       "                return \"translate(\" + d.x + \", \" + d.y + \")\";\n",
       "            });\n",
       "    }\n",
       "\n",
       "\n",
       "    simulation\n",
       "        .nodes(graph.nodes)\n",
       "        .on(\"tick\", ticked);\n",
       "\n",
       "    simulation.force(\"link\")\n",
       "        .links(graph.links);\n",
       "\n",
       "    // Definition of links nodes text...\n",
       "\n",
       "    var link = g.selectAll(\".link\")\n",
       "        .data(graph.links)\n",
       "        .enter().append(\"line\")\n",
       "        .style(\"stroke-width\", nominal_stroke)\n",
       "        .style(\"stroke\", default_link_color)\n",
       "        .style(\"stroke-dasharray\", function (d) {\n",
       "            if (['decreases', 'directlyDecreases', 'increases', 'directlyIncreases', 'negativeCorrelation',\n",
       "                    'positiveCorrelation'].indexOf(d.relation) >= 0) {\n",
       "                return \"none\"\n",
       "            } else {\n",
       "                return \"4, 4\"\n",
       "            }\n",
       "        })\n",
       "        .attr(\"marker-start\", function (d) {\n",
       "            if ('positiveCorrelation' == d.relation) {\n",
       "                return \"url(#arrowhead)\"\n",
       "            }\n",
       "            else if ('negativeCorrelation' == d.relation) {\n",
       "                return \"url(#stub)\"\n",
       "            }\n",
       "            else {\n",
       "                return \"\"\n",
       "            }\n",
       "        })\n",
       "        .attr(\"marker-end\", function (d) {\n",
       "            if (['increases', 'directlyIncreases', 'positiveCorrelation'].indexOf(d.relation) >= 0) {\n",
       "                return \"url(#arrowhead)\"\n",
       "            } else if (['decreases', 'directlyDecreases', 'negativeCorrelation'].indexOf(d.relation) >= 0) {\n",
       "                return \"url(#stub)\"\n",
       "            } else {\n",
       "                return \"\"\n",
       "            }\n",
       "        });\n",
       "\n",
       "    var node = g.selectAll(\".nodes\")\n",
       "        .data(graph.nodes)\n",
       "        .enter().append(\"g\")\n",
       "        .attr(\"class\", \"node\")\n",
       "        // Next two lines -> Pin down functionality\n",
       "        .on('dblclick', releasenode)\n",
       "        .call(node_drag);\n",
       "\n",
       "    var circle = node.append(\"path\")\n",
       "        .attr(\"d\", d3.symbol()\n",
       "            .size(function (d) {\n",
       "                return Math.PI * Math.pow(size(d.size) || nominal_base_node_size, 2);\n",
       "            })\n",
       "        )\n",
       "        .attr(\"class\", function (d) {\n",
       "            return d.function\n",
       "        })\n",
       "        .style('fill', function (d) {\n",
       "            return function_colors[d.function]\n",
       "        })\n",
       "        .style(\"stroke-width\", nominal_stroke)\n",
       "        .style(\"stroke\", color_circunferencia);\n",
       "\n",
       "    var text = node.append(\"text\")\n",
       "        .attr(\"class\", \"node-name\")\n",
       "        // .attr(\"id\", nodehashes[d])\n",
       "        .attr(\"fill\", \"black\")\n",
       "        .attr(\"dx\", 12)\n",
       "        .attr(\"dy\", \".35em\")\n",
       "        .text(function (d) {\n",
       "            return d.cname\n",
       "        });\n",
       "\n",
       "    // Highlight on mouseenter and back to normal on mouseout\n",
       "    node.on(\"mouseenter\", function (d) {\n",
       "        set_highlight(d);\n",
       "    })\n",
       "        .on(\"mousedown\", function () {\n",
       "            d3.event.stopPropagation();\n",
       "        }).on(\"mouseout\", function () {\n",
       "        exit_highlight();\n",
       "    });\n",
       "\n",
       "    function exit_highlight() {\n",
       "        highlight_node = null;\n",
       "        if (focus_node === null) {\n",
       "            if (highlight_node_boundering != color_circunferencia) {\n",
       "                circle.style(\"stroke\", color_circunferencia);\n",
       "                text.style(\"fill\", \"black\");\n",
       "                link.style(\"stroke\", default_link_color);\n",
       "            }\n",
       "        }\n",
       "    }\n",
       "\n",
       "    function set_highlight(d) {\n",
       "        if (focus_node !== null) d = focus_node;\n",
       "        highlight_node = d;\n",
       "\n",
       "        if (highlight_node_boundering != color_circunferencia) {\n",
       "            circle.style(\"stroke\", function (o) {\n",
       "                return isConnected(d, o) ? highlight_node_boundering : color_circunferencia;\n",
       "            });\n",
       "            text.style(\"fill\", function (o) {\n",
       "                return isConnected(d, o) ? highlight_text : \"black\";\n",
       "            });\n",
       "            link.style(\"stroke\", function (o) {\n",
       "                return o.source.index == d.index || o.target.index == d.index ? highlighted_link_color : default_link_color;\n",
       "            });\n",
       "        }\n",
       "    }\n",
       "\n",
       "\n",
       "    // Freeze the graph when space is pressed\n",
       "    function freezeGraph() {\n",
       "        // Space button Triggers STOP\n",
       "        if (d3.event.keyCode == 32) {\n",
       "            simulation.stop();\n",
       "        }\n",
       "    }\n",
       "\n",
       "    // Call freezeGraph when a key is pressed, freezeGraph checks whether this key is \"Space\" that triggers the freeze\n",
       "    d3.select(window).on(\"keydown\", freezeGraph);\n",
       "}\n",
       "        var chart = \"uqpvhyqxsbomcefd\";\n",
       "        var width = 1000;\n",
       "        var height = 650;\n",
       "        var graph = {\"directed\": true, \"multigraph\": true, \"graph\": {\"document_metadata\": {}, \"pybel_version\": \"0.7.2\", \"namespace_url\": {}, \"namespace_owl\": {}, \"namespace_pattern\": {}, \"annotation_url\": {}, \"annotation_owl\": {}, \"annotation_pattern\": {}, \"annotation_list\": {}}, \"nodes\": [{\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"APP\", \"variants\": [{\"kind\": \"frag\", \"start\": 672, \"stop\": 713}], \"description\": \"This gene encodes a cell surface receptor and transmembrane precursor protein that is cleaved by secretases to form a number of peptides. Some of these peptides are secreted and can bind to the acetyltransferase complex APBB1/TIP60 to promote transcriptional activation, while others form the protein basis of the amyloid plaques found in the brains of patients with Alzheimer disease. In addition, two of the peptides are antimicrobial peptides, having been shown to have bacteriocidal and antifungal activities. Mutations in this gene have been implicated in autosomal dominant Alzheimer disease and cerebroarterial amyloidosis (cerebral amyloid angiopathy). Multiple transcript variants encoding several different isoforms have been found for this gene. [provided by RefSeq, Aug 2014]\", \"label\": \"amyloid beta precursor protein\", \"cname\": \"p(HGNC:APP, frag(672_713))\", \"id\": [\"Protein\", \"HGNC\", \"APP\", [\"frag\", [672, 713]]]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"EGR1\", \"description\": \"The protein encoded by this gene belongs to the EGR family of C2H2-type zinc-finger proteins. It is a nuclear protein and functions as a transcriptional regulator. The products of target genes it activates are required for differentitation and mitogenesis. Studies suggest this is a cancer suppressor gene. [provided by RefSeq, Dec 2014]\", \"label\": \"early growth response 1\", \"cname\": \"EGR1\", \"id\": [\"Protein\", \"HGNC\", \"EGR1\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"APP\", \"description\": \"This gene encodes a cell surface receptor and transmembrane precursor protein that is cleaved by secretases to form a number of peptides. Some of these peptides are secreted and can bind to the acetyltransferase complex APBB1/TIP60 to promote transcriptional activation, while others form the protein basis of the amyloid plaques found in the brains of patients with Alzheimer disease. In addition, two of the peptides are antimicrobial peptides, having been shown to have bacteriocidal and antifungal activities. Mutations in this gene have been implicated in autosomal dominant Alzheimer disease and cerebroarterial amyloidosis (cerebral amyloid angiopathy). Multiple transcript variants encoding several different isoforms have been found for this gene. [provided by RefSeq, Aug 2014]\", \"label\": \"amyloid beta precursor protein\", \"cname\": \"APP\", \"id\": [\"Protein\", \"HGNC\", \"APP\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GRIN2B\", \"variants\": [{\"kind\": \"pmod\", \"identifier\": {\"namespace\": \"bel\", \"name\": \"Ph\"}}], \"description\": \"N-methyl-D-aspartate (NMDA) receptors are a class of ionotropic glutamate receptors. NMDA receptor channel has been shown to be involved in long-term potentiation, an activity-dependent increase in the efficiency of synaptic transmission thought to underlie certain kinds of memory and learning. NMDA receptor channels are heteromers composed of three different subunits: NR1 (GRIN1), NR2 (GRIN2A, GRIN2B, GRIN2C, or GRIN2D) and NR3 (GRIN3A or GRIN3B). The NR2 subunit acts as the agonist binding site for glutamate. This receptor is the predominant excitatory neurotransmitter receptor in the mammalian brain. [provided by RefSeq, Jul 2008]\", \"label\": \"glutamate ionotropic receptor NMDA type subunit 2B\", \"cname\": \"p(HGNC:GRIN2B, pmod(Ph))\", \"id\": [\"Protein\", \"HGNC\", \"GRIN2B\", [\"pmod\", [\"bel\", \"Ph\"]]]}, {\"function\": \"Pathology\", \"namespace\": \"MESHD\", \"name\": \"Alzheimer Disease\", \"cname\": \"Alzheimer Disease\", \"id\": [\"Pathology\", \"MESHD\", \"Alzheimer Disease\"]}, {\"function\": \"BiologicalProcess\", \"namespace\": \"GOBP\", \"name\": \"synaptic transmission, cholinergic\", \"cname\": \"synaptic transmission, cholinergic\", \"id\": [\"BiologicalProcess\", \"GOBP\", \"synaptic transmission, cholinergic\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"PSEN2\", \"description\": \"Alzheimer's disease (AD) patients with an inherited form of the disease carry mutations in the presenilin proteins (PSEN1 or PSEN2) or the amyloid precursor protein (APP). These disease-linked mutations result in increased production of the longer form of amyloid-beta (main component of amyloid deposits found in AD brains). Presenilins are postulated to regulate APP processing through their effects on gamma-secretase, an enzyme that cleaves APP. Also, it is thought that the presenilins are involved in the cleavage of the Notch receptor such that, they either directly regulate gamma-secretase activity, or themselves act are protease enzymes. Two alternatively spliced transcript variants encoding different isoforms of PSEN2 have been identified. [provided by RefSeq, Jul 2008]\", \"label\": \"presenilin 2\", \"cname\": \"PSEN2\", \"id\": [\"Protein\", \"HGNC\", \"PSEN2\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"TNF\", \"description\": \"This gene encodes a multifunctional proinflammatory cytokine that belongs to the tumor necrosis factor (TNF) superfamily. This cytokine is mainly secreted by macrophages. It can bind to, and thus functions through its receptors TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR. This cytokine is involved in the regulation of a wide spectrum of biological processes including cell proliferation, differentiation, apoptosis, lipid metabolism, and coagulation. This cytokine has been implicated in a variety of diseases, including autoimmune diseases, insulin resistance, and cancer. Knockout studies in mice also suggested the neuroprotective function of this cytokine. [provided by RefSeq, Jul 2008]\", \"label\": \"tumor necrosis factor\", \"cname\": \"TNF\", \"id\": [\"Protein\", \"HGNC\", \"TNF\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRA1\", \"description\": \"This gene encodes a gamma-aminobutyric acid (GABA) receptor. GABA is the major inhibitory neurotransmitter in the mammalian brain where it acts at GABA-A receptors, which are ligand-gated chloride channels. Chloride conductance of these channels can be modulated by agents such as benzodiazepines that bind to the GABA-A receptor. GABA-A receptors are pentameric, consisting of proteins from several subunit classes: alpha, beta, gamma, delta and rho. Mutations in this gene cause juvenile myoclonic epilepsy and childhood absence epilepsy type 4. Multiple transcript variants encoding the same protein have been identified for this gene. [provided by RefSeq, Jul 2008]\", \"label\": \"gamma-aminobutyric acid type A receptor alpha1 subunit\", \"cname\": \"GABRA1\", \"id\": [\"Protein\", \"HGNC\", \"GABRA1\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRA2\", \"description\": \"GABA is the major inhibitory neurotransmitter in the mammalian brain where it acts at GABA-A receptors, which are ligand-gated chloride channels. Chloride conductance of these channels can be modulated by agents such as benzodiazepines that bind to the GABA-A receptor. At least 16 distinct subunits of GABA-A receptors have been identified. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Nov 2013]\", \"label\": \"gamma-aminobutyric acid type A receptor alpha2 subunit\", \"cname\": \"GABRA2\", \"id\": [\"Protein\", \"HGNC\", \"GABRA2\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRA3\", \"description\": \"GABA is the major inhibitory neurotransmitter in the mammalian brain where it acts at GABA-A receptors, which are ligand-gated chloride channels. Chloride conductance of these channels can be modulated by agents such as benzodiazepines that bind to the GABA-A receptor. At least 16 distinct subunits of GABA-A receptors have been identified. [provided by RefSeq, Jul 2008]\", \"label\": \"gamma-aminobutyric acid type A receptor alpha3 subunit\", \"cname\": \"GABRA3\", \"id\": [\"Protein\", \"HGNC\", \"GABRA3\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRA4\", \"description\": \"Gamma-aminobutyric acid (GABA) is the major inhibitory neurotransmitter in the mammalian brain where it acts at GABA-A receptors, which are ligand-gated chloride channels. Chloride conductance of these channels can be modulated by agents such as benzodiazepines that bind to the GABA-A receptor. At least 16 distinct subunits of GABA-A receptors have been identified. This gene encodes subunit alpha-4, which is involved in the etiology of autism and eventually increases autism risk through interaction with another subunit, gamma-aminobutyric acid receptor beta-1 (GABRB1). Alternatively spliced transcript variants encoding different isoforms have been found in this gene.[provided by RefSeq, Feb 2011]\", \"label\": \"gamma-aminobutyric acid type A receptor alpha4 subunit\", \"cname\": \"GABRA4\", \"id\": [\"Protein\", \"HGNC\", \"GABRA4\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRA5\", \"description\": \"GABA is the major inhibitory neurotransmitter in the mammalian brain where it acts at GABA-A receptors, which are ligand-gated chloride channels. Chloride conductance of these channels can be modulated by agents such as benzodiazepines that bind to the GABA-A receptor. At least 16 distinct subunits of GABA-A receptors have been identified. Transcript variants utilizing three different alternative non-coding first exons have been described. [provided by RefSeq, Jul 2008]\", \"label\": \"gamma-aminobutyric acid type A receptor alpha5 subunit\", \"cname\": \"GABRA5\", \"id\": [\"Protein\", \"HGNC\", \"GABRA5\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRA6\", \"description\": \"GABA is the major inhibitory neurotransmitter in the mammalian brain where it acts at GABA-A receptors, which are ligand-gated chloride channels. Chloride conductance of these channels can be modulated by agents such as benzodiazepines that bind to the GABA-A receptor. At least 16 distinct subunits of GABA-A receptors have been identified. [provided by RefSeq, Jul 2008]\", \"label\": \"gamma-aminobutyric acid type A receptor alpha6 subunit\", \"cname\": \"GABRA6\", \"id\": [\"Protein\", \"HGNC\", \"GABRA6\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRB1\", \"description\": \"The gamma-aminobutyric acid (GABA) A receptor is a multisubunit chloride channel that mediates the fastest inhibitory synaptic transmission in the central nervous system. This gene encodes GABA A receptor, beta 1 subunit. It is mapped to chromosome 4p12 in a cluster comprised of genes encoding alpha 4, alpha 2 and gamma 1 subunits of the GABA A receptor. Alteration of this gene is implicated in the pathogenetics of schizophrenia. [provided by RefSeq, Jul 2008]\", \"label\": \"gamma-aminobutyric acid type A receptor beta1 subunit\", \"cname\": \"GABRB1\", \"id\": [\"Protein\", \"HGNC\", \"GABRB1\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRB2\", \"description\": null, \"cname\": \"GABRB2\", \"id\": [\"Protein\", \"HGNC\", \"GABRB2\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRB3\", \"description\": \"This gene encodes a member of the ligand-gated ionic channel family. The encoded protein is one the subunits of a multi-subunit chloride channel that serves as the receptor for gamma-aminobutyric acid, a major inhibitory neurotransmitter of the mammalian nervous system. This gene is located on the long arm of chromosome 15 in a cluster with two other genes encoding related subunits of the family. This gene may be associated with the pathogenesis of several disorders including Angelman syndrome, Prader-Willi syndrome, nonsyndromic orofacial clefts, epilepsy and autism. Alternatively spliced transcript variants encoding distinct isoforms have been described. [provided by RefSeq, Jul 2013]\", \"label\": \"gamma-aminobutyric acid type A receptor beta3 subunit\", \"cname\": \"GABRB3\", \"id\": [\"Protein\", \"HGNC\", \"GABRB3\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRG1\", \"description\": \"The protein encoded by this gene belongs to the ligand-gated ionic channel family. It is an integral membrane protein and plays an important role in inhibiting neurotransmission by binding to the benzodiazepine receptor and opening an integral chloride channel. This gene is clustered with three other family members on chromosome 4. [provided by RefSeq, Jul 2008]\", \"label\": \"gamma-aminobutyric acid type A receptor gamma1 subunit\", \"cname\": \"GABRG1\", \"id\": [\"Protein\", \"HGNC\", \"GABRG1\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRG2\", \"description\": null, \"cname\": \"GABRG2\", \"id\": [\"Protein\", \"HGNC\", \"GABRG2\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRG3\", \"description\": \"This gene encodes a gamma-aminobutyric acid (GABA) receptor. GABA is the major inhibitory neurotransmitter in the mammalian brain where it acts at GABA-A receptors, which are ligand-gated chloride channels. Chloride conductance of these channels can be modulated by agents such as benzodiazepines that bind to the GABA-A receptor. GABA-A receptors are pentameric, consisting of proteins from several subunit classes: alpha, beta, gamma, delta and rho. The protein encoded by this gene is a gamma subunit, which contains the benzodiazepine binding site. Two transcript variants encoding distinct isoforms have been found for this gene. [provided by RefSeq, Aug 2012]\", \"label\": \"gamma-aminobutyric acid type A receptor gamma3 subunit\", \"cname\": \"GABRG3\", \"id\": [\"Protein\", \"HGNC\", \"GABRG3\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRD\", \"description\": \"Gamma-aminobutyric acid (GABA) is the major inhibitory neurotransmitter in the mammalian brain where it acts at GABA-A receptors, which are ligand-gated chloride channels. Chloride conductance of these channels can be modulated by agents such as benzodiazepines that bind to the GABA-A receptor. The GABA-A receptor is generally pentameric and there are five types of subunits: alpha, beta, gamma, delta, and rho. This gene encodes the delta subunit. Mutations in this gene have been associated with susceptibility to generalized epilepsy with febrile seizures, type 5. Alternatively spliced transcript variants have been described for this gene, but their biological validity has not been determined. [provided by RefSeq, Jul 2008]\", \"label\": \"gamma-aminobutyric acid type A receptor delta subunit\", \"cname\": \"GABRD\", \"id\": [\"Protein\", \"HGNC\", \"GABRD\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRE\", \"description\": \"The product of this gene belongs to the ligand-gated ionic channel (TC 1.A.9) family. It encodes the gamma-aminobutyric acid (GABA) A receptor which is a multisubunit chloride channel that mediates the fastest inhibitory synaptic transmission in the central nervous system. This gene encodes an epsilon subunit. It is mapped to chromosome Xq28 in a cluster comprised of genes encoding alpha 3, beta 4 and theta subunits of the same receptor. Alternatively spliced transcript variants have been identified, but only one is thought to encode a protein. [provided by RefSeq, Oct 2008]\", \"label\": \"gamma-aminobutyric acid type A receptor epsilon subunit\", \"cname\": \"GABRE\", \"id\": [\"Protein\", \"HGNC\", \"GABRE\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRP\", \"description\": \"The gamma-aminobutyric acid (GABA) A receptor is a multisubunit chloride channel that mediates the fastest inhibitory synaptic transmission in the central nervous system. The subunit encoded by this gene is expressed in several non-neuronal tissues including the uterus and ovaries. This subunit can assemble with known GABA A receptor subunits, and the presence of this subunit alters the sensitivity of recombinant receptors to modulatory agents such as pregnanolone. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, May 2014]\", \"label\": \"gamma-aminobutyric acid type A receptor pi subunit\", \"cname\": \"GABRP\", \"id\": [\"Protein\", \"HGNC\", \"GABRP\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRQ\", \"description\": \"The gamma-aminobutyric acid (GABA) A receptor is a multisubunit chloride channel that mediates the fastest inhibitory synaptic transmission in the central nervous system. This gene encodes the theta subunit of the GABA A receptor. The gene is mapped to chromosome Xq28 in a cluster of genes including those that encode the alpha 3 and epsilon subunits of the GABA A receptor. [provided by RefSeq, Jul 2017]\", \"label\": \"gamma-aminobutyric acid type A receptor theta subunit\", \"cname\": \"GABRQ\", \"id\": [\"Protein\", \"HGNC\", \"GABRQ\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABBR1\", \"description\": \"This gene encodes a receptor for gamma-aminobutyric acid (GABA), which is the main inhibitory neurotransmitter in the mammalian central nervous system. This receptor functions as a heterodimer with GABA(B) receptor 2. Defects in this gene may underlie brain disorders such as schizophrenia and epilepsy. Alternative splicing generates multiple transcript variants, but the full-length nature of some of these variants has not been determined. [provided by RefSeq, Jan 2016]\", \"label\": \"gamma-aminobutyric acid type B receptor subunit 1\", \"cname\": \"GABBR1\", \"id\": [\"Protein\", \"HGNC\", \"GABBR1\"]}, {\"function\": \"BiologicalProcess\", \"namespace\": \"GOBP\", \"name\": \"regulation of N-methyl-D-aspartate selective glutamate receptor activity\", \"cname\": \"regulation of N-methyl-D-aspartate selective glutamate receptor activity\", \"id\": [\"BiologicalProcess\", \"GOBP\", \"regulation of N-methyl-D-aspartate selective glutamate receptor activity\"]}, {\"function\": \"BiologicalProcess\", \"namespace\": \"GOBP\", \"name\": \"regulation of synaptic plasticity\", \"cname\": \"regulation of synaptic plasticity\", \"id\": [\"BiologicalProcess\", \"GOBP\", \"regulation of synaptic plasticity\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GRIN2B\", \"description\": \"N-methyl-D-aspartate (NMDA) receptors are a class of ionotropic glutamate receptors. NMDA receptor channel has been shown to be involved in long-term potentiation, an activity-dependent increase in the efficiency of synaptic transmission thought to underlie certain kinds of memory and learning. NMDA receptor channels are heteromers composed of three different subunits: NR1 (GRIN1), NR2 (GRIN2A, GRIN2B, GRIN2C, or GRIN2D) and NR3 (GRIN3A or GRIN3B). The NR2 subunit acts as the agonist binding site for glutamate. This receptor is the predominant excitatory neurotransmitter receptor in the mammalian brain. [provided by RefSeq, Jul 2008]\", \"label\": \"glutamate ionotropic receptor NMDA type subunit 2B\", \"cname\": \"GRIN2B\", \"id\": [\"Protein\", \"HGNC\", \"GRIN2B\"]}, {\"function\": \"BiologicalProcess\", \"namespace\": \"GOBP\", \"name\": \"cognition\", \"cname\": \"cognition\", \"id\": [\"BiologicalProcess\", \"GOBP\", \"cognition\"]}, {\"function\": \"BiologicalProcess\", \"namespace\": \"GOBP\", \"name\": \"learning\", \"cname\": \"learning\", \"id\": [\"BiologicalProcess\", \"GOBP\", \"learning\"]}, {\"function\": \"BiologicalProcess\", \"namespace\": \"GOBP\", \"name\": \"memory\", \"cname\": \"memory\", \"id\": [\"BiologicalProcess\", \"GOBP\", \"memory\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CHRNA4\", \"description\": \"This gene encodes a nicotinic acetylcholine receptor, which belongs to a superfamily of ligand-gated ion channels that play a role in fast signal transmission at synapses. These pentameric receptors can bind acetylcholine, which causes an extensive change in conformation that leads to the opening of an ion-conducting channel across the plasma membrane. This protein is an integral membrane receptor subunit that can interact with either nAChR beta-2 or nAChR beta-4 to form a functional receptor. Mutations in this gene cause nocturnal frontal lobe epilepsy type 1. Polymorphisms in this gene that provide protection against nicotine addiction have been described. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Feb 2012]\", \"label\": \"cholinergic receptor nicotinic alpha 4 subunit\", \"cname\": \"CHRNA4\", \"id\": [\"Protein\", \"HGNC\", \"CHRNA4\"]}, {\"function\": \"Abundance\", \"namespace\": \"CHEBI\", \"name\": \"gamma-aminobutyric acid\", \"cname\": \"gamma-aminobutyric acid\", \"id\": [\"Abundance\", \"CHEBI\", \"gamma-aminobutyric acid\"]}, {\"function\": \"Abundance\", \"namespace\": \"CHEBI\", \"name\": \"glutamate(1-)\", \"cname\": \"glutamate(1-)\", \"id\": [\"Abundance\", \"CHEBI\", \"glutamate(1-)\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CHRNB2\", \"description\": \"Neuronal acetylcholine receptors are homo- or heteropentameric complexes composed of homologous alpha and beta subunits. They belong to a superfamily of ligand-gated ion channels which allow the flow of sodium and potassium across the plasma membrane in response to ligands such as acetylcholine and nicotine. This gene encodes one of several beta subunits. Mutations in this gene are associated with autosomal dominant nocturnal frontal lobe epilepsy. [provided by RefSeq, Jul 2008]\", \"label\": \"cholinergic receptor nicotinic beta 2 subunit\", \"cname\": \"CHRNB2\", \"id\": [\"Protein\", \"HGNC\", \"CHRNB2\"]}, {\"function\": \"BiologicalProcess\", \"namespace\": \"GOBP\", \"name\": \"regulation of neuronal synaptic plasticity\", \"cname\": \"regulation of neuronal synaptic plasticity\", \"id\": [\"BiologicalProcess\", \"GOBP\", \"regulation of neuronal synaptic plasticity\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CHRNA2\", \"description\": \"Nicotinic acetylcholine receptors (nAChRs) are ligand-gated ion channels formed by a pentameric arrangement of alpha and beta subunits to create distinct muscle and neuronal receptors. Neuronal receptors are found throughout the peripheral and central nervous system where they are involved in fast synaptic transmission. This gene encodes an alpha subunit that is widely expressed in the brain. The proposed structure for nAChR subunits is a conserved N-terminal extracellular domain followed by three conserved transmembrane domains, a variable cytoplasmic loop, a fourth conserved transmembrane domain, and a short C-terminal extracellular region. Mutations in this gene cause autosomal dominant nocturnal frontal lobe epilepsy type 4. Single nucleotide polymorphisms (SNPs) in this gene have been associated with nicotine dependence. [provided by RefSeq, Nov 2009]\", \"label\": \"cholinergic receptor nicotinic alpha 2 subunit\", \"cname\": \"CHRNA2\", \"id\": [\"Protein\", \"HGNC\", \"CHRNA2\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CHRNA3\", \"description\": \"This locus encodes a member of the nicotinic acetylcholine receptor family of proteins. Members of this family of proteins form pentameric complexes comprised of both alpha and beta subunits. This locus encodes an alpha-type subunit, as it contains characteristic adjacent cysteine residues. The encoded protein is a ligand-gated ion channel that likely plays a role in neurotransmission. Polymorphisms in this gene have been associated with an increased risk of smoking initiation and an increased susceptibility to lung cancer. Alternatively spliced transcript variants have been described. [provided by RefSeq, Nov 2009]\", \"label\": \"cholinergic receptor nicotinic alpha 3 subunit\", \"cname\": \"CHRNA3\", \"id\": [\"Protein\", \"HGNC\", \"CHRNA3\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CHRNA5\", \"description\": \"The protein encoded by this gene is a nicotinic acetylcholine receptor subunit and a member of a superfamily of ligand-gated ion channels that mediate fast signal transmission at synapses. These receptors are thought to be heteropentamers composed of separate but similar subunits. Defects in this gene have been linked to susceptibility to lung cancer type 2 (LNCR2).[provided by RefSeq, Jun 2010]\", \"label\": \"cholinergic receptor nicotinic alpha 5 subunit\", \"cname\": \"CHRNA5\", \"id\": [\"Protein\", \"HGNC\", \"CHRNA5\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CHRNA6\", \"description\": \"This gene encodes an alpha subunit of neuronal nicotinic acetylcholine receptors. These receptors consist of five subunits and function as ion channels involved in neurotransmission. The encoded protein is a subunit of neuronal nicotinic acetylcholine receptors that mediate dopaminergic neurotransmission and are activated by acetylcholine and exogenous nicotine. Alternatively spliced transcript variants have been observed for this gene. Single nucleotide polymorphisms in this gene have been associated with both nicotine and alcohol dependence. [provided by RefSeq, Dec 2010]\", \"label\": \"cholinergic receptor nicotinic alpha 6 subunit\", \"cname\": \"CHRNA6\", \"id\": [\"Protein\", \"HGNC\", \"CHRNA6\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CHRNA7\", \"description\": \"The nicotinic acetylcholine receptors (nAChRs) are members of a superfamily of ligand-gated ion channels that mediate fast signal transmission at synapses. The nAChRs are thought to be hetero-pentamers composed of homologous subunits. The proposed structure for each subunit is a conserved N-terminal extracellular domain followed by three conserved transmembrane domains, a variable cytoplasmic loop, a fourth conserved transmembrane domain, and a short C-terminal extracellular region. The protein encoded by this gene forms a homo-oligomeric channel, displays marked permeability to calcium ions and is a major component of brain nicotinic receptors that are blocked by, and highly sensitive to, alpha-bungarotoxin. Once this receptor binds acetylcholine, it undergoes an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. This gene is located in a region identified as a major susceptibility locus for juvenile myoclonic epilepsy and a chromosomal location involved in the genetic transmission of schizophrenia. An evolutionarily recent partial duplication event in this region results in a hybrid containing sequence from this gene and a novel FAM7A gene. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Feb 2012]\", \"label\": \"cholinergic receptor nicotinic alpha 7 subunit\", \"cname\": \"CHRNA7\", \"id\": [\"Protein\", \"HGNC\", \"CHRNA7\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CHRNA9\", \"description\": \"This gene is a member of the ligand-gated ionic channel family and nicotinic acetylcholine receptor gene superfamily. It encodes a plasma membrane protein that forms homo- or hetero-oligomeric divalent cation channels. This protein is involved in cochlea hair cell development and is also expressed in the outer hair cells (OHCs) of the adult cochlea. [provided by RefSeq, Feb 2012]\", \"label\": \"cholinergic receptor nicotinic alpha 9 subunit\", \"cname\": \"CHRNA9\", \"id\": [\"Protein\", \"HGNC\", \"CHRNA9\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CHRNA10\", \"description\": null, \"label\": \"cholinergic receptor nicotinic alpha 10 subunit\", \"cname\": \"CHRNA10\", \"id\": [\"Protein\", \"HGNC\", \"CHRNA10\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CHRNB3\", \"description\": \"The nicotinic acetylcholine receptors (nAChRs) are members of a superfamily of ligand-gated ion channels that mediate fast signal transmission at synapses. The nAChRs are (hetero)pentamers composed of homologous subunits. The subunits that make up the muscle and neuronal forms of nAChRs are encoded by separate genes and have different primary structure. There are several subtypes of neuronal nAChRs that vary based on which homologous subunits are arranged around the central channel. They are classified as alpha-subunits if, like muscle alpha-1 (MIM 100690), they have a pair of adjacent cysteines as part of the presumed acetylcholine binding site. Subunits lacking these cysteine residues are classified as beta-subunits (Groot Kormelink and Luyten, 1997 [PubMed 9009220]). Elliott et al. (1996) [PubMed 8906617] stated that the proposed structure for each subunit is a conserved N-terminal extracellular domain followed by 3 conserved transmembrane domains, a variable cytoplasmic loop, a fourth conserved transmembrane domain, and a short C-terminal extracellular region.[supplied by OMIM, Apr 2010]\", \"label\": \"cholinergic receptor nicotinic beta 3 subunit\", \"cname\": \"CHRNB3\", \"id\": [\"Protein\", \"HGNC\", \"CHRNB3\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CHRNB4\", \"description\": null, \"label\": \"cholinergic receptor nicotinic beta 4 subunit\", \"cname\": \"CHRNB4\", \"id\": [\"Protein\", \"HGNC\", \"CHRNB4\"]}, {\"function\": \"Abundance\", \"namespace\": \"CHEBI\", \"name\": \"galanthamine\", \"cname\": \"galanthamine\", \"id\": [\"Abundance\", \"CHEBI\", \"galanthamine\"]}, {\"function\": \"Abundance\", \"namespace\": \"CHEBI\", \"name\": \"1-(3-chlorophenyl)piperazine\", \"cname\": \"1-(3-chlorophenyl)piperazine\", \"id\": [\"Abundance\", \"CHEBI\", \"1-(3-chlorophenyl)piperazine\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABBR2\", \"description\": \"The multi-pass membrane protein encoded by this gene belongs to the G-protein coupled receptor 3 family and GABA-B receptor subfamily. The GABA-B receptors inhibit neuronal activity through G protein-coupled second-messenger systems, which regulate the release of neurotransmitters, and the activity of ion channels and adenylyl cyclase. This receptor subunit forms an active heterodimeric complex with GABA-B receptor subunit 1, neither of which is effective on its own. Allelic variants of this gene have been associated with nicotine dependence.[provided by RefSeq, Jan 2010]\", \"label\": \"gamma-aminobutyric acid type B receptor subunit 2\", \"cname\": \"GABBR2\", \"id\": [\"Protein\", \"HGNC\", \"GABBR2\"]}, {\"function\": \"BiologicalProcess\", \"namespace\": \"GOBP\", \"name\": \"cAMP catabolic process\", \"cname\": \"cAMP catabolic process\", \"id\": [\"BiologicalProcess\", \"GOBP\", \"cAMP catabolic process\"]}, {\"function\": \"Abundance\", \"namespace\": \"CHEBI\", \"name\": \"nefiracetam\", \"cname\": \"nefiracetam\", \"id\": [\"Abundance\", \"CHEBI\", \"nefiracetam\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"PRKCA\", \"description\": \"Protein kinase C (PKC) is a family of serine- and threonine-specific protein kinases that can be activated by calcium and the second messenger diacylglycerol. PKC family members phosphorylate a wide variety of protein targets and are known to be involved in diverse cellular signaling pathways. PKC family members also serve as major receptors for phorbol esters, a class of tumor promoters. Each member of the PKC family has a specific expression profile and is believed to play a distinct role in cells. The protein encoded by this gene is one of the PKC family members. This kinase has been reported to play roles in many different cellular processes, such as cell adhesion, cell transformation, cell cycle checkpoint, and cell volume control. Knockout studies in mice suggest that this kinase may be a fundamental regulator of cardiac contractility and Ca(2+) handling in myocytes. [provided by RefSeq, Jul 2008]\", \"label\": \"protein kinase C alpha\", \"cname\": \"PRKCA\", \"id\": [\"Protein\", \"HGNC\", \"PRKCA\"]}, {\"function\": \"BiologicalProcess\", \"namespace\": \"GOBP\", \"name\": \"protein kinase A signaling\", \"cname\": \"protein kinase A signaling\", \"id\": [\"BiologicalProcess\", \"GOBP\", \"protein kinase A signaling\"]}, {\"function\": \"Abundance\", \"namespace\": \"CHEBI\", \"name\": \"EC 3.1.1.7 (acetylcholinesterase) inhibitor\", \"cname\": \"EC 3.1.1.7 (acetylcholinesterase) inhibitor\", \"id\": [\"Abundance\", \"CHEBI\", \"EC 3.1.1.7 (acetylcholinesterase) inhibitor\"]}, {\"function\": \"BiologicalProcess\", \"namespace\": \"GOBP\", \"name\": \"long-term synaptic potentiation\", \"cname\": \"long-term synaptic potentiation\", \"id\": [\"BiologicalProcess\", \"GOBP\", \"long-term synaptic potentiation\"]}, {\"function\": \"Complex\", \"namespace\": \"SCOMP\", \"name\": \"CAMK2 Complex\", \"cname\": \"CAMK2 Complex\", \"id\": [\"Complex\", \"SCOMP\", \"CAMK2 Complex\"]}, {\"function\": \"Complex\", \"cname\": \"complex(a(CHEBI:nefiracetam), p(HGNC:PRKCA))\", \"id\": [\"Complex\", [\"Abundance\", \"CHEBI\", \"nefiracetam\"], [\"Protein\", \"HGNC\", \"PRKCA\"]]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GRIA1\", \"variants\": [{\"kind\": \"pmod\", \"identifier\": {\"namespace\": \"bel\", \"name\": \"Ph\"}, \"code\": \"Ser\", \"pos\": 831}], \"description\": \"Glutamate receptors are the predominant excitatory neurotransmitter receptors in the mammalian brain and are activated in a variety of normal neurophysiologic processes. These receptors are heteromeric protein complexes with multiple subunits, each possessing transmembrane regions, and all arranged to form a ligand-gated ion channel. The classification of glutamate receptors is based on their activation by different pharmacologic agonists. This gene belongs to a family of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) receptors. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]\", \"label\": \"glutamate ionotropic receptor AMPA type subunit 1\", \"cname\": \"p(HGNC:GRIA1, pmod(Ph, Ser, 831))\", \"id\": [\"Protein\", \"HGNC\", \"GRIA1\", [\"pmod\", [\"bel\", \"Ph\"], \"Ser\", 831]]}, {\"function\": \"Complex\", \"namespace\": \"GOCC\", \"name\": \"proteasome complex\", \"cname\": \"proteasome complex\", \"id\": [\"Complex\", \"GOCC\", \"proteasome complex\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GPHN\", \"description\": \"This gene encodes a neuronal assembly protein that anchors inhibitory neurotransmitter receptors to the postsynaptic cytoskeleton via high affinity binding to a receptor subunit domain and tubulin dimers. In nonneuronal tissues, the encoded protein is also required for molybdenum cofactor biosynthesis. Mutations in this gene may be associated with the neurological condition hyperplexia and also lead to molybdenum cofactor deficiency. Numerous alternatively spliced transcript variants encoding different isoforms have been described; however, the full-length nature of all transcript variants is not currently known. [provided by RefSeq, Jul 2008]\", \"label\": \"gephyrin\", \"cname\": \"GPHN\", \"id\": [\"Protein\", \"HGNC\", \"GPHN\"]}, {\"function\": \"Pathology\", \"namespace\": \"MESHD\", \"name\": \"Glaucoma\", \"cname\": \"Glaucoma\", \"id\": [\"Pathology\", \"MESHD\", \"Glaucoma\"]}, {\"function\": \"Complex\", \"cname\": \"complex(p(HGNC:EGR1), p(HGNC:PSEN2))\", \"id\": [\"Complex\", [\"Protein\", \"HGNC\", \"EGR1\"], [\"Protein\", \"HGNC\", \"PSEN2\"]]}, {\"function\": \"Abundance\", \"namespace\": \"CHEBI\", \"name\": \"estradiol\", \"cname\": \"estradiol\", \"id\": [\"Abundance\", \"CHEBI\", \"estradiol\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"GABRA4\", \"description\": \"Gamma-aminobutyric acid (GABA) is the major inhibitory neurotransmitter in the mammalian brain where it acts at GABA-A receptors, which are ligand-gated chloride channels. Chloride conductance of these channels can be modulated by agents such as benzodiazepines that bind to the GABA-A receptor. At least 16 distinct subunits of GABA-A receptors have been identified. This gene encodes subunit alpha-4, which is involved in the etiology of autism and eventually increases autism risk through interaction with another subunit, gamma-aminobutyric acid receptor beta-1 (GABRB1). Alternatively spliced transcript variants encoding different isoforms have been found in this gene.[provided by RefSeq, Feb 2011]\", \"label\": \"gamma-aminobutyric acid type A receptor alpha4 subunit\", \"cname\": \"GABRA4\", \"id\": [\"RNA\", \"HGNC\", \"GABRA4\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"GABRA3\", \"description\": \"GABA is the major inhibitory neurotransmitter in the mammalian brain where it acts at GABA-A receptors, which are ligand-gated chloride channels. Chloride conductance of these channels can be modulated by agents such as benzodiazepines that bind to the GABA-A receptor. At least 16 distinct subunits of GABA-A receptors have been identified. [provided by RefSeq, Jul 2008]\", \"label\": \"gamma-aminobutyric acid type A receptor alpha3 subunit\", \"cname\": \"GABRA3\", \"id\": [\"RNA\", \"HGNC\", \"GABRA3\"]}, {\"function\": \"Abundance\", \"namespace\": \"CHEBI\", \"name\": \"Midazolam\", \"cname\": \"Midazolam\", \"id\": [\"Abundance\", \"CHEBI\", \"Midazolam\"]}], \"links\": [{\"relation\": \"negativeCorrelation\", \"evidence\": \"Further, EGR1 levels were negatively correlated with hippocampal amyloid- plaque burden.This study presents global gene expression profiles associated with GA immunization in a glaucoma rat model.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Investigative ophthalmology &amp; visual science\", \"reference\": \"21969301\", \"authors\": [\"Bakalash S\", \"Pham M\", \"Koronyo Y\", \"Salumbides BC\", \"Kramerov A\", \"Seidenberg H\", \"Berel D\", \"Black KL\", \"Koronyo-Hamaoui M\"], \"date\": \"2011-11-21\", \"title\": \"Egr1 expression is induced following glatiramer acetate immunotherapy in rodent models of glaucoma and Alzheimer's disease.\", \"lastauthor\": \"Koronyo-Hamaoui M\", \"volume\": \"52\", \"issue\": \"12\", \"pages\": \"9033-46\", \"firstauthor\": \"Bakalash S\"}, \"line\": 17223, \"annotations\": {\"Disease\": \"Alzheimer's disease\", \"Species\": \"10116\", \"MeSHDisease\": \"Glaucoma\", \"MeSHAnatomy\": \"Hippocampus\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 0, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"In AD-Tg mice, a significant increase in hippocampal EGR1 protein levels was also found in response to GA immunization.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Investigative ophthalmology &amp; visual science\", \"reference\": \"21969301\", \"authors\": [\"Bakalash S\", \"Pham M\", \"Koronyo Y\", \"Salumbides BC\", \"Kramerov A\", \"Seidenberg H\", \"Berel D\", \"Black KL\", \"Koronyo-Hamaoui M\"], \"date\": \"2011-11-21\", \"title\": \"Egr1 expression is induced following glatiramer acetate immunotherapy in rodent models of glaucoma and Alzheimer's disease.\", \"lastauthor\": \"Koronyo-Hamaoui M\", \"volume\": \"52\", \"issue\": \"12\", \"pages\": \"9033-46\", \"firstauthor\": \"Bakalash S\"}, \"line\": 17211, \"annotations\": {\"Disease\": \"Alzheimer's disease\", \"MeSHAnatomy\": \"Hippocampus\", \"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 4, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Egr-1 upregulates the Alzheimer's disease presenilin-2 gene in neuronal cells.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Gene\", \"reference\": \"14585504\", \"authors\": [\"Renbaum P\", \"Beeri R\", \"Gabai E\", \"Amiel M\", \"Gal M\", \"Ehrengruber MU\", \"Levy-Lahad E\"], \"date\": \"2003-10-30\", \"title\": \"Egr-1 upregulates the Alzheimer's disease presenilin-2 gene in neuronal cells.\", \"lastauthor\": \"Levy-Lahad E\", \"volume\": \"318\", \"issue\": \"\", \"pages\": \"113-24\", \"firstauthor\": \"Renbaum P\"}, \"line\": 17249, \"annotations\": {\"Disease\": \"Alzheimer's disease\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 4, \"key\": 1}, {\"relation\": \"association\", \"evidence\": \"Most forms of neuronal plasticity are associated with the induction of the transcription factor zif268 (egr1).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17148, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 35, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17154, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 8, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17155, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 9, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17156, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 10, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17157, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 11, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17158, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 12, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17159, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 13, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17160, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 14, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17161, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 15, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17162, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 16, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17163, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 17, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17164, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 18, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17165, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 19, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17166, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 20, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17167, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 21, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17168, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 22, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17169, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 23, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17170, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 25, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Induction of zif268 in neurons leads to altered expression of proteasome subunit and proteasome-regulatory genes, thereby changing the capacity of the neuron to degrade synaptic proteins, including receptors and receptor subunits.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17177, \"annotations\": {\"MeSHAnatomy\": \"Neurons\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 57, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"In addition, zif268 alters the transcription of genes associated with GABA(A)R expression and trafficking, such as ubiquilin and gephyrin.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17182, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 58, \"key\": 0}, {\"relation\": \"negativeCorrelation\", \"evidence\": \"Further, EGR1 levels were negatively correlated with hippocampal amyloid- plaque burden.This study presents global gene expression profiles associated with GA immunization in a glaucoma rat model.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Investigative ophthalmology &amp; visual science\", \"reference\": \"21969301\", \"authors\": [\"Bakalash S\", \"Pham M\", \"Koronyo Y\", \"Salumbides BC\", \"Kramerov A\", \"Seidenberg H\", \"Berel D\", \"Black KL\", \"Koronyo-Hamaoui M\"], \"date\": \"2011-11-21\", \"title\": \"Egr1 expression is induced following glatiramer acetate immunotherapy in rodent models of glaucoma and Alzheimer's disease.\", \"lastauthor\": \"Koronyo-Hamaoui M\", \"volume\": \"52\", \"issue\": \"12\", \"pages\": \"9033-46\", \"firstauthor\": \"Bakalash S\"}, \"line\": 17223, \"annotations\": {\"Disease\": \"Alzheimer's disease\", \"Species\": \"10116\", \"MeSHDisease\": \"Glaucoma\", \"MeSHAnatomy\": \"Hippocampus\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 0, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Further, EGR1 levels were negatively correlated with hippocampal amyloid- plaque burden.This study presents global gene expression profiles associated with GA immunization in a glaucoma rat model.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Investigative ophthalmology &amp; visual science\", \"reference\": \"21969301\", \"authors\": [\"Bakalash S\", \"Pham M\", \"Koronyo Y\", \"Salumbides BC\", \"Kramerov A\", \"Seidenberg H\", \"Berel D\", \"Black KL\", \"Koronyo-Hamaoui M\"], \"date\": \"2011-11-21\", \"title\": \"Egr1 expression is induced following glatiramer acetate immunotherapy in rodent models of glaucoma and Alzheimer's disease.\", \"lastauthor\": \"Koronyo-Hamaoui M\", \"volume\": \"52\", \"issue\": \"12\", \"pages\": \"9033-46\", \"firstauthor\": \"Bakalash S\"}, \"line\": 17224, \"annotations\": {\"Disease\": \"Alzheimer's disease\", \"Species\": \"10116\", \"MeSHDisease\": \"Glaucoma\", \"MeSHAnatomy\": \"Hippocampus\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 59, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Egr-1 upregulates the Alzheimer's disease presenilin-2 gene in neuronal cells.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Gene\", \"reference\": \"14585504\", \"authors\": [\"Renbaum P\", \"Beeri R\", \"Gabai E\", \"Amiel M\", \"Gal M\", \"Ehrengruber MU\", \"Levy-Lahad E\"], \"date\": \"2003-10-30\", \"title\": \"Egr-1 upregulates the Alzheimer's disease presenilin-2 gene in neuronal cells.\", \"lastauthor\": \"Levy-Lahad E\", \"volume\": \"318\", \"issue\": \"\", \"pages\": \"113-24\", \"firstauthor\": \"Renbaum P\"}, \"line\": 17248, \"annotations\": {\"Disease\": \"Alzheimer's disease\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 6, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"In immunoblotting analysis, nefiracetam treatment increased the PKCalpha activity with a bell-shaped dose-response relationship peaking at 10 nM, thereby increasing phosphorylation of PKC substrate and NMDA receptor. Nefiracetam treatment did not affect the PKA activity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Molecular pharmacology\", \"reference\": \"17095583\", \"authors\": [\"Moriguchi S\", \"Shioda N\", \"Maejima H\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2007-02-01\", \"title\": \"Nefiracetam potentiates N-methyl-D-aspartate (NMDA) receptor function via protein kinase C activation and reduces magnesium block of NMDA receptor.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"71\", \"issue\": \"2\", \"pages\": \"580-7\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14364, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 2, \"target\": 3, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"The nefiracetam-induced increase in the frequency of mEPSCs and mIPSCs over and above the level achieved by ACh alone would contribute to the therapeutic effect of nefiracetam as the cholinergic system is known to be downregulated in the brain of Alzheimer's disease patients.The therapeutic effects of galantamine are ascribed to the modest potentiation of nACh receptor and NMDA receptor activities in addition to the modest inhibition of acetylcholinesterase.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14418, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 4, \"target\": 5, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"In AD-Tg mice, a significant increase in hippocampal EGR1 protein levels was also found in response to GA immunization.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Investigative ophthalmology &amp; visual science\", \"reference\": \"21969301\", \"authors\": [\"Bakalash S\", \"Pham M\", \"Koronyo Y\", \"Salumbides BC\", \"Kramerov A\", \"Seidenberg H\", \"Berel D\", \"Black KL\", \"Koronyo-Hamaoui M\"], \"date\": \"2011-11-21\", \"title\": \"Egr1 expression is induced following glatiramer acetate immunotherapy in rodent models of glaucoma and Alzheimer's disease.\", \"lastauthor\": \"Koronyo-Hamaoui M\", \"volume\": \"52\", \"issue\": \"12\", \"pages\": \"9033-46\", \"firstauthor\": \"Bakalash S\"}, \"line\": 17211, \"annotations\": {\"Disease\": \"Alzheimer's disease\", \"MeSHAnatomy\": \"Hippocampus\", \"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 4, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Egr-1 upregulates the Alzheimer's disease presenilin-2 gene in neuronal cells.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Gene\", \"reference\": \"14585504\", \"authors\": [\"Renbaum P\", \"Beeri R\", \"Gabai E\", \"Amiel M\", \"Gal M\", \"Ehrengruber MU\", \"Levy-Lahad E\"], \"date\": \"2003-10-30\", \"title\": \"Egr-1 upregulates the Alzheimer's disease presenilin-2 gene in neuronal cells.\", \"lastauthor\": \"Levy-Lahad E\", \"volume\": \"318\", \"issue\": \"\", \"pages\": \"113-24\", \"firstauthor\": \"Renbaum P\"}, \"line\": 17249, \"annotations\": {\"Disease\": \"Alzheimer's disease\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 4, \"target\": 1, \"key\": 1}, {\"relation\": \"association\", \"evidence\": \"Egr-1 upregulates the Alzheimer's disease presenilin-2 gene in neuronal cells.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Gene\", \"reference\": \"14585504\", \"authors\": [\"Renbaum P\", \"Beeri R\", \"Gabai E\", \"Amiel M\", \"Gal M\", \"Ehrengruber MU\", \"Levy-Lahad E\"], \"date\": \"2003-10-30\", \"title\": \"Egr-1 upregulates the Alzheimer's disease presenilin-2 gene in neuronal cells.\", \"lastauthor\": \"Levy-Lahad E\", \"volume\": \"318\", \"issue\": \"\", \"pages\": \"113-24\", \"firstauthor\": \"Renbaum P\"}, \"line\": 17250, \"annotations\": {\"Disease\": \"Alzheimer's disease\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 4, \"target\": 6, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Egr-1 upregulates the Alzheimer's disease presenilin-2 gene in neuronal cells.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Gene\", \"reference\": \"14585504\", \"authors\": [\"Renbaum P\", \"Beeri R\", \"Gabai E\", \"Amiel M\", \"Gal M\", \"Ehrengruber MU\", \"Levy-Lahad E\"], \"date\": \"2003-10-30\", \"title\": \"Egr-1 upregulates the Alzheimer's disease presenilin-2 gene in neuronal cells.\", \"lastauthor\": \"Levy-Lahad E\", \"volume\": \"318\", \"issue\": \"\", \"pages\": \"113-24\", \"firstauthor\": \"Renbaum P\"}, \"line\": 17250, \"annotations\": {\"Disease\": \"Alzheimer's disease\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 6, \"target\": 4, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF-  can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators of inflammation\", \"reference\": \"24966471\", \"authors\": [\"Olmos G\", \"Llad J\"], \"date\": \"2014-01-01\", \"title\": \"Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity.\", \"lastauthor\": \"Llad J\", \"volume\": \"2014\", \"issue\": \"\", \"pages\": \"861231\", \"firstauthor\": \"Olmos G\"}, \"line\": 21557, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 8, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF-  can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators of inflammation\", \"reference\": \"24966471\", \"authors\": [\"Olmos G\", \"Llad J\"], \"date\": \"2014-01-01\", \"title\": \"Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity.\", \"lastauthor\": \"Llad J\", \"volume\": \"2014\", \"issue\": \"\", \"pages\": \"861231\", \"firstauthor\": \"Olmos G\"}, \"line\": 21558, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 9, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF-  can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators of inflammation\", \"reference\": \"24966471\", \"authors\": [\"Olmos G\", \"Llad J\"], \"date\": \"2014-01-01\", \"title\": \"Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity.\", \"lastauthor\": \"Llad J\", \"volume\": \"2014\", \"issue\": \"\", \"pages\": \"861231\", \"firstauthor\": \"Olmos G\"}, \"line\": 21559, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 10, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF-  can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators of inflammation\", \"reference\": \"24966471\", \"authors\": [\"Olmos G\", \"Llad J\"], \"date\": \"2014-01-01\", \"title\": \"Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity.\", \"lastauthor\": \"Llad J\", \"volume\": \"2014\", \"issue\": \"\", \"pages\": \"861231\", \"firstauthor\": \"Olmos G\"}, \"line\": 21560, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 11, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF-  can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators of inflammation\", \"reference\": \"24966471\", \"authors\": [\"Olmos G\", \"Llad J\"], \"date\": \"2014-01-01\", \"title\": \"Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity.\", \"lastauthor\": \"Llad J\", \"volume\": \"2014\", \"issue\": \"\", \"pages\": \"861231\", \"firstauthor\": \"Olmos G\"}, \"line\": 21561, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 12, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF-  can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators of inflammation\", \"reference\": \"24966471\", \"authors\": [\"Olmos G\", \"Llad J\"], \"date\": \"2014-01-01\", \"title\": \"Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity.\", \"lastauthor\": \"Llad J\", \"volume\": \"2014\", \"issue\": \"\", \"pages\": \"861231\", \"firstauthor\": \"Olmos G\"}, \"line\": 21562, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 13, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF-  can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators of inflammation\", \"reference\": \"24966471\", \"authors\": [\"Olmos G\", \"Llad J\"], \"date\": \"2014-01-01\", \"title\": \"Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity.\", \"lastauthor\": \"Llad J\", \"volume\": \"2014\", \"issue\": \"\", \"pages\": \"861231\", \"firstauthor\": \"Olmos G\"}, \"line\": 21563, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 14, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF-  can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators of inflammation\", \"reference\": \"24966471\", \"authors\": [\"Olmos G\", \"Llad J\"], \"date\": \"2014-01-01\", \"title\": \"Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity.\", \"lastauthor\": \"Llad J\", \"volume\": \"2014\", \"issue\": \"\", \"pages\": \"861231\", \"firstauthor\": \"Olmos G\"}, \"line\": 21564, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 15, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF-  can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators of inflammation\", \"reference\": \"24966471\", \"authors\": [\"Olmos G\", \"Llad J\"], \"date\": \"2014-01-01\", \"title\": \"Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity.\", \"lastauthor\": \"Llad J\", \"volume\": \"2014\", \"issue\": \"\", \"pages\": \"861231\", \"firstauthor\": \"Olmos G\"}, \"line\": 21565, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 16, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF-  can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators of inflammation\", \"reference\": \"24966471\", \"authors\": [\"Olmos G\", \"Llad J\"], \"date\": \"2014-01-01\", \"title\": \"Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity.\", \"lastauthor\": \"Llad J\", \"volume\": \"2014\", \"issue\": \"\", \"pages\": \"861231\", \"firstauthor\": \"Olmos G\"}, \"line\": 21566, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 17, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF-  can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators of inflammation\", \"reference\": \"24966471\", \"authors\": [\"Olmos G\", \"Llad J\"], \"date\": \"2014-01-01\", \"title\": \"Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity.\", \"lastauthor\": \"Llad J\", \"volume\": \"2014\", \"issue\": \"\", \"pages\": \"861231\", \"firstauthor\": \"Olmos G\"}, \"line\": 21567, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 18, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF-  can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators of inflammation\", \"reference\": \"24966471\", \"authors\": [\"Olmos G\", \"Llad J\"], \"date\": \"2014-01-01\", \"title\": \"Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity.\", \"lastauthor\": \"Llad J\", \"volume\": \"2014\", \"issue\": \"\", \"pages\": \"861231\", \"firstauthor\": \"Olmos G\"}, \"line\": 21568, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 19, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF-  can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators of inflammation\", \"reference\": \"24966471\", \"authors\": [\"Olmos G\", \"Llad J\"], \"date\": \"2014-01-01\", \"title\": \"Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity.\", \"lastauthor\": \"Llad J\", \"volume\": \"2014\", \"issue\": \"\", \"pages\": \"861231\", \"firstauthor\": \"Olmos G\"}, \"line\": 21569, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 20, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF-  can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators of inflammation\", \"reference\": \"24966471\", \"authors\": [\"Olmos G\", \"Llad J\"], \"date\": \"2014-01-01\", \"title\": \"Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity.\", \"lastauthor\": \"Llad J\", \"volume\": \"2014\", \"issue\": \"\", \"pages\": \"861231\", \"firstauthor\": \"Olmos G\"}, \"line\": 21570, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 21, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF-  can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators of inflammation\", \"reference\": \"24966471\", \"authors\": [\"Olmos G\", \"Llad J\"], \"date\": \"2014-01-01\", \"title\": \"Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity.\", \"lastauthor\": \"Llad J\", \"volume\": \"2014\", \"issue\": \"\", \"pages\": \"861231\", \"firstauthor\": \"Olmos G\"}, \"line\": 21571, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 22, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF-  can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators of inflammation\", \"reference\": \"24966471\", \"authors\": [\"Olmos G\", \"Llad J\"], \"date\": \"2014-01-01\", \"title\": \"Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity.\", \"lastauthor\": \"Llad J\", \"volume\": \"2014\", \"issue\": \"\", \"pages\": \"861231\", \"firstauthor\": \"Olmos G\"}, \"line\": 21572, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 23, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF-  can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators of inflammation\", \"reference\": \"24966471\", \"authors\": [\"Olmos G\", \"Llad J\"], \"date\": \"2014-01-01\", \"title\": \"Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity.\", \"lastauthor\": \"Llad J\", \"volume\": \"2014\", \"issue\": \"\", \"pages\": \"861231\", \"firstauthor\": \"Olmos G\"}, \"line\": 21573, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 24, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17128, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 8, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17154, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 8, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"1-(3-chlorophenyl)piperazine affects the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein co-treated with GABBR2 protein co-treated with GABRG2 protein]]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neurotoxicology\", \"reference\": \"21729720\", \"authors\": [\"Hondebrink L\", \"Meulenbelt J\", \"van Kleef RG\", \"van den Berg M\", \"Westerink RH\"], \"date\": \"2011-12-01\", \"title\": \"Modulation of human GABAA receptor function: a novel mode of action of drugs of abuse.\", \"lastauthor\": \"Westerink RH\", \"volume\": \"32\", \"issue\": \"6\", \"pages\": \"823-7\", \"firstauthor\": \"Hondebrink L\"}, \"line\": 46705, \"annotations\": {\"Species\": \"9606\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 8, \"target\": 46, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17129, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 9, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17155, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 9, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17130, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 10, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17156, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 10, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17131, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 11, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17157, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 11, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17132, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 12, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17158, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 12, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17133, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 13, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17159, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 13, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17134, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 14, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17160, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 14, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17135, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 15, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17161, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 15, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17136, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 16, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17162, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 16, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17137, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 17, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17163, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 17, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17138, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 18, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17164, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 18, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17139, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 19, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17165, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 19, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17140, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 20, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17166, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 20, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17141, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 21, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17167, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 21, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17142, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 22, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17168, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 22, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17143, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 23, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17169, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 23, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17144, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 25, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17170, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 25, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17128, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 8, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17129, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 9, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17130, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 10, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17131, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 11, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17132, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 12, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17133, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 13, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17134, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 14, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17135, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 15, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17136, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 16, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17137, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 17, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17138, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 18, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17139, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 19, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17140, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 20, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17141, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 21, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17142, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 22, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17143, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 23, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17144, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 25, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"In conclusion, nefiracetam enhances NMDA-receptor function through stimulation of its glycine binding site and nefiracetam-induced CaMKII activation likely contributes to improvement of cognition, learning, and memory.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of pharmacological sciences\", \"reference\": \"21821968\", \"authors\": [\"Moriguchi S\"], \"date\": \"2011-01-01\", \"title\": \"Pharmacological study on Alzheimer's drugs targeting calcium/calmodulin-dependent protein kinase II.\", \"lastauthor\": \"Moriguchi S\", \"volume\": \"117\", \"issue\": \"1\", \"pages\": \"6-11\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14460, \"annotations\": {\"Species\": \"10116\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 27, \"target\": 28, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"In conclusion, nefiracetam enhances NMDA-receptor function through stimulation of its glycine binding site and nefiracetam-induced CaMKII activation likely contributes to improvement of cognition, learning, and memory.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of pharmacological sciences\", \"reference\": \"21821968\", \"authors\": [\"Moriguchi S\"], \"date\": \"2011-01-01\", \"title\": \"Pharmacological study on Alzheimer's drugs targeting calcium/calmodulin-dependent protein kinase II.\", \"lastauthor\": \"Moriguchi S\", \"volume\": \"117\", \"issue\": \"1\", \"pages\": \"6-11\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14461, \"annotations\": {\"Species\": \"10116\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 27, \"target\": 29, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"In conclusion, nefiracetam enhances NMDA-receptor function through stimulation of its glycine binding site and nefiracetam-induced CaMKII activation likely contributes to improvement of cognition, learning, and memory.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of pharmacological sciences\", \"reference\": \"21821968\", \"authors\": [\"Moriguchi S\"], \"date\": \"2011-01-01\", \"title\": \"Pharmacological study on Alzheimer's drugs targeting calcium/calmodulin-dependent protein kinase II.\", \"lastauthor\": \"Moriguchi S\", \"volume\": \"117\", \"issue\": \"1\", \"pages\": \"6-11\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14462, \"annotations\": {\"Species\": \"10116\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 27, \"target\": 30, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14391, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 31, \"target\": 32, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14402, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 31, \"target\": 33, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14397, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 34, \"target\": 33, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14408, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 34, \"target\": 33, \"key\": 1}, {\"relation\": \"association\", \"evidence\": \"Most forms of neuronal plasticity are associated with the induction of the transcription factor zif268 (egr1).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17148, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 35, \"target\": 1, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14389, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 36, \"target\": 32, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14400, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 36, \"target\": 33, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14390, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 37, \"target\": 32, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14401, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 37, \"target\": 33, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14392, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 38, \"target\": 32, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14403, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 38, \"target\": 33, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14393, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 39, \"target\": 32, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14404, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 39, \"target\": 33, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14394, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 40, \"target\": 32, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14405, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 40, \"target\": 33, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14395, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 41, \"target\": 32, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14406, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 41, \"target\": 33, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14396, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 42, \"target\": 32, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14407, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 42, \"target\": 33, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14398, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 43, \"target\": 33, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14409, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 43, \"target\": 33, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14399, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 44, \"target\": 33, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14410, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 44, \"target\": 33, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14378, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 45, \"target\": 36, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14379, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 45, \"target\": 37, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14380, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 45, \"target\": 31, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14381, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 45, \"target\": 38, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14382, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 45, \"target\": 39, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14383, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 45, \"target\": 40, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14384, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 45, \"target\": 41, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14385, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 45, \"target\": 42, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14386, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 45, \"target\": 34, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14387, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 45, \"target\": 43, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14388, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 45, \"target\": 44, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"1-(3-chlorophenyl)piperazine affects the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein co-treated with GABBR2 protein co-treated with GABRG2 protein]]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neurotoxicology\", \"reference\": \"21729720\", \"authors\": [\"Hondebrink L\", \"Meulenbelt J\", \"van Kleef RG\", \"van den Berg M\", \"Westerink RH\"], \"date\": \"2011-12-01\", \"title\": \"Modulation of human GABAA receptor function: a novel mode of action of drugs of abuse.\", \"lastauthor\": \"Westerink RH\", \"volume\": \"32\", \"issue\": \"6\", \"pages\": \"823-7\", \"firstauthor\": \"Hondebrink L\"}, \"line\": 46705, \"annotations\": {\"Species\": \"9606\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 46, \"target\": 8, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"In this work, we describe a novel non-coding (nc) RNA (named 17A) RNA polymerase (pol) III-dependent embedded in the human G-protein-coupled receptor 51 gene (GPR51, GABA B2 receptor). The stable expression of 17A in SHSY5Y neuroblastoma cells induces the synthesis of an alternative splicing isoform that abolish GABA B2 intracellular signaling (i.e., inhibition of cAMP accumulation and activation of K(+) channels). Indeed, 17A is expressed in human brain, and we report that it is upregulated in cerebral tissues derived from Alzheimer disease patients. We demonstrate that 17A expression in neuroblastoma cells enhances the secretion of amyloid  peptide (Abeta) and the Abeta x-42/ x-40 peptide ratio and that its synthesis is induced in response to inflammatory stimuli.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neurobiology of disease\", \"reference\": \"20888417\", \"authors\": [\"Massone S\", \"Vassallo I\", \"Fiorino G\", \"Castelnuovo M\", \"Barbieri F\", \"Borghi R\", \"Tabaton M\", \"Robello M\", \"Gatta E\", \"Russo C\", \"Florio T\", \"Dieci G\", \"Cancedda R\", \"Pagano A\"], \"date\": \"2011-02-01\", \"title\": \"17A, a novel non-coding RNA, regulates GABA B alternative splicing and signaling in response to inflammatory stimuli and in Alzheimer disease.\", \"lastauthor\": \"Pagano A\", \"volume\": \"41\", \"issue\": \"2\", \"pages\": \"308-17\", \"firstauthor\": \"Massone S\"}, \"line\": 33227, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 47, \"target\": 48, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Nefiracetam is undergoing preclinical and clinical tests as a cognition-enhancing drug in Alzheimer's disease (AD).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Psychopharmacology\", \"reference\": \"9201800\", \"authors\": [\"Woodruff-Pak DS\", \"Hinchliffe RM\"], \"date\": \"1997-05-01\", \"title\": \"Mecamylamine- or scopolamine-induced learning impairment: ameliorated by nefiracetam.\", \"lastauthor\": \"Hinchliffe RM\", \"volume\": \"131\", \"issue\": \"2\", \"pages\": \"130-9\", \"firstauthor\": \"Woodruff-Pak DS\"}, \"line\": 14320, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 28, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The nootropic compound nefiracetam was evaluated in 88 older rabbits in a 750-ms delay paradigm of eyeblink classical conditioning (EBCC). Nefiracetam facilitated acquisition of EBCC in older rabbits. EBCC is performed poorly by older humans and is seriously impaired in Alzheimer's disease. These preclinical data in an animal model with clear parallels in humans suggest that nefiracetam may prove effective as a cognition enhancer in clinical trials.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Psychopharmacology\", \"reference\": \"7838908\", \"authors\": [\"Woodruff-Pak DS\", \"Li YT\"], \"date\": \"1994-03-01\", \"title\": \"Nefiracetam (DM-9384): effect on eyeblink classical conditioning in older rabbits.\", \"lastauthor\": \"Li YT\", \"volume\": \"114\", \"issue\": \"2\", \"pages\": \"200-8\", \"firstauthor\": \"Woodruff-Pak DS\"}, \"line\": 14332, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 28, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain research. Molecular brain research\", \"reference\": \"11039729\", \"authors\": [\"Nishizaki T\", \"Nomura T\", \"Matuoka T\", \"Kondoh T\", \"Enikolopov G\", \"Sumikawa K\", \"Watabe S\", \"Shiotani T\", \"Yoshii M\"], \"date\": \"2000-08-14\", \"title\": \"The anti-dementia drug nefiracetam facilitates hippocampal synaptic transmission by functionally targeting presynaptic nicotinic ACh receptors.\", \"lastauthor\": \"Yoshii M\", \"volume\": \"80\", \"issue\": \"1\", \"pages\": \"53-62\", \"firstauthor\": \"Nishizaki T\"}, \"line\": 14492, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 28, \"key\": 2}, {\"relation\": \"increases\", \"evidence\": \"We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Molecular pharmacology\", \"reference\": \"17095583\", \"authors\": [\"Moriguchi S\", \"Shioda N\", \"Maejima H\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2007-02-01\", \"title\": \"Nefiracetam potentiates N-methyl-D-aspartate (NMDA) receptor function via protein kinase C activation and reduces magnesium block of NMDA receptor.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"71\", \"issue\": \"2\", \"pages\": \"580-7\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14346, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 27, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"In conclusion, nefiracetam enhances NMDA-receptor function through stimulation of its glycine binding site and nefiracetam-induced CaMKII activation likely contributes to improvement of cognition, learning, and memory.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of pharmacological sciences\", \"reference\": \"21821968\", \"authors\": [\"Moriguchi S\"], \"date\": \"2011-01-01\", \"title\": \"Pharmacological study on Alzheimer's drugs targeting calcium/calmodulin-dependent protein kinase II.\", \"lastauthor\": \"Moriguchi S\", \"volume\": \"117\", \"issue\": \"1\", \"pages\": \"6-11\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14458, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10116\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 27, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Molecular pharmacology\", \"reference\": \"17095583\", \"authors\": [\"Moriguchi S\", \"Shioda N\", \"Maejima H\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2007-02-01\", \"title\": \"Nefiracetam potentiates N-methyl-D-aspartate (NMDA) receptor function via protein kinase C activation and reduces magnesium block of NMDA receptor.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"71\", \"issue\": \"2\", \"pages\": \"580-7\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14347, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 36, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Molecular pharmacology\", \"reference\": \"17095583\", \"authors\": [\"Moriguchi S\", \"Shioda N\", \"Maejima H\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2007-02-01\", \"title\": \"Nefiracetam potentiates N-methyl-D-aspartate (NMDA) receptor function via protein kinase C activation and reduces magnesium block of NMDA receptor.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"71\", \"issue\": \"2\", \"pages\": \"580-7\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14348, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 37, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Molecular pharmacology\", \"reference\": \"17095583\", \"authors\": [\"Moriguchi S\", \"Shioda N\", \"Maejima H\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2007-02-01\", \"title\": \"Nefiracetam potentiates N-methyl-D-aspartate (NMDA) receptor function via protein kinase C activation and reduces magnesium block of NMDA receptor.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"71\", \"issue\": \"2\", \"pages\": \"580-7\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14349, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 31, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Molecular pharmacology\", \"reference\": \"17095583\", \"authors\": [\"Moriguchi S\", \"Shioda N\", \"Maejima H\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2007-02-01\", \"title\": \"Nefiracetam potentiates N-methyl-D-aspartate (NMDA) receptor function via protein kinase C activation and reduces magnesium block of NMDA receptor.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"71\", \"issue\": \"2\", \"pages\": \"580-7\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14350, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 38, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Molecular pharmacology\", \"reference\": \"17095583\", \"authors\": [\"Moriguchi S\", \"Shioda N\", \"Maejima H\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2007-02-01\", \"title\": \"Nefiracetam potentiates N-methyl-D-aspartate (NMDA) receptor function via protein kinase C activation and reduces magnesium block of NMDA receptor.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"71\", \"issue\": \"2\", \"pages\": \"580-7\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14351, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 39, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Molecular pharmacology\", \"reference\": \"17095583\", \"authors\": [\"Moriguchi S\", \"Shioda N\", \"Maejima H\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2007-02-01\", \"title\": \"Nefiracetam potentiates N-methyl-D-aspartate (NMDA) receptor function via protein kinase C activation and reduces magnesium block of NMDA receptor.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"71\", \"issue\": \"2\", \"pages\": \"580-7\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14352, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 40, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Molecular pharmacology\", \"reference\": \"17095583\", \"authors\": [\"Moriguchi S\", \"Shioda N\", \"Maejima H\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2007-02-01\", \"title\": \"Nefiracetam potentiates N-methyl-D-aspartate (NMDA) receptor function via protein kinase C activation and reduces magnesium block of NMDA receptor.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"71\", \"issue\": \"2\", \"pages\": \"580-7\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14353, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 41, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Molecular pharmacology\", \"reference\": \"17095583\", \"authors\": [\"Moriguchi S\", \"Shioda N\", \"Maejima H\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2007-02-01\", \"title\": \"Nefiracetam potentiates N-methyl-D-aspartate (NMDA) receptor function via protein kinase C activation and reduces magnesium block of NMDA receptor.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"71\", \"issue\": \"2\", \"pages\": \"580-7\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14354, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 42, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Molecular pharmacology\", \"reference\": \"17095583\", \"authors\": [\"Moriguchi S\", \"Shioda N\", \"Maejima H\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2007-02-01\", \"title\": \"Nefiracetam potentiates N-methyl-D-aspartate (NMDA) receptor function via protein kinase C activation and reduces magnesium block of NMDA receptor.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"71\", \"issue\": \"2\", \"pages\": \"580-7\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14355, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 34, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Molecular pharmacology\", \"reference\": \"17095583\", \"authors\": [\"Moriguchi S\", \"Shioda N\", \"Maejima H\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2007-02-01\", \"title\": \"Nefiracetam potentiates N-methyl-D-aspartate (NMDA) receptor function via protein kinase C activation and reduces magnesium block of NMDA receptor.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"71\", \"issue\": \"2\", \"pages\": \"580-7\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14356, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 43, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"In immunoblotting analysis, nefiracetam treatment increased the PKCalpha activity with a bell-shaped dose-response relationship peaking at 10 nM, thereby increasing phosphorylation of PKC substrate and NMDA receptor. Nefiracetam treatment did not affect the PKA activity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Molecular pharmacology\", \"reference\": \"17095583\", \"authors\": [\"Moriguchi S\", \"Shioda N\", \"Maejima H\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2007-02-01\", \"title\": \"Nefiracetam potentiates N-methyl-D-aspartate (NMDA) receptor function via protein kinase C activation and reduces magnesium block of NMDA receptor.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"71\", \"issue\": \"2\", \"pages\": \"580-7\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14363, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 50, \"key\": 0}, {\"relation\": \"causesNoChange\", \"evidence\": \"In immunoblotting analysis, nefiracetam treatment increased the PKCalpha activity with a bell-shaped dose-response relationship peaking at 10 nM, thereby increasing phosphorylation of PKC substrate and NMDA receptor. Nefiracetam treatment did not affect the PKA activity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Molecular pharmacology\", \"reference\": \"17095583\", \"authors\": [\"Moriguchi S\", \"Shioda N\", \"Maejima H\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2007-02-01\", \"title\": \"Nefiracetam potentiates N-methyl-D-aspartate (NMDA) receptor function via protein kinase C activation and reduces magnesium block of NMDA receptor.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"71\", \"issue\": \"2\", \"pages\": \"580-7\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14365, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 51, \"key\": 0}, {\"relation\": \"isA\", \"evidence\": \"The nefiracetam-induced increase in the frequency of mEPSCs and mIPSCs over and above the level achieved by ACh alone would contribute to the therapeutic effect of nefiracetam as the cholinergic system is known to be downregulated in the brain of Alzheimer's disease patients.The therapeutic effects of galantamine are ascribed to the modest potentiation of nACh receptor and NMDA receptor activities in addition to the modest inhibition of acetylcholinesterase.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14419, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 52, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Nefiracetam treatment significantly enhanced long-term potentiation (LTP) with the same bell-shaped dose-response curve. Furthermore, nefiracetam-induced LTP enhancement was closely associated with calcium/calmodulin-dependent protein kinase II (CaMKII) activation with increase in phosphorylation of AMPA-type glutamate receptor subunit 1 (GluA1) (Ser-831) as a postsynaptic CaMKII substrate. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of pharmacological sciences\", \"reference\": \"21821968\", \"authors\": [\"Moriguchi S\"], \"date\": \"2011-01-01\", \"title\": \"Pharmacological study on Alzheimer's drugs targeting calcium/calmodulin-dependent protein kinase II.\", \"lastauthor\": \"Moriguchi S\", \"volume\": \"117\", \"issue\": \"1\", \"pages\": \"6-11\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14450, \"annotations\": {\"Species\": \"10116\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 53, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Nefiracetam treatment significantly enhanced long-term potentiation (LTP) with the same bell-shaped dose-response curve. Furthermore, nefiracetam-induced LTP enhancement was closely associated with calcium/calmodulin-dependent protein kinase II (CaMKII) activation with increase in phosphorylation of AMPA-type glutamate receptor subunit 1 (GluA1) (Ser-831) as a postsynaptic CaMKII substrate. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of pharmacological sciences\", \"reference\": \"21821968\", \"authors\": [\"Moriguchi S\"], \"date\": \"2011-01-01\", \"title\": \"Pharmacological study on Alzheimer's drugs targeting calcium/calmodulin-dependent protein kinase II.\", \"lastauthor\": \"Moriguchi S\", \"volume\": \"117\", \"issue\": \"1\", \"pages\": \"6-11\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14451, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10116\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 54, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"In conclusion, nefiracetam enhances NMDA-receptor function through stimulation of its glycine binding site and nefiracetam-induced CaMKII activation likely contributes to improvement of cognition, learning, and memory.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of pharmacological sciences\", \"reference\": \"21821968\", \"authors\": [\"Moriguchi S\"], \"date\": \"2011-01-01\", \"title\": \"Pharmacological study on Alzheimer's drugs targeting calcium/calmodulin-dependent protein kinase II.\", \"lastauthor\": \"Moriguchi S\", \"volume\": \"117\", \"issue\": \"1\", \"pages\": \"6-11\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14459, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10116\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 54, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain research. Molecular brain research\", \"reference\": \"11039729\", \"authors\": [\"Nishizaki T\", \"Nomura T\", \"Matuoka T\", \"Kondoh T\", \"Enikolopov G\", \"Sumikawa K\", \"Watabe S\", \"Shiotani T\", \"Yoshii M\"], \"date\": \"2000-08-14\", \"title\": \"The anti-dementia drug nefiracetam facilitates hippocampal synaptic transmission by functionally targeting presynaptic nicotinic ACh receptors.\", \"lastauthor\": \"Yoshii M\", \"volume\": \"80\", \"issue\": \"1\", \"pages\": \"53-62\", \"firstauthor\": \"Nishizaki T\"}, \"line\": 14480, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 55, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Nefiracetam treatment significantly enhanced long-term potentiation (LTP) with the same bell-shaped dose-response curve. Furthermore, nefiracetam-induced LTP enhancement was closely associated with calcium/calmodulin-dependent protein kinase II (CaMKII) activation with increase in phosphorylation of AMPA-type glutamate receptor subunit 1 (GluA1) (Ser-831) as a postsynaptic CaMKII substrate. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of pharmacological sciences\", \"reference\": \"21821968\", \"authors\": [\"Moriguchi S\"], \"date\": \"2011-01-01\", \"title\": \"Pharmacological study on Alzheimer's drugs targeting calcium/calmodulin-dependent protein kinase II.\", \"lastauthor\": \"Moriguchi S\", \"volume\": \"117\", \"issue\": \"1\", \"pages\": \"6-11\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14452, \"annotations\": {\"Species\": \"10116\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 54, \"target\": 56, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain research. Molecular brain research\", \"reference\": \"11039729\", \"authors\": [\"Nishizaki T\", \"Nomura T\", \"Matuoka T\", \"Kondoh T\", \"Enikolopov G\", \"Sumikawa K\", \"Watabe S\", \"Shiotani T\", \"Yoshii M\"], \"date\": \"2000-08-14\", \"title\": \"The anti-dementia drug nefiracetam facilitates hippocampal synaptic transmission by functionally targeting presynaptic nicotinic ACh receptors.\", \"lastauthor\": \"Yoshii M\", \"volume\": \"80\", \"issue\": \"1\", \"pages\": \"53-62\", \"firstauthor\": \"Nishizaki T\"}, \"line\": 14481, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 55, \"target\": 36, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain research. Molecular brain research\", \"reference\": \"11039729\", \"authors\": [\"Nishizaki T\", \"Nomura T\", \"Matuoka T\", \"Kondoh T\", \"Enikolopov G\", \"Sumikawa K\", \"Watabe S\", \"Shiotani T\", \"Yoshii M\"], \"date\": \"2000-08-14\", \"title\": \"The anti-dementia drug nefiracetam facilitates hippocampal synaptic transmission by functionally targeting presynaptic nicotinic ACh receptors.\", \"lastauthor\": \"Yoshii M\", \"volume\": \"80\", \"issue\": \"1\", \"pages\": \"53-62\", \"firstauthor\": \"Nishizaki T\"}, \"line\": 14482, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 55, \"target\": 37, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain research. Molecular brain research\", \"reference\": \"11039729\", \"authors\": [\"Nishizaki T\", \"Nomura T\", \"Matuoka T\", \"Kondoh T\", \"Enikolopov G\", \"Sumikawa K\", \"Watabe S\", \"Shiotani T\", \"Yoshii M\"], \"date\": \"2000-08-14\", \"title\": \"The anti-dementia drug nefiracetam facilitates hippocampal synaptic transmission by functionally targeting presynaptic nicotinic ACh receptors.\", \"lastauthor\": \"Yoshii M\", \"volume\": \"80\", \"issue\": \"1\", \"pages\": \"53-62\", \"firstauthor\": \"Nishizaki T\"}, \"line\": 14483, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 55, \"target\": 31, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain research. Molecular brain research\", \"reference\": \"11039729\", \"authors\": [\"Nishizaki T\", \"Nomura T\", \"Matuoka T\", \"Kondoh T\", \"Enikolopov G\", \"Sumikawa K\", \"Watabe S\", \"Shiotani T\", \"Yoshii M\"], \"date\": \"2000-08-14\", \"title\": \"The anti-dementia drug nefiracetam facilitates hippocampal synaptic transmission by functionally targeting presynaptic nicotinic ACh receptors.\", \"lastauthor\": \"Yoshii M\", \"volume\": \"80\", \"issue\": \"1\", \"pages\": \"53-62\", \"firstauthor\": \"Nishizaki T\"}, \"line\": 14484, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 55, \"target\": 38, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain research. Molecular brain research\", \"reference\": \"11039729\", \"authors\": [\"Nishizaki T\", \"Nomura T\", \"Matuoka T\", \"Kondoh T\", \"Enikolopov G\", \"Sumikawa K\", \"Watabe S\", \"Shiotani T\", \"Yoshii M\"], \"date\": \"2000-08-14\", \"title\": \"The anti-dementia drug nefiracetam facilitates hippocampal synaptic transmission by functionally targeting presynaptic nicotinic ACh receptors.\", \"lastauthor\": \"Yoshii M\", \"volume\": \"80\", \"issue\": \"1\", \"pages\": \"53-62\", \"firstauthor\": \"Nishizaki T\"}, \"line\": 14485, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 55, \"target\": 39, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain research. Molecular brain research\", \"reference\": \"11039729\", \"authors\": [\"Nishizaki T\", \"Nomura T\", \"Matuoka T\", \"Kondoh T\", \"Enikolopov G\", \"Sumikawa K\", \"Watabe S\", \"Shiotani T\", \"Yoshii M\"], \"date\": \"2000-08-14\", \"title\": \"The anti-dementia drug nefiracetam facilitates hippocampal synaptic transmission by functionally targeting presynaptic nicotinic ACh receptors.\", \"lastauthor\": \"Yoshii M\", \"volume\": \"80\", \"issue\": \"1\", \"pages\": \"53-62\", \"firstauthor\": \"Nishizaki T\"}, \"line\": 14486, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 55, \"target\": 40, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain research. Molecular brain research\", \"reference\": \"11039729\", \"authors\": [\"Nishizaki T\", \"Nomura T\", \"Matuoka T\", \"Kondoh T\", \"Enikolopov G\", \"Sumikawa K\", \"Watabe S\", \"Shiotani T\", \"Yoshii M\"], \"date\": \"2000-08-14\", \"title\": \"The anti-dementia drug nefiracetam facilitates hippocampal synaptic transmission by functionally targeting presynaptic nicotinic ACh receptors.\", \"lastauthor\": \"Yoshii M\", \"volume\": \"80\", \"issue\": \"1\", \"pages\": \"53-62\", \"firstauthor\": \"Nishizaki T\"}, \"line\": 14487, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 55, \"target\": 41, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain research. Molecular brain research\", \"reference\": \"11039729\", \"authors\": [\"Nishizaki T\", \"Nomura T\", \"Matuoka T\", \"Kondoh T\", \"Enikolopov G\", \"Sumikawa K\", \"Watabe S\", \"Shiotani T\", \"Yoshii M\"], \"date\": \"2000-08-14\", \"title\": \"The anti-dementia drug nefiracetam facilitates hippocampal synaptic transmission by functionally targeting presynaptic nicotinic ACh receptors.\", \"lastauthor\": \"Yoshii M\", \"volume\": \"80\", \"issue\": \"1\", \"pages\": \"53-62\", \"firstauthor\": \"Nishizaki T\"}, \"line\": 14488, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 55, \"target\": 42, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain research. Molecular brain research\", \"reference\": \"11039729\", \"authors\": [\"Nishizaki T\", \"Nomura T\", \"Matuoka T\", \"Kondoh T\", \"Enikolopov G\", \"Sumikawa K\", \"Watabe S\", \"Shiotani T\", \"Yoshii M\"], \"date\": \"2000-08-14\", \"title\": \"The anti-dementia drug nefiracetam facilitates hippocampal synaptic transmission by functionally targeting presynaptic nicotinic ACh receptors.\", \"lastauthor\": \"Yoshii M\", \"volume\": \"80\", \"issue\": \"1\", \"pages\": \"53-62\", \"firstauthor\": \"Nishizaki T\"}, \"line\": 14489, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 55, \"target\": 34, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain research. Molecular brain research\", \"reference\": \"11039729\", \"authors\": [\"Nishizaki T\", \"Nomura T\", \"Matuoka T\", \"Kondoh T\", \"Enikolopov G\", \"Sumikawa K\", \"Watabe S\", \"Shiotani T\", \"Yoshii M\"], \"date\": \"2000-08-14\", \"title\": \"The anti-dementia drug nefiracetam facilitates hippocampal synaptic transmission by functionally targeting presynaptic nicotinic ACh receptors.\", \"lastauthor\": \"Yoshii M\", \"volume\": \"80\", \"issue\": \"1\", \"pages\": \"53-62\", \"firstauthor\": \"Nishizaki T\"}, \"line\": 14490, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 55, \"target\": 43, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain research. Molecular brain research\", \"reference\": \"11039729\", \"authors\": [\"Nishizaki T\", \"Nomura T\", \"Matuoka T\", \"Kondoh T\", \"Enikolopov G\", \"Sumikawa K\", \"Watabe S\", \"Shiotani T\", \"Yoshii M\"], \"date\": \"2000-08-14\", \"title\": \"The anti-dementia drug nefiracetam facilitates hippocampal synaptic transmission by functionally targeting presynaptic nicotinic ACh receptors.\", \"lastauthor\": \"Yoshii M\", \"volume\": \"80\", \"issue\": \"1\", \"pages\": \"53-62\", \"firstauthor\": \"Nishizaki T\"}, \"line\": 14491, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 55, \"target\": 44, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Induction of zif268 in neurons leads to altered expression of proteasome subunit and proteasome-regulatory genes, thereby changing the capacity of the neuron to degrade synaptic proteins, including receptors and receptor subunits.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17177, \"annotations\": {\"MeSHAnatomy\": \"Neurons\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 57, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"In addition, zif268 alters the transcription of genes associated with GABA(A)R expression and trafficking, such as ubiquilin and gephyrin.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17182, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 58, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Further, EGR1 levels were negatively correlated with hippocampal amyloid- plaque burden.This study presents global gene expression profiles associated with GA immunization in a glaucoma rat model.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Investigative ophthalmology &amp; visual science\", \"reference\": \"21969301\", \"authors\": [\"Bakalash S\", \"Pham M\", \"Koronyo Y\", \"Salumbides BC\", \"Kramerov A\", \"Seidenberg H\", \"Berel D\", \"Black KL\", \"Koronyo-Hamaoui M\"], \"date\": \"2011-11-21\", \"title\": \"Egr1 expression is induced following glatiramer acetate immunotherapy in rodent models of glaucoma and Alzheimer's disease.\", \"lastauthor\": \"Koronyo-Hamaoui M\", \"volume\": \"52\", \"issue\": \"12\", \"pages\": \"9033-46\", \"firstauthor\": \"Bakalash S\"}, \"line\": 17224, \"annotations\": {\"Disease\": \"Alzheimer's disease\", \"Species\": \"10116\", \"MeSHDisease\": \"Glaucoma\", \"MeSHAnatomy\": \"Hippocampus\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 59, \"target\": 1, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We show that Egr-1 binds to PSEN-P2, and that PSEN-P2 activity is increased threefold by overexpression of Egr-1, and by 12-O-tetradecanoylphorbol-13-acetate (TPA), which induces physiological Egr-1 levels.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Gene\", \"reference\": \"14585504\", \"authors\": [\"Renbaum P\", \"Beeri R\", \"Gabai E\", \"Amiel M\", \"Gal M\", \"Ehrengruber MU\", \"Levy-Lahad E\"], \"date\": \"2003-10-30\", \"title\": \"Egr-1 upregulates the Alzheimer's disease presenilin-2 gene in neuronal cells.\", \"lastauthor\": \"Levy-Lahad E\", \"volume\": \"318\", \"issue\": \"\", \"pages\": \"113-24\", \"firstauthor\": \"Renbaum P\"}, \"line\": 17256, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Disease\": \"Alzheimer's disease\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 60, \"target\": 6, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Estradiol affects the expression of GABRA4 mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain research. Molecular brain research\", \"reference\": \"16000229\", \"authors\": [\"Pierson RC\", \"Lyons AM\", \"Greenfield LJ Jr\"], \"date\": \"2005-08-18\", \"title\": \"Gonadal steroids regulate GABAA receptor subunit mRNA expression in NT2-N neurons.\", \"lastauthor\": \"Greenfield LJ Jr\", \"volume\": \"138\", \"issue\": \"2\", \"pages\": \"105-15\", \"firstauthor\": \"Pierson RC\"}, \"line\": 46602, \"annotations\": {\"Species\": \"9606\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 61, \"target\": 62, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Estradiol results in increased expression of GABRA3 mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain research. Molecular brain research\", \"reference\": \"16000229\", \"authors\": [\"Pierson RC\", \"Lyons AM\", \"Greenfield LJ Jr\"], \"date\": \"2005-08-18\", \"title\": \"Gonadal steroids regulate GABAA receptor subunit mRNA expression in NT2-N neurons.\", \"lastauthor\": \"Greenfield LJ Jr\", \"volume\": \"138\", \"issue\": \"2\", \"pages\": \"105-15\", \"firstauthor\": \"Pierson RC\"}, \"line\": 47285, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 61, \"target\": 63, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Estradiol affects the expression of GABRA4 mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain research. Molecular brain research\", \"reference\": \"16000229\", \"authors\": [\"Pierson RC\", \"Lyons AM\", \"Greenfield LJ Jr\"], \"date\": \"2005-08-18\", \"title\": \"Gonadal steroids regulate GABAA receptor subunit mRNA expression in NT2-N neurons.\", \"lastauthor\": \"Greenfield LJ Jr\", \"volume\": \"138\", \"issue\": \"2\", \"pages\": \"105-15\", \"firstauthor\": \"Pierson RC\"}, \"line\": 46602, \"annotations\": {\"Species\": \"9606\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 62, \"target\": 61, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"GABRA6 protein mutant form results in decreased susceptibility to Midazolam\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of clinical anesthesia\", \"reference\": \"12031754\", \"authors\": [\"Hoffman WE\", \"Balyasnikova IV\", \"Mahay H\", \"Danilov SM\", \"Baughman VL\"], \"date\": \"2002-05-01\", \"title\": \"GABA alpha6 receptors mediate midazolam-induced anxiolysis.\", \"lastauthor\": \"Baughman VL\", \"volume\": \"14\", \"issue\": \"3\", \"pages\": \"206-9\", \"firstauthor\": \"Hoffman WE\"}, \"line\": 48542, \"annotations\": {\"Species\": \"9606\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 64, \"target\": 13, \"key\": 0}]};\n",
       "        const color_map = {'Protein': '#1F77B4', 'Pathology': '#FF7F0E', 'BiologicalProcess': '#2CA02C', 'miRNA': '#D62728', 'Complex': '#9467bd', 'Composite': '#9467bd', 'Reaction': '#8c564b', 'Gene': '#e377c2', 'Abundance': '#bcbd22', 'RNA': '#17becf'};\n",
       "    \n",
       "        require.config({\n",
       "          paths: {\n",
       "              d3: '//cdnjs.cloudflare.com/ajax/libs/d3/4.5.0/d3.min'\n",
       "          }\n",
       "        });\n",
       "\n",
       "        var elementInnerHTML = \"<div id='\" + chart + \"'></div>\";\n",
       "\n",
       "        element.append(elementInnerHTML);\n",
       "\n",
       "        var chartQualified = \"#\" + chart;\n",
       "\n",
       "        require(['d3'], function(d3) {\n",
       "            return init_d3_force(d3, graph, chartQualified, width, height, color_map);\n",
       "        });\n",
       "    "
      ],
      "text/plain": [
       "<IPython.core.display.Javascript object>"
      ]
     },
     "execution_count": 13,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "to_jupyter(subgraph)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "The subgraph also contains elements with important unqualified edges, like the relationships between complexes and their members. These relationships can be enriched from the original graph using the function [pbt.mutation.enrich_unqualified](http://pybel-tools.readthedocs.io/en/latest/mutation.html#pybel_tools.mutation.enrich_unqualified). For example, the connection between `complex(p(HGNC:EGR1), p(HGNC:PSEN2))` and `p(HGNC:PSEN2)` is added during this process. The connection between the `p(HGNC:APP)` and `p(HGNC:APP, frag(672_713))` is also recovered."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Nodes: 66\n",
      "Edges: 189\n",
      "Citations: 14\n",
      "Authors: 69\n",
      "Network density: 0.044055944055944055\n",
      "Components: 3\n",
      "Average degree: 2.8636363636363638\n"
     ]
    }
   ],
   "source": [
    "pbt.mutation.enrich_unqualified(graph, subgraph)\n",
    "\n",
    "pbt.summary.print_summary(subgraph)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/javascript": [
       "function init_d3_force(d3, graph, chart, width, height, function_colors) {\n",
       "    var focus_node = null;\n",
       "    var highlight_node = null;\n",
       "\n",
       "    // Highlight color variables\n",
       "\n",
       "    // Highlight color of the node boundering\n",
       "    const highlight_node_boundering = \"#4EB2D4\";\n",
       "\n",
       "    // Highlight color of the edge\n",
       "    const highlighted_link_color = \"#4EB2D4\";\n",
       "\n",
       "    // Text highlight color\n",
       "    const highlight_text = \"#4EB2D4\";\n",
       "\n",
       "    // Size when zooming scale\n",
       "    var size = d3.scalePow().exponent(1)\n",
       "        .domain([1, 100])\n",
       "        .range([8, 24]);\n",
       "\n",
       "    // Simulation parameters\n",
       "    const linkDistance = 100;\n",
       "    const fCharge = -1000;\n",
       "    const linkStrength = 0.7;\n",
       "    const collideStrength = 1;\n",
       "\n",
       "    // Simulation defined with variables\n",
       "    var simulation = d3.forceSimulation()\n",
       "        .force(\"link\", d3.forceLink()\n",
       "            .distance(linkDistance)\n",
       "            .strength(linkStrength)\n",
       "        )\n",
       "        .force(\"collide\", d3.forceCollide()\n",
       "            .radius(function (d) {\n",
       "                return d.r + 10\n",
       "            })\n",
       "            .strength(collideStrength)\n",
       "        )\n",
       "        .force(\"charge\", d3.forceManyBody()\n",
       "            .strength(fCharge)\n",
       "        )\n",
       "        .force(\"center\", d3.forceCenter(width / 2, height / 2))\n",
       "        .force(\"y\", d3.forceY(0))\n",
       "        .force(\"x\", d3.forceX(0));\n",
       "\n",
       "    // Pin down functionality\n",
       "    var node_drag = d3.drag()\n",
       "        .on(\"start\", dragstarted)\n",
       "        .on(\"drag\", dragged)\n",
       "        .on(\"end\", dragended);\n",
       "\n",
       "    function dragstarted(d) {\n",
       "        if (!d3.event.active) simulation.alphaTarget(0.3).restart();\n",
       "        d.fx = d.x;\n",
       "        d.fy = d.y;\n",
       "    }\n",
       "\n",
       "    function dragged(d) {\n",
       "        d.fx = d3.event.x;\n",
       "        d.fy = d3.event.y;\n",
       "    }\n",
       "\n",
       "    function dragended(d) {\n",
       "        if (!d3.event.active) simulation.alphaTarget(0);\n",
       "    }\n",
       "\n",
       "    function releasenode(d) {\n",
       "        d.fx = null;\n",
       "        d.fy = null;\n",
       "    }\n",
       "\n",
       "    //END Pin down functionality\n",
       "\n",
       "    const color_circunferencia = \"black\";\n",
       "    const default_link_color = \"#AAAAAA\";\n",
       "    const nominal_base_node_size = 8;\n",
       "\n",
       "    // Normal and highlighted stroke of the links (double the width of the link when highlighted)\n",
       "    const nominal_stroke = 1.5;\n",
       "\n",
       "    // Zoom variables\n",
       "    const min_zoom = 0.1;\n",
       "    const max_zoom = 10;\n",
       "    const border = 1;\n",
       "    const bordercolor = 'black';\n",
       "\n",
       "    var svg = d3.select(chart).append(\"svg\")\n",
       "        .attr(\"width\", width)\n",
       "        .attr(\"height\", height);\n",
       "\n",
       "    // // Create definition for arrowhead.\n",
       "    svg.append(\"defs\").append(\"marker\")\n",
       "        .attr(\"id\", \"arrowhead\")\n",
       "        .attr(\"viewBox\", \"0 -5 10 10\")\n",
       "        .attr(\"refX\", 20)\n",
       "        .attr(\"refY\", 0)\n",
       "        .attr(\"markerUnits\", \"strokeWidth\")\n",
       "        .attr(\"markerWidth\", 6)\n",
       "        .attr(\"markerHeight\", 6)\n",
       "        .attr(\"orient\", \"auto\")\n",
       "        .append(\"path\")\n",
       "        .attr(\"d\", \"M0,-5L10,0L0,5\");\n",
       "\n",
       "    // // Create definition for stub.\n",
       "    svg.append(\"defs\").append(\"marker\")\n",
       "        .attr(\"id\", \"stub\")\n",
       "        .attr(\"viewBox\", \"-1 -5 2 10\")\n",
       "        .attr(\"refX\", 15)\n",
       "        .attr(\"refY\", 0)\n",
       "        .attr(\"markerUnits\", \"strokeWidth\")\n",
       "        .attr(\"markerWidth\", 6)\n",
       "        .attr(\"markerHeight\", 6)\n",
       "        .attr(\"orient\", \"auto\")\n",
       "        .append(\"path\")\n",
       "        .attr(\"d\", \"M 0,0 m -1,-5 L 1,-5 L 1,5 L -1,5 Z\");\n",
       "\n",
       "    // Background\n",
       "    svg.append(\"rect\")\n",
       "        .attr(\"width\", \"100%\")\n",
       "        .attr(\"height\", \"100%\")\n",
       "        .attr(\"fill\", \"#ffffff\")\n",
       "        .style(\"pointer-events\", \"all\")\n",
       "        // Zoom + panning functionality\n",
       "        .call(d3.zoom()\n",
       "            .scaleExtent([min_zoom, max_zoom])\n",
       "            .on(\"zoom\", zoomed))\n",
       "        .on(\"dblclick.zoom\", null);\n",
       "\n",
       "\n",
       "    function zoomed() {\n",
       "        g.attr(\"transform\", d3.event.transform);\n",
       "    }\n",
       "\n",
       "    // g = svg object where the graph will be appended\n",
       "    var g = svg.append(\"g\");\n",
       "\n",
       "    var linkedByIndex = {};\n",
       "    graph.links.forEach(function (d) {\n",
       "        linkedByIndex[d.source + \",\" + d.target] = true;\n",
       "    });\n",
       "\n",
       "    function isConnected(a, b) {\n",
       "        return linkedByIndex[a.index + \",\" + b.index] || linkedByIndex[b.index + \",\" + a.index] || a.index == b.index;\n",
       "    }\n",
       "\n",
       "    function ticked() {\n",
       "        link.attr(\"x1\", function (d) {\n",
       "            return d.source.x;\n",
       "        })\n",
       "            .attr(\"y1\", function (d) {\n",
       "                return d.source.y;\n",
       "            })\n",
       "            .attr(\"x2\", function (d) {\n",
       "                return d.target.x;\n",
       "            })\n",
       "            .attr(\"y2\", function (d) {\n",
       "                return d.target.y;\n",
       "            });\n",
       "\n",
       "        node\n",
       "            .attr(\"transform\", function (d) {\n",
       "                return \"translate(\" + d.x + \", \" + d.y + \")\";\n",
       "            });\n",
       "    }\n",
       "\n",
       "\n",
       "    simulation\n",
       "        .nodes(graph.nodes)\n",
       "        .on(\"tick\", ticked);\n",
       "\n",
       "    simulation.force(\"link\")\n",
       "        .links(graph.links);\n",
       "\n",
       "    // Definition of links nodes text...\n",
       "\n",
       "    var link = g.selectAll(\".link\")\n",
       "        .data(graph.links)\n",
       "        .enter().append(\"line\")\n",
       "        .style(\"stroke-width\", nominal_stroke)\n",
       "        .style(\"stroke\", default_link_color)\n",
       "        .style(\"stroke-dasharray\", function (d) {\n",
       "            if (['decreases', 'directlyDecreases', 'increases', 'directlyIncreases', 'negativeCorrelation',\n",
       "                    'positiveCorrelation'].indexOf(d.relation) >= 0) {\n",
       "                return \"none\"\n",
       "            } else {\n",
       "                return \"4, 4\"\n",
       "            }\n",
       "        })\n",
       "        .attr(\"marker-start\", function (d) {\n",
       "            if ('positiveCorrelation' == d.relation) {\n",
       "                return \"url(#arrowhead)\"\n",
       "            }\n",
       "            else if ('negativeCorrelation' == d.relation) {\n",
       "                return \"url(#stub)\"\n",
       "            }\n",
       "            else {\n",
       "                return \"\"\n",
       "            }\n",
       "        })\n",
       "        .attr(\"marker-end\", function (d) {\n",
       "            if (['increases', 'directlyIncreases', 'positiveCorrelation'].indexOf(d.relation) >= 0) {\n",
       "                return \"url(#arrowhead)\"\n",
       "            } else if (['decreases', 'directlyDecreases', 'negativeCorrelation'].indexOf(d.relation) >= 0) {\n",
       "                return \"url(#stub)\"\n",
       "            } else {\n",
       "                return \"\"\n",
       "            }\n",
       "        });\n",
       "\n",
       "    var node = g.selectAll(\".nodes\")\n",
       "        .data(graph.nodes)\n",
       "        .enter().append(\"g\")\n",
       "        .attr(\"class\", \"node\")\n",
       "        // Next two lines -> Pin down functionality\n",
       "        .on('dblclick', releasenode)\n",
       "        .call(node_drag);\n",
       "\n",
       "    var circle = node.append(\"path\")\n",
       "        .attr(\"d\", d3.symbol()\n",
       "            .size(function (d) {\n",
       "                return Math.PI * Math.pow(size(d.size) || nominal_base_node_size, 2);\n",
       "            })\n",
       "        )\n",
       "        .attr(\"class\", function (d) {\n",
       "            return d.function\n",
       "        })\n",
       "        .style('fill', function (d) {\n",
       "            return function_colors[d.function]\n",
       "        })\n",
       "        .style(\"stroke-width\", nominal_stroke)\n",
       "        .style(\"stroke\", color_circunferencia);\n",
       "\n",
       "    var text = node.append(\"text\")\n",
       "        .attr(\"class\", \"node-name\")\n",
       "        // .attr(\"id\", nodehashes[d])\n",
       "        .attr(\"fill\", \"black\")\n",
       "        .attr(\"dx\", 12)\n",
       "        .attr(\"dy\", \".35em\")\n",
       "        .text(function (d) {\n",
       "            return d.cname\n",
       "        });\n",
       "\n",
       "    // Highlight on mouseenter and back to normal on mouseout\n",
       "    node.on(\"mouseenter\", function (d) {\n",
       "        set_highlight(d);\n",
       "    })\n",
       "        .on(\"mousedown\", function () {\n",
       "            d3.event.stopPropagation();\n",
       "        }).on(\"mouseout\", function () {\n",
       "        exit_highlight();\n",
       "    });\n",
       "\n",
       "    function exit_highlight() {\n",
       "        highlight_node = null;\n",
       "        if (focus_node === null) {\n",
       "            if (highlight_node_boundering != color_circunferencia) {\n",
       "                circle.style(\"stroke\", color_circunferencia);\n",
       "                text.style(\"fill\", \"black\");\n",
       "                link.style(\"stroke\", default_link_color);\n",
       "            }\n",
       "        }\n",
       "    }\n",
       "\n",
       "    function set_highlight(d) {\n",
       "        if (focus_node !== null) d = focus_node;\n",
       "        highlight_node = d;\n",
       "\n",
       "        if (highlight_node_boundering != color_circunferencia) {\n",
       "            circle.style(\"stroke\", function (o) {\n",
       "                return isConnected(d, o) ? highlight_node_boundering : color_circunferencia;\n",
       "            });\n",
       "            text.style(\"fill\", function (o) {\n",
       "                return isConnected(d, o) ? highlight_text : \"black\";\n",
       "            });\n",
       "            link.style(\"stroke\", function (o) {\n",
       "                return o.source.index == d.index || o.target.index == d.index ? highlighted_link_color : default_link_color;\n",
       "            });\n",
       "        }\n",
       "    }\n",
       "\n",
       "\n",
       "    // Freeze the graph when space is pressed\n",
       "    function freezeGraph() {\n",
       "        // Space button Triggers STOP\n",
       "        if (d3.event.keyCode == 32) {\n",
       "            simulation.stop();\n",
       "        }\n",
       "    }\n",
       "\n",
       "    // Call freezeGraph when a key is pressed, freezeGraph checks whether this key is \"Space\" that triggers the freeze\n",
       "    d3.select(window).on(\"keydown\", freezeGraph);\n",
       "}\n",
       "        var chart = \"edrbcxhtskzufvjg\";\n",
       "        var width = 1000;\n",
       "        var height = 650;\n",
       "        var graph = {\"directed\": true, \"multigraph\": true, \"graph\": {\"document_metadata\": {}, \"pybel_version\": \"0.7.2\", \"namespace_url\": {}, \"namespace_owl\": {}, \"namespace_pattern\": {}, \"annotation_url\": {}, \"annotation_owl\": {}, \"annotation_pattern\": {}, \"annotation_list\": {}}, \"nodes\": [{\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"APP\", \"variants\": [{\"kind\": \"frag\", \"start\": 672, \"stop\": 713}], \"description\": \"This gene encodes a cell surface receptor and transmembrane precursor protein that is cleaved by secretases to form a number of peptides. Some of these peptides are secreted and can bind to the acetyltransferase complex APBB1/TIP60 to promote transcriptional activation, while others form the protein basis of the amyloid plaques found in the brains of patients with Alzheimer disease. In addition, two of the peptides are antimicrobial peptides, having been shown to have bacteriocidal and antifungal activities. Mutations in this gene have been implicated in autosomal dominant Alzheimer disease and cerebroarterial amyloidosis (cerebral amyloid angiopathy). Multiple transcript variants encoding several different isoforms have been found for this gene. [provided by RefSeq, Aug 2014]\", \"label\": \"amyloid beta precursor protein\", \"cname\": \"p(HGNC:APP, frag(672_713))\", \"id\": [\"Protein\", \"HGNC\", \"APP\", [\"frag\", [672, 713]]]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"EGR1\", \"description\": \"The protein encoded by this gene belongs to the EGR family of C2H2-type zinc-finger proteins. It is a nuclear protein and functions as a transcriptional regulator. The products of target genes it activates are required for differentitation and mitogenesis. Studies suggest this is a cancer suppressor gene. [provided by RefSeq, Dec 2014]\", \"label\": \"early growth response 1\", \"cname\": \"EGR1\", \"id\": [\"Protein\", \"HGNC\", \"EGR1\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"APP\", \"description\": \"This gene encodes a cell surface receptor and transmembrane precursor protein that is cleaved by secretases to form a number of peptides. Some of these peptides are secreted and can bind to the acetyltransferase complex APBB1/TIP60 to promote transcriptional activation, while others form the protein basis of the amyloid plaques found in the brains of patients with Alzheimer disease. In addition, two of the peptides are antimicrobial peptides, having been shown to have bacteriocidal and antifungal activities. Mutations in this gene have been implicated in autosomal dominant Alzheimer disease and cerebroarterial amyloidosis (cerebral amyloid angiopathy). Multiple transcript variants encoding several different isoforms have been found for this gene. [provided by RefSeq, Aug 2014]\", \"label\": \"amyloid beta precursor protein\", \"cname\": \"APP\", \"id\": [\"Protein\", \"HGNC\", \"APP\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GRIN2B\", \"variants\": [{\"kind\": \"pmod\", \"identifier\": {\"namespace\": \"bel\", \"name\": \"Ph\"}}], \"description\": \"N-methyl-D-aspartate (NMDA) receptors are a class of ionotropic glutamate receptors. NMDA receptor channel has been shown to be involved in long-term potentiation, an activity-dependent increase in the efficiency of synaptic transmission thought to underlie certain kinds of memory and learning. NMDA receptor channels are heteromers composed of three different subunits: NR1 (GRIN1), NR2 (GRIN2A, GRIN2B, GRIN2C, or GRIN2D) and NR3 (GRIN3A or GRIN3B). The NR2 subunit acts as the agonist binding site for glutamate. This receptor is the predominant excitatory neurotransmitter receptor in the mammalian brain. [provided by RefSeq, Jul 2008]\", \"label\": \"glutamate ionotropic receptor NMDA type subunit 2B\", \"cname\": \"p(HGNC:GRIN2B, pmod(Ph))\", \"id\": [\"Protein\", \"HGNC\", \"GRIN2B\", [\"pmod\", [\"bel\", \"Ph\"]]]}, {\"function\": \"Pathology\", \"namespace\": \"MESHD\", \"name\": \"Alzheimer Disease\", \"cname\": \"Alzheimer Disease\", \"id\": [\"Pathology\", \"MESHD\", \"Alzheimer Disease\"]}, {\"function\": \"BiologicalProcess\", \"namespace\": \"GOBP\", \"name\": \"synaptic transmission, cholinergic\", \"cname\": \"synaptic transmission, cholinergic\", \"id\": [\"BiologicalProcess\", \"GOBP\", \"synaptic transmission, cholinergic\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"PSEN2\", \"description\": \"Alzheimer's disease (AD) patients with an inherited form of the disease carry mutations in the presenilin proteins (PSEN1 or PSEN2) or the amyloid precursor protein (APP). These disease-linked mutations result in increased production of the longer form of amyloid-beta (main component of amyloid deposits found in AD brains). Presenilins are postulated to regulate APP processing through their effects on gamma-secretase, an enzyme that cleaves APP. Also, it is thought that the presenilins are involved in the cleavage of the Notch receptor such that, they either directly regulate gamma-secretase activity, or themselves act are protease enzymes. Two alternatively spliced transcript variants encoding different isoforms of PSEN2 have been identified. [provided by RefSeq, Jul 2008]\", \"label\": \"presenilin 2\", \"cname\": \"PSEN2\", \"id\": [\"Protein\", \"HGNC\", \"PSEN2\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"TNF\", \"description\": \"This gene encodes a multifunctional proinflammatory cytokine that belongs to the tumor necrosis factor (TNF) superfamily. This cytokine is mainly secreted by macrophages. It can bind to, and thus functions through its receptors TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR. This cytokine is involved in the regulation of a wide spectrum of biological processes including cell proliferation, differentiation, apoptosis, lipid metabolism, and coagulation. This cytokine has been implicated in a variety of diseases, including autoimmune diseases, insulin resistance, and cancer. Knockout studies in mice also suggested the neuroprotective function of this cytokine. [provided by RefSeq, Jul 2008]\", \"label\": \"tumor necrosis factor\", \"cname\": \"TNF\", \"id\": [\"Protein\", \"HGNC\", \"TNF\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRA1\", \"description\": \"This gene encodes a gamma-aminobutyric acid (GABA) receptor. GABA is the major inhibitory neurotransmitter in the mammalian brain where it acts at GABA-A receptors, which are ligand-gated chloride channels. Chloride conductance of these channels can be modulated by agents such as benzodiazepines that bind to the GABA-A receptor. GABA-A receptors are pentameric, consisting of proteins from several subunit classes: alpha, beta, gamma, delta and rho. Mutations in this gene cause juvenile myoclonic epilepsy and childhood absence epilepsy type 4. Multiple transcript variants encoding the same protein have been identified for this gene. [provided by RefSeq, Jul 2008]\", \"label\": \"gamma-aminobutyric acid type A receptor alpha1 subunit\", \"cname\": \"GABRA1\", \"id\": [\"Protein\", \"HGNC\", \"GABRA1\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRA2\", \"description\": \"GABA is the major inhibitory neurotransmitter in the mammalian brain where it acts at GABA-A receptors, which are ligand-gated chloride channels. Chloride conductance of these channels can be modulated by agents such as benzodiazepines that bind to the GABA-A receptor. At least 16 distinct subunits of GABA-A receptors have been identified. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Nov 2013]\", \"label\": \"gamma-aminobutyric acid type A receptor alpha2 subunit\", \"cname\": \"GABRA2\", \"id\": [\"Protein\", \"HGNC\", \"GABRA2\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRA3\", \"description\": \"GABA is the major inhibitory neurotransmitter in the mammalian brain where it acts at GABA-A receptors, which are ligand-gated chloride channels. Chloride conductance of these channels can be modulated by agents such as benzodiazepines that bind to the GABA-A receptor. At least 16 distinct subunits of GABA-A receptors have been identified. [provided by RefSeq, Jul 2008]\", \"label\": \"gamma-aminobutyric acid type A receptor alpha3 subunit\", \"cname\": \"GABRA3\", \"id\": [\"Protein\", \"HGNC\", \"GABRA3\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRA4\", \"description\": \"Gamma-aminobutyric acid (GABA) is the major inhibitory neurotransmitter in the mammalian brain where it acts at GABA-A receptors, which are ligand-gated chloride channels. Chloride conductance of these channels can be modulated by agents such as benzodiazepines that bind to the GABA-A receptor. At least 16 distinct subunits of GABA-A receptors have been identified. This gene encodes subunit alpha-4, which is involved in the etiology of autism and eventually increases autism risk through interaction with another subunit, gamma-aminobutyric acid receptor beta-1 (GABRB1). Alternatively spliced transcript variants encoding different isoforms have been found in this gene.[provided by RefSeq, Feb 2011]\", \"label\": \"gamma-aminobutyric acid type A receptor alpha4 subunit\", \"cname\": \"GABRA4\", \"id\": [\"Protein\", \"HGNC\", \"GABRA4\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRA5\", \"description\": \"GABA is the major inhibitory neurotransmitter in the mammalian brain where it acts at GABA-A receptors, which are ligand-gated chloride channels. Chloride conductance of these channels can be modulated by agents such as benzodiazepines that bind to the GABA-A receptor. At least 16 distinct subunits of GABA-A receptors have been identified. Transcript variants utilizing three different alternative non-coding first exons have been described. [provided by RefSeq, Jul 2008]\", \"label\": \"gamma-aminobutyric acid type A receptor alpha5 subunit\", \"cname\": \"GABRA5\", \"id\": [\"Protein\", \"HGNC\", \"GABRA5\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRA6\", \"description\": \"GABA is the major inhibitory neurotransmitter in the mammalian brain where it acts at GABA-A receptors, which are ligand-gated chloride channels. Chloride conductance of these channels can be modulated by agents such as benzodiazepines that bind to the GABA-A receptor. At least 16 distinct subunits of GABA-A receptors have been identified. [provided by RefSeq, Jul 2008]\", \"label\": \"gamma-aminobutyric acid type A receptor alpha6 subunit\", \"cname\": \"GABRA6\", \"id\": [\"Protein\", \"HGNC\", \"GABRA6\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRB1\", \"description\": \"The gamma-aminobutyric acid (GABA) A receptor is a multisubunit chloride channel that mediates the fastest inhibitory synaptic transmission in the central nervous system. This gene encodes GABA A receptor, beta 1 subunit. It is mapped to chromosome 4p12 in a cluster comprised of genes encoding alpha 4, alpha 2 and gamma 1 subunits of the GABA A receptor. Alteration of this gene is implicated in the pathogenetics of schizophrenia. [provided by RefSeq, Jul 2008]\", \"label\": \"gamma-aminobutyric acid type A receptor beta1 subunit\", \"cname\": \"GABRB1\", \"id\": [\"Protein\", \"HGNC\", \"GABRB1\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRB2\", \"description\": null, \"cname\": \"GABRB2\", \"id\": [\"Protein\", \"HGNC\", \"GABRB2\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRB3\", \"description\": \"This gene encodes a member of the ligand-gated ionic channel family. The encoded protein is one the subunits of a multi-subunit chloride channel that serves as the receptor for gamma-aminobutyric acid, a major inhibitory neurotransmitter of the mammalian nervous system. This gene is located on the long arm of chromosome 15 in a cluster with two other genes encoding related subunits of the family. This gene may be associated with the pathogenesis of several disorders including Angelman syndrome, Prader-Willi syndrome, nonsyndromic orofacial clefts, epilepsy and autism. Alternatively spliced transcript variants encoding distinct isoforms have been described. [provided by RefSeq, Jul 2013]\", \"label\": \"gamma-aminobutyric acid type A receptor beta3 subunit\", \"cname\": \"GABRB3\", \"id\": [\"Protein\", \"HGNC\", \"GABRB3\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRG1\", \"description\": \"The protein encoded by this gene belongs to the ligand-gated ionic channel family. It is an integral membrane protein and plays an important role in inhibiting neurotransmission by binding to the benzodiazepine receptor and opening an integral chloride channel. This gene is clustered with three other family members on chromosome 4. [provided by RefSeq, Jul 2008]\", \"label\": \"gamma-aminobutyric acid type A receptor gamma1 subunit\", \"cname\": \"GABRG1\", \"id\": [\"Protein\", \"HGNC\", \"GABRG1\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRG2\", \"description\": null, \"cname\": \"GABRG2\", \"id\": [\"Protein\", \"HGNC\", \"GABRG2\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRG3\", \"description\": \"This gene encodes a gamma-aminobutyric acid (GABA) receptor. GABA is the major inhibitory neurotransmitter in the mammalian brain where it acts at GABA-A receptors, which are ligand-gated chloride channels. Chloride conductance of these channels can be modulated by agents such as benzodiazepines that bind to the GABA-A receptor. GABA-A receptors are pentameric, consisting of proteins from several subunit classes: alpha, beta, gamma, delta and rho. The protein encoded by this gene is a gamma subunit, which contains the benzodiazepine binding site. Two transcript variants encoding distinct isoforms have been found for this gene. [provided by RefSeq, Aug 2012]\", \"label\": \"gamma-aminobutyric acid type A receptor gamma3 subunit\", \"cname\": \"GABRG3\", \"id\": [\"Protein\", \"HGNC\", \"GABRG3\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRD\", \"description\": \"Gamma-aminobutyric acid (GABA) is the major inhibitory neurotransmitter in the mammalian brain where it acts at GABA-A receptors, which are ligand-gated chloride channels. Chloride conductance of these channels can be modulated by agents such as benzodiazepines that bind to the GABA-A receptor. The GABA-A receptor is generally pentameric and there are five types of subunits: alpha, beta, gamma, delta, and rho. This gene encodes the delta subunit. Mutations in this gene have been associated with susceptibility to generalized epilepsy with febrile seizures, type 5. Alternatively spliced transcript variants have been described for this gene, but their biological validity has not been determined. [provided by RefSeq, Jul 2008]\", \"label\": \"gamma-aminobutyric acid type A receptor delta subunit\", \"cname\": \"GABRD\", \"id\": [\"Protein\", \"HGNC\", \"GABRD\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRE\", \"description\": \"The product of this gene belongs to the ligand-gated ionic channel (TC 1.A.9) family. It encodes the gamma-aminobutyric acid (GABA) A receptor which is a multisubunit chloride channel that mediates the fastest inhibitory synaptic transmission in the central nervous system. This gene encodes an epsilon subunit. It is mapped to chromosome Xq28 in a cluster comprised of genes encoding alpha 3, beta 4 and theta subunits of the same receptor. Alternatively spliced transcript variants have been identified, but only one is thought to encode a protein. [provided by RefSeq, Oct 2008]\", \"label\": \"gamma-aminobutyric acid type A receptor epsilon subunit\", \"cname\": \"GABRE\", \"id\": [\"Protein\", \"HGNC\", \"GABRE\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRP\", \"description\": \"The gamma-aminobutyric acid (GABA) A receptor is a multisubunit chloride channel that mediates the fastest inhibitory synaptic transmission in the central nervous system. The subunit encoded by this gene is expressed in several non-neuronal tissues including the uterus and ovaries. This subunit can assemble with known GABA A receptor subunits, and the presence of this subunit alters the sensitivity of recombinant receptors to modulatory agents such as pregnanolone. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, May 2014]\", \"label\": \"gamma-aminobutyric acid type A receptor pi subunit\", \"cname\": \"GABRP\", \"id\": [\"Protein\", \"HGNC\", \"GABRP\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRQ\", \"description\": \"The gamma-aminobutyric acid (GABA) A receptor is a multisubunit chloride channel that mediates the fastest inhibitory synaptic transmission in the central nervous system. This gene encodes the theta subunit of the GABA A receptor. The gene is mapped to chromosome Xq28 in a cluster of genes including those that encode the alpha 3 and epsilon subunits of the GABA A receptor. [provided by RefSeq, Jul 2017]\", \"label\": \"gamma-aminobutyric acid type A receptor theta subunit\", \"cname\": \"GABRQ\", \"id\": [\"Protein\", \"HGNC\", \"GABRQ\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABBR1\", \"description\": \"This gene encodes a receptor for gamma-aminobutyric acid (GABA), which is the main inhibitory neurotransmitter in the mammalian central nervous system. This receptor functions as a heterodimer with GABA(B) receptor 2. Defects in this gene may underlie brain disorders such as schizophrenia and epilepsy. Alternative splicing generates multiple transcript variants, but the full-length nature of some of these variants has not been determined. [provided by RefSeq, Jan 2016]\", \"label\": \"gamma-aminobutyric acid type B receptor subunit 1\", \"cname\": \"GABBR1\", \"id\": [\"Protein\", \"HGNC\", \"GABBR1\"]}, {\"function\": \"BiologicalProcess\", \"namespace\": \"GOBP\", \"name\": \"regulation of N-methyl-D-aspartate selective glutamate receptor activity\", \"cname\": \"regulation of N-methyl-D-aspartate selective glutamate receptor activity\", \"id\": [\"BiologicalProcess\", \"GOBP\", \"regulation of N-methyl-D-aspartate selective glutamate receptor activity\"]}, {\"function\": \"BiologicalProcess\", \"namespace\": \"GOBP\", \"name\": \"regulation of synaptic plasticity\", \"cname\": \"regulation of synaptic plasticity\", \"id\": [\"BiologicalProcess\", \"GOBP\", \"regulation of synaptic plasticity\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GRIN2B\", \"description\": \"N-methyl-D-aspartate (NMDA) receptors are a class of ionotropic glutamate receptors. NMDA receptor channel has been shown to be involved in long-term potentiation, an activity-dependent increase in the efficiency of synaptic transmission thought to underlie certain kinds of memory and learning. NMDA receptor channels are heteromers composed of three different subunits: NR1 (GRIN1), NR2 (GRIN2A, GRIN2B, GRIN2C, or GRIN2D) and NR3 (GRIN3A or GRIN3B). The NR2 subunit acts as the agonist binding site for glutamate. This receptor is the predominant excitatory neurotransmitter receptor in the mammalian brain. [provided by RefSeq, Jul 2008]\", \"label\": \"glutamate ionotropic receptor NMDA type subunit 2B\", \"cname\": \"GRIN2B\", \"id\": [\"Protein\", \"HGNC\", \"GRIN2B\"]}, {\"function\": \"BiologicalProcess\", \"namespace\": \"GOBP\", \"name\": \"cognition\", \"cname\": \"cognition\", \"id\": [\"BiologicalProcess\", \"GOBP\", \"cognition\"]}, {\"function\": \"BiologicalProcess\", \"namespace\": \"GOBP\", \"name\": \"learning\", \"cname\": \"learning\", \"id\": [\"BiologicalProcess\", \"GOBP\", \"learning\"]}, {\"function\": \"BiologicalProcess\", \"namespace\": \"GOBP\", \"name\": \"memory\", \"cname\": \"memory\", \"id\": [\"BiologicalProcess\", \"GOBP\", \"memory\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CHRNA4\", \"description\": \"This gene encodes a nicotinic acetylcholine receptor, which belongs to a superfamily of ligand-gated ion channels that play a role in fast signal transmission at synapses. These pentameric receptors can bind acetylcholine, which causes an extensive change in conformation that leads to the opening of an ion-conducting channel across the plasma membrane. This protein is an integral membrane receptor subunit that can interact with either nAChR beta-2 or nAChR beta-4 to form a functional receptor. Mutations in this gene cause nocturnal frontal lobe epilepsy type 1. Polymorphisms in this gene that provide protection against nicotine addiction have been described. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Feb 2012]\", \"label\": \"cholinergic receptor nicotinic alpha 4 subunit\", \"cname\": \"CHRNA4\", \"id\": [\"Protein\", \"HGNC\", \"CHRNA4\"]}, {\"function\": \"Abundance\", \"namespace\": \"CHEBI\", \"name\": \"gamma-aminobutyric acid\", \"cname\": \"gamma-aminobutyric acid\", \"id\": [\"Abundance\", \"CHEBI\", \"gamma-aminobutyric acid\"]}, {\"function\": \"Abundance\", \"namespace\": \"CHEBI\", \"name\": \"glutamate(1-)\", \"cname\": \"glutamate(1-)\", \"id\": [\"Abundance\", \"CHEBI\", \"glutamate(1-)\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CHRNB2\", \"description\": \"Neuronal acetylcholine receptors are homo- or heteropentameric complexes composed of homologous alpha and beta subunits. They belong to a superfamily of ligand-gated ion channels which allow the flow of sodium and potassium across the plasma membrane in response to ligands such as acetylcholine and nicotine. This gene encodes one of several beta subunits. Mutations in this gene are associated with autosomal dominant nocturnal frontal lobe epilepsy. [provided by RefSeq, Jul 2008]\", \"label\": \"cholinergic receptor nicotinic beta 2 subunit\", \"cname\": \"CHRNB2\", \"id\": [\"Protein\", \"HGNC\", \"CHRNB2\"]}, {\"function\": \"BiologicalProcess\", \"namespace\": \"GOBP\", \"name\": \"regulation of neuronal synaptic plasticity\", \"cname\": \"regulation of neuronal synaptic plasticity\", \"id\": [\"BiologicalProcess\", \"GOBP\", \"regulation of neuronal synaptic plasticity\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CHRNA2\", \"description\": \"Nicotinic acetylcholine receptors (nAChRs) are ligand-gated ion channels formed by a pentameric arrangement of alpha and beta subunits to create distinct muscle and neuronal receptors. Neuronal receptors are found throughout the peripheral and central nervous system where they are involved in fast synaptic transmission. This gene encodes an alpha subunit that is widely expressed in the brain. The proposed structure for nAChR subunits is a conserved N-terminal extracellular domain followed by three conserved transmembrane domains, a variable cytoplasmic loop, a fourth conserved transmembrane domain, and a short C-terminal extracellular region. Mutations in this gene cause autosomal dominant nocturnal frontal lobe epilepsy type 4. Single nucleotide polymorphisms (SNPs) in this gene have been associated with nicotine dependence. [provided by RefSeq, Nov 2009]\", \"label\": \"cholinergic receptor nicotinic alpha 2 subunit\", \"cname\": \"CHRNA2\", \"id\": [\"Protein\", \"HGNC\", \"CHRNA2\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CHRNA3\", \"description\": \"This locus encodes a member of the nicotinic acetylcholine receptor family of proteins. Members of this family of proteins form pentameric complexes comprised of both alpha and beta subunits. This locus encodes an alpha-type subunit, as it contains characteristic adjacent cysteine residues. The encoded protein is a ligand-gated ion channel that likely plays a role in neurotransmission. Polymorphisms in this gene have been associated with an increased risk of smoking initiation and an increased susceptibility to lung cancer. Alternatively spliced transcript variants have been described. [provided by RefSeq, Nov 2009]\", \"label\": \"cholinergic receptor nicotinic alpha 3 subunit\", \"cname\": \"CHRNA3\", \"id\": [\"Protein\", \"HGNC\", \"CHRNA3\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CHRNA5\", \"description\": \"The protein encoded by this gene is a nicotinic acetylcholine receptor subunit and a member of a superfamily of ligand-gated ion channels that mediate fast signal transmission at synapses. These receptors are thought to be heteropentamers composed of separate but similar subunits. Defects in this gene have been linked to susceptibility to lung cancer type 2 (LNCR2).[provided by RefSeq, Jun 2010]\", \"label\": \"cholinergic receptor nicotinic alpha 5 subunit\", \"cname\": \"CHRNA5\", \"id\": [\"Protein\", \"HGNC\", \"CHRNA5\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CHRNA6\", \"description\": \"This gene encodes an alpha subunit of neuronal nicotinic acetylcholine receptors. These receptors consist of five subunits and function as ion channels involved in neurotransmission. The encoded protein is a subunit of neuronal nicotinic acetylcholine receptors that mediate dopaminergic neurotransmission and are activated by acetylcholine and exogenous nicotine. Alternatively spliced transcript variants have been observed for this gene. Single nucleotide polymorphisms in this gene have been associated with both nicotine and alcohol dependence. [provided by RefSeq, Dec 2010]\", \"label\": \"cholinergic receptor nicotinic alpha 6 subunit\", \"cname\": \"CHRNA6\", \"id\": [\"Protein\", \"HGNC\", \"CHRNA6\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CHRNA7\", \"description\": \"The nicotinic acetylcholine receptors (nAChRs) are members of a superfamily of ligand-gated ion channels that mediate fast signal transmission at synapses. The nAChRs are thought to be hetero-pentamers composed of homologous subunits. The proposed structure for each subunit is a conserved N-terminal extracellular domain followed by three conserved transmembrane domains, a variable cytoplasmic loop, a fourth conserved transmembrane domain, and a short C-terminal extracellular region. The protein encoded by this gene forms a homo-oligomeric channel, displays marked permeability to calcium ions and is a major component of brain nicotinic receptors that are blocked by, and highly sensitive to, alpha-bungarotoxin. Once this receptor binds acetylcholine, it undergoes an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. This gene is located in a region identified as a major susceptibility locus for juvenile myoclonic epilepsy and a chromosomal location involved in the genetic transmission of schizophrenia. An evolutionarily recent partial duplication event in this region results in a hybrid containing sequence from this gene and a novel FAM7A gene. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Feb 2012]\", \"label\": \"cholinergic receptor nicotinic alpha 7 subunit\", \"cname\": \"CHRNA7\", \"id\": [\"Protein\", \"HGNC\", \"CHRNA7\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CHRNA9\", \"description\": \"This gene is a member of the ligand-gated ionic channel family and nicotinic acetylcholine receptor gene superfamily. It encodes a plasma membrane protein that forms homo- or hetero-oligomeric divalent cation channels. This protein is involved in cochlea hair cell development and is also expressed in the outer hair cells (OHCs) of the adult cochlea. [provided by RefSeq, Feb 2012]\", \"label\": \"cholinergic receptor nicotinic alpha 9 subunit\", \"cname\": \"CHRNA9\", \"id\": [\"Protein\", \"HGNC\", \"CHRNA9\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CHRNA10\", \"description\": null, \"label\": \"cholinergic receptor nicotinic alpha 10 subunit\", \"cname\": \"CHRNA10\", \"id\": [\"Protein\", \"HGNC\", \"CHRNA10\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CHRNB3\", \"description\": \"The nicotinic acetylcholine receptors (nAChRs) are members of a superfamily of ligand-gated ion channels that mediate fast signal transmission at synapses. The nAChRs are (hetero)pentamers composed of homologous subunits. The subunits that make up the muscle and neuronal forms of nAChRs are encoded by separate genes and have different primary structure. There are several subtypes of neuronal nAChRs that vary based on which homologous subunits are arranged around the central channel. They are classified as alpha-subunits if, like muscle alpha-1 (MIM 100690), they have a pair of adjacent cysteines as part of the presumed acetylcholine binding site. Subunits lacking these cysteine residues are classified as beta-subunits (Groot Kormelink and Luyten, 1997 [PubMed 9009220]). Elliott et al. (1996) [PubMed 8906617] stated that the proposed structure for each subunit is a conserved N-terminal extracellular domain followed by 3 conserved transmembrane domains, a variable cytoplasmic loop, a fourth conserved transmembrane domain, and a short C-terminal extracellular region.[supplied by OMIM, Apr 2010]\", \"label\": \"cholinergic receptor nicotinic beta 3 subunit\", \"cname\": \"CHRNB3\", \"id\": [\"Protein\", \"HGNC\", \"CHRNB3\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CHRNB4\", \"description\": null, \"label\": \"cholinergic receptor nicotinic beta 4 subunit\", \"cname\": \"CHRNB4\", \"id\": [\"Protein\", \"HGNC\", \"CHRNB4\"]}, {\"function\": \"Abundance\", \"namespace\": \"CHEBI\", \"name\": \"galanthamine\", \"cname\": \"galanthamine\", \"id\": [\"Abundance\", \"CHEBI\", \"galanthamine\"]}, {\"function\": \"Abundance\", \"namespace\": \"CHEBI\", \"name\": \"1-(3-chlorophenyl)piperazine\", \"cname\": \"1-(3-chlorophenyl)piperazine\", \"id\": [\"Abundance\", \"CHEBI\", \"1-(3-chlorophenyl)piperazine\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABBR2\", \"description\": \"The multi-pass membrane protein encoded by this gene belongs to the G-protein coupled receptor 3 family and GABA-B receptor subfamily. The GABA-B receptors inhibit neuronal activity through G protein-coupled second-messenger systems, which regulate the release of neurotransmitters, and the activity of ion channels and adenylyl cyclase. This receptor subunit forms an active heterodimeric complex with GABA-B receptor subunit 1, neither of which is effective on its own. Allelic variants of this gene have been associated with nicotine dependence.[provided by RefSeq, Jan 2010]\", \"label\": \"gamma-aminobutyric acid type B receptor subunit 2\", \"cname\": \"GABBR2\", \"id\": [\"Protein\", \"HGNC\", \"GABBR2\"]}, {\"function\": \"BiologicalProcess\", \"namespace\": \"GOBP\", \"name\": \"cAMP catabolic process\", \"cname\": \"cAMP catabolic process\", \"id\": [\"BiologicalProcess\", \"GOBP\", \"cAMP catabolic process\"]}, {\"function\": \"Abundance\", \"namespace\": \"CHEBI\", \"name\": \"nefiracetam\", \"cname\": \"nefiracetam\", \"id\": [\"Abundance\", \"CHEBI\", \"nefiracetam\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"PRKCA\", \"description\": \"Protein kinase C (PKC) is a family of serine- and threonine-specific protein kinases that can be activated by calcium and the second messenger diacylglycerol. PKC family members phosphorylate a wide variety of protein targets and are known to be involved in diverse cellular signaling pathways. PKC family members also serve as major receptors for phorbol esters, a class of tumor promoters. Each member of the PKC family has a specific expression profile and is believed to play a distinct role in cells. The protein encoded by this gene is one of the PKC family members. This kinase has been reported to play roles in many different cellular processes, such as cell adhesion, cell transformation, cell cycle checkpoint, and cell volume control. Knockout studies in mice suggest that this kinase may be a fundamental regulator of cardiac contractility and Ca(2+) handling in myocytes. [provided by RefSeq, Jul 2008]\", \"label\": \"protein kinase C alpha\", \"cname\": \"PRKCA\", \"id\": [\"Protein\", \"HGNC\", \"PRKCA\"]}, {\"function\": \"BiologicalProcess\", \"namespace\": \"GOBP\", \"name\": \"protein kinase A signaling\", \"cname\": \"protein kinase A signaling\", \"id\": [\"BiologicalProcess\", \"GOBP\", \"protein kinase A signaling\"]}, {\"function\": \"Abundance\", \"namespace\": \"CHEBI\", \"name\": \"EC 3.1.1.7 (acetylcholinesterase) inhibitor\", \"cname\": \"EC 3.1.1.7 (acetylcholinesterase) inhibitor\", \"id\": [\"Abundance\", \"CHEBI\", \"EC 3.1.1.7 (acetylcholinesterase) inhibitor\"]}, {\"function\": \"BiologicalProcess\", \"namespace\": \"GOBP\", \"name\": \"long-term synaptic potentiation\", \"cname\": \"long-term synaptic potentiation\", \"id\": [\"BiologicalProcess\", \"GOBP\", \"long-term synaptic potentiation\"]}, {\"function\": \"Complex\", \"namespace\": \"SCOMP\", \"name\": \"CAMK2 Complex\", \"cname\": \"CAMK2 Complex\", \"id\": [\"Complex\", \"SCOMP\", \"CAMK2 Complex\"]}, {\"function\": \"Complex\", \"cname\": \"complex(a(CHEBI:nefiracetam), p(HGNC:PRKCA))\", \"id\": [\"Complex\", [\"Abundance\", \"CHEBI\", \"nefiracetam\"], [\"Protein\", \"HGNC\", \"PRKCA\"]]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GRIA1\", \"variants\": [{\"kind\": \"pmod\", \"identifier\": {\"namespace\": \"bel\", \"name\": \"Ph\"}, \"code\": \"Ser\", \"pos\": 831}], \"description\": \"Glutamate receptors are the predominant excitatory neurotransmitter receptors in the mammalian brain and are activated in a variety of normal neurophysiologic processes. These receptors are heteromeric protein complexes with multiple subunits, each possessing transmembrane regions, and all arranged to form a ligand-gated ion channel. The classification of glutamate receptors is based on their activation by different pharmacologic agonists. This gene belongs to a family of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) receptors. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]\", \"label\": \"glutamate ionotropic receptor AMPA type subunit 1\", \"cname\": \"p(HGNC:GRIA1, pmod(Ph, Ser, 831))\", \"id\": [\"Protein\", \"HGNC\", \"GRIA1\", [\"pmod\", [\"bel\", \"Ph\"], \"Ser\", 831]]}, {\"function\": \"Complex\", \"namespace\": \"GOCC\", \"name\": \"proteasome complex\", \"cname\": \"proteasome complex\", \"id\": [\"Complex\", \"GOCC\", \"proteasome complex\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GPHN\", \"description\": \"This gene encodes a neuronal assembly protein that anchors inhibitory neurotransmitter receptors to the postsynaptic cytoskeleton via high affinity binding to a receptor subunit domain and tubulin dimers. In nonneuronal tissues, the encoded protein is also required for molybdenum cofactor biosynthesis. Mutations in this gene may be associated with the neurological condition hyperplexia and also lead to molybdenum cofactor deficiency. Numerous alternatively spliced transcript variants encoding different isoforms have been described; however, the full-length nature of all transcript variants is not currently known. [provided by RefSeq, Jul 2008]\", \"label\": \"gephyrin\", \"cname\": \"GPHN\", \"id\": [\"Protein\", \"HGNC\", \"GPHN\"]}, {\"function\": \"Pathology\", \"namespace\": \"MESHD\", \"name\": \"Glaucoma\", \"cname\": \"Glaucoma\", \"id\": [\"Pathology\", \"MESHD\", \"Glaucoma\"]}, {\"function\": \"Complex\", \"cname\": \"complex(p(HGNC:EGR1), p(HGNC:PSEN2))\", \"id\": [\"Complex\", [\"Protein\", \"HGNC\", \"EGR1\"], [\"Protein\", \"HGNC\", \"PSEN2\"]]}, {\"function\": \"Abundance\", \"namespace\": \"CHEBI\", \"name\": \"estradiol\", \"cname\": \"estradiol\", \"id\": [\"Abundance\", \"CHEBI\", \"estradiol\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"GABRA4\", \"description\": \"Gamma-aminobutyric acid (GABA) is the major inhibitory neurotransmitter in the mammalian brain where it acts at GABA-A receptors, which are ligand-gated chloride channels. Chloride conductance of these channels can be modulated by agents such as benzodiazepines that bind to the GABA-A receptor. At least 16 distinct subunits of GABA-A receptors have been identified. This gene encodes subunit alpha-4, which is involved in the etiology of autism and eventually increases autism risk through interaction with another subunit, gamma-aminobutyric acid receptor beta-1 (GABRB1). Alternatively spliced transcript variants encoding different isoforms have been found in this gene.[provided by RefSeq, Feb 2011]\", \"label\": \"gamma-aminobutyric acid type A receptor alpha4 subunit\", \"cname\": \"GABRA4\", \"id\": [\"RNA\", \"HGNC\", \"GABRA4\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"GABRA3\", \"description\": \"GABA is the major inhibitory neurotransmitter in the mammalian brain where it acts at GABA-A receptors, which are ligand-gated chloride channels. Chloride conductance of these channels can be modulated by agents such as benzodiazepines that bind to the GABA-A receptor. At least 16 distinct subunits of GABA-A receptors have been identified. [provided by RefSeq, Jul 2008]\", \"label\": \"gamma-aminobutyric acid type A receptor alpha3 subunit\", \"cname\": \"GABRA3\", \"id\": [\"RNA\", \"HGNC\", \"GABRA3\"]}, {\"function\": \"Abundance\", \"namespace\": \"CHEBI\", \"name\": \"Midazolam\", \"cname\": \"Midazolam\", \"id\": [\"Abundance\", \"CHEBI\", \"Midazolam\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GRIA1\", \"description\": \"Glutamate receptors are the predominant excitatory neurotransmitter receptors in the mammalian brain and are activated in a variety of normal neurophysiologic processes. These receptors are heteromeric protein complexes with multiple subunits, each possessing transmembrane regions, and all arranged to form a ligand-gated ion channel. The classification of glutamate receptors is based on their activation by different pharmacologic agonists. This gene belongs to a family of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) receptors. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]\", \"label\": \"glutamate ionotropic receptor AMPA type subunit 1\", \"cname\": \"GRIA1\", \"id\": [\"Protein\", \"HGNC\", \"GRIA1\"]}], \"links\": [{\"relation\": \"negativeCorrelation\", \"evidence\": \"Further, EGR1 levels were negatively correlated with hippocampal amyloid- plaque burden.This study presents global gene expression profiles associated with GA immunization in a glaucoma rat model.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Investigative ophthalmology &amp; visual science\", \"reference\": \"21969301\", \"authors\": [\"Bakalash S\", \"Pham M\", \"Koronyo Y\", \"Salumbides BC\", \"Kramerov A\", \"Seidenberg H\", \"Berel D\", \"Black KL\", \"Koronyo-Hamaoui M\"], \"date\": \"2011-11-21\", \"title\": \"Egr1 expression is induced following glatiramer acetate immunotherapy in rodent models of glaucoma and Alzheimer's disease.\", \"lastauthor\": \"Koronyo-Hamaoui M\", \"volume\": \"52\", \"issue\": \"12\", \"pages\": \"9033-46\", \"firstauthor\": \"Bakalash S\"}, \"line\": 17223, \"annotations\": {\"Disease\": \"Alzheimer's disease\", \"Species\": \"10116\", \"MeSHDisease\": \"Glaucoma\", \"MeSHAnatomy\": \"Hippocampus\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 0, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"In AD-Tg mice, a significant increase in hippocampal EGR1 protein levels was also found in response to GA immunization.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Investigative ophthalmology &amp; visual science\", \"reference\": \"21969301\", \"authors\": [\"Bakalash S\", \"Pham M\", \"Koronyo Y\", \"Salumbides BC\", \"Kramerov A\", \"Seidenberg H\", \"Berel D\", \"Black KL\", \"Koronyo-Hamaoui M\"], \"date\": \"2011-11-21\", \"title\": \"Egr1 expression is induced following glatiramer acetate immunotherapy in rodent models of glaucoma and Alzheimer's disease.\", \"lastauthor\": \"Koronyo-Hamaoui M\", \"volume\": \"52\", \"issue\": \"12\", \"pages\": \"9033-46\", \"firstauthor\": \"Bakalash S\"}, \"line\": 17211, \"annotations\": {\"Disease\": \"Alzheimer's disease\", \"MeSHAnatomy\": \"Hippocampus\", \"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 4, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Egr-1 upregulates the Alzheimer's disease presenilin-2 gene in neuronal cells.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Gene\", \"reference\": \"14585504\", \"authors\": [\"Renbaum P\", \"Beeri R\", \"Gabai E\", \"Amiel M\", \"Gal M\", \"Ehrengruber MU\", \"Levy-Lahad E\"], \"date\": \"2003-10-30\", \"title\": \"Egr-1 upregulates the Alzheimer's disease presenilin-2 gene in neuronal cells.\", \"lastauthor\": \"Levy-Lahad E\", \"volume\": \"318\", \"issue\": \"\", \"pages\": \"113-24\", \"firstauthor\": \"Renbaum P\"}, \"line\": 17249, \"annotations\": {\"Disease\": \"Alzheimer's disease\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 4, \"key\": 1}, {\"relation\": \"association\", \"evidence\": \"Most forms of neuronal plasticity are associated with the induction of the transcription factor zif268 (egr1).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17148, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 35, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17154, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 8, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17155, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 9, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17156, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 10, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17157, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 11, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17158, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 12, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17159, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 13, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17160, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 14, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17161, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 15, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17162, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 16, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17163, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 17, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17164, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 18, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17165, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 19, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17166, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 20, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17167, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 21, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17168, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 22, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17169, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 23, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17170, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 25, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Induction of zif268 in neurons leads to altered expression of proteasome subunit and proteasome-regulatory genes, thereby changing the capacity of the neuron to degrade synaptic proteins, including receptors and receptor subunits.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17177, \"annotations\": {\"MeSHAnatomy\": \"Neurons\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 57, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"In addition, zif268 alters the transcription of genes associated with GABA(A)R expression and trafficking, such as ubiquilin and gephyrin.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17182, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 58, \"key\": 0}, {\"relation\": \"negativeCorrelation\", \"evidence\": \"Further, EGR1 levels were negatively correlated with hippocampal amyloid- plaque burden.This study presents global gene expression profiles associated with GA immunization in a glaucoma rat model.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Investigative ophthalmology &amp; visual science\", \"reference\": \"21969301\", \"authors\": [\"Bakalash S\", \"Pham M\", \"Koronyo Y\", \"Salumbides BC\", \"Kramerov A\", \"Seidenberg H\", \"Berel D\", \"Black KL\", \"Koronyo-Hamaoui M\"], \"date\": \"2011-11-21\", \"title\": \"Egr1 expression is induced following glatiramer acetate immunotherapy in rodent models of glaucoma and Alzheimer's disease.\", \"lastauthor\": \"Koronyo-Hamaoui M\", \"volume\": \"52\", \"issue\": \"12\", \"pages\": \"9033-46\", \"firstauthor\": \"Bakalash S\"}, \"line\": 17223, \"annotations\": {\"Disease\": \"Alzheimer's disease\", \"Species\": \"10116\", \"MeSHDisease\": \"Glaucoma\", \"MeSHAnatomy\": \"Hippocampus\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 0, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Further, EGR1 levels were negatively correlated with hippocampal amyloid- plaque burden.This study presents global gene expression profiles associated with GA immunization in a glaucoma rat model.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Investigative ophthalmology &amp; visual science\", \"reference\": \"21969301\", \"authors\": [\"Bakalash S\", \"Pham M\", \"Koronyo Y\", \"Salumbides BC\", \"Kramerov A\", \"Seidenberg H\", \"Berel D\", \"Black KL\", \"Koronyo-Hamaoui M\"], \"date\": \"2011-11-21\", \"title\": \"Egr1 expression is induced following glatiramer acetate immunotherapy in rodent models of glaucoma and Alzheimer's disease.\", \"lastauthor\": \"Koronyo-Hamaoui M\", \"volume\": \"52\", \"issue\": \"12\", \"pages\": \"9033-46\", \"firstauthor\": \"Bakalash S\"}, \"line\": 17224, \"annotations\": {\"Disease\": \"Alzheimer's disease\", \"Species\": \"10116\", \"MeSHDisease\": \"Glaucoma\", \"MeSHAnatomy\": \"Hippocampus\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 59, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Egr-1 upregulates the Alzheimer's disease presenilin-2 gene in neuronal cells.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Gene\", \"reference\": \"14585504\", \"authors\": [\"Renbaum P\", \"Beeri R\", \"Gabai E\", \"Amiel M\", \"Gal M\", \"Ehrengruber MU\", \"Levy-Lahad E\"], \"date\": \"2003-10-30\", \"title\": \"Egr-1 upregulates the Alzheimer's disease presenilin-2 gene in neuronal cells.\", \"lastauthor\": \"Levy-Lahad E\", \"volume\": \"318\", \"issue\": \"\", \"pages\": \"113-24\", \"firstauthor\": \"Renbaum P\"}, \"line\": 17248, \"annotations\": {\"Disease\": \"Alzheimer's disease\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 6, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"In immunoblotting analysis, nefiracetam treatment increased the PKCalpha activity with a bell-shaped dose-response relationship peaking at 10 nM, thereby increasing phosphorylation of PKC substrate and NMDA receptor. Nefiracetam treatment did not affect the PKA activity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Molecular pharmacology\", \"reference\": \"17095583\", \"authors\": [\"Moriguchi S\", \"Shioda N\", \"Maejima H\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2007-02-01\", \"title\": \"Nefiracetam potentiates N-methyl-D-aspartate (NMDA) receptor function via protein kinase C activation and reduces magnesium block of NMDA receptor.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"71\", \"issue\": \"2\", \"pages\": \"580-7\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14364, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 2, \"target\": 3, \"key\": 0}, {\"relation\": \"hasVariant\", \"annotations\": {}, \"source\": 2, \"target\": 0, \"key\": -4}, {\"relation\": \"decreases\", \"evidence\": \"The nefiracetam-induced increase in the frequency of mEPSCs and mIPSCs over and above the level achieved by ACh alone would contribute to the therapeutic effect of nefiracetam as the cholinergic system is known to be downregulated in the brain of Alzheimer's disease patients.The therapeutic effects of galantamine are ascribed to the modest potentiation of nACh receptor and NMDA receptor activities in addition to the modest inhibition of acetylcholinesterase.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14418, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 4, \"target\": 5, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"In AD-Tg mice, a significant increase in hippocampal EGR1 protein levels was also found in response to GA immunization.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Investigative ophthalmology &amp; visual science\", \"reference\": \"21969301\", \"authors\": [\"Bakalash S\", \"Pham M\", \"Koronyo Y\", \"Salumbides BC\", \"Kramerov A\", \"Seidenberg H\", \"Berel D\", \"Black KL\", \"Koronyo-Hamaoui M\"], \"date\": \"2011-11-21\", \"title\": \"Egr1 expression is induced following glatiramer acetate immunotherapy in rodent models of glaucoma and Alzheimer's disease.\", \"lastauthor\": \"Koronyo-Hamaoui M\", \"volume\": \"52\", \"issue\": \"12\", \"pages\": \"9033-46\", \"firstauthor\": \"Bakalash S\"}, \"line\": 17211, \"annotations\": {\"Disease\": \"Alzheimer's disease\", \"MeSHAnatomy\": \"Hippocampus\", \"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 4, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Egr-1 upregulates the Alzheimer's disease presenilin-2 gene in neuronal cells.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Gene\", \"reference\": \"14585504\", \"authors\": [\"Renbaum P\", \"Beeri R\", \"Gabai E\", \"Amiel M\", \"Gal M\", \"Ehrengruber MU\", \"Levy-Lahad E\"], \"date\": \"2003-10-30\", \"title\": \"Egr-1 upregulates the Alzheimer's disease presenilin-2 gene in neuronal cells.\", \"lastauthor\": \"Levy-Lahad E\", \"volume\": \"318\", \"issue\": \"\", \"pages\": \"113-24\", \"firstauthor\": \"Renbaum P\"}, \"line\": 17249, \"annotations\": {\"Disease\": \"Alzheimer's disease\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 4, \"target\": 1, \"key\": 1}, {\"relation\": \"association\", \"evidence\": \"Egr-1 upregulates the Alzheimer's disease presenilin-2 gene in neuronal cells.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Gene\", \"reference\": \"14585504\", \"authors\": [\"Renbaum P\", \"Beeri R\", \"Gabai E\", \"Amiel M\", \"Gal M\", \"Ehrengruber MU\", \"Levy-Lahad E\"], \"date\": \"2003-10-30\", \"title\": \"Egr-1 upregulates the Alzheimer's disease presenilin-2 gene in neuronal cells.\", \"lastauthor\": \"Levy-Lahad E\", \"volume\": \"318\", \"issue\": \"\", \"pages\": \"113-24\", \"firstauthor\": \"Renbaum P\"}, \"line\": 17250, \"annotations\": {\"Disease\": \"Alzheimer's disease\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 4, \"target\": 6, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Egr-1 upregulates the Alzheimer's disease presenilin-2 gene in neuronal cells.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Gene\", \"reference\": \"14585504\", \"authors\": [\"Renbaum P\", \"Beeri R\", \"Gabai E\", \"Amiel M\", \"Gal M\", \"Ehrengruber MU\", \"Levy-Lahad E\"], \"date\": \"2003-10-30\", \"title\": \"Egr-1 upregulates the Alzheimer's disease presenilin-2 gene in neuronal cells.\", \"lastauthor\": \"Levy-Lahad E\", \"volume\": \"318\", \"issue\": \"\", \"pages\": \"113-24\", \"firstauthor\": \"Renbaum P\"}, \"line\": 17250, \"annotations\": {\"Disease\": \"Alzheimer's disease\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 6, \"target\": 4, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF-  can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators of inflammation\", \"reference\": \"24966471\", \"authors\": [\"Olmos G\", \"Llad J\"], \"date\": \"2014-01-01\", \"title\": \"Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity.\", \"lastauthor\": \"Llad J\", \"volume\": \"2014\", \"issue\": \"\", \"pages\": \"861231\", \"firstauthor\": \"Olmos G\"}, \"line\": 21557, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 8, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF-  can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators of inflammation\", \"reference\": \"24966471\", \"authors\": [\"Olmos G\", \"Llad J\"], \"date\": \"2014-01-01\", \"title\": \"Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity.\", \"lastauthor\": \"Llad J\", \"volume\": \"2014\", \"issue\": \"\", \"pages\": \"861231\", \"firstauthor\": \"Olmos G\"}, \"line\": 21558, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 9, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF-  can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators of inflammation\", \"reference\": \"24966471\", \"authors\": [\"Olmos G\", \"Llad J\"], \"date\": \"2014-01-01\", \"title\": \"Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity.\", \"lastauthor\": \"Llad J\", \"volume\": \"2014\", \"issue\": \"\", \"pages\": \"861231\", \"firstauthor\": \"Olmos G\"}, \"line\": 21559, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 10, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF-  can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators of inflammation\", \"reference\": \"24966471\", \"authors\": [\"Olmos G\", \"Llad J\"], \"date\": \"2014-01-01\", \"title\": \"Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity.\", \"lastauthor\": \"Llad J\", \"volume\": \"2014\", \"issue\": \"\", \"pages\": \"861231\", \"firstauthor\": \"Olmos G\"}, \"line\": 21560, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 11, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF-  can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators of inflammation\", \"reference\": \"24966471\", \"authors\": [\"Olmos G\", \"Llad J\"], \"date\": \"2014-01-01\", \"title\": \"Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity.\", \"lastauthor\": \"Llad J\", \"volume\": \"2014\", \"issue\": \"\", \"pages\": \"861231\", \"firstauthor\": \"Olmos G\"}, \"line\": 21561, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 12, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF-  can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators of inflammation\", \"reference\": \"24966471\", \"authors\": [\"Olmos G\", \"Llad J\"], \"date\": \"2014-01-01\", \"title\": \"Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity.\", \"lastauthor\": \"Llad J\", \"volume\": \"2014\", \"issue\": \"\", \"pages\": \"861231\", \"firstauthor\": \"Olmos G\"}, \"line\": 21562, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 13, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF-  can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators of inflammation\", \"reference\": \"24966471\", \"authors\": [\"Olmos G\", \"Llad J\"], \"date\": \"2014-01-01\", \"title\": \"Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity.\", \"lastauthor\": \"Llad J\", \"volume\": \"2014\", \"issue\": \"\", \"pages\": \"861231\", \"firstauthor\": \"Olmos G\"}, \"line\": 21563, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 14, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF-  can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators of inflammation\", \"reference\": \"24966471\", \"authors\": [\"Olmos G\", \"Llad J\"], \"date\": \"2014-01-01\", \"title\": \"Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity.\", \"lastauthor\": \"Llad J\", \"volume\": \"2014\", \"issue\": \"\", \"pages\": \"861231\", \"firstauthor\": \"Olmos G\"}, \"line\": 21564, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 15, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF-  can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators of inflammation\", \"reference\": \"24966471\", \"authors\": [\"Olmos G\", \"Llad J\"], \"date\": \"2014-01-01\", \"title\": \"Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity.\", \"lastauthor\": \"Llad J\", \"volume\": \"2014\", \"issue\": \"\", \"pages\": \"861231\", \"firstauthor\": \"Olmos G\"}, \"line\": 21565, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 16, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF-  can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators of inflammation\", \"reference\": \"24966471\", \"authors\": [\"Olmos G\", \"Llad J\"], \"date\": \"2014-01-01\", \"title\": \"Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity.\", \"lastauthor\": \"Llad J\", \"volume\": \"2014\", \"issue\": \"\", \"pages\": \"861231\", \"firstauthor\": \"Olmos G\"}, \"line\": 21566, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 17, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF-  can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators of inflammation\", \"reference\": \"24966471\", \"authors\": [\"Olmos G\", \"Llad J\"], \"date\": \"2014-01-01\", \"title\": \"Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity.\", \"lastauthor\": \"Llad J\", \"volume\": \"2014\", \"issue\": \"\", \"pages\": \"861231\", \"firstauthor\": \"Olmos G\"}, \"line\": 21567, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 18, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF-  can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators of inflammation\", \"reference\": \"24966471\", \"authors\": [\"Olmos G\", \"Llad J\"], \"date\": \"2014-01-01\", \"title\": \"Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity.\", \"lastauthor\": \"Llad J\", \"volume\": \"2014\", \"issue\": \"\", \"pages\": \"861231\", \"firstauthor\": \"Olmos G\"}, \"line\": 21568, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 19, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF-  can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators of inflammation\", \"reference\": \"24966471\", \"authors\": [\"Olmos G\", \"Llad J\"], \"date\": \"2014-01-01\", \"title\": \"Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity.\", \"lastauthor\": \"Llad J\", \"volume\": \"2014\", \"issue\": \"\", \"pages\": \"861231\", \"firstauthor\": \"Olmos G\"}, \"line\": 21569, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 20, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF-  can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators of inflammation\", \"reference\": \"24966471\", \"authors\": [\"Olmos G\", \"Llad J\"], \"date\": \"2014-01-01\", \"title\": \"Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity.\", \"lastauthor\": \"Llad J\", \"volume\": \"2014\", \"issue\": \"\", \"pages\": \"861231\", \"firstauthor\": \"Olmos G\"}, \"line\": 21570, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 21, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF-  can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators of inflammation\", \"reference\": \"24966471\", \"authors\": [\"Olmos G\", \"Llad J\"], \"date\": \"2014-01-01\", \"title\": \"Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity.\", \"lastauthor\": \"Llad J\", \"volume\": \"2014\", \"issue\": \"\", \"pages\": \"861231\", \"firstauthor\": \"Olmos G\"}, \"line\": 21571, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 22, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF-  can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators of inflammation\", \"reference\": \"24966471\", \"authors\": [\"Olmos G\", \"Llad J\"], \"date\": \"2014-01-01\", \"title\": \"Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity.\", \"lastauthor\": \"Llad J\", \"volume\": \"2014\", \"issue\": \"\", \"pages\": \"861231\", \"firstauthor\": \"Olmos G\"}, \"line\": 21572, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 23, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF-  can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators of inflammation\", \"reference\": \"24966471\", \"authors\": [\"Olmos G\", \"Llad J\"], \"date\": \"2014-01-01\", \"title\": \"Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity.\", \"lastauthor\": \"Llad J\", \"volume\": \"2014\", \"issue\": \"\", \"pages\": \"861231\", \"firstauthor\": \"Olmos G\"}, \"line\": 21573, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 24, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17128, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 8, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17154, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 8, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"1-(3-chlorophenyl)piperazine affects the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein co-treated with GABBR2 protein co-treated with GABRG2 protein]]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neurotoxicology\", \"reference\": \"21729720\", \"authors\": [\"Hondebrink L\", \"Meulenbelt J\", \"van Kleef RG\", \"van den Berg M\", \"Westerink RH\"], \"date\": \"2011-12-01\", \"title\": \"Modulation of human GABAA receptor function: a novel mode of action of drugs of abuse.\", \"lastauthor\": \"Westerink RH\", \"volume\": \"32\", \"issue\": \"6\", \"pages\": \"823-7\", \"firstauthor\": \"Hondebrink L\"}, \"line\": 46705, \"annotations\": {\"Species\": \"9606\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 8, \"target\": 46, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17129, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 9, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17155, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 9, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17130, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 10, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17156, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 10, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17131, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 11, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17157, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 11, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17132, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 12, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17158, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 12, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17133, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 13, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17159, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 13, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17134, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 14, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17160, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 14, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17135, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 15, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17161, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 15, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17136, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 16, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17162, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 16, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17137, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 17, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17163, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 17, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17138, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 18, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17164, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 18, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17139, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 19, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17165, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 19, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17140, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 20, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17166, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 20, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17141, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 21, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17167, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 21, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17142, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 22, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17168, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 22, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17143, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 23, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17169, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 23, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17144, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 25, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17170, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 25, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17128, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 8, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17129, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 9, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17130, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 10, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17131, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 11, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17132, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 12, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17133, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 13, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17134, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 14, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17135, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 15, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17136, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 16, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17137, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 17, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17138, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 18, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17139, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 19, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17140, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 20, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17141, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 21, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17142, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 22, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17143, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 23, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17144, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 25, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"In conclusion, nefiracetam enhances NMDA-receptor function through stimulation of its glycine binding site and nefiracetam-induced CaMKII activation likely contributes to improvement of cognition, learning, and memory.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of pharmacological sciences\", \"reference\": \"21821968\", \"authors\": [\"Moriguchi S\"], \"date\": \"2011-01-01\", \"title\": \"Pharmacological study on Alzheimer's drugs targeting calcium/calmodulin-dependent protein kinase II.\", \"lastauthor\": \"Moriguchi S\", \"volume\": \"117\", \"issue\": \"1\", \"pages\": \"6-11\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14460, \"annotations\": {\"Species\": \"10116\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 27, \"target\": 28, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"In conclusion, nefiracetam enhances NMDA-receptor function through stimulation of its glycine binding site and nefiracetam-induced CaMKII activation likely contributes to improvement of cognition, learning, and memory.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of pharmacological sciences\", \"reference\": \"21821968\", \"authors\": [\"Moriguchi S\"], \"date\": \"2011-01-01\", \"title\": \"Pharmacological study on Alzheimer's drugs targeting calcium/calmodulin-dependent protein kinase II.\", \"lastauthor\": \"Moriguchi S\", \"volume\": \"117\", \"issue\": \"1\", \"pages\": \"6-11\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14461, \"annotations\": {\"Species\": \"10116\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 27, \"target\": 29, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"In conclusion, nefiracetam enhances NMDA-receptor function through stimulation of its glycine binding site and nefiracetam-induced CaMKII activation likely contributes to improvement of cognition, learning, and memory.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of pharmacological sciences\", \"reference\": \"21821968\", \"authors\": [\"Moriguchi S\"], \"date\": \"2011-01-01\", \"title\": \"Pharmacological study on Alzheimer's drugs targeting calcium/calmodulin-dependent protein kinase II.\", \"lastauthor\": \"Moriguchi S\", \"volume\": \"117\", \"issue\": \"1\", \"pages\": \"6-11\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14462, \"annotations\": {\"Species\": \"10116\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 27, \"target\": 30, \"key\": 0}, {\"relation\": \"hasVariant\", \"annotations\": {}, \"source\": 27, \"target\": 3, \"key\": -4}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14391, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 31, \"target\": 32, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14402, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 31, \"target\": 33, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14397, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 34, \"target\": 33, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14408, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 34, \"target\": 33, \"key\": 1}, {\"relation\": \"association\", \"evidence\": \"Most forms of neuronal plasticity are associated with the induction of the transcription factor zif268 (egr1).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17148, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 35, \"target\": 1, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14389, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 36, \"target\": 32, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14400, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 36, \"target\": 33, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14390, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 37, \"target\": 32, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14401, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 37, \"target\": 33, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14392, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 38, \"target\": 32, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14403, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 38, \"target\": 33, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14393, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 39, \"target\": 32, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14404, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 39, \"target\": 33, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14394, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 40, \"target\": 32, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14405, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 40, \"target\": 33, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14395, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 41, \"target\": 32, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14406, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 41, \"target\": 33, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14396, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 42, \"target\": 32, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14407, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 42, \"target\": 33, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14398, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 43, \"target\": 33, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14409, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 43, \"target\": 33, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14399, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 44, \"target\": 33, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14410, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 44, \"target\": 33, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14378, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 45, \"target\": 36, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14379, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 45, \"target\": 37, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14380, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 45, \"target\": 31, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14381, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 45, \"target\": 38, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14382, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 45, \"target\": 39, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14383, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 45, \"target\": 40, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14384, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 45, \"target\": 41, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14385, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 45, \"target\": 42, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14386, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 45, \"target\": 34, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14387, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 45, \"target\": 43, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14388, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 45, \"target\": 44, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"1-(3-chlorophenyl)piperazine affects the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein co-treated with GABBR2 protein co-treated with GABRG2 protein]]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neurotoxicology\", \"reference\": \"21729720\", \"authors\": [\"Hondebrink L\", \"Meulenbelt J\", \"van Kleef RG\", \"van den Berg M\", \"Westerink RH\"], \"date\": \"2011-12-01\", \"title\": \"Modulation of human GABAA receptor function: a novel mode of action of drugs of abuse.\", \"lastauthor\": \"Westerink RH\", \"volume\": \"32\", \"issue\": \"6\", \"pages\": \"823-7\", \"firstauthor\": \"Hondebrink L\"}, \"line\": 46705, \"annotations\": {\"Species\": \"9606\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 46, \"target\": 8, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"In this work, we describe a novel non-coding (nc) RNA (named 17A) RNA polymerase (pol) III-dependent embedded in the human G-protein-coupled receptor 51 gene (GPR51, GABA B2 receptor). The stable expression of 17A in SHSY5Y neuroblastoma cells induces the synthesis of an alternative splicing isoform that abolish GABA B2 intracellular signaling (i.e., inhibition of cAMP accumulation and activation of K(+) channels). Indeed, 17A is expressed in human brain, and we report that it is upregulated in cerebral tissues derived from Alzheimer disease patients. We demonstrate that 17A expression in neuroblastoma cells enhances the secretion of amyloid  peptide (Abeta) and the Abeta x-42/ x-40 peptide ratio and that its synthesis is induced in response to inflammatory stimuli.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neurobiology of disease\", \"reference\": \"20888417\", \"authors\": [\"Massone S\", \"Vassallo I\", \"Fiorino G\", \"Castelnuovo M\", \"Barbieri F\", \"Borghi R\", \"Tabaton M\", \"Robello M\", \"Gatta E\", \"Russo C\", \"Florio T\", \"Dieci G\", \"Cancedda R\", \"Pagano A\"], \"date\": \"2011-02-01\", \"title\": \"17A, a novel non-coding RNA, regulates GABA B alternative splicing and signaling in response to inflammatory stimuli and in Alzheimer disease.\", \"lastauthor\": \"Pagano A\", \"volume\": \"41\", \"issue\": \"2\", \"pages\": \"308-17\", \"firstauthor\": \"Massone S\"}, \"line\": 33227, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 47, \"target\": 48, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Nefiracetam is undergoing preclinical and clinical tests as a cognition-enhancing drug in Alzheimer's disease (AD).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Psychopharmacology\", \"reference\": \"9201800\", \"authors\": [\"Woodruff-Pak DS\", \"Hinchliffe RM\"], \"date\": \"1997-05-01\", \"title\": \"Mecamylamine- or scopolamine-induced learning impairment: ameliorated by nefiracetam.\", \"lastauthor\": \"Hinchliffe RM\", \"volume\": \"131\", \"issue\": \"2\", \"pages\": \"130-9\", \"firstauthor\": \"Woodruff-Pak DS\"}, \"line\": 14320, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 28, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The nootropic compound nefiracetam was evaluated in 88 older rabbits in a 750-ms delay paradigm of eyeblink classical conditioning (EBCC). Nefiracetam facilitated acquisition of EBCC in older rabbits. EBCC is performed poorly by older humans and is seriously impaired in Alzheimer's disease. These preclinical data in an animal model with clear parallels in humans suggest that nefiracetam may prove effective as a cognition enhancer in clinical trials.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Psychopharmacology\", \"reference\": \"7838908\", \"authors\": [\"Woodruff-Pak DS\", \"Li YT\"], \"date\": \"1994-03-01\", \"title\": \"Nefiracetam (DM-9384): effect on eyeblink classical conditioning in older rabbits.\", \"lastauthor\": \"Li YT\", \"volume\": \"114\", \"issue\": \"2\", \"pages\": \"200-8\", \"firstauthor\": \"Woodruff-Pak DS\"}, \"line\": 14332, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 28, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain research. Molecular brain research\", \"reference\": \"11039729\", \"authors\": [\"Nishizaki T\", \"Nomura T\", \"Matuoka T\", \"Kondoh T\", \"Enikolopov G\", \"Sumikawa K\", \"Watabe S\", \"Shiotani T\", \"Yoshii M\"], \"date\": \"2000-08-14\", \"title\": \"The anti-dementia drug nefiracetam facilitates hippocampal synaptic transmission by functionally targeting presynaptic nicotinic ACh receptors.\", \"lastauthor\": \"Yoshii M\", \"volume\": \"80\", \"issue\": \"1\", \"pages\": \"53-62\", \"firstauthor\": \"Nishizaki T\"}, \"line\": 14492, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 28, \"key\": 2}, {\"relation\": \"increases\", \"evidence\": \"We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Molecular pharmacology\", \"reference\": \"17095583\", \"authors\": [\"Moriguchi S\", \"Shioda N\", \"Maejima H\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2007-02-01\", \"title\": \"Nefiracetam potentiates N-methyl-D-aspartate (NMDA) receptor function via protein kinase C activation and reduces magnesium block of NMDA receptor.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"71\", \"issue\": \"2\", \"pages\": \"580-7\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14346, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 27, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"In conclusion, nefiracetam enhances NMDA-receptor function through stimulation of its glycine binding site and nefiracetam-induced CaMKII activation likely contributes to improvement of cognition, learning, and memory.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of pharmacological sciences\", \"reference\": \"21821968\", \"authors\": [\"Moriguchi S\"], \"date\": \"2011-01-01\", \"title\": \"Pharmacological study on Alzheimer's drugs targeting calcium/calmodulin-dependent protein kinase II.\", \"lastauthor\": \"Moriguchi S\", \"volume\": \"117\", \"issue\": \"1\", \"pages\": \"6-11\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14458, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10116\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 27, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Molecular pharmacology\", \"reference\": \"17095583\", \"authors\": [\"Moriguchi S\", \"Shioda N\", \"Maejima H\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2007-02-01\", \"title\": \"Nefiracetam potentiates N-methyl-D-aspartate (NMDA) receptor function via protein kinase C activation and reduces magnesium block of NMDA receptor.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"71\", \"issue\": \"2\", \"pages\": \"580-7\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14347, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 36, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Molecular pharmacology\", \"reference\": \"17095583\", \"authors\": [\"Moriguchi S\", \"Shioda N\", \"Maejima H\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2007-02-01\", \"title\": \"Nefiracetam potentiates N-methyl-D-aspartate (NMDA) receptor function via protein kinase C activation and reduces magnesium block of NMDA receptor.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"71\", \"issue\": \"2\", \"pages\": \"580-7\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14348, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 37, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Molecular pharmacology\", \"reference\": \"17095583\", \"authors\": [\"Moriguchi S\", \"Shioda N\", \"Maejima H\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2007-02-01\", \"title\": \"Nefiracetam potentiates N-methyl-D-aspartate (NMDA) receptor function via protein kinase C activation and reduces magnesium block of NMDA receptor.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"71\", \"issue\": \"2\", \"pages\": \"580-7\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14349, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 31, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Molecular pharmacology\", \"reference\": \"17095583\", \"authors\": [\"Moriguchi S\", \"Shioda N\", \"Maejima H\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2007-02-01\", \"title\": \"Nefiracetam potentiates N-methyl-D-aspartate (NMDA) receptor function via protein kinase C activation and reduces magnesium block of NMDA receptor.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"71\", \"issue\": \"2\", \"pages\": \"580-7\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14350, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 38, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Molecular pharmacology\", \"reference\": \"17095583\", \"authors\": [\"Moriguchi S\", \"Shioda N\", \"Maejima H\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2007-02-01\", \"title\": \"Nefiracetam potentiates N-methyl-D-aspartate (NMDA) receptor function via protein kinase C activation and reduces magnesium block of NMDA receptor.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"71\", \"issue\": \"2\", \"pages\": \"580-7\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14351, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 39, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Molecular pharmacology\", \"reference\": \"17095583\", \"authors\": [\"Moriguchi S\", \"Shioda N\", \"Maejima H\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2007-02-01\", \"title\": \"Nefiracetam potentiates N-methyl-D-aspartate (NMDA) receptor function via protein kinase C activation and reduces magnesium block of NMDA receptor.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"71\", \"issue\": \"2\", \"pages\": \"580-7\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14352, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 40, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Molecular pharmacology\", \"reference\": \"17095583\", \"authors\": [\"Moriguchi S\", \"Shioda N\", \"Maejima H\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2007-02-01\", \"title\": \"Nefiracetam potentiates N-methyl-D-aspartate (NMDA) receptor function via protein kinase C activation and reduces magnesium block of NMDA receptor.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"71\", \"issue\": \"2\", \"pages\": \"580-7\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14353, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 41, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Molecular pharmacology\", \"reference\": \"17095583\", \"authors\": [\"Moriguchi S\", \"Shioda N\", \"Maejima H\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2007-02-01\", \"title\": \"Nefiracetam potentiates N-methyl-D-aspartate (NMDA) receptor function via protein kinase C activation and reduces magnesium block of NMDA receptor.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"71\", \"issue\": \"2\", \"pages\": \"580-7\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14354, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 42, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Molecular pharmacology\", \"reference\": \"17095583\", \"authors\": [\"Moriguchi S\", \"Shioda N\", \"Maejima H\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2007-02-01\", \"title\": \"Nefiracetam potentiates N-methyl-D-aspartate (NMDA) receptor function via protein kinase C activation and reduces magnesium block of NMDA receptor.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"71\", \"issue\": \"2\", \"pages\": \"580-7\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14355, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 34, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Molecular pharmacology\", \"reference\": \"17095583\", \"authors\": [\"Moriguchi S\", \"Shioda N\", \"Maejima H\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2007-02-01\", \"title\": \"Nefiracetam potentiates N-methyl-D-aspartate (NMDA) receptor function via protein kinase C activation and reduces magnesium block of NMDA receptor.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"71\", \"issue\": \"2\", \"pages\": \"580-7\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14356, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 43, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"In immunoblotting analysis, nefiracetam treatment increased the PKCalpha activity with a bell-shaped dose-response relationship peaking at 10 nM, thereby increasing phosphorylation of PKC substrate and NMDA receptor. Nefiracetam treatment did not affect the PKA activity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Molecular pharmacology\", \"reference\": \"17095583\", \"authors\": [\"Moriguchi S\", \"Shioda N\", \"Maejima H\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2007-02-01\", \"title\": \"Nefiracetam potentiates N-methyl-D-aspartate (NMDA) receptor function via protein kinase C activation and reduces magnesium block of NMDA receptor.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"71\", \"issue\": \"2\", \"pages\": \"580-7\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14363, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 50, \"key\": 0}, {\"relation\": \"causesNoChange\", \"evidence\": \"In immunoblotting analysis, nefiracetam treatment increased the PKCalpha activity with a bell-shaped dose-response relationship peaking at 10 nM, thereby increasing phosphorylation of PKC substrate and NMDA receptor. Nefiracetam treatment did not affect the PKA activity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Molecular pharmacology\", \"reference\": \"17095583\", \"authors\": [\"Moriguchi S\", \"Shioda N\", \"Maejima H\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2007-02-01\", \"title\": \"Nefiracetam potentiates N-methyl-D-aspartate (NMDA) receptor function via protein kinase C activation and reduces magnesium block of NMDA receptor.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"71\", \"issue\": \"2\", \"pages\": \"580-7\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14365, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 51, \"key\": 0}, {\"relation\": \"isA\", \"evidence\": \"The nefiracetam-induced increase in the frequency of mEPSCs and mIPSCs over and above the level achieved by ACh alone would contribute to the therapeutic effect of nefiracetam as the cholinergic system is known to be downregulated in the brain of Alzheimer's disease patients.The therapeutic effects of galantamine are ascribed to the modest potentiation of nACh receptor and NMDA receptor activities in addition to the modest inhibition of acetylcholinesterase.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14419, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 52, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Nefiracetam treatment significantly enhanced long-term potentiation (LTP) with the same bell-shaped dose-response curve. Furthermore, nefiracetam-induced LTP enhancement was closely associated with calcium/calmodulin-dependent protein kinase II (CaMKII) activation with increase in phosphorylation of AMPA-type glutamate receptor subunit 1 (GluA1) (Ser-831) as a postsynaptic CaMKII substrate. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of pharmacological sciences\", \"reference\": \"21821968\", \"authors\": [\"Moriguchi S\"], \"date\": \"2011-01-01\", \"title\": \"Pharmacological study on Alzheimer's drugs targeting calcium/calmodulin-dependent protein kinase II.\", \"lastauthor\": \"Moriguchi S\", \"volume\": \"117\", \"issue\": \"1\", \"pages\": \"6-11\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14450, \"annotations\": {\"Species\": \"10116\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 53, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Nefiracetam treatment significantly enhanced long-term potentiation (LTP) with the same bell-shaped dose-response curve. Furthermore, nefiracetam-induced LTP enhancement was closely associated with calcium/calmodulin-dependent protein kinase II (CaMKII) activation with increase in phosphorylation of AMPA-type glutamate receptor subunit 1 (GluA1) (Ser-831) as a postsynaptic CaMKII substrate. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of pharmacological sciences\", \"reference\": \"21821968\", \"authors\": [\"Moriguchi S\"], \"date\": \"2011-01-01\", \"title\": \"Pharmacological study on Alzheimer's drugs targeting calcium/calmodulin-dependent protein kinase II.\", \"lastauthor\": \"Moriguchi S\", \"volume\": \"117\", \"issue\": \"1\", \"pages\": \"6-11\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14451, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10116\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 54, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"In conclusion, nefiracetam enhances NMDA-receptor function through stimulation of its glycine binding site and nefiracetam-induced CaMKII activation likely contributes to improvement of cognition, learning, and memory.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of pharmacological sciences\", \"reference\": \"21821968\", \"authors\": [\"Moriguchi S\"], \"date\": \"2011-01-01\", \"title\": \"Pharmacological study on Alzheimer's drugs targeting calcium/calmodulin-dependent protein kinase II.\", \"lastauthor\": \"Moriguchi S\", \"volume\": \"117\", \"issue\": \"1\", \"pages\": \"6-11\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14459, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10116\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 54, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain research. Molecular brain research\", \"reference\": \"11039729\", \"authors\": [\"Nishizaki T\", \"Nomura T\", \"Matuoka T\", \"Kondoh T\", \"Enikolopov G\", \"Sumikawa K\", \"Watabe S\", \"Shiotani T\", \"Yoshii M\"], \"date\": \"2000-08-14\", \"title\": \"The anti-dementia drug nefiracetam facilitates hippocampal synaptic transmission by functionally targeting presynaptic nicotinic ACh receptors.\", \"lastauthor\": \"Yoshii M\", \"volume\": \"80\", \"issue\": \"1\", \"pages\": \"53-62\", \"firstauthor\": \"Nishizaki T\"}, \"line\": 14480, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 55, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Nefiracetam treatment significantly enhanced long-term potentiation (LTP) with the same bell-shaped dose-response curve. Furthermore, nefiracetam-induced LTP enhancement was closely associated with calcium/calmodulin-dependent protein kinase II (CaMKII) activation with increase in phosphorylation of AMPA-type glutamate receptor subunit 1 (GluA1) (Ser-831) as a postsynaptic CaMKII substrate. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of pharmacological sciences\", \"reference\": \"21821968\", \"authors\": [\"Moriguchi S\"], \"date\": \"2011-01-01\", \"title\": \"Pharmacological study on Alzheimer's drugs targeting calcium/calmodulin-dependent protein kinase II.\", \"lastauthor\": \"Moriguchi S\", \"volume\": \"117\", \"issue\": \"1\", \"pages\": \"6-11\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14452, \"annotations\": {\"Species\": \"10116\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 54, \"target\": 56, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain research. Molecular brain research\", \"reference\": \"11039729\", \"authors\": [\"Nishizaki T\", \"Nomura T\", \"Matuoka T\", \"Kondoh T\", \"Enikolopov G\", \"Sumikawa K\", \"Watabe S\", \"Shiotani T\", \"Yoshii M\"], \"date\": \"2000-08-14\", \"title\": \"The anti-dementia drug nefiracetam facilitates hippocampal synaptic transmission by functionally targeting presynaptic nicotinic ACh receptors.\", \"lastauthor\": \"Yoshii M\", \"volume\": \"80\", \"issue\": \"1\", \"pages\": \"53-62\", \"firstauthor\": \"Nishizaki T\"}, \"line\": 14481, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 55, \"target\": 36, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain research. Molecular brain research\", \"reference\": \"11039729\", \"authors\": [\"Nishizaki T\", \"Nomura T\", \"Matuoka T\", \"Kondoh T\", \"Enikolopov G\", \"Sumikawa K\", \"Watabe S\", \"Shiotani T\", \"Yoshii M\"], \"date\": \"2000-08-14\", \"title\": \"The anti-dementia drug nefiracetam facilitates hippocampal synaptic transmission by functionally targeting presynaptic nicotinic ACh receptors.\", \"lastauthor\": \"Yoshii M\", \"volume\": \"80\", \"issue\": \"1\", \"pages\": \"53-62\", \"firstauthor\": \"Nishizaki T\"}, \"line\": 14482, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 55, \"target\": 37, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain research. Molecular brain research\", \"reference\": \"11039729\", \"authors\": [\"Nishizaki T\", \"Nomura T\", \"Matuoka T\", \"Kondoh T\", \"Enikolopov G\", \"Sumikawa K\", \"Watabe S\", \"Shiotani T\", \"Yoshii M\"], \"date\": \"2000-08-14\", \"title\": \"The anti-dementia drug nefiracetam facilitates hippocampal synaptic transmission by functionally targeting presynaptic nicotinic ACh receptors.\", \"lastauthor\": \"Yoshii M\", \"volume\": \"80\", \"issue\": \"1\", \"pages\": \"53-62\", \"firstauthor\": \"Nishizaki T\"}, \"line\": 14483, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 55, \"target\": 31, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain research. Molecular brain research\", \"reference\": \"11039729\", \"authors\": [\"Nishizaki T\", \"Nomura T\", \"Matuoka T\", \"Kondoh T\", \"Enikolopov G\", \"Sumikawa K\", \"Watabe S\", \"Shiotani T\", \"Yoshii M\"], \"date\": \"2000-08-14\", \"title\": \"The anti-dementia drug nefiracetam facilitates hippocampal synaptic transmission by functionally targeting presynaptic nicotinic ACh receptors.\", \"lastauthor\": \"Yoshii M\", \"volume\": \"80\", \"issue\": \"1\", \"pages\": \"53-62\", \"firstauthor\": \"Nishizaki T\"}, \"line\": 14484, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 55, \"target\": 38, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain research. Molecular brain research\", \"reference\": \"11039729\", \"authors\": [\"Nishizaki T\", \"Nomura T\", \"Matuoka T\", \"Kondoh T\", \"Enikolopov G\", \"Sumikawa K\", \"Watabe S\", \"Shiotani T\", \"Yoshii M\"], \"date\": \"2000-08-14\", \"title\": \"The anti-dementia drug nefiracetam facilitates hippocampal synaptic transmission by functionally targeting presynaptic nicotinic ACh receptors.\", \"lastauthor\": \"Yoshii M\", \"volume\": \"80\", \"issue\": \"1\", \"pages\": \"53-62\", \"firstauthor\": \"Nishizaki T\"}, \"line\": 14485, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 55, \"target\": 39, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain research. Molecular brain research\", \"reference\": \"11039729\", \"authors\": [\"Nishizaki T\", \"Nomura T\", \"Matuoka T\", \"Kondoh T\", \"Enikolopov G\", \"Sumikawa K\", \"Watabe S\", \"Shiotani T\", \"Yoshii M\"], \"date\": \"2000-08-14\", \"title\": \"The anti-dementia drug nefiracetam facilitates hippocampal synaptic transmission by functionally targeting presynaptic nicotinic ACh receptors.\", \"lastauthor\": \"Yoshii M\", \"volume\": \"80\", \"issue\": \"1\", \"pages\": \"53-62\", \"firstauthor\": \"Nishizaki T\"}, \"line\": 14486, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 55, \"target\": 40, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain research. Molecular brain research\", \"reference\": \"11039729\", \"authors\": [\"Nishizaki T\", \"Nomura T\", \"Matuoka T\", \"Kondoh T\", \"Enikolopov G\", \"Sumikawa K\", \"Watabe S\", \"Shiotani T\", \"Yoshii M\"], \"date\": \"2000-08-14\", \"title\": \"The anti-dementia drug nefiracetam facilitates hippocampal synaptic transmission by functionally targeting presynaptic nicotinic ACh receptors.\", \"lastauthor\": \"Yoshii M\", \"volume\": \"80\", \"issue\": \"1\", \"pages\": \"53-62\", \"firstauthor\": \"Nishizaki T\"}, \"line\": 14487, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 55, \"target\": 41, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain research. Molecular brain research\", \"reference\": \"11039729\", \"authors\": [\"Nishizaki T\", \"Nomura T\", \"Matuoka T\", \"Kondoh T\", \"Enikolopov G\", \"Sumikawa K\", \"Watabe S\", \"Shiotani T\", \"Yoshii M\"], \"date\": \"2000-08-14\", \"title\": \"The anti-dementia drug nefiracetam facilitates hippocampal synaptic transmission by functionally targeting presynaptic nicotinic ACh receptors.\", \"lastauthor\": \"Yoshii M\", \"volume\": \"80\", \"issue\": \"1\", \"pages\": \"53-62\", \"firstauthor\": \"Nishizaki T\"}, \"line\": 14488, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 55, \"target\": 42, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain research. Molecular brain research\", \"reference\": \"11039729\", \"authors\": [\"Nishizaki T\", \"Nomura T\", \"Matuoka T\", \"Kondoh T\", \"Enikolopov G\", \"Sumikawa K\", \"Watabe S\", \"Shiotani T\", \"Yoshii M\"], \"date\": \"2000-08-14\", \"title\": \"The anti-dementia drug nefiracetam facilitates hippocampal synaptic transmission by functionally targeting presynaptic nicotinic ACh receptors.\", \"lastauthor\": \"Yoshii M\", \"volume\": \"80\", \"issue\": \"1\", \"pages\": \"53-62\", \"firstauthor\": \"Nishizaki T\"}, \"line\": 14489, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 55, \"target\": 34, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain research. Molecular brain research\", \"reference\": \"11039729\", \"authors\": [\"Nishizaki T\", \"Nomura T\", \"Matuoka T\", \"Kondoh T\", \"Enikolopov G\", \"Sumikawa K\", \"Watabe S\", \"Shiotani T\", \"Yoshii M\"], \"date\": \"2000-08-14\", \"title\": \"The anti-dementia drug nefiracetam facilitates hippocampal synaptic transmission by functionally targeting presynaptic nicotinic ACh receptors.\", \"lastauthor\": \"Yoshii M\", \"volume\": \"80\", \"issue\": \"1\", \"pages\": \"53-62\", \"firstauthor\": \"Nishizaki T\"}, \"line\": 14490, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 55, \"target\": 43, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain research. Molecular brain research\", \"reference\": \"11039729\", \"authors\": [\"Nishizaki T\", \"Nomura T\", \"Matuoka T\", \"Kondoh T\", \"Enikolopov G\", \"Sumikawa K\", \"Watabe S\", \"Shiotani T\", \"Yoshii M\"], \"date\": \"2000-08-14\", \"title\": \"The anti-dementia drug nefiracetam facilitates hippocampal synaptic transmission by functionally targeting presynaptic nicotinic ACh receptors.\", \"lastauthor\": \"Yoshii M\", \"volume\": \"80\", \"issue\": \"1\", \"pages\": \"53-62\", \"firstauthor\": \"Nishizaki T\"}, \"line\": 14491, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 55, \"target\": 44, \"key\": 0}, {\"relation\": \"hasComponent\", \"annotations\": {}, \"source\": 55, \"target\": 49, \"key\": -3}, {\"relation\": \"hasComponent\", \"annotations\": {}, \"source\": 55, \"target\": 50, \"key\": -3}, {\"relation\": \"association\", \"evidence\": \"Induction of zif268 in neurons leads to altered expression of proteasome subunit and proteasome-regulatory genes, thereby changing the capacity of the neuron to degrade synaptic proteins, including receptors and receptor subunits.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17177, \"annotations\": {\"MeSHAnatomy\": \"Neurons\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 57, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"In addition, zif268 alters the transcription of genes associated with GABA(A)R expression and trafficking, such as ubiquilin and gephyrin.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17182, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 58, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Further, EGR1 levels were negatively correlated with hippocampal amyloid- plaque burden.This study presents global gene expression profiles associated with GA immunization in a glaucoma rat model.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Investigative ophthalmology &amp; visual science\", \"reference\": \"21969301\", \"authors\": [\"Bakalash S\", \"Pham M\", \"Koronyo Y\", \"Salumbides BC\", \"Kramerov A\", \"Seidenberg H\", \"Berel D\", \"Black KL\", \"Koronyo-Hamaoui M\"], \"date\": \"2011-11-21\", \"title\": \"Egr1 expression is induced following glatiramer acetate immunotherapy in rodent models of glaucoma and Alzheimer's disease.\", \"lastauthor\": \"Koronyo-Hamaoui M\", \"volume\": \"52\", \"issue\": \"12\", \"pages\": \"9033-46\", \"firstauthor\": \"Bakalash S\"}, \"line\": 17224, \"annotations\": {\"Disease\": \"Alzheimer's disease\", \"Species\": \"10116\", \"MeSHDisease\": \"Glaucoma\", \"MeSHAnatomy\": \"Hippocampus\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 59, \"target\": 1, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We show that Egr-1 binds to PSEN-P2, and that PSEN-P2 activity is increased threefold by overexpression of Egr-1, and by 12-O-tetradecanoylphorbol-13-acetate (TPA), which induces physiological Egr-1 levels.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Gene\", \"reference\": \"14585504\", \"authors\": [\"Renbaum P\", \"Beeri R\", \"Gabai E\", \"Amiel M\", \"Gal M\", \"Ehrengruber MU\", \"Levy-Lahad E\"], \"date\": \"2003-10-30\", \"title\": \"Egr-1 upregulates the Alzheimer's disease presenilin-2 gene in neuronal cells.\", \"lastauthor\": \"Levy-Lahad E\", \"volume\": \"318\", \"issue\": \"\", \"pages\": \"113-24\", \"firstauthor\": \"Renbaum P\"}, \"line\": 17256, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Disease\": \"Alzheimer's disease\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 60, \"target\": 6, \"key\": 0}, {\"relation\": \"hasComponent\", \"annotations\": {}, \"source\": 60, \"target\": 6, \"key\": -3}, {\"relation\": \"hasComponent\", \"annotations\": {}, \"source\": 60, \"target\": 1, \"key\": -3}, {\"relation\": \"association\", \"evidence\": \"Estradiol affects the expression of GABRA4 mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain research. Molecular brain research\", \"reference\": \"16000229\", \"authors\": [\"Pierson RC\", \"Lyons AM\", \"Greenfield LJ Jr\"], \"date\": \"2005-08-18\", \"title\": \"Gonadal steroids regulate GABAA receptor subunit mRNA expression in NT2-N neurons.\", \"lastauthor\": \"Greenfield LJ Jr\", \"volume\": \"138\", \"issue\": \"2\", \"pages\": \"105-15\", \"firstauthor\": \"Pierson RC\"}, \"line\": 46602, \"annotations\": {\"Species\": \"9606\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 61, \"target\": 62, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Estradiol results in increased expression of GABRA3 mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain research. Molecular brain research\", \"reference\": \"16000229\", \"authors\": [\"Pierson RC\", \"Lyons AM\", \"Greenfield LJ Jr\"], \"date\": \"2005-08-18\", \"title\": \"Gonadal steroids regulate GABAA receptor subunit mRNA expression in NT2-N neurons.\", \"lastauthor\": \"Greenfield LJ Jr\", \"volume\": \"138\", \"issue\": \"2\", \"pages\": \"105-15\", \"firstauthor\": \"Pierson RC\"}, \"line\": 47285, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 61, \"target\": 63, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Estradiol affects the expression of GABRA4 mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain research. Molecular brain research\", \"reference\": \"16000229\", \"authors\": [\"Pierson RC\", \"Lyons AM\", \"Greenfield LJ Jr\"], \"date\": \"2005-08-18\", \"title\": \"Gonadal steroids regulate GABAA receptor subunit mRNA expression in NT2-N neurons.\", \"lastauthor\": \"Greenfield LJ Jr\", \"volume\": \"138\", \"issue\": \"2\", \"pages\": \"105-15\", \"firstauthor\": \"Pierson RC\"}, \"line\": 46602, \"annotations\": {\"Species\": \"9606\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 62, \"target\": 61, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"GABRA6 protein mutant form results in decreased susceptibility to Midazolam\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of clinical anesthesia\", \"reference\": \"12031754\", \"authors\": [\"Hoffman WE\", \"Balyasnikova IV\", \"Mahay H\", \"Danilov SM\", \"Baughman VL\"], \"date\": \"2002-05-01\", \"title\": \"GABA alpha6 receptors mediate midazolam-induced anxiolysis.\", \"lastauthor\": \"Baughman VL\", \"volume\": \"14\", \"issue\": \"3\", \"pages\": \"206-9\", \"firstauthor\": \"Hoffman WE\"}, \"line\": 48542, \"annotations\": {\"Species\": \"9606\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 64, \"target\": 13, \"key\": 0}, {\"relation\": \"hasVariant\", \"annotations\": {}, \"source\": 65, \"target\": 56, \"key\": -4}]};\n",
       "        const color_map = {'Protein': '#1F77B4', 'Pathology': '#FF7F0E', 'BiologicalProcess': '#2CA02C', 'miRNA': '#D62728', 'Complex': '#9467bd', 'Composite': '#9467bd', 'Reaction': '#8c564b', 'Gene': '#e377c2', 'Abundance': '#bcbd22', 'RNA': '#17becf'};\n",
       "    \n",
       "        require.config({\n",
       "          paths: {\n",
       "              d3: '//cdnjs.cloudflare.com/ajax/libs/d3/4.5.0/d3.min'\n",
       "          }\n",
       "        });\n",
       "\n",
       "        var elementInnerHTML = \"<div id='\" + chart + \"'></div>\";\n",
       "\n",
       "        element.append(elementInnerHTML);\n",
       "\n",
       "        var chartQualified = \"#\" + chart;\n",
       "\n",
       "        require(['d3'], function(d3) {\n",
       "            return init_d3_force(d3, graph, chartQualified, width, height, color_map);\n",
       "        });\n",
       "    "
      ],
      "text/plain": [
       "<IPython.core.display.Javascript object>"
      ]
     },
     "execution_count": 15,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "to_jupyter(subgraph)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "The graph also contains some related nodes, like `r(HGNC:GABRA5)` and `p(HGNC:GABRA5)` that are disconnected. Inferring the translation and transcriptional relationships between genes, RNAs, and proteins allows for connecting parts of the graph without much information. This can be accomplished with [pbt.mutation.infer_central_dogma](http://pybel-tools.readthedocs.io/en/latest/mutation.html#pybel_tools.mutation.infer_central_dogma)."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Nodes: 138\n",
      "Edges: 263\n",
      "Citations: 14\n",
      "Authors: 69\n",
      "Network density: 0.013910927747804929\n",
      "Components: 2\n",
      "Average degree: 1.9057971014492754\n"
     ]
    }
   ],
   "source": [
    "pbt.mutation.infer_central_dogma(subgraph)\n",
    "\n",
    "pbt.summary.print_summary(subgraph)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/javascript": [
       "function init_d3_force(d3, graph, chart, width, height, function_colors) {\n",
       "    var focus_node = null;\n",
       "    var highlight_node = null;\n",
       "\n",
       "    // Highlight color variables\n",
       "\n",
       "    // Highlight color of the node boundering\n",
       "    const highlight_node_boundering = \"#4EB2D4\";\n",
       "\n",
       "    // Highlight color of the edge\n",
       "    const highlighted_link_color = \"#4EB2D4\";\n",
       "\n",
       "    // Text highlight color\n",
       "    const highlight_text = \"#4EB2D4\";\n",
       "\n",
       "    // Size when zooming scale\n",
       "    var size = d3.scalePow().exponent(1)\n",
       "        .domain([1, 100])\n",
       "        .range([8, 24]);\n",
       "\n",
       "    // Simulation parameters\n",
       "    const linkDistance = 100;\n",
       "    const fCharge = -1000;\n",
       "    const linkStrength = 0.7;\n",
       "    const collideStrength = 1;\n",
       "\n",
       "    // Simulation defined with variables\n",
       "    var simulation = d3.forceSimulation()\n",
       "        .force(\"link\", d3.forceLink()\n",
       "            .distance(linkDistance)\n",
       "            .strength(linkStrength)\n",
       "        )\n",
       "        .force(\"collide\", d3.forceCollide()\n",
       "            .radius(function (d) {\n",
       "                return d.r + 10\n",
       "            })\n",
       "            .strength(collideStrength)\n",
       "        )\n",
       "        .force(\"charge\", d3.forceManyBody()\n",
       "            .strength(fCharge)\n",
       "        )\n",
       "        .force(\"center\", d3.forceCenter(width / 2, height / 2))\n",
       "        .force(\"y\", d3.forceY(0))\n",
       "        .force(\"x\", d3.forceX(0));\n",
       "\n",
       "    // Pin down functionality\n",
       "    var node_drag = d3.drag()\n",
       "        .on(\"start\", dragstarted)\n",
       "        .on(\"drag\", dragged)\n",
       "        .on(\"end\", dragended);\n",
       "\n",
       "    function dragstarted(d) {\n",
       "        if (!d3.event.active) simulation.alphaTarget(0.3).restart();\n",
       "        d.fx = d.x;\n",
       "        d.fy = d.y;\n",
       "    }\n",
       "\n",
       "    function dragged(d) {\n",
       "        d.fx = d3.event.x;\n",
       "        d.fy = d3.event.y;\n",
       "    }\n",
       "\n",
       "    function dragended(d) {\n",
       "        if (!d3.event.active) simulation.alphaTarget(0);\n",
       "    }\n",
       "\n",
       "    function releasenode(d) {\n",
       "        d.fx = null;\n",
       "        d.fy = null;\n",
       "    }\n",
       "\n",
       "    //END Pin down functionality\n",
       "\n",
       "    const color_circunferencia = \"black\";\n",
       "    const default_link_color = \"#AAAAAA\";\n",
       "    const nominal_base_node_size = 8;\n",
       "\n",
       "    // Normal and highlighted stroke of the links (double the width of the link when highlighted)\n",
       "    const nominal_stroke = 1.5;\n",
       "\n",
       "    // Zoom variables\n",
       "    const min_zoom = 0.1;\n",
       "    const max_zoom = 10;\n",
       "    const border = 1;\n",
       "    const bordercolor = 'black';\n",
       "\n",
       "    var svg = d3.select(chart).append(\"svg\")\n",
       "        .attr(\"width\", width)\n",
       "        .attr(\"height\", height);\n",
       "\n",
       "    // // Create definition for arrowhead.\n",
       "    svg.append(\"defs\").append(\"marker\")\n",
       "        .attr(\"id\", \"arrowhead\")\n",
       "        .attr(\"viewBox\", \"0 -5 10 10\")\n",
       "        .attr(\"refX\", 20)\n",
       "        .attr(\"refY\", 0)\n",
       "        .attr(\"markerUnits\", \"strokeWidth\")\n",
       "        .attr(\"markerWidth\", 6)\n",
       "        .attr(\"markerHeight\", 6)\n",
       "        .attr(\"orient\", \"auto\")\n",
       "        .append(\"path\")\n",
       "        .attr(\"d\", \"M0,-5L10,0L0,5\");\n",
       "\n",
       "    // // Create definition for stub.\n",
       "    svg.append(\"defs\").append(\"marker\")\n",
       "        .attr(\"id\", \"stub\")\n",
       "        .attr(\"viewBox\", \"-1 -5 2 10\")\n",
       "        .attr(\"refX\", 15)\n",
       "        .attr(\"refY\", 0)\n",
       "        .attr(\"markerUnits\", \"strokeWidth\")\n",
       "        .attr(\"markerWidth\", 6)\n",
       "        .attr(\"markerHeight\", 6)\n",
       "        .attr(\"orient\", \"auto\")\n",
       "        .append(\"path\")\n",
       "        .attr(\"d\", \"M 0,0 m -1,-5 L 1,-5 L 1,5 L -1,5 Z\");\n",
       "\n",
       "    // Background\n",
       "    svg.append(\"rect\")\n",
       "        .attr(\"width\", \"100%\")\n",
       "        .attr(\"height\", \"100%\")\n",
       "        .attr(\"fill\", \"#ffffff\")\n",
       "        .style(\"pointer-events\", \"all\")\n",
       "        // Zoom + panning functionality\n",
       "        .call(d3.zoom()\n",
       "            .scaleExtent([min_zoom, max_zoom])\n",
       "            .on(\"zoom\", zoomed))\n",
       "        .on(\"dblclick.zoom\", null);\n",
       "\n",
       "\n",
       "    function zoomed() {\n",
       "        g.attr(\"transform\", d3.event.transform);\n",
       "    }\n",
       "\n",
       "    // g = svg object where the graph will be appended\n",
       "    var g = svg.append(\"g\");\n",
       "\n",
       "    var linkedByIndex = {};\n",
       "    graph.links.forEach(function (d) {\n",
       "        linkedByIndex[d.source + \",\" + d.target] = true;\n",
       "    });\n",
       "\n",
       "    function isConnected(a, b) {\n",
       "        return linkedByIndex[a.index + \",\" + b.index] || linkedByIndex[b.index + \",\" + a.index] || a.index == b.index;\n",
       "    }\n",
       "\n",
       "    function ticked() {\n",
       "        link.attr(\"x1\", function (d) {\n",
       "            return d.source.x;\n",
       "        })\n",
       "            .attr(\"y1\", function (d) {\n",
       "                return d.source.y;\n",
       "            })\n",
       "            .attr(\"x2\", function (d) {\n",
       "                return d.target.x;\n",
       "            })\n",
       "            .attr(\"y2\", function (d) {\n",
       "                return d.target.y;\n",
       "            });\n",
       "\n",
       "        node\n",
       "            .attr(\"transform\", function (d) {\n",
       "                return \"translate(\" + d.x + \", \" + d.y + \")\";\n",
       "            });\n",
       "    }\n",
       "\n",
       "\n",
       "    simulation\n",
       "        .nodes(graph.nodes)\n",
       "        .on(\"tick\", ticked);\n",
       "\n",
       "    simulation.force(\"link\")\n",
       "        .links(graph.links);\n",
       "\n",
       "    // Definition of links nodes text...\n",
       "\n",
       "    var link = g.selectAll(\".link\")\n",
       "        .data(graph.links)\n",
       "        .enter().append(\"line\")\n",
       "        .style(\"stroke-width\", nominal_stroke)\n",
       "        .style(\"stroke\", default_link_color)\n",
       "        .style(\"stroke-dasharray\", function (d) {\n",
       "            if (['decreases', 'directlyDecreases', 'increases', 'directlyIncreases', 'negativeCorrelation',\n",
       "                    'positiveCorrelation'].indexOf(d.relation) >= 0) {\n",
       "                return \"none\"\n",
       "            } else {\n",
       "                return \"4, 4\"\n",
       "            }\n",
       "        })\n",
       "        .attr(\"marker-start\", function (d) {\n",
       "            if ('positiveCorrelation' == d.relation) {\n",
       "                return \"url(#arrowhead)\"\n",
       "            }\n",
       "            else if ('negativeCorrelation' == d.relation) {\n",
       "                return \"url(#stub)\"\n",
       "            }\n",
       "            else {\n",
       "                return \"\"\n",
       "            }\n",
       "        })\n",
       "        .attr(\"marker-end\", function (d) {\n",
       "            if (['increases', 'directlyIncreases', 'positiveCorrelation'].indexOf(d.relation) >= 0) {\n",
       "                return \"url(#arrowhead)\"\n",
       "            } else if (['decreases', 'directlyDecreases', 'negativeCorrelation'].indexOf(d.relation) >= 0) {\n",
       "                return \"url(#stub)\"\n",
       "            } else {\n",
       "                return \"\"\n",
       "            }\n",
       "        });\n",
       "\n",
       "    var node = g.selectAll(\".nodes\")\n",
       "        .data(graph.nodes)\n",
       "        .enter().append(\"g\")\n",
       "        .attr(\"class\", \"node\")\n",
       "        // Next two lines -> Pin down functionality\n",
       "        .on('dblclick', releasenode)\n",
       "        .call(node_drag);\n",
       "\n",
       "    var circle = node.append(\"path\")\n",
       "        .attr(\"d\", d3.symbol()\n",
       "            .size(function (d) {\n",
       "                return Math.PI * Math.pow(size(d.size) || nominal_base_node_size, 2);\n",
       "            })\n",
       "        )\n",
       "        .attr(\"class\", function (d) {\n",
       "            return d.function\n",
       "        })\n",
       "        .style('fill', function (d) {\n",
       "            return function_colors[d.function]\n",
       "        })\n",
       "        .style(\"stroke-width\", nominal_stroke)\n",
       "        .style(\"stroke\", color_circunferencia);\n",
       "\n",
       "    var text = node.append(\"text\")\n",
       "        .attr(\"class\", \"node-name\")\n",
       "        // .attr(\"id\", nodehashes[d])\n",
       "        .attr(\"fill\", \"black\")\n",
       "        .attr(\"dx\", 12)\n",
       "        .attr(\"dy\", \".35em\")\n",
       "        .text(function (d) {\n",
       "            return d.cname\n",
       "        });\n",
       "\n",
       "    // Highlight on mouseenter and back to normal on mouseout\n",
       "    node.on(\"mouseenter\", function (d) {\n",
       "        set_highlight(d);\n",
       "    })\n",
       "        .on(\"mousedown\", function () {\n",
       "            d3.event.stopPropagation();\n",
       "        }).on(\"mouseout\", function () {\n",
       "        exit_highlight();\n",
       "    });\n",
       "\n",
       "    function exit_highlight() {\n",
       "        highlight_node = null;\n",
       "        if (focus_node === null) {\n",
       "            if (highlight_node_boundering != color_circunferencia) {\n",
       "                circle.style(\"stroke\", color_circunferencia);\n",
       "                text.style(\"fill\", \"black\");\n",
       "                link.style(\"stroke\", default_link_color);\n",
       "            }\n",
       "        }\n",
       "    }\n",
       "\n",
       "    function set_highlight(d) {\n",
       "        if (focus_node !== null) d = focus_node;\n",
       "        highlight_node = d;\n",
       "\n",
       "        if (highlight_node_boundering != color_circunferencia) {\n",
       "            circle.style(\"stroke\", function (o) {\n",
       "                return isConnected(d, o) ? highlight_node_boundering : color_circunferencia;\n",
       "            });\n",
       "            text.style(\"fill\", function (o) {\n",
       "                return isConnected(d, o) ? highlight_text : \"black\";\n",
       "            });\n",
       "            link.style(\"stroke\", function (o) {\n",
       "                return o.source.index == d.index || o.target.index == d.index ? highlighted_link_color : default_link_color;\n",
       "            });\n",
       "        }\n",
       "    }\n",
       "\n",
       "\n",
       "    // Freeze the graph when space is pressed\n",
       "    function freezeGraph() {\n",
       "        // Space button Triggers STOP\n",
       "        if (d3.event.keyCode == 32) {\n",
       "            simulation.stop();\n",
       "        }\n",
       "    }\n",
       "\n",
       "    // Call freezeGraph when a key is pressed, freezeGraph checks whether this key is \"Space\" that triggers the freeze\n",
       "    d3.select(window).on(\"keydown\", freezeGraph);\n",
       "}\n",
       "        var chart = \"yzrcjgxdemfpqsob\";\n",
       "        var width = 1000;\n",
       "        var height = 650;\n",
       "        var graph = {\"directed\": true, \"multigraph\": true, \"graph\": {\"document_metadata\": {}, \"pybel_version\": \"0.7.2\", \"namespace_url\": {}, \"namespace_owl\": {}, \"namespace_pattern\": {}, \"annotation_url\": {}, \"annotation_owl\": {}, \"annotation_pattern\": {}, \"annotation_list\": {}}, \"nodes\": [{\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"APP\", \"variants\": [{\"kind\": \"frag\", \"start\": 672, \"stop\": 713}], \"description\": \"This gene encodes a cell surface receptor and transmembrane precursor protein that is cleaved by secretases to form a number of peptides. Some of these peptides are secreted and can bind to the acetyltransferase complex APBB1/TIP60 to promote transcriptional activation, while others form the protein basis of the amyloid plaques found in the brains of patients with Alzheimer disease. In addition, two of the peptides are antimicrobial peptides, having been shown to have bacteriocidal and antifungal activities. Mutations in this gene have been implicated in autosomal dominant Alzheimer disease and cerebroarterial amyloidosis (cerebral amyloid angiopathy). Multiple transcript variants encoding several different isoforms have been found for this gene. [provided by RefSeq, Aug 2014]\", \"label\": \"amyloid beta precursor protein\", \"cname\": \"p(HGNC:APP, frag(672_713))\", \"id\": [\"Protein\", \"HGNC\", \"APP\", [\"frag\", [672, 713]]]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"EGR1\", \"description\": \"The protein encoded by this gene belongs to the EGR family of C2H2-type zinc-finger proteins. It is a nuclear protein and functions as a transcriptional regulator. The products of target genes it activates are required for differentitation and mitogenesis. Studies suggest this is a cancer suppressor gene. [provided by RefSeq, Dec 2014]\", \"label\": \"early growth response 1\", \"cname\": \"EGR1\", \"id\": [\"Protein\", \"HGNC\", \"EGR1\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"APP\", \"description\": \"This gene encodes a cell surface receptor and transmembrane precursor protein that is cleaved by secretases to form a number of peptides. Some of these peptides are secreted and can bind to the acetyltransferase complex APBB1/TIP60 to promote transcriptional activation, while others form the protein basis of the amyloid plaques found in the brains of patients with Alzheimer disease. In addition, two of the peptides are antimicrobial peptides, having been shown to have bacteriocidal and antifungal activities. Mutations in this gene have been implicated in autosomal dominant Alzheimer disease and cerebroarterial amyloidosis (cerebral amyloid angiopathy). Multiple transcript variants encoding several different isoforms have been found for this gene. [provided by RefSeq, Aug 2014]\", \"label\": \"amyloid beta precursor protein\", \"cname\": \"APP\", \"id\": [\"Protein\", \"HGNC\", \"APP\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GRIN2B\", \"variants\": [{\"kind\": \"pmod\", \"identifier\": {\"namespace\": \"bel\", \"name\": \"Ph\"}}], \"description\": \"N-methyl-D-aspartate (NMDA) receptors are a class of ionotropic glutamate receptors. NMDA receptor channel has been shown to be involved in long-term potentiation, an activity-dependent increase in the efficiency of synaptic transmission thought to underlie certain kinds of memory and learning. NMDA receptor channels are heteromers composed of three different subunits: NR1 (GRIN1), NR2 (GRIN2A, GRIN2B, GRIN2C, or GRIN2D) and NR3 (GRIN3A or GRIN3B). The NR2 subunit acts as the agonist binding site for glutamate. This receptor is the predominant excitatory neurotransmitter receptor in the mammalian brain. [provided by RefSeq, Jul 2008]\", \"label\": \"glutamate ionotropic receptor NMDA type subunit 2B\", \"cname\": \"p(HGNC:GRIN2B, pmod(Ph))\", \"id\": [\"Protein\", \"HGNC\", \"GRIN2B\", [\"pmod\", [\"bel\", \"Ph\"]]]}, {\"function\": \"Pathology\", \"namespace\": \"MESHD\", \"name\": \"Alzheimer Disease\", \"cname\": \"Alzheimer Disease\", \"id\": [\"Pathology\", \"MESHD\", \"Alzheimer Disease\"]}, {\"function\": \"BiologicalProcess\", \"namespace\": \"GOBP\", \"name\": \"synaptic transmission, cholinergic\", \"cname\": \"synaptic transmission, cholinergic\", \"id\": [\"BiologicalProcess\", \"GOBP\", \"synaptic transmission, cholinergic\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"PSEN2\", \"description\": \"Alzheimer's disease (AD) patients with an inherited form of the disease carry mutations in the presenilin proteins (PSEN1 or PSEN2) or the amyloid precursor protein (APP). These disease-linked mutations result in increased production of the longer form of amyloid-beta (main component of amyloid deposits found in AD brains). Presenilins are postulated to regulate APP processing through their effects on gamma-secretase, an enzyme that cleaves APP. Also, it is thought that the presenilins are involved in the cleavage of the Notch receptor such that, they either directly regulate gamma-secretase activity, or themselves act are protease enzymes. Two alternatively spliced transcript variants encoding different isoforms of PSEN2 have been identified. [provided by RefSeq, Jul 2008]\", \"label\": \"presenilin 2\", \"cname\": \"PSEN2\", \"id\": [\"Protein\", \"HGNC\", \"PSEN2\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"TNF\", \"description\": \"This gene encodes a multifunctional proinflammatory cytokine that belongs to the tumor necrosis factor (TNF) superfamily. This cytokine is mainly secreted by macrophages. It can bind to, and thus functions through its receptors TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR. This cytokine is involved in the regulation of a wide spectrum of biological processes including cell proliferation, differentiation, apoptosis, lipid metabolism, and coagulation. This cytokine has been implicated in a variety of diseases, including autoimmune diseases, insulin resistance, and cancer. Knockout studies in mice also suggested the neuroprotective function of this cytokine. [provided by RefSeq, Jul 2008]\", \"label\": \"tumor necrosis factor\", \"cname\": \"TNF\", \"id\": [\"Protein\", \"HGNC\", \"TNF\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRA1\", \"description\": \"This gene encodes a gamma-aminobutyric acid (GABA) receptor. GABA is the major inhibitory neurotransmitter in the mammalian brain where it acts at GABA-A receptors, which are ligand-gated chloride channels. Chloride conductance of these channels can be modulated by agents such as benzodiazepines that bind to the GABA-A receptor. GABA-A receptors are pentameric, consisting of proteins from several subunit classes: alpha, beta, gamma, delta and rho. Mutations in this gene cause juvenile myoclonic epilepsy and childhood absence epilepsy type 4. Multiple transcript variants encoding the same protein have been identified for this gene. [provided by RefSeq, Jul 2008]\", \"label\": \"gamma-aminobutyric acid type A receptor alpha1 subunit\", \"cname\": \"GABRA1\", \"id\": [\"Protein\", \"HGNC\", \"GABRA1\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRA2\", \"description\": \"GABA is the major inhibitory neurotransmitter in the mammalian brain where it acts at GABA-A receptors, which are ligand-gated chloride channels. Chloride conductance of these channels can be modulated by agents such as benzodiazepines that bind to the GABA-A receptor. At least 16 distinct subunits of GABA-A receptors have been identified. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Nov 2013]\", \"label\": \"gamma-aminobutyric acid type A receptor alpha2 subunit\", \"cname\": \"GABRA2\", \"id\": [\"Protein\", \"HGNC\", \"GABRA2\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRA3\", \"description\": \"GABA is the major inhibitory neurotransmitter in the mammalian brain where it acts at GABA-A receptors, which are ligand-gated chloride channels. Chloride conductance of these channels can be modulated by agents such as benzodiazepines that bind to the GABA-A receptor. At least 16 distinct subunits of GABA-A receptors have been identified. [provided by RefSeq, Jul 2008]\", \"label\": \"gamma-aminobutyric acid type A receptor alpha3 subunit\", \"cname\": \"GABRA3\", \"id\": [\"Protein\", \"HGNC\", \"GABRA3\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRA4\", \"description\": \"Gamma-aminobutyric acid (GABA) is the major inhibitory neurotransmitter in the mammalian brain where it acts at GABA-A receptors, which are ligand-gated chloride channels. Chloride conductance of these channels can be modulated by agents such as benzodiazepines that bind to the GABA-A receptor. At least 16 distinct subunits of GABA-A receptors have been identified. This gene encodes subunit alpha-4, which is involved in the etiology of autism and eventually increases autism risk through interaction with another subunit, gamma-aminobutyric acid receptor beta-1 (GABRB1). Alternatively spliced transcript variants encoding different isoforms have been found in this gene.[provided by RefSeq, Feb 2011]\", \"label\": \"gamma-aminobutyric acid type A receptor alpha4 subunit\", \"cname\": \"GABRA4\", \"id\": [\"Protein\", \"HGNC\", \"GABRA4\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRA5\", \"description\": \"GABA is the major inhibitory neurotransmitter in the mammalian brain where it acts at GABA-A receptors, which are ligand-gated chloride channels. Chloride conductance of these channels can be modulated by agents such as benzodiazepines that bind to the GABA-A receptor. At least 16 distinct subunits of GABA-A receptors have been identified. Transcript variants utilizing three different alternative non-coding first exons have been described. [provided by RefSeq, Jul 2008]\", \"label\": \"gamma-aminobutyric acid type A receptor alpha5 subunit\", \"cname\": \"GABRA5\", \"id\": [\"Protein\", \"HGNC\", \"GABRA5\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRA6\", \"description\": \"GABA is the major inhibitory neurotransmitter in the mammalian brain where it acts at GABA-A receptors, which are ligand-gated chloride channels. Chloride conductance of these channels can be modulated by agents such as benzodiazepines that bind to the GABA-A receptor. At least 16 distinct subunits of GABA-A receptors have been identified. [provided by RefSeq, Jul 2008]\", \"label\": \"gamma-aminobutyric acid type A receptor alpha6 subunit\", \"cname\": \"GABRA6\", \"id\": [\"Protein\", \"HGNC\", \"GABRA6\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRB1\", \"description\": \"The gamma-aminobutyric acid (GABA) A receptor is a multisubunit chloride channel that mediates the fastest inhibitory synaptic transmission in the central nervous system. This gene encodes GABA A receptor, beta 1 subunit. It is mapped to chromosome 4p12 in a cluster comprised of genes encoding alpha 4, alpha 2 and gamma 1 subunits of the GABA A receptor. Alteration of this gene is implicated in the pathogenetics of schizophrenia. [provided by RefSeq, Jul 2008]\", \"label\": \"gamma-aminobutyric acid type A receptor beta1 subunit\", \"cname\": \"GABRB1\", \"id\": [\"Protein\", \"HGNC\", \"GABRB1\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRB2\", \"description\": null, \"cname\": \"GABRB2\", \"id\": [\"Protein\", \"HGNC\", \"GABRB2\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRB3\", \"description\": \"This gene encodes a member of the ligand-gated ionic channel family. The encoded protein is one the subunits of a multi-subunit chloride channel that serves as the receptor for gamma-aminobutyric acid, a major inhibitory neurotransmitter of the mammalian nervous system. This gene is located on the long arm of chromosome 15 in a cluster with two other genes encoding related subunits of the family. This gene may be associated with the pathogenesis of several disorders including Angelman syndrome, Prader-Willi syndrome, nonsyndromic orofacial clefts, epilepsy and autism. Alternatively spliced transcript variants encoding distinct isoforms have been described. [provided by RefSeq, Jul 2013]\", \"label\": \"gamma-aminobutyric acid type A receptor beta3 subunit\", \"cname\": \"GABRB3\", \"id\": [\"Protein\", \"HGNC\", \"GABRB3\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRG1\", \"description\": \"The protein encoded by this gene belongs to the ligand-gated ionic channel family. It is an integral membrane protein and plays an important role in inhibiting neurotransmission by binding to the benzodiazepine receptor and opening an integral chloride channel. This gene is clustered with three other family members on chromosome 4. [provided by RefSeq, Jul 2008]\", \"label\": \"gamma-aminobutyric acid type A receptor gamma1 subunit\", \"cname\": \"GABRG1\", \"id\": [\"Protein\", \"HGNC\", \"GABRG1\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRG2\", \"description\": null, \"cname\": \"GABRG2\", \"id\": [\"Protein\", \"HGNC\", \"GABRG2\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRG3\", \"description\": \"This gene encodes a gamma-aminobutyric acid (GABA) receptor. GABA is the major inhibitory neurotransmitter in the mammalian brain where it acts at GABA-A receptors, which are ligand-gated chloride channels. Chloride conductance of these channels can be modulated by agents such as benzodiazepines that bind to the GABA-A receptor. GABA-A receptors are pentameric, consisting of proteins from several subunit classes: alpha, beta, gamma, delta and rho. The protein encoded by this gene is a gamma subunit, which contains the benzodiazepine binding site. Two transcript variants encoding distinct isoforms have been found for this gene. [provided by RefSeq, Aug 2012]\", \"label\": \"gamma-aminobutyric acid type A receptor gamma3 subunit\", \"cname\": \"GABRG3\", \"id\": [\"Protein\", \"HGNC\", \"GABRG3\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRD\", \"description\": \"Gamma-aminobutyric acid (GABA) is the major inhibitory neurotransmitter in the mammalian brain where it acts at GABA-A receptors, which are ligand-gated chloride channels. Chloride conductance of these channels can be modulated by agents such as benzodiazepines that bind to the GABA-A receptor. The GABA-A receptor is generally pentameric and there are five types of subunits: alpha, beta, gamma, delta, and rho. This gene encodes the delta subunit. Mutations in this gene have been associated with susceptibility to generalized epilepsy with febrile seizures, type 5. Alternatively spliced transcript variants have been described for this gene, but their biological validity has not been determined. [provided by RefSeq, Jul 2008]\", \"label\": \"gamma-aminobutyric acid type A receptor delta subunit\", \"cname\": \"GABRD\", \"id\": [\"Protein\", \"HGNC\", \"GABRD\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRE\", \"description\": \"The product of this gene belongs to the ligand-gated ionic channel (TC 1.A.9) family. It encodes the gamma-aminobutyric acid (GABA) A receptor which is a multisubunit chloride channel that mediates the fastest inhibitory synaptic transmission in the central nervous system. This gene encodes an epsilon subunit. It is mapped to chromosome Xq28 in a cluster comprised of genes encoding alpha 3, beta 4 and theta subunits of the same receptor. Alternatively spliced transcript variants have been identified, but only one is thought to encode a protein. [provided by RefSeq, Oct 2008]\", \"label\": \"gamma-aminobutyric acid type A receptor epsilon subunit\", \"cname\": \"GABRE\", \"id\": [\"Protein\", \"HGNC\", \"GABRE\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRP\", \"description\": \"The gamma-aminobutyric acid (GABA) A receptor is a multisubunit chloride channel that mediates the fastest inhibitory synaptic transmission in the central nervous system. The subunit encoded by this gene is expressed in several non-neuronal tissues including the uterus and ovaries. This subunit can assemble with known GABA A receptor subunits, and the presence of this subunit alters the sensitivity of recombinant receptors to modulatory agents such as pregnanolone. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, May 2014]\", \"label\": \"gamma-aminobutyric acid type A receptor pi subunit\", \"cname\": \"GABRP\", \"id\": [\"Protein\", \"HGNC\", \"GABRP\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRQ\", \"description\": \"The gamma-aminobutyric acid (GABA) A receptor is a multisubunit chloride channel that mediates the fastest inhibitory synaptic transmission in the central nervous system. This gene encodes the theta subunit of the GABA A receptor. The gene is mapped to chromosome Xq28 in a cluster of genes including those that encode the alpha 3 and epsilon subunits of the GABA A receptor. [provided by RefSeq, Jul 2017]\", \"label\": \"gamma-aminobutyric acid type A receptor theta subunit\", \"cname\": \"GABRQ\", \"id\": [\"Protein\", \"HGNC\", \"GABRQ\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABBR1\", \"description\": \"This gene encodes a receptor for gamma-aminobutyric acid (GABA), which is the main inhibitory neurotransmitter in the mammalian central nervous system. This receptor functions as a heterodimer with GABA(B) receptor 2. Defects in this gene may underlie brain disorders such as schizophrenia and epilepsy. Alternative splicing generates multiple transcript variants, but the full-length nature of some of these variants has not been determined. [provided by RefSeq, Jan 2016]\", \"label\": \"gamma-aminobutyric acid type B receptor subunit 1\", \"cname\": \"GABBR1\", \"id\": [\"Protein\", \"HGNC\", \"GABBR1\"]}, {\"function\": \"BiologicalProcess\", \"namespace\": \"GOBP\", \"name\": \"regulation of N-methyl-D-aspartate selective glutamate receptor activity\", \"cname\": \"regulation of N-methyl-D-aspartate selective glutamate receptor activity\", \"id\": [\"BiologicalProcess\", \"GOBP\", \"regulation of N-methyl-D-aspartate selective glutamate receptor activity\"]}, {\"function\": \"BiologicalProcess\", \"namespace\": \"GOBP\", \"name\": \"regulation of synaptic plasticity\", \"cname\": \"regulation of synaptic plasticity\", \"id\": [\"BiologicalProcess\", \"GOBP\", \"regulation of synaptic plasticity\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GRIN2B\", \"description\": \"N-methyl-D-aspartate (NMDA) receptors are a class of ionotropic glutamate receptors. NMDA receptor channel has been shown to be involved in long-term potentiation, an activity-dependent increase in the efficiency of synaptic transmission thought to underlie certain kinds of memory and learning. NMDA receptor channels are heteromers composed of three different subunits: NR1 (GRIN1), NR2 (GRIN2A, GRIN2B, GRIN2C, or GRIN2D) and NR3 (GRIN3A or GRIN3B). The NR2 subunit acts as the agonist binding site for glutamate. This receptor is the predominant excitatory neurotransmitter receptor in the mammalian brain. [provided by RefSeq, Jul 2008]\", \"label\": \"glutamate ionotropic receptor NMDA type subunit 2B\", \"cname\": \"GRIN2B\", \"id\": [\"Protein\", \"HGNC\", \"GRIN2B\"]}, {\"function\": \"BiologicalProcess\", \"namespace\": \"GOBP\", \"name\": \"cognition\", \"cname\": \"cognition\", \"id\": [\"BiologicalProcess\", \"GOBP\", \"cognition\"]}, {\"function\": \"BiologicalProcess\", \"namespace\": \"GOBP\", \"name\": \"learning\", \"cname\": \"learning\", \"id\": [\"BiologicalProcess\", \"GOBP\", \"learning\"]}, {\"function\": \"BiologicalProcess\", \"namespace\": \"GOBP\", \"name\": \"memory\", \"cname\": \"memory\", \"id\": [\"BiologicalProcess\", \"GOBP\", \"memory\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CHRNA4\", \"description\": \"This gene encodes a nicotinic acetylcholine receptor, which belongs to a superfamily of ligand-gated ion channels that play a role in fast signal transmission at synapses. These pentameric receptors can bind acetylcholine, which causes an extensive change in conformation that leads to the opening of an ion-conducting channel across the plasma membrane. This protein is an integral membrane receptor subunit that can interact with either nAChR beta-2 or nAChR beta-4 to form a functional receptor. Mutations in this gene cause nocturnal frontal lobe epilepsy type 1. Polymorphisms in this gene that provide protection against nicotine addiction have been described. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Feb 2012]\", \"label\": \"cholinergic receptor nicotinic alpha 4 subunit\", \"cname\": \"CHRNA4\", \"id\": [\"Protein\", \"HGNC\", \"CHRNA4\"]}, {\"function\": \"Abundance\", \"namespace\": \"CHEBI\", \"name\": \"gamma-aminobutyric acid\", \"cname\": \"gamma-aminobutyric acid\", \"id\": [\"Abundance\", \"CHEBI\", \"gamma-aminobutyric acid\"]}, {\"function\": \"Abundance\", \"namespace\": \"CHEBI\", \"name\": \"glutamate(1-)\", \"cname\": \"glutamate(1-)\", \"id\": [\"Abundance\", \"CHEBI\", \"glutamate(1-)\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CHRNB2\", \"description\": \"Neuronal acetylcholine receptors are homo- or heteropentameric complexes composed of homologous alpha and beta subunits. They belong to a superfamily of ligand-gated ion channels which allow the flow of sodium and potassium across the plasma membrane in response to ligands such as acetylcholine and nicotine. This gene encodes one of several beta subunits. Mutations in this gene are associated with autosomal dominant nocturnal frontal lobe epilepsy. [provided by RefSeq, Jul 2008]\", \"label\": \"cholinergic receptor nicotinic beta 2 subunit\", \"cname\": \"CHRNB2\", \"id\": [\"Protein\", \"HGNC\", \"CHRNB2\"]}, {\"function\": \"BiologicalProcess\", \"namespace\": \"GOBP\", \"name\": \"regulation of neuronal synaptic plasticity\", \"cname\": \"regulation of neuronal synaptic plasticity\", \"id\": [\"BiologicalProcess\", \"GOBP\", \"regulation of neuronal synaptic plasticity\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CHRNA2\", \"description\": \"Nicotinic acetylcholine receptors (nAChRs) are ligand-gated ion channels formed by a pentameric arrangement of alpha and beta subunits to create distinct muscle and neuronal receptors. Neuronal receptors are found throughout the peripheral and central nervous system where they are involved in fast synaptic transmission. This gene encodes an alpha subunit that is widely expressed in the brain. The proposed structure for nAChR subunits is a conserved N-terminal extracellular domain followed by three conserved transmembrane domains, a variable cytoplasmic loop, a fourth conserved transmembrane domain, and a short C-terminal extracellular region. Mutations in this gene cause autosomal dominant nocturnal frontal lobe epilepsy type 4. Single nucleotide polymorphisms (SNPs) in this gene have been associated with nicotine dependence. [provided by RefSeq, Nov 2009]\", \"label\": \"cholinergic receptor nicotinic alpha 2 subunit\", \"cname\": \"CHRNA2\", \"id\": [\"Protein\", \"HGNC\", \"CHRNA2\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CHRNA3\", \"description\": \"This locus encodes a member of the nicotinic acetylcholine receptor family of proteins. Members of this family of proteins form pentameric complexes comprised of both alpha and beta subunits. This locus encodes an alpha-type subunit, as it contains characteristic adjacent cysteine residues. The encoded protein is a ligand-gated ion channel that likely plays a role in neurotransmission. Polymorphisms in this gene have been associated with an increased risk of smoking initiation and an increased susceptibility to lung cancer. Alternatively spliced transcript variants have been described. [provided by RefSeq, Nov 2009]\", \"label\": \"cholinergic receptor nicotinic alpha 3 subunit\", \"cname\": \"CHRNA3\", \"id\": [\"Protein\", \"HGNC\", \"CHRNA3\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CHRNA5\", \"description\": \"The protein encoded by this gene is a nicotinic acetylcholine receptor subunit and a member of a superfamily of ligand-gated ion channels that mediate fast signal transmission at synapses. These receptors are thought to be heteropentamers composed of separate but similar subunits. Defects in this gene have been linked to susceptibility to lung cancer type 2 (LNCR2).[provided by RefSeq, Jun 2010]\", \"label\": \"cholinergic receptor nicotinic alpha 5 subunit\", \"cname\": \"CHRNA5\", \"id\": [\"Protein\", \"HGNC\", \"CHRNA5\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CHRNA6\", \"description\": \"This gene encodes an alpha subunit of neuronal nicotinic acetylcholine receptors. These receptors consist of five subunits and function as ion channels involved in neurotransmission. The encoded protein is a subunit of neuronal nicotinic acetylcholine receptors that mediate dopaminergic neurotransmission and are activated by acetylcholine and exogenous nicotine. Alternatively spliced transcript variants have been observed for this gene. Single nucleotide polymorphisms in this gene have been associated with both nicotine and alcohol dependence. [provided by RefSeq, Dec 2010]\", \"label\": \"cholinergic receptor nicotinic alpha 6 subunit\", \"cname\": \"CHRNA6\", \"id\": [\"Protein\", \"HGNC\", \"CHRNA6\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CHRNA7\", \"description\": \"The nicotinic acetylcholine receptors (nAChRs) are members of a superfamily of ligand-gated ion channels that mediate fast signal transmission at synapses. The nAChRs are thought to be hetero-pentamers composed of homologous subunits. The proposed structure for each subunit is a conserved N-terminal extracellular domain followed by three conserved transmembrane domains, a variable cytoplasmic loop, a fourth conserved transmembrane domain, and a short C-terminal extracellular region. The protein encoded by this gene forms a homo-oligomeric channel, displays marked permeability to calcium ions and is a major component of brain nicotinic receptors that are blocked by, and highly sensitive to, alpha-bungarotoxin. Once this receptor binds acetylcholine, it undergoes an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. This gene is located in a region identified as a major susceptibility locus for juvenile myoclonic epilepsy and a chromosomal location involved in the genetic transmission of schizophrenia. An evolutionarily recent partial duplication event in this region results in a hybrid containing sequence from this gene and a novel FAM7A gene. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Feb 2012]\", \"label\": \"cholinergic receptor nicotinic alpha 7 subunit\", \"cname\": \"CHRNA7\", \"id\": [\"Protein\", \"HGNC\", \"CHRNA7\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CHRNA9\", \"description\": \"This gene is a member of the ligand-gated ionic channel family and nicotinic acetylcholine receptor gene superfamily. It encodes a plasma membrane protein that forms homo- or hetero-oligomeric divalent cation channels. This protein is involved in cochlea hair cell development and is also expressed in the outer hair cells (OHCs) of the adult cochlea. [provided by RefSeq, Feb 2012]\", \"label\": \"cholinergic receptor nicotinic alpha 9 subunit\", \"cname\": \"CHRNA9\", \"id\": [\"Protein\", \"HGNC\", \"CHRNA9\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CHRNA10\", \"description\": null, \"label\": \"cholinergic receptor nicotinic alpha 10 subunit\", \"cname\": \"CHRNA10\", \"id\": [\"Protein\", \"HGNC\", \"CHRNA10\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CHRNB3\", \"description\": \"The nicotinic acetylcholine receptors (nAChRs) are members of a superfamily of ligand-gated ion channels that mediate fast signal transmission at synapses. The nAChRs are (hetero)pentamers composed of homologous subunits. The subunits that make up the muscle and neuronal forms of nAChRs are encoded by separate genes and have different primary structure. There are several subtypes of neuronal nAChRs that vary based on which homologous subunits are arranged around the central channel. They are classified as alpha-subunits if, like muscle alpha-1 (MIM 100690), they have a pair of adjacent cysteines as part of the presumed acetylcholine binding site. Subunits lacking these cysteine residues are classified as beta-subunits (Groot Kormelink and Luyten, 1997 [PubMed 9009220]). Elliott et al. (1996) [PubMed 8906617] stated that the proposed structure for each subunit is a conserved N-terminal extracellular domain followed by 3 conserved transmembrane domains, a variable cytoplasmic loop, a fourth conserved transmembrane domain, and a short C-terminal extracellular region.[supplied by OMIM, Apr 2010]\", \"label\": \"cholinergic receptor nicotinic beta 3 subunit\", \"cname\": \"CHRNB3\", \"id\": [\"Protein\", \"HGNC\", \"CHRNB3\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CHRNB4\", \"description\": null, \"label\": \"cholinergic receptor nicotinic beta 4 subunit\", \"cname\": \"CHRNB4\", \"id\": [\"Protein\", \"HGNC\", \"CHRNB4\"]}, {\"function\": \"Abundance\", \"namespace\": \"CHEBI\", \"name\": \"galanthamine\", \"cname\": \"galanthamine\", \"id\": [\"Abundance\", \"CHEBI\", \"galanthamine\"]}, {\"function\": \"Abundance\", \"namespace\": \"CHEBI\", \"name\": \"1-(3-chlorophenyl)piperazine\", \"cname\": \"1-(3-chlorophenyl)piperazine\", \"id\": [\"Abundance\", \"CHEBI\", \"1-(3-chlorophenyl)piperazine\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABBR2\", \"description\": \"The multi-pass membrane protein encoded by this gene belongs to the G-protein coupled receptor 3 family and GABA-B receptor subfamily. The GABA-B receptors inhibit neuronal activity through G protein-coupled second-messenger systems, which regulate the release of neurotransmitters, and the activity of ion channels and adenylyl cyclase. This receptor subunit forms an active heterodimeric complex with GABA-B receptor subunit 1, neither of which is effective on its own. Allelic variants of this gene have been associated with nicotine dependence.[provided by RefSeq, Jan 2010]\", \"label\": \"gamma-aminobutyric acid type B receptor subunit 2\", \"cname\": \"GABBR2\", \"id\": [\"Protein\", \"HGNC\", \"GABBR2\"]}, {\"function\": \"BiologicalProcess\", \"namespace\": \"GOBP\", \"name\": \"cAMP catabolic process\", \"cname\": \"cAMP catabolic process\", \"id\": [\"BiologicalProcess\", \"GOBP\", \"cAMP catabolic process\"]}, {\"function\": \"Abundance\", \"namespace\": \"CHEBI\", \"name\": \"nefiracetam\", \"cname\": \"nefiracetam\", \"id\": [\"Abundance\", \"CHEBI\", \"nefiracetam\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"PRKCA\", \"description\": \"Protein kinase C (PKC) is a family of serine- and threonine-specific protein kinases that can be activated by calcium and the second messenger diacylglycerol. PKC family members phosphorylate a wide variety of protein targets and are known to be involved in diverse cellular signaling pathways. PKC family members also serve as major receptors for phorbol esters, a class of tumor promoters. Each member of the PKC family has a specific expression profile and is believed to play a distinct role in cells. The protein encoded by this gene is one of the PKC family members. This kinase has been reported to play roles in many different cellular processes, such as cell adhesion, cell transformation, cell cycle checkpoint, and cell volume control. Knockout studies in mice suggest that this kinase may be a fundamental regulator of cardiac contractility and Ca(2+) handling in myocytes. [provided by RefSeq, Jul 2008]\", \"label\": \"protein kinase C alpha\", \"cname\": \"PRKCA\", \"id\": [\"Protein\", \"HGNC\", \"PRKCA\"]}, {\"function\": \"BiologicalProcess\", \"namespace\": \"GOBP\", \"name\": \"protein kinase A signaling\", \"cname\": \"protein kinase A signaling\", \"id\": [\"BiologicalProcess\", \"GOBP\", \"protein kinase A signaling\"]}, {\"function\": \"Abundance\", \"namespace\": \"CHEBI\", \"name\": \"EC 3.1.1.7 (acetylcholinesterase) inhibitor\", \"cname\": \"EC 3.1.1.7 (acetylcholinesterase) inhibitor\", \"id\": [\"Abundance\", \"CHEBI\", \"EC 3.1.1.7 (acetylcholinesterase) inhibitor\"]}, {\"function\": \"BiologicalProcess\", \"namespace\": \"GOBP\", \"name\": \"long-term synaptic potentiation\", \"cname\": \"long-term synaptic potentiation\", \"id\": [\"BiologicalProcess\", \"GOBP\", \"long-term synaptic potentiation\"]}, {\"function\": \"Complex\", \"namespace\": \"SCOMP\", \"name\": \"CAMK2 Complex\", \"cname\": \"CAMK2 Complex\", \"id\": [\"Complex\", \"SCOMP\", \"CAMK2 Complex\"]}, {\"function\": \"Complex\", \"cname\": \"complex(a(CHEBI:nefiracetam), p(HGNC:PRKCA))\", \"id\": [\"Complex\", [\"Abundance\", \"CHEBI\", \"nefiracetam\"], [\"Protein\", \"HGNC\", \"PRKCA\"]]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GRIA1\", \"variants\": [{\"kind\": \"pmod\", \"identifier\": {\"namespace\": \"bel\", \"name\": \"Ph\"}, \"code\": \"Ser\", \"pos\": 831}], \"description\": \"Glutamate receptors are the predominant excitatory neurotransmitter receptors in the mammalian brain and are activated in a variety of normal neurophysiologic processes. These receptors are heteromeric protein complexes with multiple subunits, each possessing transmembrane regions, and all arranged to form a ligand-gated ion channel. The classification of glutamate receptors is based on their activation by different pharmacologic agonists. This gene belongs to a family of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) receptors. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]\", \"label\": \"glutamate ionotropic receptor AMPA type subunit 1\", \"cname\": \"p(HGNC:GRIA1, pmod(Ph, Ser, 831))\", \"id\": [\"Protein\", \"HGNC\", \"GRIA1\", [\"pmod\", [\"bel\", \"Ph\"], \"Ser\", 831]]}, {\"function\": \"Complex\", \"namespace\": \"GOCC\", \"name\": \"proteasome complex\", \"cname\": \"proteasome complex\", \"id\": [\"Complex\", \"GOCC\", \"proteasome complex\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GPHN\", \"description\": \"This gene encodes a neuronal assembly protein that anchors inhibitory neurotransmitter receptors to the postsynaptic cytoskeleton via high affinity binding to a receptor subunit domain and tubulin dimers. In nonneuronal tissues, the encoded protein is also required for molybdenum cofactor biosynthesis. Mutations in this gene may be associated with the neurological condition hyperplexia and also lead to molybdenum cofactor deficiency. Numerous alternatively spliced transcript variants encoding different isoforms have been described; however, the full-length nature of all transcript variants is not currently known. [provided by RefSeq, Jul 2008]\", \"label\": \"gephyrin\", \"cname\": \"GPHN\", \"id\": [\"Protein\", \"HGNC\", \"GPHN\"]}, {\"function\": \"Pathology\", \"namespace\": \"MESHD\", \"name\": \"Glaucoma\", \"cname\": \"Glaucoma\", \"id\": [\"Pathology\", \"MESHD\", \"Glaucoma\"]}, {\"function\": \"Complex\", \"cname\": \"complex(p(HGNC:EGR1), p(HGNC:PSEN2))\", \"id\": [\"Complex\", [\"Protein\", \"HGNC\", \"EGR1\"], [\"Protein\", \"HGNC\", \"PSEN2\"]]}, {\"function\": \"Abundance\", \"namespace\": \"CHEBI\", \"name\": \"estradiol\", \"cname\": \"estradiol\", \"id\": [\"Abundance\", \"CHEBI\", \"estradiol\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"GABRA4\", \"description\": \"Gamma-aminobutyric acid (GABA) is the major inhibitory neurotransmitter in the mammalian brain where it acts at GABA-A receptors, which are ligand-gated chloride channels. Chloride conductance of these channels can be modulated by agents such as benzodiazepines that bind to the GABA-A receptor. At least 16 distinct subunits of GABA-A receptors have been identified. This gene encodes subunit alpha-4, which is involved in the etiology of autism and eventually increases autism risk through interaction with another subunit, gamma-aminobutyric acid receptor beta-1 (GABRB1). Alternatively spliced transcript variants encoding different isoforms have been found in this gene.[provided by RefSeq, Feb 2011]\", \"label\": \"gamma-aminobutyric acid type A receptor alpha4 subunit\", \"cname\": \"GABRA4\", \"id\": [\"RNA\", \"HGNC\", \"GABRA4\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"GABRA3\", \"description\": \"GABA is the major inhibitory neurotransmitter in the mammalian brain where it acts at GABA-A receptors, which are ligand-gated chloride channels. Chloride conductance of these channels can be modulated by agents such as benzodiazepines that bind to the GABA-A receptor. At least 16 distinct subunits of GABA-A receptors have been identified. [provided by RefSeq, Jul 2008]\", \"label\": \"gamma-aminobutyric acid type A receptor alpha3 subunit\", \"cname\": \"GABRA3\", \"id\": [\"RNA\", \"HGNC\", \"GABRA3\"]}, {\"function\": \"Abundance\", \"namespace\": \"CHEBI\", \"name\": \"Midazolam\", \"cname\": \"Midazolam\", \"id\": [\"Abundance\", \"CHEBI\", \"Midazolam\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GRIA1\", \"description\": \"Glutamate receptors are the predominant excitatory neurotransmitter receptors in the mammalian brain and are activated in a variety of normal neurophysiologic processes. These receptors are heteromeric protein complexes with multiple subunits, each possessing transmembrane regions, and all arranged to form a ligand-gated ion channel. The classification of glutamate receptors is based on their activation by different pharmacologic agonists. This gene belongs to a family of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) receptors. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]\", \"label\": \"glutamate ionotropic receptor AMPA type subunit 1\", \"cname\": \"GRIA1\", \"id\": [\"Protein\", \"HGNC\", \"GRIA1\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"EGR1\", \"description\": \"The protein encoded by this gene belongs to the EGR family of C2H2-type zinc-finger proteins. It is a nuclear protein and functions as a transcriptional regulator. The products of target genes it activates are required for differentitation and mitogenesis. Studies suggest this is a cancer suppressor gene. [provided by RefSeq, Dec 2014]\", \"label\": \"early growth response 1\", \"cname\": \"EGR1\", \"id\": [\"RNA\", \"HGNC\", \"EGR1\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"APP\", \"description\": \"This gene encodes a cell surface receptor and transmembrane precursor protein that is cleaved by secretases to form a number of peptides. Some of these peptides are secreted and can bind to the acetyltransferase complex APBB1/TIP60 to promote transcriptional activation, while others form the protein basis of the amyloid plaques found in the brains of patients with Alzheimer disease. In addition, two of the peptides are antimicrobial peptides, having been shown to have bacteriocidal and antifungal activities. Mutations in this gene have been implicated in autosomal dominant Alzheimer disease and cerebroarterial amyloidosis (cerebral amyloid angiopathy). Multiple transcript variants encoding several different isoforms have been found for this gene. [provided by RefSeq, Aug 2014]\", \"label\": \"amyloid beta precursor protein\", \"cname\": \"APP\", \"id\": [\"RNA\", \"HGNC\", \"APP\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"PSEN2\", \"description\": \"Alzheimer's disease (AD) patients with an inherited form of the disease carry mutations in the presenilin proteins (PSEN1 or PSEN2) or the amyloid precursor protein (APP). These disease-linked mutations result in increased production of the longer form of amyloid-beta (main component of amyloid deposits found in AD brains). Presenilins are postulated to regulate APP processing through their effects on gamma-secretase, an enzyme that cleaves APP. Also, it is thought that the presenilins are involved in the cleavage of the Notch receptor such that, they either directly regulate gamma-secretase activity, or themselves act are protease enzymes. Two alternatively spliced transcript variants encoding different isoforms of PSEN2 have been identified. [provided by RefSeq, Jul 2008]\", \"label\": \"presenilin 2\", \"cname\": \"PSEN2\", \"id\": [\"RNA\", \"HGNC\", \"PSEN2\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"TNF\", \"description\": \"This gene encodes a multifunctional proinflammatory cytokine that belongs to the tumor necrosis factor (TNF) superfamily. This cytokine is mainly secreted by macrophages. It can bind to, and thus functions through its receptors TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR. This cytokine is involved in the regulation of a wide spectrum of biological processes including cell proliferation, differentiation, apoptosis, lipid metabolism, and coagulation. This cytokine has been implicated in a variety of diseases, including autoimmune diseases, insulin resistance, and cancer. Knockout studies in mice also suggested the neuroprotective function of this cytokine. [provided by RefSeq, Jul 2008]\", \"label\": \"tumor necrosis factor\", \"cname\": \"TNF\", \"id\": [\"RNA\", \"HGNC\", \"TNF\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"GABRA1\", \"description\": \"This gene encodes a gamma-aminobutyric acid (GABA) receptor. GABA is the major inhibitory neurotransmitter in the mammalian brain where it acts at GABA-A receptors, which are ligand-gated chloride channels. Chloride conductance of these channels can be modulated by agents such as benzodiazepines that bind to the GABA-A receptor. GABA-A receptors are pentameric, consisting of proteins from several subunit classes: alpha, beta, gamma, delta and rho. Mutations in this gene cause juvenile myoclonic epilepsy and childhood absence epilepsy type 4. Multiple transcript variants encoding the same protein have been identified for this gene. [provided by RefSeq, Jul 2008]\", \"label\": \"gamma-aminobutyric acid type A receptor alpha1 subunit\", \"cname\": \"GABRA1\", \"id\": [\"RNA\", \"HGNC\", \"GABRA1\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"GABRA2\", \"description\": \"GABA is the major inhibitory neurotransmitter in the mammalian brain where it acts at GABA-A receptors, which are ligand-gated chloride channels. Chloride conductance of these channels can be modulated by agents such as benzodiazepines that bind to the GABA-A receptor. At least 16 distinct subunits of GABA-A receptors have been identified. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Nov 2013]\", \"label\": \"gamma-aminobutyric acid type A receptor alpha2 subunit\", \"cname\": \"GABRA2\", \"id\": [\"RNA\", \"HGNC\", \"GABRA2\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"GABRA5\", \"description\": \"GABA is the major inhibitory neurotransmitter in the mammalian brain where it acts at GABA-A receptors, which are ligand-gated chloride channels. Chloride conductance of these channels can be modulated by agents such as benzodiazepines that bind to the GABA-A receptor. At least 16 distinct subunits of GABA-A receptors have been identified. Transcript variants utilizing three different alternative non-coding first exons have been described. [provided by RefSeq, Jul 2008]\", \"label\": \"gamma-aminobutyric acid type A receptor alpha5 subunit\", \"cname\": \"GABRA5\", \"id\": [\"RNA\", \"HGNC\", \"GABRA5\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"GABRA6\", \"description\": \"GABA is the major inhibitory neurotransmitter in the mammalian brain where it acts at GABA-A receptors, which are ligand-gated chloride channels. Chloride conductance of these channels can be modulated by agents such as benzodiazepines that bind to the GABA-A receptor. At least 16 distinct subunits of GABA-A receptors have been identified. [provided by RefSeq, Jul 2008]\", \"label\": \"gamma-aminobutyric acid type A receptor alpha6 subunit\", \"cname\": \"GABRA6\", \"id\": [\"RNA\", \"HGNC\", \"GABRA6\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"GABRB1\", \"description\": \"The gamma-aminobutyric acid (GABA) A receptor is a multisubunit chloride channel that mediates the fastest inhibitory synaptic transmission in the central nervous system. This gene encodes GABA A receptor, beta 1 subunit. It is mapped to chromosome 4p12 in a cluster comprised of genes encoding alpha 4, alpha 2 and gamma 1 subunits of the GABA A receptor. Alteration of this gene is implicated in the pathogenetics of schizophrenia. [provided by RefSeq, Jul 2008]\", \"label\": \"gamma-aminobutyric acid type A receptor beta1 subunit\", \"cname\": \"GABRB1\", \"id\": [\"RNA\", \"HGNC\", \"GABRB1\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"GABRB2\", \"description\": null, \"cname\": \"GABRB2\", \"id\": [\"RNA\", \"HGNC\", \"GABRB2\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"GABRB3\", \"description\": \"This gene encodes a member of the ligand-gated ionic channel family. The encoded protein is one the subunits of a multi-subunit chloride channel that serves as the receptor for gamma-aminobutyric acid, a major inhibitory neurotransmitter of the mammalian nervous system. This gene is located on the long arm of chromosome 15 in a cluster with two other genes encoding related subunits of the family. This gene may be associated with the pathogenesis of several disorders including Angelman syndrome, Prader-Willi syndrome, nonsyndromic orofacial clefts, epilepsy and autism. Alternatively spliced transcript variants encoding distinct isoforms have been described. [provided by RefSeq, Jul 2013]\", \"label\": \"gamma-aminobutyric acid type A receptor beta3 subunit\", \"cname\": \"GABRB3\", \"id\": [\"RNA\", \"HGNC\", \"GABRB3\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"GABRG1\", \"description\": \"The protein encoded by this gene belongs to the ligand-gated ionic channel family. It is an integral membrane protein and plays an important role in inhibiting neurotransmission by binding to the benzodiazepine receptor and opening an integral chloride channel. This gene is clustered with three other family members on chromosome 4. [provided by RefSeq, Jul 2008]\", \"label\": \"gamma-aminobutyric acid type A receptor gamma1 subunit\", \"cname\": \"GABRG1\", \"id\": [\"RNA\", \"HGNC\", \"GABRG1\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"GABRG2\", \"description\": null, \"cname\": \"GABRG2\", \"id\": [\"RNA\", \"HGNC\", \"GABRG2\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"GABRG3\", \"description\": \"This gene encodes a gamma-aminobutyric acid (GABA) receptor. GABA is the major inhibitory neurotransmitter in the mammalian brain where it acts at GABA-A receptors, which are ligand-gated chloride channels. Chloride conductance of these channels can be modulated by agents such as benzodiazepines that bind to the GABA-A receptor. GABA-A receptors are pentameric, consisting of proteins from several subunit classes: alpha, beta, gamma, delta and rho. The protein encoded by this gene is a gamma subunit, which contains the benzodiazepine binding site. Two transcript variants encoding distinct isoforms have been found for this gene. [provided by RefSeq, Aug 2012]\", \"label\": \"gamma-aminobutyric acid type A receptor gamma3 subunit\", \"cname\": \"GABRG3\", \"id\": [\"RNA\", \"HGNC\", \"GABRG3\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"GABRD\", \"description\": \"Gamma-aminobutyric acid (GABA) is the major inhibitory neurotransmitter in the mammalian brain where it acts at GABA-A receptors, which are ligand-gated chloride channels. Chloride conductance of these channels can be modulated by agents such as benzodiazepines that bind to the GABA-A receptor. The GABA-A receptor is generally pentameric and there are five types of subunits: alpha, beta, gamma, delta, and rho. This gene encodes the delta subunit. Mutations in this gene have been associated with susceptibility to generalized epilepsy with febrile seizures, type 5. Alternatively spliced transcript variants have been described for this gene, but their biological validity has not been determined. [provided by RefSeq, Jul 2008]\", \"label\": \"gamma-aminobutyric acid type A receptor delta subunit\", \"cname\": \"GABRD\", \"id\": [\"RNA\", \"HGNC\", \"GABRD\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"GABRE\", \"description\": \"The product of this gene belongs to the ligand-gated ionic channel (TC 1.A.9) family. It encodes the gamma-aminobutyric acid (GABA) A receptor which is a multisubunit chloride channel that mediates the fastest inhibitory synaptic transmission in the central nervous system. This gene encodes an epsilon subunit. It is mapped to chromosome Xq28 in a cluster comprised of genes encoding alpha 3, beta 4 and theta subunits of the same receptor. Alternatively spliced transcript variants have been identified, but only one is thought to encode a protein. [provided by RefSeq, Oct 2008]\", \"label\": \"gamma-aminobutyric acid type A receptor epsilon subunit\", \"cname\": \"GABRE\", \"id\": [\"RNA\", \"HGNC\", \"GABRE\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"GABRP\", \"description\": \"The gamma-aminobutyric acid (GABA) A receptor is a multisubunit chloride channel that mediates the fastest inhibitory synaptic transmission in the central nervous system. The subunit encoded by this gene is expressed in several non-neuronal tissues including the uterus and ovaries. This subunit can assemble with known GABA A receptor subunits, and the presence of this subunit alters the sensitivity of recombinant receptors to modulatory agents such as pregnanolone. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, May 2014]\", \"label\": \"gamma-aminobutyric acid type A receptor pi subunit\", \"cname\": \"GABRP\", \"id\": [\"RNA\", \"HGNC\", \"GABRP\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"GABRQ\", \"description\": \"The gamma-aminobutyric acid (GABA) A receptor is a multisubunit chloride channel that mediates the fastest inhibitory synaptic transmission in the central nervous system. This gene encodes the theta subunit of the GABA A receptor. The gene is mapped to chromosome Xq28 in a cluster of genes including those that encode the alpha 3 and epsilon subunits of the GABA A receptor. [provided by RefSeq, Jul 2017]\", \"label\": \"gamma-aminobutyric acid type A receptor theta subunit\", \"cname\": \"GABRQ\", \"id\": [\"RNA\", \"HGNC\", \"GABRQ\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"GABBR1\", \"description\": \"This gene encodes a receptor for gamma-aminobutyric acid (GABA), which is the main inhibitory neurotransmitter in the mammalian central nervous system. This receptor functions as a heterodimer with GABA(B) receptor 2. Defects in this gene may underlie brain disorders such as schizophrenia and epilepsy. Alternative splicing generates multiple transcript variants, but the full-length nature of some of these variants has not been determined. [provided by RefSeq, Jan 2016]\", \"label\": \"gamma-aminobutyric acid type B receptor subunit 1\", \"cname\": \"GABBR1\", \"id\": [\"RNA\", \"HGNC\", \"GABBR1\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"GRIN2B\", \"description\": \"N-methyl-D-aspartate (NMDA) receptors are a class of ionotropic glutamate receptors. NMDA receptor channel has been shown to be involved in long-term potentiation, an activity-dependent increase in the efficiency of synaptic transmission thought to underlie certain kinds of memory and learning. NMDA receptor channels are heteromers composed of three different subunits: NR1 (GRIN1), NR2 (GRIN2A, GRIN2B, GRIN2C, or GRIN2D) and NR3 (GRIN3A or GRIN3B). The NR2 subunit acts as the agonist binding site for glutamate. This receptor is the predominant excitatory neurotransmitter receptor in the mammalian brain. [provided by RefSeq, Jul 2008]\", \"label\": \"glutamate ionotropic receptor NMDA type subunit 2B\", \"cname\": \"GRIN2B\", \"id\": [\"RNA\", \"HGNC\", \"GRIN2B\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"CHRNA4\", \"description\": \"This gene encodes a nicotinic acetylcholine receptor, which belongs to a superfamily of ligand-gated ion channels that play a role in fast signal transmission at synapses. These pentameric receptors can bind acetylcholine, which causes an extensive change in conformation that leads to the opening of an ion-conducting channel across the plasma membrane. This protein is an integral membrane receptor subunit that can interact with either nAChR beta-2 or nAChR beta-4 to form a functional receptor. Mutations in this gene cause nocturnal frontal lobe epilepsy type 1. Polymorphisms in this gene that provide protection against nicotine addiction have been described. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Feb 2012]\", \"label\": \"cholinergic receptor nicotinic alpha 4 subunit\", \"cname\": \"CHRNA4\", \"id\": [\"RNA\", \"HGNC\", \"CHRNA4\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"CHRNB2\", \"description\": \"Neuronal acetylcholine receptors are homo- or heteropentameric complexes composed of homologous alpha and beta subunits. They belong to a superfamily of ligand-gated ion channels which allow the flow of sodium and potassium across the plasma membrane in response to ligands such as acetylcholine and nicotine. This gene encodes one of several beta subunits. Mutations in this gene are associated with autosomal dominant nocturnal frontal lobe epilepsy. [provided by RefSeq, Jul 2008]\", \"label\": \"cholinergic receptor nicotinic beta 2 subunit\", \"cname\": \"CHRNB2\", \"id\": [\"RNA\", \"HGNC\", \"CHRNB2\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"CHRNA2\", \"description\": \"Nicotinic acetylcholine receptors (nAChRs) are ligand-gated ion channels formed by a pentameric arrangement of alpha and beta subunits to create distinct muscle and neuronal receptors. Neuronal receptors are found throughout the peripheral and central nervous system where they are involved in fast synaptic transmission. This gene encodes an alpha subunit that is widely expressed in the brain. The proposed structure for nAChR subunits is a conserved N-terminal extracellular domain followed by three conserved transmembrane domains, a variable cytoplasmic loop, a fourth conserved transmembrane domain, and a short C-terminal extracellular region. Mutations in this gene cause autosomal dominant nocturnal frontal lobe epilepsy type 4. Single nucleotide polymorphisms (SNPs) in this gene have been associated with nicotine dependence. [provided by RefSeq, Nov 2009]\", \"label\": \"cholinergic receptor nicotinic alpha 2 subunit\", \"cname\": \"CHRNA2\", \"id\": [\"RNA\", \"HGNC\", \"CHRNA2\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"CHRNA3\", \"description\": \"This locus encodes a member of the nicotinic acetylcholine receptor family of proteins. Members of this family of proteins form pentameric complexes comprised of both alpha and beta subunits. This locus encodes an alpha-type subunit, as it contains characteristic adjacent cysteine residues. The encoded protein is a ligand-gated ion channel that likely plays a role in neurotransmission. Polymorphisms in this gene have been associated with an increased risk of smoking initiation and an increased susceptibility to lung cancer. Alternatively spliced transcript variants have been described. [provided by RefSeq, Nov 2009]\", \"label\": \"cholinergic receptor nicotinic alpha 3 subunit\", \"cname\": \"CHRNA3\", \"id\": [\"RNA\", \"HGNC\", \"CHRNA3\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"CHRNA5\", \"description\": \"The protein encoded by this gene is a nicotinic acetylcholine receptor subunit and a member of a superfamily of ligand-gated ion channels that mediate fast signal transmission at synapses. These receptors are thought to be heteropentamers composed of separate but similar subunits. Defects in this gene have been linked to susceptibility to lung cancer type 2 (LNCR2).[provided by RefSeq, Jun 2010]\", \"label\": \"cholinergic receptor nicotinic alpha 5 subunit\", \"cname\": \"CHRNA5\", \"id\": [\"RNA\", \"HGNC\", \"CHRNA5\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"CHRNA6\", \"description\": \"This gene encodes an alpha subunit of neuronal nicotinic acetylcholine receptors. These receptors consist of five subunits and function as ion channels involved in neurotransmission. The encoded protein is a subunit of neuronal nicotinic acetylcholine receptors that mediate dopaminergic neurotransmission and are activated by acetylcholine and exogenous nicotine. Alternatively spliced transcript variants have been observed for this gene. Single nucleotide polymorphisms in this gene have been associated with both nicotine and alcohol dependence. [provided by RefSeq, Dec 2010]\", \"label\": \"cholinergic receptor nicotinic alpha 6 subunit\", \"cname\": \"CHRNA6\", \"id\": [\"RNA\", \"HGNC\", \"CHRNA6\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"CHRNA7\", \"description\": \"The nicotinic acetylcholine receptors (nAChRs) are members of a superfamily of ligand-gated ion channels that mediate fast signal transmission at synapses. The nAChRs are thought to be hetero-pentamers composed of homologous subunits. The proposed structure for each subunit is a conserved N-terminal extracellular domain followed by three conserved transmembrane domains, a variable cytoplasmic loop, a fourth conserved transmembrane domain, and a short C-terminal extracellular region. The protein encoded by this gene forms a homo-oligomeric channel, displays marked permeability to calcium ions and is a major component of brain nicotinic receptors that are blocked by, and highly sensitive to, alpha-bungarotoxin. Once this receptor binds acetylcholine, it undergoes an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. This gene is located in a region identified as a major susceptibility locus for juvenile myoclonic epilepsy and a chromosomal location involved in the genetic transmission of schizophrenia. An evolutionarily recent partial duplication event in this region results in a hybrid containing sequence from this gene and a novel FAM7A gene. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Feb 2012]\", \"label\": \"cholinergic receptor nicotinic alpha 7 subunit\", \"cname\": \"CHRNA7\", \"id\": [\"RNA\", \"HGNC\", \"CHRNA7\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"CHRNA9\", \"description\": \"This gene is a member of the ligand-gated ionic channel family and nicotinic acetylcholine receptor gene superfamily. It encodes a plasma membrane protein that forms homo- or hetero-oligomeric divalent cation channels. This protein is involved in cochlea hair cell development and is also expressed in the outer hair cells (OHCs) of the adult cochlea. [provided by RefSeq, Feb 2012]\", \"label\": \"cholinergic receptor nicotinic alpha 9 subunit\", \"cname\": \"CHRNA9\", \"id\": [\"RNA\", \"HGNC\", \"CHRNA9\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"CHRNA10\", \"description\": null, \"label\": \"cholinergic receptor nicotinic alpha 10 subunit\", \"cname\": \"CHRNA10\", \"id\": [\"RNA\", \"HGNC\", \"CHRNA10\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"CHRNB3\", \"description\": \"The nicotinic acetylcholine receptors (nAChRs) are members of a superfamily of ligand-gated ion channels that mediate fast signal transmission at synapses. The nAChRs are (hetero)pentamers composed of homologous subunits. The subunits that make up the muscle and neuronal forms of nAChRs are encoded by separate genes and have different primary structure. There are several subtypes of neuronal nAChRs that vary based on which homologous subunits are arranged around the central channel. They are classified as alpha-subunits if, like muscle alpha-1 (MIM 100690), they have a pair of adjacent cysteines as part of the presumed acetylcholine binding site. Subunits lacking these cysteine residues are classified as beta-subunits (Groot Kormelink and Luyten, 1997 [PubMed 9009220]). Elliott et al. (1996) [PubMed 8906617] stated that the proposed structure for each subunit is a conserved N-terminal extracellular domain followed by 3 conserved transmembrane domains, a variable cytoplasmic loop, a fourth conserved transmembrane domain, and a short C-terminal extracellular region.[supplied by OMIM, Apr 2010]\", \"label\": \"cholinergic receptor nicotinic beta 3 subunit\", \"cname\": \"CHRNB3\", \"id\": [\"RNA\", \"HGNC\", \"CHRNB3\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"CHRNB4\", \"description\": null, \"label\": \"cholinergic receptor nicotinic beta 4 subunit\", \"cname\": \"CHRNB4\", \"id\": [\"RNA\", \"HGNC\", \"CHRNB4\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"GABBR2\", \"description\": \"The multi-pass membrane protein encoded by this gene belongs to the G-protein coupled receptor 3 family and GABA-B receptor subfamily. The GABA-B receptors inhibit neuronal activity through G protein-coupled second-messenger systems, which regulate the release of neurotransmitters, and the activity of ion channels and adenylyl cyclase. This receptor subunit forms an active heterodimeric complex with GABA-B receptor subunit 1, neither of which is effective on its own. Allelic variants of this gene have been associated with nicotine dependence.[provided by RefSeq, Jan 2010]\", \"label\": \"gamma-aminobutyric acid type B receptor subunit 2\", \"cname\": \"GABBR2\", \"id\": [\"RNA\", \"HGNC\", \"GABBR2\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"PRKCA\", \"description\": \"Protein kinase C (PKC) is a family of serine- and threonine-specific protein kinases that can be activated by calcium and the second messenger diacylglycerol. PKC family members phosphorylate a wide variety of protein targets and are known to be involved in diverse cellular signaling pathways. PKC family members also serve as major receptors for phorbol esters, a class of tumor promoters. Each member of the PKC family has a specific expression profile and is believed to play a distinct role in cells. The protein encoded by this gene is one of the PKC family members. This kinase has been reported to play roles in many different cellular processes, such as cell adhesion, cell transformation, cell cycle checkpoint, and cell volume control. Knockout studies in mice suggest that this kinase may be a fundamental regulator of cardiac contractility and Ca(2+) handling in myocytes. [provided by RefSeq, Jul 2008]\", \"label\": \"protein kinase C alpha\", \"cname\": \"PRKCA\", \"id\": [\"RNA\", \"HGNC\", \"PRKCA\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"GPHN\", \"description\": \"This gene encodes a neuronal assembly protein that anchors inhibitory neurotransmitter receptors to the postsynaptic cytoskeleton via high affinity binding to a receptor subunit domain and tubulin dimers. In nonneuronal tissues, the encoded protein is also required for molybdenum cofactor biosynthesis. Mutations in this gene may be associated with the neurological condition hyperplexia and also lead to molybdenum cofactor deficiency. Numerous alternatively spliced transcript variants encoding different isoforms have been described; however, the full-length nature of all transcript variants is not currently known. [provided by RefSeq, Jul 2008]\", \"label\": \"gephyrin\", \"cname\": \"GPHN\", \"id\": [\"RNA\", \"HGNC\", \"GPHN\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"GRIA1\", \"description\": \"Glutamate receptors are the predominant excitatory neurotransmitter receptors in the mammalian brain and are activated in a variety of normal neurophysiologic processes. These receptors are heteromeric protein complexes with multiple subunits, each possessing transmembrane regions, and all arranged to form a ligand-gated ion channel. The classification of glutamate receptors is based on their activation by different pharmacologic agonists. This gene belongs to a family of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) receptors. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]\", \"label\": \"glutamate ionotropic receptor AMPA type subunit 1\", \"cname\": \"GRIA1\", \"id\": [\"RNA\", \"HGNC\", \"GRIA1\"]}, {\"function\": \"Gene\", \"namespace\": \"HGNC\", \"name\": \"GABRA4\", \"description\": \"Gamma-aminobutyric acid (GABA) is the major inhibitory neurotransmitter in the mammalian brain where it acts at GABA-A receptors, which are ligand-gated chloride channels. Chloride conductance of these channels can be modulated by agents such as benzodiazepines that bind to the GABA-A receptor. At least 16 distinct subunits of GABA-A receptors have been identified. This gene encodes subunit alpha-4, which is involved in the etiology of autism and eventually increases autism risk through interaction with another subunit, gamma-aminobutyric acid receptor beta-1 (GABRB1). Alternatively spliced transcript variants encoding different isoforms have been found in this gene.[provided by RefSeq, Feb 2011]\", \"label\": \"gamma-aminobutyric acid type A receptor alpha4 subunit\", \"cname\": \"GABRA4\", \"id\": [\"Gene\", \"HGNC\", \"GABRA4\"]}, {\"function\": \"Gene\", \"namespace\": \"HGNC\", \"name\": \"GABRA3\", \"description\": \"GABA is the major inhibitory neurotransmitter in the mammalian brain where it acts at GABA-A receptors, which are ligand-gated chloride channels. Chloride conductance of these channels can be modulated by agents such as benzodiazepines that bind to the GABA-A receptor. At least 16 distinct subunits of GABA-A receptors have been identified. [provided by RefSeq, Jul 2008]\", \"label\": \"gamma-aminobutyric acid type A receptor alpha3 subunit\", \"cname\": \"GABRA3\", \"id\": [\"Gene\", \"HGNC\", \"GABRA3\"]}, {\"function\": \"Gene\", \"namespace\": \"HGNC\", \"name\": \"EGR1\", \"description\": \"The protein encoded by this gene belongs to the EGR family of C2H2-type zinc-finger proteins. It is a nuclear protein and functions as a transcriptional regulator. The products of target genes it activates are required for differentitation and mitogenesis. Studies suggest this is a cancer suppressor gene. [provided by RefSeq, Dec 2014]\", \"label\": \"early growth response 1\", \"cname\": \"EGR1\", \"id\": [\"Gene\", \"HGNC\", \"EGR1\"]}, {\"function\": \"Gene\", \"namespace\": \"HGNC\", \"name\": \"APP\", \"description\": \"This gene encodes a cell surface receptor and transmembrane precursor protein that is cleaved by secretases to form a number of peptides. Some of these peptides are secreted and can bind to the acetyltransferase complex APBB1/TIP60 to promote transcriptional activation, while others form the protein basis of the amyloid plaques found in the brains of patients with Alzheimer disease. In addition, two of the peptides are antimicrobial peptides, having been shown to have bacteriocidal and antifungal activities. Mutations in this gene have been implicated in autosomal dominant Alzheimer disease and cerebroarterial amyloidosis (cerebral amyloid angiopathy). Multiple transcript variants encoding several different isoforms have been found for this gene. [provided by RefSeq, Aug 2014]\", \"label\": \"amyloid beta precursor protein\", \"cname\": \"APP\", \"id\": [\"Gene\", \"HGNC\", \"APP\"]}, {\"function\": \"Gene\", \"namespace\": \"HGNC\", \"name\": \"PSEN2\", \"description\": \"Alzheimer's disease (AD) patients with an inherited form of the disease carry mutations in the presenilin proteins (PSEN1 or PSEN2) or the amyloid precursor protein (APP). These disease-linked mutations result in increased production of the longer form of amyloid-beta (main component of amyloid deposits found in AD brains). Presenilins are postulated to regulate APP processing through their effects on gamma-secretase, an enzyme that cleaves APP. Also, it is thought that the presenilins are involved in the cleavage of the Notch receptor such that, they either directly regulate gamma-secretase activity, or themselves act are protease enzymes. Two alternatively spliced transcript variants encoding different isoforms of PSEN2 have been identified. [provided by RefSeq, Jul 2008]\", \"label\": \"presenilin 2\", \"cname\": \"PSEN2\", \"id\": [\"Gene\", \"HGNC\", \"PSEN2\"]}, {\"function\": \"Gene\", \"namespace\": \"HGNC\", \"name\": \"TNF\", \"description\": \"This gene encodes a multifunctional proinflammatory cytokine that belongs to the tumor necrosis factor (TNF) superfamily. This cytokine is mainly secreted by macrophages. It can bind to, and thus functions through its receptors TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR. This cytokine is involved in the regulation of a wide spectrum of biological processes including cell proliferation, differentiation, apoptosis, lipid metabolism, and coagulation. This cytokine has been implicated in a variety of diseases, including autoimmune diseases, insulin resistance, and cancer. Knockout studies in mice also suggested the neuroprotective function of this cytokine. [provided by RefSeq, Jul 2008]\", \"label\": \"tumor necrosis factor\", \"cname\": \"TNF\", \"id\": [\"Gene\", \"HGNC\", \"TNF\"]}, {\"function\": \"Gene\", \"namespace\": \"HGNC\", \"name\": \"GABRA1\", \"description\": \"This gene encodes a gamma-aminobutyric acid (GABA) receptor. GABA is the major inhibitory neurotransmitter in the mammalian brain where it acts at GABA-A receptors, which are ligand-gated chloride channels. Chloride conductance of these channels can be modulated by agents such as benzodiazepines that bind to the GABA-A receptor. GABA-A receptors are pentameric, consisting of proteins from several subunit classes: alpha, beta, gamma, delta and rho. Mutations in this gene cause juvenile myoclonic epilepsy and childhood absence epilepsy type 4. Multiple transcript variants encoding the same protein have been identified for this gene. [provided by RefSeq, Jul 2008]\", \"label\": \"gamma-aminobutyric acid type A receptor alpha1 subunit\", \"cname\": \"GABRA1\", \"id\": [\"Gene\", \"HGNC\", \"GABRA1\"]}, {\"function\": \"Gene\", \"namespace\": \"HGNC\", \"name\": \"GABRA2\", \"description\": \"GABA is the major inhibitory neurotransmitter in the mammalian brain where it acts at GABA-A receptors, which are ligand-gated chloride channels. Chloride conductance of these channels can be modulated by agents such as benzodiazepines that bind to the GABA-A receptor. At least 16 distinct subunits of GABA-A receptors have been identified. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Nov 2013]\", \"label\": \"gamma-aminobutyric acid type A receptor alpha2 subunit\", \"cname\": \"GABRA2\", \"id\": [\"Gene\", \"HGNC\", \"GABRA2\"]}, {\"function\": \"Gene\", \"namespace\": \"HGNC\", \"name\": \"GABRA5\", \"description\": \"GABA is the major inhibitory neurotransmitter in the mammalian brain where it acts at GABA-A receptors, which are ligand-gated chloride channels. Chloride conductance of these channels can be modulated by agents such as benzodiazepines that bind to the GABA-A receptor. At least 16 distinct subunits of GABA-A receptors have been identified. Transcript variants utilizing three different alternative non-coding first exons have been described. [provided by RefSeq, Jul 2008]\", \"label\": \"gamma-aminobutyric acid type A receptor alpha5 subunit\", \"cname\": \"GABRA5\", \"id\": [\"Gene\", \"HGNC\", \"GABRA5\"]}, {\"function\": \"Gene\", \"namespace\": \"HGNC\", \"name\": \"GABRA6\", \"description\": \"GABA is the major inhibitory neurotransmitter in the mammalian brain where it acts at GABA-A receptors, which are ligand-gated chloride channels. Chloride conductance of these channels can be modulated by agents such as benzodiazepines that bind to the GABA-A receptor. At least 16 distinct subunits of GABA-A receptors have been identified. [provided by RefSeq, Jul 2008]\", \"label\": \"gamma-aminobutyric acid type A receptor alpha6 subunit\", \"cname\": \"GABRA6\", \"id\": [\"Gene\", \"HGNC\", \"GABRA6\"]}, {\"function\": \"Gene\", \"namespace\": \"HGNC\", \"name\": \"GABRB1\", \"description\": \"The gamma-aminobutyric acid (GABA) A receptor is a multisubunit chloride channel that mediates the fastest inhibitory synaptic transmission in the central nervous system. This gene encodes GABA A receptor, beta 1 subunit. It is mapped to chromosome 4p12 in a cluster comprised of genes encoding alpha 4, alpha 2 and gamma 1 subunits of the GABA A receptor. Alteration of this gene is implicated in the pathogenetics of schizophrenia. [provided by RefSeq, Jul 2008]\", \"label\": \"gamma-aminobutyric acid type A receptor beta1 subunit\", \"cname\": \"GABRB1\", \"id\": [\"Gene\", \"HGNC\", \"GABRB1\"]}, {\"function\": \"Gene\", \"namespace\": \"HGNC\", \"name\": \"GABRB2\", \"description\": null, \"cname\": \"GABRB2\", \"id\": [\"Gene\", \"HGNC\", \"GABRB2\"]}, {\"function\": \"Gene\", \"namespace\": \"HGNC\", \"name\": \"GABRB3\", \"description\": \"This gene encodes a member of the ligand-gated ionic channel family. The encoded protein is one the subunits of a multi-subunit chloride channel that serves as the receptor for gamma-aminobutyric acid, a major inhibitory neurotransmitter of the mammalian nervous system. This gene is located on the long arm of chromosome 15 in a cluster with two other genes encoding related subunits of the family. This gene may be associated with the pathogenesis of several disorders including Angelman syndrome, Prader-Willi syndrome, nonsyndromic orofacial clefts, epilepsy and autism. Alternatively spliced transcript variants encoding distinct isoforms have been described. [provided by RefSeq, Jul 2013]\", \"label\": \"gamma-aminobutyric acid type A receptor beta3 subunit\", \"cname\": \"GABRB3\", \"id\": [\"Gene\", \"HGNC\", \"GABRB3\"]}, {\"function\": \"Gene\", \"namespace\": \"HGNC\", \"name\": \"GABRG1\", \"description\": \"The protein encoded by this gene belongs to the ligand-gated ionic channel family. It is an integral membrane protein and plays an important role in inhibiting neurotransmission by binding to the benzodiazepine receptor and opening an integral chloride channel. This gene is clustered with three other family members on chromosome 4. [provided by RefSeq, Jul 2008]\", \"label\": \"gamma-aminobutyric acid type A receptor gamma1 subunit\", \"cname\": \"GABRG1\", \"id\": [\"Gene\", \"HGNC\", \"GABRG1\"]}, {\"function\": \"Gene\", \"namespace\": \"HGNC\", \"name\": \"GABRG2\", \"description\": null, \"cname\": \"GABRG2\", \"id\": [\"Gene\", \"HGNC\", \"GABRG2\"]}, {\"function\": \"Gene\", \"namespace\": \"HGNC\", \"name\": \"GABRG3\", \"description\": \"This gene encodes a gamma-aminobutyric acid (GABA) receptor. GABA is the major inhibitory neurotransmitter in the mammalian brain where it acts at GABA-A receptors, which are ligand-gated chloride channels. Chloride conductance of these channels can be modulated by agents such as benzodiazepines that bind to the GABA-A receptor. GABA-A receptors are pentameric, consisting of proteins from several subunit classes: alpha, beta, gamma, delta and rho. The protein encoded by this gene is a gamma subunit, which contains the benzodiazepine binding site. Two transcript variants encoding distinct isoforms have been found for this gene. [provided by RefSeq, Aug 2012]\", \"label\": \"gamma-aminobutyric acid type A receptor gamma3 subunit\", \"cname\": \"GABRG3\", \"id\": [\"Gene\", \"HGNC\", \"GABRG3\"]}, {\"function\": \"Gene\", \"namespace\": \"HGNC\", \"name\": \"GABRD\", \"description\": \"Gamma-aminobutyric acid (GABA) is the major inhibitory neurotransmitter in the mammalian brain where it acts at GABA-A receptors, which are ligand-gated chloride channels. Chloride conductance of these channels can be modulated by agents such as benzodiazepines that bind to the GABA-A receptor. The GABA-A receptor is generally pentameric and there are five types of subunits: alpha, beta, gamma, delta, and rho. This gene encodes the delta subunit. Mutations in this gene have been associated with susceptibility to generalized epilepsy with febrile seizures, type 5. Alternatively spliced transcript variants have been described for this gene, but their biological validity has not been determined. [provided by RefSeq, Jul 2008]\", \"label\": \"gamma-aminobutyric acid type A receptor delta subunit\", \"cname\": \"GABRD\", \"id\": [\"Gene\", \"HGNC\", \"GABRD\"]}, {\"function\": \"Gene\", \"namespace\": \"HGNC\", \"name\": \"GABRE\", \"description\": \"The product of this gene belongs to the ligand-gated ionic channel (TC 1.A.9) family. It encodes the gamma-aminobutyric acid (GABA) A receptor which is a multisubunit chloride channel that mediates the fastest inhibitory synaptic transmission in the central nervous system. This gene encodes an epsilon subunit. It is mapped to chromosome Xq28 in a cluster comprised of genes encoding alpha 3, beta 4 and theta subunits of the same receptor. Alternatively spliced transcript variants have been identified, but only one is thought to encode a protein. [provided by RefSeq, Oct 2008]\", \"label\": \"gamma-aminobutyric acid type A receptor epsilon subunit\", \"cname\": \"GABRE\", \"id\": [\"Gene\", \"HGNC\", \"GABRE\"]}, {\"function\": \"Gene\", \"namespace\": \"HGNC\", \"name\": \"GABRP\", \"description\": \"The gamma-aminobutyric acid (GABA) A receptor is a multisubunit chloride channel that mediates the fastest inhibitory synaptic transmission in the central nervous system. The subunit encoded by this gene is expressed in several non-neuronal tissues including the uterus and ovaries. This subunit can assemble with known GABA A receptor subunits, and the presence of this subunit alters the sensitivity of recombinant receptors to modulatory agents such as pregnanolone. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, May 2014]\", \"label\": \"gamma-aminobutyric acid type A receptor pi subunit\", \"cname\": \"GABRP\", \"id\": [\"Gene\", \"HGNC\", \"GABRP\"]}, {\"function\": \"Gene\", \"namespace\": \"HGNC\", \"name\": \"GABRQ\", \"description\": \"The gamma-aminobutyric acid (GABA) A receptor is a multisubunit chloride channel that mediates the fastest inhibitory synaptic transmission in the central nervous system. This gene encodes the theta subunit of the GABA A receptor. The gene is mapped to chromosome Xq28 in a cluster of genes including those that encode the alpha 3 and epsilon subunits of the GABA A receptor. [provided by RefSeq, Jul 2017]\", \"label\": \"gamma-aminobutyric acid type A receptor theta subunit\", \"cname\": \"GABRQ\", \"id\": [\"Gene\", \"HGNC\", \"GABRQ\"]}, {\"function\": \"Gene\", \"namespace\": \"HGNC\", \"name\": \"GABBR1\", \"description\": \"This gene encodes a receptor for gamma-aminobutyric acid (GABA), which is the main inhibitory neurotransmitter in the mammalian central nervous system. This receptor functions as a heterodimer with GABA(B) receptor 2. Defects in this gene may underlie brain disorders such as schizophrenia and epilepsy. Alternative splicing generates multiple transcript variants, but the full-length nature of some of these variants has not been determined. [provided by RefSeq, Jan 2016]\", \"label\": \"gamma-aminobutyric acid type B receptor subunit 1\", \"cname\": \"GABBR1\", \"id\": [\"Gene\", \"HGNC\", \"GABBR1\"]}, {\"function\": \"Gene\", \"namespace\": \"HGNC\", \"name\": \"GRIN2B\", \"description\": \"N-methyl-D-aspartate (NMDA) receptors are a class of ionotropic glutamate receptors. NMDA receptor channel has been shown to be involved in long-term potentiation, an activity-dependent increase in the efficiency of synaptic transmission thought to underlie certain kinds of memory and learning. NMDA receptor channels are heteromers composed of three different subunits: NR1 (GRIN1), NR2 (GRIN2A, GRIN2B, GRIN2C, or GRIN2D) and NR3 (GRIN3A or GRIN3B). The NR2 subunit acts as the agonist binding site for glutamate. This receptor is the predominant excitatory neurotransmitter receptor in the mammalian brain. [provided by RefSeq, Jul 2008]\", \"label\": \"glutamate ionotropic receptor NMDA type subunit 2B\", \"cname\": \"GRIN2B\", \"id\": [\"Gene\", \"HGNC\", \"GRIN2B\"]}, {\"function\": \"Gene\", \"namespace\": \"HGNC\", \"name\": \"CHRNA4\", \"description\": \"This gene encodes a nicotinic acetylcholine receptor, which belongs to a superfamily of ligand-gated ion channels that play a role in fast signal transmission at synapses. These pentameric receptors can bind acetylcholine, which causes an extensive change in conformation that leads to the opening of an ion-conducting channel across the plasma membrane. This protein is an integral membrane receptor subunit that can interact with either nAChR beta-2 or nAChR beta-4 to form a functional receptor. Mutations in this gene cause nocturnal frontal lobe epilepsy type 1. Polymorphisms in this gene that provide protection against nicotine addiction have been described. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Feb 2012]\", \"label\": \"cholinergic receptor nicotinic alpha 4 subunit\", \"cname\": \"CHRNA4\", \"id\": [\"Gene\", \"HGNC\", \"CHRNA4\"]}, {\"function\": \"Gene\", \"namespace\": \"HGNC\", \"name\": \"CHRNB2\", \"description\": \"Neuronal acetylcholine receptors are homo- or heteropentameric complexes composed of homologous alpha and beta subunits. They belong to a superfamily of ligand-gated ion channels which allow the flow of sodium and potassium across the plasma membrane in response to ligands such as acetylcholine and nicotine. This gene encodes one of several beta subunits. Mutations in this gene are associated with autosomal dominant nocturnal frontal lobe epilepsy. [provided by RefSeq, Jul 2008]\", \"label\": \"cholinergic receptor nicotinic beta 2 subunit\", \"cname\": \"CHRNB2\", \"id\": [\"Gene\", \"HGNC\", \"CHRNB2\"]}, {\"function\": \"Gene\", \"namespace\": \"HGNC\", \"name\": \"CHRNA2\", \"description\": \"Nicotinic acetylcholine receptors (nAChRs) are ligand-gated ion channels formed by a pentameric arrangement of alpha and beta subunits to create distinct muscle and neuronal receptors. Neuronal receptors are found throughout the peripheral and central nervous system where they are involved in fast synaptic transmission. This gene encodes an alpha subunit that is widely expressed in the brain. The proposed structure for nAChR subunits is a conserved N-terminal extracellular domain followed by three conserved transmembrane domains, a variable cytoplasmic loop, a fourth conserved transmembrane domain, and a short C-terminal extracellular region. Mutations in this gene cause autosomal dominant nocturnal frontal lobe epilepsy type 4. Single nucleotide polymorphisms (SNPs) in this gene have been associated with nicotine dependence. [provided by RefSeq, Nov 2009]\", \"label\": \"cholinergic receptor nicotinic alpha 2 subunit\", \"cname\": \"CHRNA2\", \"id\": [\"Gene\", \"HGNC\", \"CHRNA2\"]}, {\"function\": \"Gene\", \"namespace\": \"HGNC\", \"name\": \"CHRNA3\", \"description\": \"This locus encodes a member of the nicotinic acetylcholine receptor family of proteins. Members of this family of proteins form pentameric complexes comprised of both alpha and beta subunits. This locus encodes an alpha-type subunit, as it contains characteristic adjacent cysteine residues. The encoded protein is a ligand-gated ion channel that likely plays a role in neurotransmission. Polymorphisms in this gene have been associated with an increased risk of smoking initiation and an increased susceptibility to lung cancer. Alternatively spliced transcript variants have been described. [provided by RefSeq, Nov 2009]\", \"label\": \"cholinergic receptor nicotinic alpha 3 subunit\", \"cname\": \"CHRNA3\", \"id\": [\"Gene\", \"HGNC\", \"CHRNA3\"]}, {\"function\": \"Gene\", \"namespace\": \"HGNC\", \"name\": \"CHRNA5\", \"description\": \"The protein encoded by this gene is a nicotinic acetylcholine receptor subunit and a member of a superfamily of ligand-gated ion channels that mediate fast signal transmission at synapses. These receptors are thought to be heteropentamers composed of separate but similar subunits. Defects in this gene have been linked to susceptibility to lung cancer type 2 (LNCR2).[provided by RefSeq, Jun 2010]\", \"label\": \"cholinergic receptor nicotinic alpha 5 subunit\", \"cname\": \"CHRNA5\", \"id\": [\"Gene\", \"HGNC\", \"CHRNA5\"]}, {\"function\": \"Gene\", \"namespace\": \"HGNC\", \"name\": \"CHRNA6\", \"description\": \"This gene encodes an alpha subunit of neuronal nicotinic acetylcholine receptors. These receptors consist of five subunits and function as ion channels involved in neurotransmission. The encoded protein is a subunit of neuronal nicotinic acetylcholine receptors that mediate dopaminergic neurotransmission and are activated by acetylcholine and exogenous nicotine. Alternatively spliced transcript variants have been observed for this gene. Single nucleotide polymorphisms in this gene have been associated with both nicotine and alcohol dependence. [provided by RefSeq, Dec 2010]\", \"label\": \"cholinergic receptor nicotinic alpha 6 subunit\", \"cname\": \"CHRNA6\", \"id\": [\"Gene\", \"HGNC\", \"CHRNA6\"]}, {\"function\": \"Gene\", \"namespace\": \"HGNC\", \"name\": \"CHRNA7\", \"description\": \"The nicotinic acetylcholine receptors (nAChRs) are members of a superfamily of ligand-gated ion channels that mediate fast signal transmission at synapses. The nAChRs are thought to be hetero-pentamers composed of homologous subunits. The proposed structure for each subunit is a conserved N-terminal extracellular domain followed by three conserved transmembrane domains, a variable cytoplasmic loop, a fourth conserved transmembrane domain, and a short C-terminal extracellular region. The protein encoded by this gene forms a homo-oligomeric channel, displays marked permeability to calcium ions and is a major component of brain nicotinic receptors that are blocked by, and highly sensitive to, alpha-bungarotoxin. Once this receptor binds acetylcholine, it undergoes an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. This gene is located in a region identified as a major susceptibility locus for juvenile myoclonic epilepsy and a chromosomal location involved in the genetic transmission of schizophrenia. An evolutionarily recent partial duplication event in this region results in a hybrid containing sequence from this gene and a novel FAM7A gene. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Feb 2012]\", \"label\": \"cholinergic receptor nicotinic alpha 7 subunit\", \"cname\": \"CHRNA7\", \"id\": [\"Gene\", \"HGNC\", \"CHRNA7\"]}, {\"function\": \"Gene\", \"namespace\": \"HGNC\", \"name\": \"CHRNA9\", \"description\": \"This gene is a member of the ligand-gated ionic channel family and nicotinic acetylcholine receptor gene superfamily. It encodes a plasma membrane protein that forms homo- or hetero-oligomeric divalent cation channels. This protein is involved in cochlea hair cell development and is also expressed in the outer hair cells (OHCs) of the adult cochlea. [provided by RefSeq, Feb 2012]\", \"label\": \"cholinergic receptor nicotinic alpha 9 subunit\", \"cname\": \"CHRNA9\", \"id\": [\"Gene\", \"HGNC\", \"CHRNA9\"]}, {\"function\": \"Gene\", \"namespace\": \"HGNC\", \"name\": \"CHRNA10\", \"description\": null, \"label\": \"cholinergic receptor nicotinic alpha 10 subunit\", \"cname\": \"CHRNA10\", \"id\": [\"Gene\", \"HGNC\", \"CHRNA10\"]}, {\"function\": \"Gene\", \"namespace\": \"HGNC\", \"name\": \"CHRNB3\", \"description\": \"The nicotinic acetylcholine receptors (nAChRs) are members of a superfamily of ligand-gated ion channels that mediate fast signal transmission at synapses. The nAChRs are (hetero)pentamers composed of homologous subunits. The subunits that make up the muscle and neuronal forms of nAChRs are encoded by separate genes and have different primary structure. There are several subtypes of neuronal nAChRs that vary based on which homologous subunits are arranged around the central channel. They are classified as alpha-subunits if, like muscle alpha-1 (MIM 100690), they have a pair of adjacent cysteines as part of the presumed acetylcholine binding site. Subunits lacking these cysteine residues are classified as beta-subunits (Groot Kormelink and Luyten, 1997 [PubMed 9009220]). Elliott et al. (1996) [PubMed 8906617] stated that the proposed structure for each subunit is a conserved N-terminal extracellular domain followed by 3 conserved transmembrane domains, a variable cytoplasmic loop, a fourth conserved transmembrane domain, and a short C-terminal extracellular region.[supplied by OMIM, Apr 2010]\", \"label\": \"cholinergic receptor nicotinic beta 3 subunit\", \"cname\": \"CHRNB3\", \"id\": [\"Gene\", \"HGNC\", \"CHRNB3\"]}, {\"function\": \"Gene\", \"namespace\": \"HGNC\", \"name\": \"CHRNB4\", \"description\": null, \"label\": \"cholinergic receptor nicotinic beta 4 subunit\", \"cname\": \"CHRNB4\", \"id\": [\"Gene\", \"HGNC\", \"CHRNB4\"]}, {\"function\": \"Gene\", \"namespace\": \"HGNC\", \"name\": \"GABBR2\", \"description\": \"The multi-pass membrane protein encoded by this gene belongs to the G-protein coupled receptor 3 family and GABA-B receptor subfamily. The GABA-B receptors inhibit neuronal activity through G protein-coupled second-messenger systems, which regulate the release of neurotransmitters, and the activity of ion channels and adenylyl cyclase. This receptor subunit forms an active heterodimeric complex with GABA-B receptor subunit 1, neither of which is effective on its own. Allelic variants of this gene have been associated with nicotine dependence.[provided by RefSeq, Jan 2010]\", \"label\": \"gamma-aminobutyric acid type B receptor subunit 2\", \"cname\": \"GABBR2\", \"id\": [\"Gene\", \"HGNC\", \"GABBR2\"]}, {\"function\": \"Gene\", \"namespace\": \"HGNC\", \"name\": \"PRKCA\", \"description\": \"Protein kinase C (PKC) is a family of serine- and threonine-specific protein kinases that can be activated by calcium and the second messenger diacylglycerol. PKC family members phosphorylate a wide variety of protein targets and are known to be involved in diverse cellular signaling pathways. PKC family members also serve as major receptors for phorbol esters, a class of tumor promoters. Each member of the PKC family has a specific expression profile and is believed to play a distinct role in cells. The protein encoded by this gene is one of the PKC family members. This kinase has been reported to play roles in many different cellular processes, such as cell adhesion, cell transformation, cell cycle checkpoint, and cell volume control. Knockout studies in mice suggest that this kinase may be a fundamental regulator of cardiac contractility and Ca(2+) handling in myocytes. [provided by RefSeq, Jul 2008]\", \"label\": \"protein kinase C alpha\", \"cname\": \"PRKCA\", \"id\": [\"Gene\", \"HGNC\", \"PRKCA\"]}, {\"function\": \"Gene\", \"namespace\": \"HGNC\", \"name\": \"GPHN\", \"description\": \"This gene encodes a neuronal assembly protein that anchors inhibitory neurotransmitter receptors to the postsynaptic cytoskeleton via high affinity binding to a receptor subunit domain and tubulin dimers. In nonneuronal tissues, the encoded protein is also required for molybdenum cofactor biosynthesis. Mutations in this gene may be associated with the neurological condition hyperplexia and also lead to molybdenum cofactor deficiency. Numerous alternatively spliced transcript variants encoding different isoforms have been described; however, the full-length nature of all transcript variants is not currently known. [provided by RefSeq, Jul 2008]\", \"label\": \"gephyrin\", \"cname\": \"GPHN\", \"id\": [\"Gene\", \"HGNC\", \"GPHN\"]}, {\"function\": \"Gene\", \"namespace\": \"HGNC\", \"name\": \"GRIA1\", \"description\": \"Glutamate receptors are the predominant excitatory neurotransmitter receptors in the mammalian brain and are activated in a variety of normal neurophysiologic processes. These receptors are heteromeric protein complexes with multiple subunits, each possessing transmembrane regions, and all arranged to form a ligand-gated ion channel. The classification of glutamate receptors is based on their activation by different pharmacologic agonists. This gene belongs to a family of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) receptors. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]\", \"label\": \"glutamate ionotropic receptor AMPA type subunit 1\", \"cname\": \"GRIA1\", \"id\": [\"Gene\", \"HGNC\", \"GRIA1\"]}], \"links\": [{\"relation\": \"negativeCorrelation\", \"evidence\": \"Further, EGR1 levels were negatively correlated with hippocampal amyloid- plaque burden.This study presents global gene expression profiles associated with GA immunization in a glaucoma rat model.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Investigative ophthalmology &amp; visual science\", \"reference\": \"21969301\", \"authors\": [\"Bakalash S\", \"Pham M\", \"Koronyo Y\", \"Salumbides BC\", \"Kramerov A\", \"Seidenberg H\", \"Berel D\", \"Black KL\", \"Koronyo-Hamaoui M\"], \"date\": \"2011-11-21\", \"title\": \"Egr1 expression is induced following glatiramer acetate immunotherapy in rodent models of glaucoma and Alzheimer's disease.\", \"lastauthor\": \"Koronyo-Hamaoui M\", \"volume\": \"52\", \"issue\": \"12\", \"pages\": \"9033-46\", \"firstauthor\": \"Bakalash S\"}, \"line\": 17223, \"annotations\": {\"Disease\": \"Alzheimer's disease\", \"Species\": \"10116\", \"MeSHDisease\": \"Glaucoma\", \"MeSHAnatomy\": \"Hippocampus\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 0, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"In AD-Tg mice, a significant increase in hippocampal EGR1 protein levels was also found in response to GA immunization.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Investigative ophthalmology &amp; visual science\", \"reference\": \"21969301\", \"authors\": [\"Bakalash S\", \"Pham M\", \"Koronyo Y\", \"Salumbides BC\", \"Kramerov A\", \"Seidenberg H\", \"Berel D\", \"Black KL\", \"Koronyo-Hamaoui M\"], \"date\": \"2011-11-21\", \"title\": \"Egr1 expression is induced following glatiramer acetate immunotherapy in rodent models of glaucoma and Alzheimer's disease.\", \"lastauthor\": \"Koronyo-Hamaoui M\", \"volume\": \"52\", \"issue\": \"12\", \"pages\": \"9033-46\", \"firstauthor\": \"Bakalash S\"}, \"line\": 17211, \"annotations\": {\"Disease\": \"Alzheimer's disease\", \"MeSHAnatomy\": \"Hippocampus\", \"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 4, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Egr-1 upregulates the Alzheimer's disease presenilin-2 gene in neuronal cells.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Gene\", \"reference\": \"14585504\", \"authors\": [\"Renbaum P\", \"Beeri R\", \"Gabai E\", \"Amiel M\", \"Gal M\", \"Ehrengruber MU\", \"Levy-Lahad E\"], \"date\": \"2003-10-30\", \"title\": \"Egr-1 upregulates the Alzheimer's disease presenilin-2 gene in neuronal cells.\", \"lastauthor\": \"Levy-Lahad E\", \"volume\": \"318\", \"issue\": \"\", \"pages\": \"113-24\", \"firstauthor\": \"Renbaum P\"}, \"line\": 17249, \"annotations\": {\"Disease\": \"Alzheimer's disease\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 4, \"key\": 1}, {\"relation\": \"association\", \"evidence\": \"Most forms of neuronal plasticity are associated with the induction of the transcription factor zif268 (egr1).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17148, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 35, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17154, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 8, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17155, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 9, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17156, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 10, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17157, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 11, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17158, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 12, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17159, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 13, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17160, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 14, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17161, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 15, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17162, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 16, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17163, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 17, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17164, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 18, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17165, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 19, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17166, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 20, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17167, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 21, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17168, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 22, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17169, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 23, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17170, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 25, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Induction of zif268 in neurons leads to altered expression of proteasome subunit and proteasome-regulatory genes, thereby changing the capacity of the neuron to degrade synaptic proteins, including receptors and receptor subunits.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17177, \"annotations\": {\"MeSHAnatomy\": \"Neurons\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 57, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"In addition, zif268 alters the transcription of genes associated with GABA(A)R expression and trafficking, such as ubiquilin and gephyrin.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17182, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 58, \"key\": 0}, {\"relation\": \"negativeCorrelation\", \"evidence\": \"Further, EGR1 levels were negatively correlated with hippocampal amyloid- plaque burden.This study presents global gene expression profiles associated with GA immunization in a glaucoma rat model.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Investigative ophthalmology &amp; visual science\", \"reference\": \"21969301\", \"authors\": [\"Bakalash S\", \"Pham M\", \"Koronyo Y\", \"Salumbides BC\", \"Kramerov A\", \"Seidenberg H\", \"Berel D\", \"Black KL\", \"Koronyo-Hamaoui M\"], \"date\": \"2011-11-21\", \"title\": \"Egr1 expression is induced following glatiramer acetate immunotherapy in rodent models of glaucoma and Alzheimer's disease.\", \"lastauthor\": \"Koronyo-Hamaoui M\", \"volume\": \"52\", \"issue\": \"12\", \"pages\": \"9033-46\", \"firstauthor\": \"Bakalash S\"}, \"line\": 17223, \"annotations\": {\"Disease\": \"Alzheimer's disease\", \"Species\": \"10116\", \"MeSHDisease\": \"Glaucoma\", \"MeSHAnatomy\": \"Hippocampus\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 0, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Further, EGR1 levels were negatively correlated with hippocampal amyloid- plaque burden.This study presents global gene expression profiles associated with GA immunization in a glaucoma rat model.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Investigative ophthalmology &amp; visual science\", \"reference\": \"21969301\", \"authors\": [\"Bakalash S\", \"Pham M\", \"Koronyo Y\", \"Salumbides BC\", \"Kramerov A\", \"Seidenberg H\", \"Berel D\", \"Black KL\", \"Koronyo-Hamaoui M\"], \"date\": \"2011-11-21\", \"title\": \"Egr1 expression is induced following glatiramer acetate immunotherapy in rodent models of glaucoma and Alzheimer's disease.\", \"lastauthor\": \"Koronyo-Hamaoui M\", \"volume\": \"52\", \"issue\": \"12\", \"pages\": \"9033-46\", \"firstauthor\": \"Bakalash S\"}, \"line\": 17224, \"annotations\": {\"Disease\": \"Alzheimer's disease\", \"Species\": \"10116\", \"MeSHDisease\": \"Glaucoma\", \"MeSHAnatomy\": \"Hippocampus\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 59, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Egr-1 upregulates the Alzheimer's disease presenilin-2 gene in neuronal cells.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Gene\", \"reference\": \"14585504\", \"authors\": [\"Renbaum P\", \"Beeri R\", \"Gabai E\", \"Amiel M\", \"Gal M\", \"Ehrengruber MU\", \"Levy-Lahad E\"], \"date\": \"2003-10-30\", \"title\": \"Egr-1 upregulates the Alzheimer's disease presenilin-2 gene in neuronal cells.\", \"lastauthor\": \"Levy-Lahad E\", \"volume\": \"318\", \"issue\": \"\", \"pages\": \"113-24\", \"firstauthor\": \"Renbaum P\"}, \"line\": 17248, \"annotations\": {\"Disease\": \"Alzheimer's disease\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 6, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"In immunoblotting analysis, nefiracetam treatment increased the PKCalpha activity with a bell-shaped dose-response relationship peaking at 10 nM, thereby increasing phosphorylation of PKC substrate and NMDA receptor. Nefiracetam treatment did not affect the PKA activity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Molecular pharmacology\", \"reference\": \"17095583\", \"authors\": [\"Moriguchi S\", \"Shioda N\", \"Maejima H\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2007-02-01\", \"title\": \"Nefiracetam potentiates N-methyl-D-aspartate (NMDA) receptor function via protein kinase C activation and reduces magnesium block of NMDA receptor.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"71\", \"issue\": \"2\", \"pages\": \"580-7\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14364, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 2, \"target\": 3, \"key\": 0}, {\"relation\": \"hasVariant\", \"annotations\": {}, \"source\": 2, \"target\": 0, \"key\": -4}, {\"relation\": \"decreases\", \"evidence\": \"The nefiracetam-induced increase in the frequency of mEPSCs and mIPSCs over and above the level achieved by ACh alone would contribute to the therapeutic effect of nefiracetam as the cholinergic system is known to be downregulated in the brain of Alzheimer's disease patients.The therapeutic effects of galantamine are ascribed to the modest potentiation of nACh receptor and NMDA receptor activities in addition to the modest inhibition of acetylcholinesterase.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14418, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 4, \"target\": 5, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"In AD-Tg mice, a significant increase in hippocampal EGR1 protein levels was also found in response to GA immunization.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Investigative ophthalmology &amp; visual science\", \"reference\": \"21969301\", \"authors\": [\"Bakalash S\", \"Pham M\", \"Koronyo Y\", \"Salumbides BC\", \"Kramerov A\", \"Seidenberg H\", \"Berel D\", \"Black KL\", \"Koronyo-Hamaoui M\"], \"date\": \"2011-11-21\", \"title\": \"Egr1 expression is induced following glatiramer acetate immunotherapy in rodent models of glaucoma and Alzheimer's disease.\", \"lastauthor\": \"Koronyo-Hamaoui M\", \"volume\": \"52\", \"issue\": \"12\", \"pages\": \"9033-46\", \"firstauthor\": \"Bakalash S\"}, \"line\": 17211, \"annotations\": {\"Disease\": \"Alzheimer's disease\", \"MeSHAnatomy\": \"Hippocampus\", \"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 4, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Egr-1 upregulates the Alzheimer's disease presenilin-2 gene in neuronal cells.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Gene\", \"reference\": \"14585504\", \"authors\": [\"Renbaum P\", \"Beeri R\", \"Gabai E\", \"Amiel M\", \"Gal M\", \"Ehrengruber MU\", \"Levy-Lahad E\"], \"date\": \"2003-10-30\", \"title\": \"Egr-1 upregulates the Alzheimer's disease presenilin-2 gene in neuronal cells.\", \"lastauthor\": \"Levy-Lahad E\", \"volume\": \"318\", \"issue\": \"\", \"pages\": \"113-24\", \"firstauthor\": \"Renbaum P\"}, \"line\": 17249, \"annotations\": {\"Disease\": \"Alzheimer's disease\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 4, \"target\": 1, \"key\": 1}, {\"relation\": \"association\", \"evidence\": \"Egr-1 upregulates the Alzheimer's disease presenilin-2 gene in neuronal cells.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Gene\", \"reference\": \"14585504\", \"authors\": [\"Renbaum P\", \"Beeri R\", \"Gabai E\", \"Amiel M\", \"Gal M\", \"Ehrengruber MU\", \"Levy-Lahad E\"], \"date\": \"2003-10-30\", \"title\": \"Egr-1 upregulates the Alzheimer's disease presenilin-2 gene in neuronal cells.\", \"lastauthor\": \"Levy-Lahad E\", \"volume\": \"318\", \"issue\": \"\", \"pages\": \"113-24\", \"firstauthor\": \"Renbaum P\"}, \"line\": 17250, \"annotations\": {\"Disease\": \"Alzheimer's disease\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 4, \"target\": 6, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Egr-1 upregulates the Alzheimer's disease presenilin-2 gene in neuronal cells.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Gene\", \"reference\": \"14585504\", \"authors\": [\"Renbaum P\", \"Beeri R\", \"Gabai E\", \"Amiel M\", \"Gal M\", \"Ehrengruber MU\", \"Levy-Lahad E\"], \"date\": \"2003-10-30\", \"title\": \"Egr-1 upregulates the Alzheimer's disease presenilin-2 gene in neuronal cells.\", \"lastauthor\": \"Levy-Lahad E\", \"volume\": \"318\", \"issue\": \"\", \"pages\": \"113-24\", \"firstauthor\": \"Renbaum P\"}, \"line\": 17250, \"annotations\": {\"Disease\": \"Alzheimer's disease\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 6, \"target\": 4, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF-  can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators of inflammation\", \"reference\": \"24966471\", \"authors\": [\"Olmos G\", \"Llad J\"], \"date\": \"2014-01-01\", \"title\": \"Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity.\", \"lastauthor\": \"Llad J\", \"volume\": \"2014\", \"issue\": \"\", \"pages\": \"861231\", \"firstauthor\": \"Olmos G\"}, \"line\": 21557, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 8, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF-  can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators of inflammation\", \"reference\": \"24966471\", \"authors\": [\"Olmos G\", \"Llad J\"], \"date\": \"2014-01-01\", \"title\": \"Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity.\", \"lastauthor\": \"Llad J\", \"volume\": \"2014\", \"issue\": \"\", \"pages\": \"861231\", \"firstauthor\": \"Olmos G\"}, \"line\": 21558, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 9, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF-  can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators of inflammation\", \"reference\": \"24966471\", \"authors\": [\"Olmos G\", \"Llad J\"], \"date\": \"2014-01-01\", \"title\": \"Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity.\", \"lastauthor\": \"Llad J\", \"volume\": \"2014\", \"issue\": \"\", \"pages\": \"861231\", \"firstauthor\": \"Olmos G\"}, \"line\": 21559, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 10, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF-  can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators of inflammation\", \"reference\": \"24966471\", \"authors\": [\"Olmos G\", \"Llad J\"], \"date\": \"2014-01-01\", \"title\": \"Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity.\", \"lastauthor\": \"Llad J\", \"volume\": \"2014\", \"issue\": \"\", \"pages\": \"861231\", \"firstauthor\": \"Olmos G\"}, \"line\": 21560, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 11, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF-  can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators of inflammation\", \"reference\": \"24966471\", \"authors\": [\"Olmos G\", \"Llad J\"], \"date\": \"2014-01-01\", \"title\": \"Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity.\", \"lastauthor\": \"Llad J\", \"volume\": \"2014\", \"issue\": \"\", \"pages\": \"861231\", \"firstauthor\": \"Olmos G\"}, \"line\": 21561, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 12, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF-  can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators of inflammation\", \"reference\": \"24966471\", \"authors\": [\"Olmos G\", \"Llad J\"], \"date\": \"2014-01-01\", \"title\": \"Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity.\", \"lastauthor\": \"Llad J\", \"volume\": \"2014\", \"issue\": \"\", \"pages\": \"861231\", \"firstauthor\": \"Olmos G\"}, \"line\": 21562, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 13, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF-  can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators of inflammation\", \"reference\": \"24966471\", \"authors\": [\"Olmos G\", \"Llad J\"], \"date\": \"2014-01-01\", \"title\": \"Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity.\", \"lastauthor\": \"Llad J\", \"volume\": \"2014\", \"issue\": \"\", \"pages\": \"861231\", \"firstauthor\": \"Olmos G\"}, \"line\": 21563, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 14, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF-  can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators of inflammation\", \"reference\": \"24966471\", \"authors\": [\"Olmos G\", \"Llad J\"], \"date\": \"2014-01-01\", \"title\": \"Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity.\", \"lastauthor\": \"Llad J\", \"volume\": \"2014\", \"issue\": \"\", \"pages\": \"861231\", \"firstauthor\": \"Olmos G\"}, \"line\": 21564, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 15, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF-  can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators of inflammation\", \"reference\": \"24966471\", \"authors\": [\"Olmos G\", \"Llad J\"], \"date\": \"2014-01-01\", \"title\": \"Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity.\", \"lastauthor\": \"Llad J\", \"volume\": \"2014\", \"issue\": \"\", \"pages\": \"861231\", \"firstauthor\": \"Olmos G\"}, \"line\": 21565, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 16, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF-  can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators of inflammation\", \"reference\": \"24966471\", \"authors\": [\"Olmos G\", \"Llad J\"], \"date\": \"2014-01-01\", \"title\": \"Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity.\", \"lastauthor\": \"Llad J\", \"volume\": \"2014\", \"issue\": \"\", \"pages\": \"861231\", \"firstauthor\": \"Olmos G\"}, \"line\": 21566, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 17, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF-  can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators of inflammation\", \"reference\": \"24966471\", \"authors\": [\"Olmos G\", \"Llad J\"], \"date\": \"2014-01-01\", \"title\": \"Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity.\", \"lastauthor\": \"Llad J\", \"volume\": \"2014\", \"issue\": \"\", \"pages\": \"861231\", \"firstauthor\": \"Olmos G\"}, \"line\": 21567, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 18, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF-  can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators of inflammation\", \"reference\": \"24966471\", \"authors\": [\"Olmos G\", \"Llad J\"], \"date\": \"2014-01-01\", \"title\": \"Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity.\", \"lastauthor\": \"Llad J\", \"volume\": \"2014\", \"issue\": \"\", \"pages\": \"861231\", \"firstauthor\": \"Olmos G\"}, \"line\": 21568, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 19, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF-  can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators of inflammation\", \"reference\": \"24966471\", \"authors\": [\"Olmos G\", \"Llad J\"], \"date\": \"2014-01-01\", \"title\": \"Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity.\", \"lastauthor\": \"Llad J\", \"volume\": \"2014\", \"issue\": \"\", \"pages\": \"861231\", \"firstauthor\": \"Olmos G\"}, \"line\": 21569, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 20, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF-  can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators of inflammation\", \"reference\": \"24966471\", \"authors\": [\"Olmos G\", \"Llad J\"], \"date\": \"2014-01-01\", \"title\": \"Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity.\", \"lastauthor\": \"Llad J\", \"volume\": \"2014\", \"issue\": \"\", \"pages\": \"861231\", \"firstauthor\": \"Olmos G\"}, \"line\": 21570, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 21, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF-  can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators of inflammation\", \"reference\": \"24966471\", \"authors\": [\"Olmos G\", \"Llad J\"], \"date\": \"2014-01-01\", \"title\": \"Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity.\", \"lastauthor\": \"Llad J\", \"volume\": \"2014\", \"issue\": \"\", \"pages\": \"861231\", \"firstauthor\": \"Olmos G\"}, \"line\": 21571, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 22, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF-  can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators of inflammation\", \"reference\": \"24966471\", \"authors\": [\"Olmos G\", \"Llad J\"], \"date\": \"2014-01-01\", \"title\": \"Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity.\", \"lastauthor\": \"Llad J\", \"volume\": \"2014\", \"issue\": \"\", \"pages\": \"861231\", \"firstauthor\": \"Olmos G\"}, \"line\": 21572, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 23, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF-  can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators of inflammation\", \"reference\": \"24966471\", \"authors\": [\"Olmos G\", \"Llad J\"], \"date\": \"2014-01-01\", \"title\": \"Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity.\", \"lastauthor\": \"Llad J\", \"volume\": \"2014\", \"issue\": \"\", \"pages\": \"861231\", \"firstauthor\": \"Olmos G\"}, \"line\": 21573, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 24, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17128, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 8, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17154, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 8, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"1-(3-chlorophenyl)piperazine affects the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein co-treated with GABBR2 protein co-treated with GABRG2 protein]]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neurotoxicology\", \"reference\": \"21729720\", \"authors\": [\"Hondebrink L\", \"Meulenbelt J\", \"van Kleef RG\", \"van den Berg M\", \"Westerink RH\"], \"date\": \"2011-12-01\", \"title\": \"Modulation of human GABAA receptor function: a novel mode of action of drugs of abuse.\", \"lastauthor\": \"Westerink RH\", \"volume\": \"32\", \"issue\": \"6\", \"pages\": \"823-7\", \"firstauthor\": \"Hondebrink L\"}, \"line\": 46705, \"annotations\": {\"Species\": \"9606\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 8, \"target\": 46, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17129, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 9, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17155, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 9, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17130, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 10, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17156, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 10, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17131, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 11, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17157, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 11, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17132, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 12, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17158, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 12, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17133, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 13, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17159, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 13, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17134, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 14, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17160, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 14, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17135, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 15, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17161, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 15, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17136, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 16, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17162, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 16, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17137, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 17, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17163, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 17, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17138, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 18, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17164, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 18, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17139, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 19, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17165, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 19, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17140, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 20, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17166, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 20, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17141, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 21, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17167, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 21, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17142, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 22, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17168, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 22, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17143, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 23, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17169, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 23, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17144, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 25, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17170, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 25, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17128, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 8, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17129, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 9, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17130, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 10, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17131, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 11, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17132, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 12, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17133, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 13, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17134, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 14, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17135, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 15, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17136, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 16, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17137, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 17, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17138, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 18, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17139, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 19, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17140, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 20, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17141, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 21, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17142, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 22, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17143, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 23, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17144, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 25, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"In conclusion, nefiracetam enhances NMDA-receptor function through stimulation of its glycine binding site and nefiracetam-induced CaMKII activation likely contributes to improvement of cognition, learning, and memory.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of pharmacological sciences\", \"reference\": \"21821968\", \"authors\": [\"Moriguchi S\"], \"date\": \"2011-01-01\", \"title\": \"Pharmacological study on Alzheimer's drugs targeting calcium/calmodulin-dependent protein kinase II.\", \"lastauthor\": \"Moriguchi S\", \"volume\": \"117\", \"issue\": \"1\", \"pages\": \"6-11\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14460, \"annotations\": {\"Species\": \"10116\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 27, \"target\": 28, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"In conclusion, nefiracetam enhances NMDA-receptor function through stimulation of its glycine binding site and nefiracetam-induced CaMKII activation likely contributes to improvement of cognition, learning, and memory.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of pharmacological sciences\", \"reference\": \"21821968\", \"authors\": [\"Moriguchi S\"], \"date\": \"2011-01-01\", \"title\": \"Pharmacological study on Alzheimer's drugs targeting calcium/calmodulin-dependent protein kinase II.\", \"lastauthor\": \"Moriguchi S\", \"volume\": \"117\", \"issue\": \"1\", \"pages\": \"6-11\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14461, \"annotations\": {\"Species\": \"10116\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 27, \"target\": 29, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"In conclusion, nefiracetam enhances NMDA-receptor function through stimulation of its glycine binding site and nefiracetam-induced CaMKII activation likely contributes to improvement of cognition, learning, and memory.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of pharmacological sciences\", \"reference\": \"21821968\", \"authors\": [\"Moriguchi S\"], \"date\": \"2011-01-01\", \"title\": \"Pharmacological study on Alzheimer's drugs targeting calcium/calmodulin-dependent protein kinase II.\", \"lastauthor\": \"Moriguchi S\", \"volume\": \"117\", \"issue\": \"1\", \"pages\": \"6-11\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14462, \"annotations\": {\"Species\": \"10116\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 27, \"target\": 30, \"key\": 0}, {\"relation\": \"hasVariant\", \"annotations\": {}, \"source\": 27, \"target\": 3, \"key\": -4}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14391, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 31, \"target\": 32, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14402, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 31, \"target\": 33, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14397, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 34, \"target\": 33, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14408, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 34, \"target\": 33, \"key\": 1}, {\"relation\": \"association\", \"evidence\": \"Most forms of neuronal plasticity are associated with the induction of the transcription factor zif268 (egr1).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17148, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 35, \"target\": 1, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14389, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 36, \"target\": 32, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14400, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 36, \"target\": 33, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14390, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 37, \"target\": 32, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14401, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 37, \"target\": 33, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14392, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 38, \"target\": 32, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14403, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 38, \"target\": 33, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14393, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 39, \"target\": 32, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14404, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 39, \"target\": 33, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14394, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 40, \"target\": 32, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14405, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 40, \"target\": 33, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14395, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 41, \"target\": 32, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14406, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 41, \"target\": 33, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14396, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 42, \"target\": 32, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14407, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 42, \"target\": 33, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14398, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 43, \"target\": 33, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14409, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 43, \"target\": 33, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14399, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 44, \"target\": 33, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14410, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 44, \"target\": 33, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14378, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 45, \"target\": 36, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14379, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 45, \"target\": 37, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14380, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 45, \"target\": 31, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14381, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 45, \"target\": 38, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14382, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 45, \"target\": 39, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14383, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 45, \"target\": 40, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14384, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 45, \"target\": 41, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14385, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 45, \"target\": 42, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14386, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 45, \"target\": 34, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14387, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 45, \"target\": 43, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14388, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 45, \"target\": 44, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"1-(3-chlorophenyl)piperazine affects the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein co-treated with GABBR2 protein co-treated with GABRG2 protein]]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neurotoxicology\", \"reference\": \"21729720\", \"authors\": [\"Hondebrink L\", \"Meulenbelt J\", \"van Kleef RG\", \"van den Berg M\", \"Westerink RH\"], \"date\": \"2011-12-01\", \"title\": \"Modulation of human GABAA receptor function: a novel mode of action of drugs of abuse.\", \"lastauthor\": \"Westerink RH\", \"volume\": \"32\", \"issue\": \"6\", \"pages\": \"823-7\", \"firstauthor\": \"Hondebrink L\"}, \"line\": 46705, \"annotations\": {\"Species\": \"9606\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 46, \"target\": 8, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"In this work, we describe a novel non-coding (nc) RNA (named 17A) RNA polymerase (pol) III-dependent embedded in the human G-protein-coupled receptor 51 gene (GPR51, GABA B2 receptor). The stable expression of 17A in SHSY5Y neuroblastoma cells induces the synthesis of an alternative splicing isoform that abolish GABA B2 intracellular signaling (i.e., inhibition of cAMP accumulation and activation of K(+) channels). Indeed, 17A is expressed in human brain, and we report that it is upregulated in cerebral tissues derived from Alzheimer disease patients. We demonstrate that 17A expression in neuroblastoma cells enhances the secretion of amyloid  peptide (Abeta) and the Abeta x-42/ x-40 peptide ratio and that its synthesis is induced in response to inflammatory stimuli.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neurobiology of disease\", \"reference\": \"20888417\", \"authors\": [\"Massone S\", \"Vassallo I\", \"Fiorino G\", \"Castelnuovo M\", \"Barbieri F\", \"Borghi R\", \"Tabaton M\", \"Robello M\", \"Gatta E\", \"Russo C\", \"Florio T\", \"Dieci G\", \"Cancedda R\", \"Pagano A\"], \"date\": \"2011-02-01\", \"title\": \"17A, a novel non-coding RNA, regulates GABA B alternative splicing and signaling in response to inflammatory stimuli and in Alzheimer disease.\", \"lastauthor\": \"Pagano A\", \"volume\": \"41\", \"issue\": \"2\", \"pages\": \"308-17\", \"firstauthor\": \"Massone S\"}, \"line\": 33227, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 47, \"target\": 48, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Nefiracetam is undergoing preclinical and clinical tests as a cognition-enhancing drug in Alzheimer's disease (AD).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Psychopharmacology\", \"reference\": \"9201800\", \"authors\": [\"Woodruff-Pak DS\", \"Hinchliffe RM\"], \"date\": \"1997-05-01\", \"title\": \"Mecamylamine- or scopolamine-induced learning impairment: ameliorated by nefiracetam.\", \"lastauthor\": \"Hinchliffe RM\", \"volume\": \"131\", \"issue\": \"2\", \"pages\": \"130-9\", \"firstauthor\": \"Woodruff-Pak DS\"}, \"line\": 14320, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 28, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The nootropic compound nefiracetam was evaluated in 88 older rabbits in a 750-ms delay paradigm of eyeblink classical conditioning (EBCC). Nefiracetam facilitated acquisition of EBCC in older rabbits. EBCC is performed poorly by older humans and is seriously impaired in Alzheimer's disease. These preclinical data in an animal model with clear parallels in humans suggest that nefiracetam may prove effective as a cognition enhancer in clinical trials.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Psychopharmacology\", \"reference\": \"7838908\", \"authors\": [\"Woodruff-Pak DS\", \"Li YT\"], \"date\": \"1994-03-01\", \"title\": \"Nefiracetam (DM-9384): effect on eyeblink classical conditioning in older rabbits.\", \"lastauthor\": \"Li YT\", \"volume\": \"114\", \"issue\": \"2\", \"pages\": \"200-8\", \"firstauthor\": \"Woodruff-Pak DS\"}, \"line\": 14332, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 28, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain research. Molecular brain research\", \"reference\": \"11039729\", \"authors\": [\"Nishizaki T\", \"Nomura T\", \"Matuoka T\", \"Kondoh T\", \"Enikolopov G\", \"Sumikawa K\", \"Watabe S\", \"Shiotani T\", \"Yoshii M\"], \"date\": \"2000-08-14\", \"title\": \"The anti-dementia drug nefiracetam facilitates hippocampal synaptic transmission by functionally targeting presynaptic nicotinic ACh receptors.\", \"lastauthor\": \"Yoshii M\", \"volume\": \"80\", \"issue\": \"1\", \"pages\": \"53-62\", \"firstauthor\": \"Nishizaki T\"}, \"line\": 14492, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 28, \"key\": 2}, {\"relation\": \"increases\", \"evidence\": \"We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Molecular pharmacology\", \"reference\": \"17095583\", \"authors\": [\"Moriguchi S\", \"Shioda N\", \"Maejima H\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2007-02-01\", \"title\": \"Nefiracetam potentiates N-methyl-D-aspartate (NMDA) receptor function via protein kinase C activation and reduces magnesium block of NMDA receptor.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"71\", \"issue\": \"2\", \"pages\": \"580-7\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14346, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 27, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"In conclusion, nefiracetam enhances NMDA-receptor function through stimulation of its glycine binding site and nefiracetam-induced CaMKII activation likely contributes to improvement of cognition, learning, and memory.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of pharmacological sciences\", \"reference\": \"21821968\", \"authors\": [\"Moriguchi S\"], \"date\": \"2011-01-01\", \"title\": \"Pharmacological study on Alzheimer's drugs targeting calcium/calmodulin-dependent protein kinase II.\", \"lastauthor\": \"Moriguchi S\", \"volume\": \"117\", \"issue\": \"1\", \"pages\": \"6-11\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14458, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10116\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 27, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Molecular pharmacology\", \"reference\": \"17095583\", \"authors\": [\"Moriguchi S\", \"Shioda N\", \"Maejima H\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2007-02-01\", \"title\": \"Nefiracetam potentiates N-methyl-D-aspartate (NMDA) receptor function via protein kinase C activation and reduces magnesium block of NMDA receptor.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"71\", \"issue\": \"2\", \"pages\": \"580-7\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14347, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 36, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Molecular pharmacology\", \"reference\": \"17095583\", \"authors\": [\"Moriguchi S\", \"Shioda N\", \"Maejima H\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2007-02-01\", \"title\": \"Nefiracetam potentiates N-methyl-D-aspartate (NMDA) receptor function via protein kinase C activation and reduces magnesium block of NMDA receptor.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"71\", \"issue\": \"2\", \"pages\": \"580-7\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14348, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 37, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Molecular pharmacology\", \"reference\": \"17095583\", \"authors\": [\"Moriguchi S\", \"Shioda N\", \"Maejima H\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2007-02-01\", \"title\": \"Nefiracetam potentiates N-methyl-D-aspartate (NMDA) receptor function via protein kinase C activation and reduces magnesium block of NMDA receptor.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"71\", \"issue\": \"2\", \"pages\": \"580-7\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14349, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 31, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Molecular pharmacology\", \"reference\": \"17095583\", \"authors\": [\"Moriguchi S\", \"Shioda N\", \"Maejima H\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2007-02-01\", \"title\": \"Nefiracetam potentiates N-methyl-D-aspartate (NMDA) receptor function via protein kinase C activation and reduces magnesium block of NMDA receptor.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"71\", \"issue\": \"2\", \"pages\": \"580-7\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14350, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 38, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Molecular pharmacology\", \"reference\": \"17095583\", \"authors\": [\"Moriguchi S\", \"Shioda N\", \"Maejima H\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2007-02-01\", \"title\": \"Nefiracetam potentiates N-methyl-D-aspartate (NMDA) receptor function via protein kinase C activation and reduces magnesium block of NMDA receptor.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"71\", \"issue\": \"2\", \"pages\": \"580-7\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14351, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 39, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Molecular pharmacology\", \"reference\": \"17095583\", \"authors\": [\"Moriguchi S\", \"Shioda N\", \"Maejima H\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2007-02-01\", \"title\": \"Nefiracetam potentiates N-methyl-D-aspartate (NMDA) receptor function via protein kinase C activation and reduces magnesium block of NMDA receptor.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"71\", \"issue\": \"2\", \"pages\": \"580-7\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14352, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 40, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Molecular pharmacology\", \"reference\": \"17095583\", \"authors\": [\"Moriguchi S\", \"Shioda N\", \"Maejima H\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2007-02-01\", \"title\": \"Nefiracetam potentiates N-methyl-D-aspartate (NMDA) receptor function via protein kinase C activation and reduces magnesium block of NMDA receptor.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"71\", \"issue\": \"2\", \"pages\": \"580-7\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14353, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 41, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Molecular pharmacology\", \"reference\": \"17095583\", \"authors\": [\"Moriguchi S\", \"Shioda N\", \"Maejima H\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2007-02-01\", \"title\": \"Nefiracetam potentiates N-methyl-D-aspartate (NMDA) receptor function via protein kinase C activation and reduces magnesium block of NMDA receptor.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"71\", \"issue\": \"2\", \"pages\": \"580-7\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14354, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 42, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Molecular pharmacology\", \"reference\": \"17095583\", \"authors\": [\"Moriguchi S\", \"Shioda N\", \"Maejima H\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2007-02-01\", \"title\": \"Nefiracetam potentiates N-methyl-D-aspartate (NMDA) receptor function via protein kinase C activation and reduces magnesium block of NMDA receptor.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"71\", \"issue\": \"2\", \"pages\": \"580-7\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14355, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 34, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Molecular pharmacology\", \"reference\": \"17095583\", \"authors\": [\"Moriguchi S\", \"Shioda N\", \"Maejima H\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2007-02-01\", \"title\": \"Nefiracetam potentiates N-methyl-D-aspartate (NMDA) receptor function via protein kinase C activation and reduces magnesium block of NMDA receptor.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"71\", \"issue\": \"2\", \"pages\": \"580-7\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14356, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 43, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"In immunoblotting analysis, nefiracetam treatment increased the PKCalpha activity with a bell-shaped dose-response relationship peaking at 10 nM, thereby increasing phosphorylation of PKC substrate and NMDA receptor. Nefiracetam treatment did not affect the PKA activity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Molecular pharmacology\", \"reference\": \"17095583\", \"authors\": [\"Moriguchi S\", \"Shioda N\", \"Maejima H\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2007-02-01\", \"title\": \"Nefiracetam potentiates N-methyl-D-aspartate (NMDA) receptor function via protein kinase C activation and reduces magnesium block of NMDA receptor.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"71\", \"issue\": \"2\", \"pages\": \"580-7\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14363, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 50, \"key\": 0}, {\"relation\": \"causesNoChange\", \"evidence\": \"In immunoblotting analysis, nefiracetam treatment increased the PKCalpha activity with a bell-shaped dose-response relationship peaking at 10 nM, thereby increasing phosphorylation of PKC substrate and NMDA receptor. Nefiracetam treatment did not affect the PKA activity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Molecular pharmacology\", \"reference\": \"17095583\", \"authors\": [\"Moriguchi S\", \"Shioda N\", \"Maejima H\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2007-02-01\", \"title\": \"Nefiracetam potentiates N-methyl-D-aspartate (NMDA) receptor function via protein kinase C activation and reduces magnesium block of NMDA receptor.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"71\", \"issue\": \"2\", \"pages\": \"580-7\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14365, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 51, \"key\": 0}, {\"relation\": \"isA\", \"evidence\": \"The nefiracetam-induced increase in the frequency of mEPSCs and mIPSCs over and above the level achieved by ACh alone would contribute to the therapeutic effect of nefiracetam as the cholinergic system is known to be downregulated in the brain of Alzheimer's disease patients.The therapeutic effects of galantamine are ascribed to the modest potentiation of nACh receptor and NMDA receptor activities in addition to the modest inhibition of acetylcholinesterase.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14419, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 52, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Nefiracetam treatment significantly enhanced long-term potentiation (LTP) with the same bell-shaped dose-response curve. Furthermore, nefiracetam-induced LTP enhancement was closely associated with calcium/calmodulin-dependent protein kinase II (CaMKII) activation with increase in phosphorylation of AMPA-type glutamate receptor subunit 1 (GluA1) (Ser-831) as a postsynaptic CaMKII substrate. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of pharmacological sciences\", \"reference\": \"21821968\", \"authors\": [\"Moriguchi S\"], \"date\": \"2011-01-01\", \"title\": \"Pharmacological study on Alzheimer's drugs targeting calcium/calmodulin-dependent protein kinase II.\", \"lastauthor\": \"Moriguchi S\", \"volume\": \"117\", \"issue\": \"1\", \"pages\": \"6-11\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14450, \"annotations\": {\"Species\": \"10116\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 53, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Nefiracetam treatment significantly enhanced long-term potentiation (LTP) with the same bell-shaped dose-response curve. Furthermore, nefiracetam-induced LTP enhancement was closely associated with calcium/calmodulin-dependent protein kinase II (CaMKII) activation with increase in phosphorylation of AMPA-type glutamate receptor subunit 1 (GluA1) (Ser-831) as a postsynaptic CaMKII substrate. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of pharmacological sciences\", \"reference\": \"21821968\", \"authors\": [\"Moriguchi S\"], \"date\": \"2011-01-01\", \"title\": \"Pharmacological study on Alzheimer's drugs targeting calcium/calmodulin-dependent protein kinase II.\", \"lastauthor\": \"Moriguchi S\", \"volume\": \"117\", \"issue\": \"1\", \"pages\": \"6-11\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14451, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10116\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 54, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"In conclusion, nefiracetam enhances NMDA-receptor function through stimulation of its glycine binding site and nefiracetam-induced CaMKII activation likely contributes to improvement of cognition, learning, and memory.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of pharmacological sciences\", \"reference\": \"21821968\", \"authors\": [\"Moriguchi S\"], \"date\": \"2011-01-01\", \"title\": \"Pharmacological study on Alzheimer's drugs targeting calcium/calmodulin-dependent protein kinase II.\", \"lastauthor\": \"Moriguchi S\", \"volume\": \"117\", \"issue\": \"1\", \"pages\": \"6-11\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14459, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10116\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 54, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain research. Molecular brain research\", \"reference\": \"11039729\", \"authors\": [\"Nishizaki T\", \"Nomura T\", \"Matuoka T\", \"Kondoh T\", \"Enikolopov G\", \"Sumikawa K\", \"Watabe S\", \"Shiotani T\", \"Yoshii M\"], \"date\": \"2000-08-14\", \"title\": \"The anti-dementia drug nefiracetam facilitates hippocampal synaptic transmission by functionally targeting presynaptic nicotinic ACh receptors.\", \"lastauthor\": \"Yoshii M\", \"volume\": \"80\", \"issue\": \"1\", \"pages\": \"53-62\", \"firstauthor\": \"Nishizaki T\"}, \"line\": 14480, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 55, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Nefiracetam treatment significantly enhanced long-term potentiation (LTP) with the same bell-shaped dose-response curve. Furthermore, nefiracetam-induced LTP enhancement was closely associated with calcium/calmodulin-dependent protein kinase II (CaMKII) activation with increase in phosphorylation of AMPA-type glutamate receptor subunit 1 (GluA1) (Ser-831) as a postsynaptic CaMKII substrate. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of pharmacological sciences\", \"reference\": \"21821968\", \"authors\": [\"Moriguchi S\"], \"date\": \"2011-01-01\", \"title\": \"Pharmacological study on Alzheimer's drugs targeting calcium/calmodulin-dependent protein kinase II.\", \"lastauthor\": \"Moriguchi S\", \"volume\": \"117\", \"issue\": \"1\", \"pages\": \"6-11\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14452, \"annotations\": {\"Species\": \"10116\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 54, \"target\": 56, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain research. Molecular brain research\", \"reference\": \"11039729\", \"authors\": [\"Nishizaki T\", \"Nomura T\", \"Matuoka T\", \"Kondoh T\", \"Enikolopov G\", \"Sumikawa K\", \"Watabe S\", \"Shiotani T\", \"Yoshii M\"], \"date\": \"2000-08-14\", \"title\": \"The anti-dementia drug nefiracetam facilitates hippocampal synaptic transmission by functionally targeting presynaptic nicotinic ACh receptors.\", \"lastauthor\": \"Yoshii M\", \"volume\": \"80\", \"issue\": \"1\", \"pages\": \"53-62\", \"firstauthor\": \"Nishizaki T\"}, \"line\": 14481, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 55, \"target\": 36, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain research. Molecular brain research\", \"reference\": \"11039729\", \"authors\": [\"Nishizaki T\", \"Nomura T\", \"Matuoka T\", \"Kondoh T\", \"Enikolopov G\", \"Sumikawa K\", \"Watabe S\", \"Shiotani T\", \"Yoshii M\"], \"date\": \"2000-08-14\", \"title\": \"The anti-dementia drug nefiracetam facilitates hippocampal synaptic transmission by functionally targeting presynaptic nicotinic ACh receptors.\", \"lastauthor\": \"Yoshii M\", \"volume\": \"80\", \"issue\": \"1\", \"pages\": \"53-62\", \"firstauthor\": \"Nishizaki T\"}, \"line\": 14482, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 55, \"target\": 37, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain research. Molecular brain research\", \"reference\": \"11039729\", \"authors\": [\"Nishizaki T\", \"Nomura T\", \"Matuoka T\", \"Kondoh T\", \"Enikolopov G\", \"Sumikawa K\", \"Watabe S\", \"Shiotani T\", \"Yoshii M\"], \"date\": \"2000-08-14\", \"title\": \"The anti-dementia drug nefiracetam facilitates hippocampal synaptic transmission by functionally targeting presynaptic nicotinic ACh receptors.\", \"lastauthor\": \"Yoshii M\", \"volume\": \"80\", \"issue\": \"1\", \"pages\": \"53-62\", \"firstauthor\": \"Nishizaki T\"}, \"line\": 14483, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 55, \"target\": 31, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain research. Molecular brain research\", \"reference\": \"11039729\", \"authors\": [\"Nishizaki T\", \"Nomura T\", \"Matuoka T\", \"Kondoh T\", \"Enikolopov G\", \"Sumikawa K\", \"Watabe S\", \"Shiotani T\", \"Yoshii M\"], \"date\": \"2000-08-14\", \"title\": \"The anti-dementia drug nefiracetam facilitates hippocampal synaptic transmission by functionally targeting presynaptic nicotinic ACh receptors.\", \"lastauthor\": \"Yoshii M\", \"volume\": \"80\", \"issue\": \"1\", \"pages\": \"53-62\", \"firstauthor\": \"Nishizaki T\"}, \"line\": 14484, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 55, \"target\": 38, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain research. Molecular brain research\", \"reference\": \"11039729\", \"authors\": [\"Nishizaki T\", \"Nomura T\", \"Matuoka T\", \"Kondoh T\", \"Enikolopov G\", \"Sumikawa K\", \"Watabe S\", \"Shiotani T\", \"Yoshii M\"], \"date\": \"2000-08-14\", \"title\": \"The anti-dementia drug nefiracetam facilitates hippocampal synaptic transmission by functionally targeting presynaptic nicotinic ACh receptors.\", \"lastauthor\": \"Yoshii M\", \"volume\": \"80\", \"issue\": \"1\", \"pages\": \"53-62\", \"firstauthor\": \"Nishizaki T\"}, \"line\": 14485, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 55, \"target\": 39, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain research. Molecular brain research\", \"reference\": \"11039729\", \"authors\": [\"Nishizaki T\", \"Nomura T\", \"Matuoka T\", \"Kondoh T\", \"Enikolopov G\", \"Sumikawa K\", \"Watabe S\", \"Shiotani T\", \"Yoshii M\"], \"date\": \"2000-08-14\", \"title\": \"The anti-dementia drug nefiracetam facilitates hippocampal synaptic transmission by functionally targeting presynaptic nicotinic ACh receptors.\", \"lastauthor\": \"Yoshii M\", \"volume\": \"80\", \"issue\": \"1\", \"pages\": \"53-62\", \"firstauthor\": \"Nishizaki T\"}, \"line\": 14486, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 55, \"target\": 40, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain research. Molecular brain research\", \"reference\": \"11039729\", \"authors\": [\"Nishizaki T\", \"Nomura T\", \"Matuoka T\", \"Kondoh T\", \"Enikolopov G\", \"Sumikawa K\", \"Watabe S\", \"Shiotani T\", \"Yoshii M\"], \"date\": \"2000-08-14\", \"title\": \"The anti-dementia drug nefiracetam facilitates hippocampal synaptic transmission by functionally targeting presynaptic nicotinic ACh receptors.\", \"lastauthor\": \"Yoshii M\", \"volume\": \"80\", \"issue\": \"1\", \"pages\": \"53-62\", \"firstauthor\": \"Nishizaki T\"}, \"line\": 14487, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 55, \"target\": 41, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain research. Molecular brain research\", \"reference\": \"11039729\", \"authors\": [\"Nishizaki T\", \"Nomura T\", \"Matuoka T\", \"Kondoh T\", \"Enikolopov G\", \"Sumikawa K\", \"Watabe S\", \"Shiotani T\", \"Yoshii M\"], \"date\": \"2000-08-14\", \"title\": \"The anti-dementia drug nefiracetam facilitates hippocampal synaptic transmission by functionally targeting presynaptic nicotinic ACh receptors.\", \"lastauthor\": \"Yoshii M\", \"volume\": \"80\", \"issue\": \"1\", \"pages\": \"53-62\", \"firstauthor\": \"Nishizaki T\"}, \"line\": 14488, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 55, \"target\": 42, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain research. Molecular brain research\", \"reference\": \"11039729\", \"authors\": [\"Nishizaki T\", \"Nomura T\", \"Matuoka T\", \"Kondoh T\", \"Enikolopov G\", \"Sumikawa K\", \"Watabe S\", \"Shiotani T\", \"Yoshii M\"], \"date\": \"2000-08-14\", \"title\": \"The anti-dementia drug nefiracetam facilitates hippocampal synaptic transmission by functionally targeting presynaptic nicotinic ACh receptors.\", \"lastauthor\": \"Yoshii M\", \"volume\": \"80\", \"issue\": \"1\", \"pages\": \"53-62\", \"firstauthor\": \"Nishizaki T\"}, \"line\": 14489, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 55, \"target\": 34, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain research. Molecular brain research\", \"reference\": \"11039729\", \"authors\": [\"Nishizaki T\", \"Nomura T\", \"Matuoka T\", \"Kondoh T\", \"Enikolopov G\", \"Sumikawa K\", \"Watabe S\", \"Shiotani T\", \"Yoshii M\"], \"date\": \"2000-08-14\", \"title\": \"The anti-dementia drug nefiracetam facilitates hippocampal synaptic transmission by functionally targeting presynaptic nicotinic ACh receptors.\", \"lastauthor\": \"Yoshii M\", \"volume\": \"80\", \"issue\": \"1\", \"pages\": \"53-62\", \"firstauthor\": \"Nishizaki T\"}, \"line\": 14490, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 55, \"target\": 43, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain research. Molecular brain research\", \"reference\": \"11039729\", \"authors\": [\"Nishizaki T\", \"Nomura T\", \"Matuoka T\", \"Kondoh T\", \"Enikolopov G\", \"Sumikawa K\", \"Watabe S\", \"Shiotani T\", \"Yoshii M\"], \"date\": \"2000-08-14\", \"title\": \"The anti-dementia drug nefiracetam facilitates hippocampal synaptic transmission by functionally targeting presynaptic nicotinic ACh receptors.\", \"lastauthor\": \"Yoshii M\", \"volume\": \"80\", \"issue\": \"1\", \"pages\": \"53-62\", \"firstauthor\": \"Nishizaki T\"}, \"line\": 14491, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 55, \"target\": 44, \"key\": 0}, {\"relation\": \"hasComponent\", \"annotations\": {}, \"source\": 55, \"target\": 49, \"key\": -3}, {\"relation\": \"hasComponent\", \"annotations\": {}, \"source\": 55, \"target\": 50, \"key\": -3}, {\"relation\": \"association\", \"evidence\": \"Induction of zif268 in neurons leads to altered expression of proteasome subunit and proteasome-regulatory genes, thereby changing the capacity of the neuron to degrade synaptic proteins, including receptors and receptor subunits.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17177, \"annotations\": {\"MeSHAnatomy\": \"Neurons\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 57, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"In addition, zif268 alters the transcription of genes associated with GABA(A)R expression and trafficking, such as ubiquilin and gephyrin.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17182, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 58, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Further, EGR1 levels were negatively correlated with hippocampal amyloid- plaque burden.This study presents global gene expression profiles associated with GA immunization in a glaucoma rat model.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Investigative ophthalmology &amp; visual science\", \"reference\": \"21969301\", \"authors\": [\"Bakalash S\", \"Pham M\", \"Koronyo Y\", \"Salumbides BC\", \"Kramerov A\", \"Seidenberg H\", \"Berel D\", \"Black KL\", \"Koronyo-Hamaoui M\"], \"date\": \"2011-11-21\", \"title\": \"Egr1 expression is induced following glatiramer acetate immunotherapy in rodent models of glaucoma and Alzheimer's disease.\", \"lastauthor\": \"Koronyo-Hamaoui M\", \"volume\": \"52\", \"issue\": \"12\", \"pages\": \"9033-46\", \"firstauthor\": \"Bakalash S\"}, \"line\": 17224, \"annotations\": {\"Disease\": \"Alzheimer's disease\", \"Species\": \"10116\", \"MeSHDisease\": \"Glaucoma\", \"MeSHAnatomy\": \"Hippocampus\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 59, \"target\": 1, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We show that Egr-1 binds to PSEN-P2, and that PSEN-P2 activity is increased threefold by overexpression of Egr-1, and by 12-O-tetradecanoylphorbol-13-acetate (TPA), which induces physiological Egr-1 levels.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Gene\", \"reference\": \"14585504\", \"authors\": [\"Renbaum P\", \"Beeri R\", \"Gabai E\", \"Amiel M\", \"Gal M\", \"Ehrengruber MU\", \"Levy-Lahad E\"], \"date\": \"2003-10-30\", \"title\": \"Egr-1 upregulates the Alzheimer's disease presenilin-2 gene in neuronal cells.\", \"lastauthor\": \"Levy-Lahad E\", \"volume\": \"318\", \"issue\": \"\", \"pages\": \"113-24\", \"firstauthor\": \"Renbaum P\"}, \"line\": 17256, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Disease\": \"Alzheimer's disease\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 60, \"target\": 6, \"key\": 0}, {\"relation\": \"hasComponent\", \"annotations\": {}, \"source\": 60, \"target\": 6, \"key\": -3}, {\"relation\": \"hasComponent\", \"annotations\": {}, \"source\": 60, \"target\": 1, \"key\": -3}, {\"relation\": \"association\", \"evidence\": \"Estradiol affects the expression of GABRA4 mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain research. Molecular brain research\", \"reference\": \"16000229\", \"authors\": [\"Pierson RC\", \"Lyons AM\", \"Greenfield LJ Jr\"], \"date\": \"2005-08-18\", \"title\": \"Gonadal steroids regulate GABAA receptor subunit mRNA expression in NT2-N neurons.\", \"lastauthor\": \"Greenfield LJ Jr\", \"volume\": \"138\", \"issue\": \"2\", \"pages\": \"105-15\", \"firstauthor\": \"Pierson RC\"}, \"line\": 46602, \"annotations\": {\"Species\": \"9606\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 61, \"target\": 62, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Estradiol results in increased expression of GABRA3 mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain research. Molecular brain research\", \"reference\": \"16000229\", \"authors\": [\"Pierson RC\", \"Lyons AM\", \"Greenfield LJ Jr\"], \"date\": \"2005-08-18\", \"title\": \"Gonadal steroids regulate GABAA receptor subunit mRNA expression in NT2-N neurons.\", \"lastauthor\": \"Greenfield LJ Jr\", \"volume\": \"138\", \"issue\": \"2\", \"pages\": \"105-15\", \"firstauthor\": \"Pierson RC\"}, \"line\": 47285, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 61, \"target\": 63, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Estradiol affects the expression of GABRA4 mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain research. Molecular brain research\", \"reference\": \"16000229\", \"authors\": [\"Pierson RC\", \"Lyons AM\", \"Greenfield LJ Jr\"], \"date\": \"2005-08-18\", \"title\": \"Gonadal steroids regulate GABAA receptor subunit mRNA expression in NT2-N neurons.\", \"lastauthor\": \"Greenfield LJ Jr\", \"volume\": \"138\", \"issue\": \"2\", \"pages\": \"105-15\", \"firstauthor\": \"Pierson RC\"}, \"line\": 46602, \"annotations\": {\"Species\": \"9606\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 62, \"target\": 61, \"key\": 0}, {\"relation\": \"translatedTo\", \"annotations\": {}, \"source\": 62, \"target\": 11, \"key\": -6}, {\"relation\": \"translatedTo\", \"annotations\": {}, \"source\": 63, \"target\": 10, \"key\": -6}, {\"relation\": \"decreases\", \"evidence\": \"GABRA6 protein mutant form results in decreased susceptibility to Midazolam\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of clinical anesthesia\", \"reference\": \"12031754\", \"authors\": [\"Hoffman WE\", \"Balyasnikova IV\", \"Mahay H\", \"Danilov SM\", \"Baughman VL\"], \"date\": \"2002-05-01\", \"title\": \"GABA alpha6 receptors mediate midazolam-induced anxiolysis.\", \"lastauthor\": \"Baughman VL\", \"volume\": \"14\", \"issue\": \"3\", \"pages\": \"206-9\", \"firstauthor\": \"Hoffman WE\"}, \"line\": 48542, \"annotations\": {\"Species\": \"9606\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 64, \"target\": 13, \"key\": 0}, {\"relation\": \"hasVariant\", \"annotations\": {}, \"source\": 65, \"target\": 56, \"key\": -4}, {\"relation\": \"translatedTo\", \"annotations\": {}, \"source\": 66, \"target\": 1, \"key\": -6}, {\"relation\": \"translatedTo\", \"annotations\": {}, \"source\": 67, \"target\": 2, \"key\": -6}, {\"relation\": \"translatedTo\", \"annotations\": {}, \"source\": 68, \"target\": 6, \"key\": -6}, {\"relation\": \"translatedTo\", \"annotations\": {}, \"source\": 69, \"target\": 7, \"key\": -6}, {\"relation\": \"translatedTo\", \"annotations\": {}, \"source\": 70, \"target\": 8, \"key\": -6}, {\"relation\": \"translatedTo\", \"annotations\": {}, \"source\": 71, \"target\": 9, \"key\": -6}, {\"relation\": \"translatedTo\", \"annotations\": {}, \"source\": 72, \"target\": 12, \"key\": -6}, {\"relation\": \"translatedTo\", \"annotations\": {}, \"source\": 73, \"target\": 13, \"key\": -6}, {\"relation\": \"translatedTo\", \"annotations\": {}, \"source\": 74, \"target\": 14, \"key\": -6}, {\"relation\": \"translatedTo\", \"annotations\": {}, \"source\": 75, \"target\": 15, \"key\": -6}, {\"relation\": \"translatedTo\", \"annotations\": {}, \"source\": 76, \"target\": 16, \"key\": -6}, {\"relation\": \"translatedTo\", \"annotations\": {}, \"source\": 77, \"target\": 17, \"key\": -6}, {\"relation\": \"translatedTo\", \"annotations\": {}, \"source\": 78, \"target\": 18, \"key\": -6}, {\"relation\": \"translatedTo\", \"annotations\": {}, \"source\": 79, \"target\": 19, \"key\": -6}, {\"relation\": \"translatedTo\", \"annotations\": {}, \"source\": 80, \"target\": 20, \"key\": -6}, {\"relation\": \"translatedTo\", \"annotations\": {}, \"source\": 81, \"target\": 21, \"key\": -6}, {\"relation\": \"translatedTo\", \"annotations\": {}, \"source\": 82, \"target\": 22, \"key\": -6}, {\"relation\": \"translatedTo\", \"annotations\": {}, \"source\": 83, \"target\": 23, \"key\": -6}, {\"relation\": \"translatedTo\", \"annotations\": {}, \"source\": 84, \"target\": 24, \"key\": -6}, {\"relation\": \"translatedTo\", \"annotations\": {}, \"source\": 85, \"target\": 27, \"key\": -6}, {\"relation\": \"translatedTo\", \"annotations\": {}, \"source\": 86, \"target\": 31, \"key\": -6}, {\"relation\": \"translatedTo\", \"annotations\": {}, \"source\": 87, \"target\": 34, \"key\": -6}, {\"relation\": \"translatedTo\", \"annotations\": {}, \"source\": 88, \"target\": 36, \"key\": -6}, {\"relation\": \"translatedTo\", \"annotations\": {}, \"source\": 89, \"target\": 37, \"key\": -6}, {\"relation\": \"translatedTo\", \"annotations\": {}, \"source\": 90, \"target\": 38, \"key\": -6}, {\"relation\": \"translatedTo\", \"annotations\": {}, \"source\": 91, \"target\": 39, \"key\": -6}, {\"relation\": \"translatedTo\", \"annotations\": {}, \"source\": 92, \"target\": 40, \"key\": -6}, {\"relation\": \"translatedTo\", \"annotations\": {}, \"source\": 93, \"target\": 41, \"key\": -6}, {\"relation\": \"translatedTo\", \"annotations\": {}, \"source\": 94, \"target\": 42, \"key\": -6}, {\"relation\": \"translatedTo\", \"annotations\": {}, \"source\": 95, \"target\": 43, \"key\": -6}, {\"relation\": \"translatedTo\", \"annotations\": {}, \"source\": 96, \"target\": 44, \"key\": -6}, {\"relation\": \"translatedTo\", \"annotations\": {}, \"source\": 97, \"target\": 47, \"key\": -6}, {\"relation\": \"translatedTo\", \"annotations\": {}, \"source\": 98, \"target\": 50, \"key\": -6}, {\"relation\": \"translatedTo\", \"annotations\": {}, \"source\": 99, \"target\": 58, \"key\": -6}, {\"relation\": \"translatedTo\", \"annotations\": {}, \"source\": 100, \"target\": 65, \"key\": -6}, {\"relation\": \"transcribedTo\", \"annotations\": {}, \"source\": 101, \"target\": 62, \"key\": -5}, {\"relation\": \"transcribedTo\", \"annotations\": {}, \"source\": 102, \"target\": 63, \"key\": -5}, {\"relation\": \"transcribedTo\", \"annotations\": {}, \"source\": 103, \"target\": 66, \"key\": -5}, {\"relation\": \"transcribedTo\", \"annotations\": {}, \"source\": 104, \"target\": 67, \"key\": -5}, {\"relation\": \"transcribedTo\", \"annotations\": {}, \"source\": 105, \"target\": 68, \"key\": -5}, {\"relation\": \"transcribedTo\", \"annotations\": {}, \"source\": 106, \"target\": 69, \"key\": -5}, {\"relation\": \"transcribedTo\", \"annotations\": {}, \"source\": 107, \"target\": 70, \"key\": -5}, {\"relation\": \"transcribedTo\", \"annotations\": {}, \"source\": 108, \"target\": 71, \"key\": -5}, {\"relation\": \"transcribedTo\", \"annotations\": {}, \"source\": 109, \"target\": 72, \"key\": -5}, {\"relation\": \"transcribedTo\", \"annotations\": {}, \"source\": 110, \"target\": 73, \"key\": -5}, {\"relation\": \"transcribedTo\", \"annotations\": {}, \"source\": 111, \"target\": 74, \"key\": -5}, {\"relation\": \"transcribedTo\", \"annotations\": {}, \"source\": 112, \"target\": 75, \"key\": -5}, {\"relation\": \"transcribedTo\", \"annotations\": {}, \"source\": 113, \"target\": 76, \"key\": -5}, {\"relation\": \"transcribedTo\", \"annotations\": {}, \"source\": 114, \"target\": 77, \"key\": -5}, {\"relation\": \"transcribedTo\", \"annotations\": {}, \"source\": 115, \"target\": 78, \"key\": -5}, {\"relation\": \"transcribedTo\", \"annotations\": {}, \"source\": 116, \"target\": 79, \"key\": -5}, {\"relation\": \"transcribedTo\", \"annotations\": {}, \"source\": 117, \"target\": 80, \"key\": -5}, {\"relation\": \"transcribedTo\", \"annotations\": {}, \"source\": 118, \"target\": 81, \"key\": -5}, {\"relation\": \"transcribedTo\", \"annotations\": {}, \"source\": 119, \"target\": 82, \"key\": -5}, {\"relation\": \"transcribedTo\", \"annotations\": {}, \"source\": 120, \"target\": 83, \"key\": -5}, {\"relation\": \"transcribedTo\", \"annotations\": {}, \"source\": 121, \"target\": 84, \"key\": -5}, {\"relation\": \"transcribedTo\", \"annotations\": {}, \"source\": 122, \"target\": 85, \"key\": -5}, {\"relation\": \"transcribedTo\", \"annotations\": {}, \"source\": 123, \"target\": 86, \"key\": -5}, {\"relation\": \"transcribedTo\", \"annotations\": {}, \"source\": 124, \"target\": 87, \"key\": -5}, {\"relation\": \"transcribedTo\", \"annotations\": {}, \"source\": 125, \"target\": 88, \"key\": -5}, {\"relation\": \"transcribedTo\", \"annotations\": {}, \"source\": 126, \"target\": 89, \"key\": -5}, {\"relation\": \"transcribedTo\", \"annotations\": {}, \"source\": 127, \"target\": 90, \"key\": -5}, {\"relation\": \"transcribedTo\", \"annotations\": {}, \"source\": 128, \"target\": 91, \"key\": -5}, {\"relation\": \"transcribedTo\", \"annotations\": {}, \"source\": 129, \"target\": 92, \"key\": -5}, {\"relation\": \"transcribedTo\", \"annotations\": {}, \"source\": 130, \"target\": 93, \"key\": -5}, {\"relation\": \"transcribedTo\", \"annotations\": {}, \"source\": 131, \"target\": 94, \"key\": -5}, {\"relation\": \"transcribedTo\", \"annotations\": {}, \"source\": 132, \"target\": 95, \"key\": -5}, {\"relation\": \"transcribedTo\", \"annotations\": {}, \"source\": 133, \"target\": 96, \"key\": -5}, {\"relation\": \"transcribedTo\", \"annotations\": {}, \"source\": 134, \"target\": 97, \"key\": -5}, {\"relation\": \"transcribedTo\", \"annotations\": {}, \"source\": 135, \"target\": 98, \"key\": -5}, {\"relation\": \"transcribedTo\", \"annotations\": {}, \"source\": 136, \"target\": 99, \"key\": -5}, {\"relation\": \"transcribedTo\", \"annotations\": {}, \"source\": 137, \"target\": 100, \"key\": -5}]};\n",
       "        const color_map = {'Protein': '#1F77B4', 'Pathology': '#FF7F0E', 'BiologicalProcess': '#2CA02C', 'miRNA': '#D62728', 'Complex': '#9467bd', 'Composite': '#9467bd', 'Reaction': '#8c564b', 'Gene': '#e377c2', 'Abundance': '#bcbd22', 'RNA': '#17becf'};\n",
       "    \n",
       "        require.config({\n",
       "          paths: {\n",
       "              d3: '//cdnjs.cloudflare.com/ajax/libs/d3/4.5.0/d3.min'\n",
       "          }\n",
       "        });\n",
       "\n",
       "        var elementInnerHTML = \"<div id='\" + chart + \"'></div>\";\n",
       "\n",
       "        element.append(elementInnerHTML);\n",
       "\n",
       "        var chartQualified = \"#\" + chart;\n",
       "\n",
       "        require(['d3'], function(d3) {\n",
       "            return init_d3_force(d3, graph, chartQualified, width, height, color_map);\n",
       "        });\n",
       "    "
      ],
      "text/plain": [
       "<IPython.core.display.Javascript object>"
      ]
     },
     "execution_count": 17,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "to_jupyter(subgraph)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Finally, some of the genes and RNAs that have been added have no connections, and can be removed with [pbt.mutation.prune_central_dogma](http://pybel-tools.readthedocs.io/en/latest/mutation.html#pybel_tools.mutation.prune_central_dogma)."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Nodes: 66\n",
      "Edges: 191\n",
      "Citations: 14\n",
      "Authors: 69\n",
      "Network density: 0.04452214452214452\n",
      "Components: 2\n",
      "Average degree: 2.893939393939394\n"
     ]
    }
   ],
   "source": [
    "pbt.mutation.prune_central_dogma(subgraph)\n",
    "\n",
    "pbt.summary.print_summary(subgraph)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/javascript": [
       "function init_d3_force(d3, graph, chart, width, height, function_colors) {\n",
       "    var focus_node = null;\n",
       "    var highlight_node = null;\n",
       "\n",
       "    // Highlight color variables\n",
       "\n",
       "    // Highlight color of the node boundering\n",
       "    const highlight_node_boundering = \"#4EB2D4\";\n",
       "\n",
       "    // Highlight color of the edge\n",
       "    const highlighted_link_color = \"#4EB2D4\";\n",
       "\n",
       "    // Text highlight color\n",
       "    const highlight_text = \"#4EB2D4\";\n",
       "\n",
       "    // Size when zooming scale\n",
       "    var size = d3.scalePow().exponent(1)\n",
       "        .domain([1, 100])\n",
       "        .range([8, 24]);\n",
       "\n",
       "    // Simulation parameters\n",
       "    const linkDistance = 100;\n",
       "    const fCharge = -1000;\n",
       "    const linkStrength = 0.7;\n",
       "    const collideStrength = 1;\n",
       "\n",
       "    // Simulation defined with variables\n",
       "    var simulation = d3.forceSimulation()\n",
       "        .force(\"link\", d3.forceLink()\n",
       "            .distance(linkDistance)\n",
       "            .strength(linkStrength)\n",
       "        )\n",
       "        .force(\"collide\", d3.forceCollide()\n",
       "            .radius(function (d) {\n",
       "                return d.r + 10\n",
       "            })\n",
       "            .strength(collideStrength)\n",
       "        )\n",
       "        .force(\"charge\", d3.forceManyBody()\n",
       "            .strength(fCharge)\n",
       "        )\n",
       "        .force(\"center\", d3.forceCenter(width / 2, height / 2))\n",
       "        .force(\"y\", d3.forceY(0))\n",
       "        .force(\"x\", d3.forceX(0));\n",
       "\n",
       "    // Pin down functionality\n",
       "    var node_drag = d3.drag()\n",
       "        .on(\"start\", dragstarted)\n",
       "        .on(\"drag\", dragged)\n",
       "        .on(\"end\", dragended);\n",
       "\n",
       "    function dragstarted(d) {\n",
       "        if (!d3.event.active) simulation.alphaTarget(0.3).restart();\n",
       "        d.fx = d.x;\n",
       "        d.fy = d.y;\n",
       "    }\n",
       "\n",
       "    function dragged(d) {\n",
       "        d.fx = d3.event.x;\n",
       "        d.fy = d3.event.y;\n",
       "    }\n",
       "\n",
       "    function dragended(d) {\n",
       "        if (!d3.event.active) simulation.alphaTarget(0);\n",
       "    }\n",
       "\n",
       "    function releasenode(d) {\n",
       "        d.fx = null;\n",
       "        d.fy = null;\n",
       "    }\n",
       "\n",
       "    //END Pin down functionality\n",
       "\n",
       "    const color_circunferencia = \"black\";\n",
       "    const default_link_color = \"#AAAAAA\";\n",
       "    const nominal_base_node_size = 8;\n",
       "\n",
       "    // Normal and highlighted stroke of the links (double the width of the link when highlighted)\n",
       "    const nominal_stroke = 1.5;\n",
       "\n",
       "    // Zoom variables\n",
       "    const min_zoom = 0.1;\n",
       "    const max_zoom = 10;\n",
       "    const border = 1;\n",
       "    const bordercolor = 'black';\n",
       "\n",
       "    var svg = d3.select(chart).append(\"svg\")\n",
       "        .attr(\"width\", width)\n",
       "        .attr(\"height\", height);\n",
       "\n",
       "    // // Create definition for arrowhead.\n",
       "    svg.append(\"defs\").append(\"marker\")\n",
       "        .attr(\"id\", \"arrowhead\")\n",
       "        .attr(\"viewBox\", \"0 -5 10 10\")\n",
       "        .attr(\"refX\", 20)\n",
       "        .attr(\"refY\", 0)\n",
       "        .attr(\"markerUnits\", \"strokeWidth\")\n",
       "        .attr(\"markerWidth\", 6)\n",
       "        .attr(\"markerHeight\", 6)\n",
       "        .attr(\"orient\", \"auto\")\n",
       "        .append(\"path\")\n",
       "        .attr(\"d\", \"M0,-5L10,0L0,5\");\n",
       "\n",
       "    // // Create definition for stub.\n",
       "    svg.append(\"defs\").append(\"marker\")\n",
       "        .attr(\"id\", \"stub\")\n",
       "        .attr(\"viewBox\", \"-1 -5 2 10\")\n",
       "        .attr(\"refX\", 15)\n",
       "        .attr(\"refY\", 0)\n",
       "        .attr(\"markerUnits\", \"strokeWidth\")\n",
       "        .attr(\"markerWidth\", 6)\n",
       "        .attr(\"markerHeight\", 6)\n",
       "        .attr(\"orient\", \"auto\")\n",
       "        .append(\"path\")\n",
       "        .attr(\"d\", \"M 0,0 m -1,-5 L 1,-5 L 1,5 L -1,5 Z\");\n",
       "\n",
       "    // Background\n",
       "    svg.append(\"rect\")\n",
       "        .attr(\"width\", \"100%\")\n",
       "        .attr(\"height\", \"100%\")\n",
       "        .attr(\"fill\", \"#ffffff\")\n",
       "        .style(\"pointer-events\", \"all\")\n",
       "        // Zoom + panning functionality\n",
       "        .call(d3.zoom()\n",
       "            .scaleExtent([min_zoom, max_zoom])\n",
       "            .on(\"zoom\", zoomed))\n",
       "        .on(\"dblclick.zoom\", null);\n",
       "\n",
       "\n",
       "    function zoomed() {\n",
       "        g.attr(\"transform\", d3.event.transform);\n",
       "    }\n",
       "\n",
       "    // g = svg object where the graph will be appended\n",
       "    var g = svg.append(\"g\");\n",
       "\n",
       "    var linkedByIndex = {};\n",
       "    graph.links.forEach(function (d) {\n",
       "        linkedByIndex[d.source + \",\" + d.target] = true;\n",
       "    });\n",
       "\n",
       "    function isConnected(a, b) {\n",
       "        return linkedByIndex[a.index + \",\" + b.index] || linkedByIndex[b.index + \",\" + a.index] || a.index == b.index;\n",
       "    }\n",
       "\n",
       "    function ticked() {\n",
       "        link.attr(\"x1\", function (d) {\n",
       "            return d.source.x;\n",
       "        })\n",
       "            .attr(\"y1\", function (d) {\n",
       "                return d.source.y;\n",
       "            })\n",
       "            .attr(\"x2\", function (d) {\n",
       "                return d.target.x;\n",
       "            })\n",
       "            .attr(\"y2\", function (d) {\n",
       "                return d.target.y;\n",
       "            });\n",
       "\n",
       "        node\n",
       "            .attr(\"transform\", function (d) {\n",
       "                return \"translate(\" + d.x + \", \" + d.y + \")\";\n",
       "            });\n",
       "    }\n",
       "\n",
       "\n",
       "    simulation\n",
       "        .nodes(graph.nodes)\n",
       "        .on(\"tick\", ticked);\n",
       "\n",
       "    simulation.force(\"link\")\n",
       "        .links(graph.links);\n",
       "\n",
       "    // Definition of links nodes text...\n",
       "\n",
       "    var link = g.selectAll(\".link\")\n",
       "        .data(graph.links)\n",
       "        .enter().append(\"line\")\n",
       "        .style(\"stroke-width\", nominal_stroke)\n",
       "        .style(\"stroke\", default_link_color)\n",
       "        .style(\"stroke-dasharray\", function (d) {\n",
       "            if (['decreases', 'directlyDecreases', 'increases', 'directlyIncreases', 'negativeCorrelation',\n",
       "                    'positiveCorrelation'].indexOf(d.relation) >= 0) {\n",
       "                return \"none\"\n",
       "            } else {\n",
       "                return \"4, 4\"\n",
       "            }\n",
       "        })\n",
       "        .attr(\"marker-start\", function (d) {\n",
       "            if ('positiveCorrelation' == d.relation) {\n",
       "                return \"url(#arrowhead)\"\n",
       "            }\n",
       "            else if ('negativeCorrelation' == d.relation) {\n",
       "                return \"url(#stub)\"\n",
       "            }\n",
       "            else {\n",
       "                return \"\"\n",
       "            }\n",
       "        })\n",
       "        .attr(\"marker-end\", function (d) {\n",
       "            if (['increases', 'directlyIncreases', 'positiveCorrelation'].indexOf(d.relation) >= 0) {\n",
       "                return \"url(#arrowhead)\"\n",
       "            } else if (['decreases', 'directlyDecreases', 'negativeCorrelation'].indexOf(d.relation) >= 0) {\n",
       "                return \"url(#stub)\"\n",
       "            } else {\n",
       "                return \"\"\n",
       "            }\n",
       "        });\n",
       "\n",
       "    var node = g.selectAll(\".nodes\")\n",
       "        .data(graph.nodes)\n",
       "        .enter().append(\"g\")\n",
       "        .attr(\"class\", \"node\")\n",
       "        // Next two lines -> Pin down functionality\n",
       "        .on('dblclick', releasenode)\n",
       "        .call(node_drag);\n",
       "\n",
       "    var circle = node.append(\"path\")\n",
       "        .attr(\"d\", d3.symbol()\n",
       "            .size(function (d) {\n",
       "                return Math.PI * Math.pow(size(d.size) || nominal_base_node_size, 2);\n",
       "            })\n",
       "        )\n",
       "        .attr(\"class\", function (d) {\n",
       "            return d.function\n",
       "        })\n",
       "        .style('fill', function (d) {\n",
       "            return function_colors[d.function]\n",
       "        })\n",
       "        .style(\"stroke-width\", nominal_stroke)\n",
       "        .style(\"stroke\", color_circunferencia);\n",
       "\n",
       "    var text = node.append(\"text\")\n",
       "        .attr(\"class\", \"node-name\")\n",
       "        // .attr(\"id\", nodehashes[d])\n",
       "        .attr(\"fill\", \"black\")\n",
       "        .attr(\"dx\", 12)\n",
       "        .attr(\"dy\", \".35em\")\n",
       "        .text(function (d) {\n",
       "            return d.cname\n",
       "        });\n",
       "\n",
       "    // Highlight on mouseenter and back to normal on mouseout\n",
       "    node.on(\"mouseenter\", function (d) {\n",
       "        set_highlight(d);\n",
       "    })\n",
       "        .on(\"mousedown\", function () {\n",
       "            d3.event.stopPropagation();\n",
       "        }).on(\"mouseout\", function () {\n",
       "        exit_highlight();\n",
       "    });\n",
       "\n",
       "    function exit_highlight() {\n",
       "        highlight_node = null;\n",
       "        if (focus_node === null) {\n",
       "            if (highlight_node_boundering != color_circunferencia) {\n",
       "                circle.style(\"stroke\", color_circunferencia);\n",
       "                text.style(\"fill\", \"black\");\n",
       "                link.style(\"stroke\", default_link_color);\n",
       "            }\n",
       "        }\n",
       "    }\n",
       "\n",
       "    function set_highlight(d) {\n",
       "        if (focus_node !== null) d = focus_node;\n",
       "        highlight_node = d;\n",
       "\n",
       "        if (highlight_node_boundering != color_circunferencia) {\n",
       "            circle.style(\"stroke\", function (o) {\n",
       "                return isConnected(d, o) ? highlight_node_boundering : color_circunferencia;\n",
       "            });\n",
       "            text.style(\"fill\", function (o) {\n",
       "                return isConnected(d, o) ? highlight_text : \"black\";\n",
       "            });\n",
       "            link.style(\"stroke\", function (o) {\n",
       "                return o.source.index == d.index || o.target.index == d.index ? highlighted_link_color : default_link_color;\n",
       "            });\n",
       "        }\n",
       "    }\n",
       "\n",
       "\n",
       "    // Freeze the graph when space is pressed\n",
       "    function freezeGraph() {\n",
       "        // Space button Triggers STOP\n",
       "        if (d3.event.keyCode == 32) {\n",
       "            simulation.stop();\n",
       "        }\n",
       "    }\n",
       "\n",
       "    // Call freezeGraph when a key is pressed, freezeGraph checks whether this key is \"Space\" that triggers the freeze\n",
       "    d3.select(window).on(\"keydown\", freezeGraph);\n",
       "}\n",
       "        var chart = \"auvzohbkrexdyqps\";\n",
       "        var width = 1000;\n",
       "        var height = 650;\n",
       "        var graph = {\"directed\": true, \"multigraph\": true, \"graph\": {\"document_metadata\": {}, \"pybel_version\": \"0.7.2\", \"namespace_url\": {}, \"namespace_owl\": {}, \"namespace_pattern\": {}, \"annotation_url\": {}, \"annotation_owl\": {}, \"annotation_pattern\": {}, \"annotation_list\": {}}, \"nodes\": [{\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"APP\", \"variants\": [{\"kind\": \"frag\", \"start\": 672, \"stop\": 713}], \"description\": \"This gene encodes a cell surface receptor and transmembrane precursor protein that is cleaved by secretases to form a number of peptides. Some of these peptides are secreted and can bind to the acetyltransferase complex APBB1/TIP60 to promote transcriptional activation, while others form the protein basis of the amyloid plaques found in the brains of patients with Alzheimer disease. In addition, two of the peptides are antimicrobial peptides, having been shown to have bacteriocidal and antifungal activities. Mutations in this gene have been implicated in autosomal dominant Alzheimer disease and cerebroarterial amyloidosis (cerebral amyloid angiopathy). Multiple transcript variants encoding several different isoforms have been found for this gene. [provided by RefSeq, Aug 2014]\", \"label\": \"amyloid beta precursor protein\", \"cname\": \"p(HGNC:APP, frag(672_713))\", \"id\": [\"Protein\", \"HGNC\", \"APP\", [\"frag\", [672, 713]]]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"EGR1\", \"description\": \"The protein encoded by this gene belongs to the EGR family of C2H2-type zinc-finger proteins. It is a nuclear protein and functions as a transcriptional regulator. The products of target genes it activates are required for differentitation and mitogenesis. Studies suggest this is a cancer suppressor gene. [provided by RefSeq, Dec 2014]\", \"label\": \"early growth response 1\", \"cname\": \"EGR1\", \"id\": [\"Protein\", \"HGNC\", \"EGR1\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"APP\", \"description\": \"This gene encodes a cell surface receptor and transmembrane precursor protein that is cleaved by secretases to form a number of peptides. Some of these peptides are secreted and can bind to the acetyltransferase complex APBB1/TIP60 to promote transcriptional activation, while others form the protein basis of the amyloid plaques found in the brains of patients with Alzheimer disease. In addition, two of the peptides are antimicrobial peptides, having been shown to have bacteriocidal and antifungal activities. Mutations in this gene have been implicated in autosomal dominant Alzheimer disease and cerebroarterial amyloidosis (cerebral amyloid angiopathy). Multiple transcript variants encoding several different isoforms have been found for this gene. [provided by RefSeq, Aug 2014]\", \"label\": \"amyloid beta precursor protein\", \"cname\": \"APP\", \"id\": [\"Protein\", \"HGNC\", \"APP\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GRIN2B\", \"variants\": [{\"kind\": \"pmod\", \"identifier\": {\"namespace\": \"bel\", \"name\": \"Ph\"}}], \"description\": \"N-methyl-D-aspartate (NMDA) receptors are a class of ionotropic glutamate receptors. NMDA receptor channel has been shown to be involved in long-term potentiation, an activity-dependent increase in the efficiency of synaptic transmission thought to underlie certain kinds of memory and learning. NMDA receptor channels are heteromers composed of three different subunits: NR1 (GRIN1), NR2 (GRIN2A, GRIN2B, GRIN2C, or GRIN2D) and NR3 (GRIN3A or GRIN3B). The NR2 subunit acts as the agonist binding site for glutamate. This receptor is the predominant excitatory neurotransmitter receptor in the mammalian brain. [provided by RefSeq, Jul 2008]\", \"label\": \"glutamate ionotropic receptor NMDA type subunit 2B\", \"cname\": \"p(HGNC:GRIN2B, pmod(Ph))\", \"id\": [\"Protein\", \"HGNC\", \"GRIN2B\", [\"pmod\", [\"bel\", \"Ph\"]]]}, {\"function\": \"Pathology\", \"namespace\": \"MESHD\", \"name\": \"Alzheimer Disease\", \"cname\": \"Alzheimer Disease\", \"id\": [\"Pathology\", \"MESHD\", \"Alzheimer Disease\"]}, {\"function\": \"BiologicalProcess\", \"namespace\": \"GOBP\", \"name\": \"synaptic transmission, cholinergic\", \"cname\": \"synaptic transmission, cholinergic\", \"id\": [\"BiologicalProcess\", \"GOBP\", \"synaptic transmission, cholinergic\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"PSEN2\", \"description\": \"Alzheimer's disease (AD) patients with an inherited form of the disease carry mutations in the presenilin proteins (PSEN1 or PSEN2) or the amyloid precursor protein (APP). These disease-linked mutations result in increased production of the longer form of amyloid-beta (main component of amyloid deposits found in AD brains). Presenilins are postulated to regulate APP processing through their effects on gamma-secretase, an enzyme that cleaves APP. Also, it is thought that the presenilins are involved in the cleavage of the Notch receptor such that, they either directly regulate gamma-secretase activity, or themselves act are protease enzymes. Two alternatively spliced transcript variants encoding different isoforms of PSEN2 have been identified. [provided by RefSeq, Jul 2008]\", \"label\": \"presenilin 2\", \"cname\": \"PSEN2\", \"id\": [\"Protein\", \"HGNC\", \"PSEN2\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"TNF\", \"description\": \"This gene encodes a multifunctional proinflammatory cytokine that belongs to the tumor necrosis factor (TNF) superfamily. This cytokine is mainly secreted by macrophages. It can bind to, and thus functions through its receptors TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR. This cytokine is involved in the regulation of a wide spectrum of biological processes including cell proliferation, differentiation, apoptosis, lipid metabolism, and coagulation. This cytokine has been implicated in a variety of diseases, including autoimmune diseases, insulin resistance, and cancer. Knockout studies in mice also suggested the neuroprotective function of this cytokine. [provided by RefSeq, Jul 2008]\", \"label\": \"tumor necrosis factor\", \"cname\": \"TNF\", \"id\": [\"Protein\", \"HGNC\", \"TNF\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRA1\", \"description\": \"This gene encodes a gamma-aminobutyric acid (GABA) receptor. GABA is the major inhibitory neurotransmitter in the mammalian brain where it acts at GABA-A receptors, which are ligand-gated chloride channels. Chloride conductance of these channels can be modulated by agents such as benzodiazepines that bind to the GABA-A receptor. GABA-A receptors are pentameric, consisting of proteins from several subunit classes: alpha, beta, gamma, delta and rho. Mutations in this gene cause juvenile myoclonic epilepsy and childhood absence epilepsy type 4. Multiple transcript variants encoding the same protein have been identified for this gene. [provided by RefSeq, Jul 2008]\", \"label\": \"gamma-aminobutyric acid type A receptor alpha1 subunit\", \"cname\": \"GABRA1\", \"id\": [\"Protein\", \"HGNC\", \"GABRA1\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRA2\", \"description\": \"GABA is the major inhibitory neurotransmitter in the mammalian brain where it acts at GABA-A receptors, which are ligand-gated chloride channels. Chloride conductance of these channels can be modulated by agents such as benzodiazepines that bind to the GABA-A receptor. At least 16 distinct subunits of GABA-A receptors have been identified. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Nov 2013]\", \"label\": \"gamma-aminobutyric acid type A receptor alpha2 subunit\", \"cname\": \"GABRA2\", \"id\": [\"Protein\", \"HGNC\", \"GABRA2\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRA3\", \"description\": \"GABA is the major inhibitory neurotransmitter in the mammalian brain where it acts at GABA-A receptors, which are ligand-gated chloride channels. Chloride conductance of these channels can be modulated by agents such as benzodiazepines that bind to the GABA-A receptor. At least 16 distinct subunits of GABA-A receptors have been identified. [provided by RefSeq, Jul 2008]\", \"label\": \"gamma-aminobutyric acid type A receptor alpha3 subunit\", \"cname\": \"GABRA3\", \"id\": [\"Protein\", \"HGNC\", \"GABRA3\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRA4\", \"description\": \"Gamma-aminobutyric acid (GABA) is the major inhibitory neurotransmitter in the mammalian brain where it acts at GABA-A receptors, which are ligand-gated chloride channels. Chloride conductance of these channels can be modulated by agents such as benzodiazepines that bind to the GABA-A receptor. At least 16 distinct subunits of GABA-A receptors have been identified. This gene encodes subunit alpha-4, which is involved in the etiology of autism and eventually increases autism risk through interaction with another subunit, gamma-aminobutyric acid receptor beta-1 (GABRB1). Alternatively spliced transcript variants encoding different isoforms have been found in this gene.[provided by RefSeq, Feb 2011]\", \"label\": \"gamma-aminobutyric acid type A receptor alpha4 subunit\", \"cname\": \"GABRA4\", \"id\": [\"Protein\", \"HGNC\", \"GABRA4\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRA5\", \"description\": \"GABA is the major inhibitory neurotransmitter in the mammalian brain where it acts at GABA-A receptors, which are ligand-gated chloride channels. Chloride conductance of these channels can be modulated by agents such as benzodiazepines that bind to the GABA-A receptor. At least 16 distinct subunits of GABA-A receptors have been identified. Transcript variants utilizing three different alternative non-coding first exons have been described. [provided by RefSeq, Jul 2008]\", \"label\": \"gamma-aminobutyric acid type A receptor alpha5 subunit\", \"cname\": \"GABRA5\", \"id\": [\"Protein\", \"HGNC\", \"GABRA5\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRA6\", \"description\": \"GABA is the major inhibitory neurotransmitter in the mammalian brain where it acts at GABA-A receptors, which are ligand-gated chloride channels. Chloride conductance of these channels can be modulated by agents such as benzodiazepines that bind to the GABA-A receptor. At least 16 distinct subunits of GABA-A receptors have been identified. [provided by RefSeq, Jul 2008]\", \"label\": \"gamma-aminobutyric acid type A receptor alpha6 subunit\", \"cname\": \"GABRA6\", \"id\": [\"Protein\", \"HGNC\", \"GABRA6\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRB1\", \"description\": \"The gamma-aminobutyric acid (GABA) A receptor is a multisubunit chloride channel that mediates the fastest inhibitory synaptic transmission in the central nervous system. This gene encodes GABA A receptor, beta 1 subunit. It is mapped to chromosome 4p12 in a cluster comprised of genes encoding alpha 4, alpha 2 and gamma 1 subunits of the GABA A receptor. Alteration of this gene is implicated in the pathogenetics of schizophrenia. [provided by RefSeq, Jul 2008]\", \"label\": \"gamma-aminobutyric acid type A receptor beta1 subunit\", \"cname\": \"GABRB1\", \"id\": [\"Protein\", \"HGNC\", \"GABRB1\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRB2\", \"description\": null, \"cname\": \"GABRB2\", \"id\": [\"Protein\", \"HGNC\", \"GABRB2\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRB3\", \"description\": \"This gene encodes a member of the ligand-gated ionic channel family. The encoded protein is one the subunits of a multi-subunit chloride channel that serves as the receptor for gamma-aminobutyric acid, a major inhibitory neurotransmitter of the mammalian nervous system. This gene is located on the long arm of chromosome 15 in a cluster with two other genes encoding related subunits of the family. This gene may be associated with the pathogenesis of several disorders including Angelman syndrome, Prader-Willi syndrome, nonsyndromic orofacial clefts, epilepsy and autism. Alternatively spliced transcript variants encoding distinct isoforms have been described. [provided by RefSeq, Jul 2013]\", \"label\": \"gamma-aminobutyric acid type A receptor beta3 subunit\", \"cname\": \"GABRB3\", \"id\": [\"Protein\", \"HGNC\", \"GABRB3\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRG1\", \"description\": \"The protein encoded by this gene belongs to the ligand-gated ionic channel family. It is an integral membrane protein and plays an important role in inhibiting neurotransmission by binding to the benzodiazepine receptor and opening an integral chloride channel. This gene is clustered with three other family members on chromosome 4. [provided by RefSeq, Jul 2008]\", \"label\": \"gamma-aminobutyric acid type A receptor gamma1 subunit\", \"cname\": \"GABRG1\", \"id\": [\"Protein\", \"HGNC\", \"GABRG1\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRG2\", \"description\": null, \"cname\": \"GABRG2\", \"id\": [\"Protein\", \"HGNC\", \"GABRG2\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRG3\", \"description\": \"This gene encodes a gamma-aminobutyric acid (GABA) receptor. GABA is the major inhibitory neurotransmitter in the mammalian brain where it acts at GABA-A receptors, which are ligand-gated chloride channels. Chloride conductance of these channels can be modulated by agents such as benzodiazepines that bind to the GABA-A receptor. GABA-A receptors are pentameric, consisting of proteins from several subunit classes: alpha, beta, gamma, delta and rho. The protein encoded by this gene is a gamma subunit, which contains the benzodiazepine binding site. Two transcript variants encoding distinct isoforms have been found for this gene. [provided by RefSeq, Aug 2012]\", \"label\": \"gamma-aminobutyric acid type A receptor gamma3 subunit\", \"cname\": \"GABRG3\", \"id\": [\"Protein\", \"HGNC\", \"GABRG3\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRD\", \"description\": \"Gamma-aminobutyric acid (GABA) is the major inhibitory neurotransmitter in the mammalian brain where it acts at GABA-A receptors, which are ligand-gated chloride channels. Chloride conductance of these channels can be modulated by agents such as benzodiazepines that bind to the GABA-A receptor. The GABA-A receptor is generally pentameric and there are five types of subunits: alpha, beta, gamma, delta, and rho. This gene encodes the delta subunit. Mutations in this gene have been associated with susceptibility to generalized epilepsy with febrile seizures, type 5. Alternatively spliced transcript variants have been described for this gene, but their biological validity has not been determined. [provided by RefSeq, Jul 2008]\", \"label\": \"gamma-aminobutyric acid type A receptor delta subunit\", \"cname\": \"GABRD\", \"id\": [\"Protein\", \"HGNC\", \"GABRD\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRE\", \"description\": \"The product of this gene belongs to the ligand-gated ionic channel (TC 1.A.9) family. It encodes the gamma-aminobutyric acid (GABA) A receptor which is a multisubunit chloride channel that mediates the fastest inhibitory synaptic transmission in the central nervous system. This gene encodes an epsilon subunit. It is mapped to chromosome Xq28 in a cluster comprised of genes encoding alpha 3, beta 4 and theta subunits of the same receptor. Alternatively spliced transcript variants have been identified, but only one is thought to encode a protein. [provided by RefSeq, Oct 2008]\", \"label\": \"gamma-aminobutyric acid type A receptor epsilon subunit\", \"cname\": \"GABRE\", \"id\": [\"Protein\", \"HGNC\", \"GABRE\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRP\", \"description\": \"The gamma-aminobutyric acid (GABA) A receptor is a multisubunit chloride channel that mediates the fastest inhibitory synaptic transmission in the central nervous system. The subunit encoded by this gene is expressed in several non-neuronal tissues including the uterus and ovaries. This subunit can assemble with known GABA A receptor subunits, and the presence of this subunit alters the sensitivity of recombinant receptors to modulatory agents such as pregnanolone. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, May 2014]\", \"label\": \"gamma-aminobutyric acid type A receptor pi subunit\", \"cname\": \"GABRP\", \"id\": [\"Protein\", \"HGNC\", \"GABRP\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABRQ\", \"description\": \"The gamma-aminobutyric acid (GABA) A receptor is a multisubunit chloride channel that mediates the fastest inhibitory synaptic transmission in the central nervous system. This gene encodes the theta subunit of the GABA A receptor. The gene is mapped to chromosome Xq28 in a cluster of genes including those that encode the alpha 3 and epsilon subunits of the GABA A receptor. [provided by RefSeq, Jul 2017]\", \"label\": \"gamma-aminobutyric acid type A receptor theta subunit\", \"cname\": \"GABRQ\", \"id\": [\"Protein\", \"HGNC\", \"GABRQ\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABBR1\", \"description\": \"This gene encodes a receptor for gamma-aminobutyric acid (GABA), which is the main inhibitory neurotransmitter in the mammalian central nervous system. This receptor functions as a heterodimer with GABA(B) receptor 2. Defects in this gene may underlie brain disorders such as schizophrenia and epilepsy. Alternative splicing generates multiple transcript variants, but the full-length nature of some of these variants has not been determined. [provided by RefSeq, Jan 2016]\", \"label\": \"gamma-aminobutyric acid type B receptor subunit 1\", \"cname\": \"GABBR1\", \"id\": [\"Protein\", \"HGNC\", \"GABBR1\"]}, {\"function\": \"BiologicalProcess\", \"namespace\": \"GOBP\", \"name\": \"regulation of N-methyl-D-aspartate selective glutamate receptor activity\", \"cname\": \"regulation of N-methyl-D-aspartate selective glutamate receptor activity\", \"id\": [\"BiologicalProcess\", \"GOBP\", \"regulation of N-methyl-D-aspartate selective glutamate receptor activity\"]}, {\"function\": \"BiologicalProcess\", \"namespace\": \"GOBP\", \"name\": \"regulation of synaptic plasticity\", \"cname\": \"regulation of synaptic plasticity\", \"id\": [\"BiologicalProcess\", \"GOBP\", \"regulation of synaptic plasticity\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GRIN2B\", \"description\": \"N-methyl-D-aspartate (NMDA) receptors are a class of ionotropic glutamate receptors. NMDA receptor channel has been shown to be involved in long-term potentiation, an activity-dependent increase in the efficiency of synaptic transmission thought to underlie certain kinds of memory and learning. NMDA receptor channels are heteromers composed of three different subunits: NR1 (GRIN1), NR2 (GRIN2A, GRIN2B, GRIN2C, or GRIN2D) and NR3 (GRIN3A or GRIN3B). The NR2 subunit acts as the agonist binding site for glutamate. This receptor is the predominant excitatory neurotransmitter receptor in the mammalian brain. [provided by RefSeq, Jul 2008]\", \"label\": \"glutamate ionotropic receptor NMDA type subunit 2B\", \"cname\": \"GRIN2B\", \"id\": [\"Protein\", \"HGNC\", \"GRIN2B\"]}, {\"function\": \"BiologicalProcess\", \"namespace\": \"GOBP\", \"name\": \"cognition\", \"cname\": \"cognition\", \"id\": [\"BiologicalProcess\", \"GOBP\", \"cognition\"]}, {\"function\": \"BiologicalProcess\", \"namespace\": \"GOBP\", \"name\": \"learning\", \"cname\": \"learning\", \"id\": [\"BiologicalProcess\", \"GOBP\", \"learning\"]}, {\"function\": \"BiologicalProcess\", \"namespace\": \"GOBP\", \"name\": \"memory\", \"cname\": \"memory\", \"id\": [\"BiologicalProcess\", \"GOBP\", \"memory\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CHRNA4\", \"description\": \"This gene encodes a nicotinic acetylcholine receptor, which belongs to a superfamily of ligand-gated ion channels that play a role in fast signal transmission at synapses. These pentameric receptors can bind acetylcholine, which causes an extensive change in conformation that leads to the opening of an ion-conducting channel across the plasma membrane. This protein is an integral membrane receptor subunit that can interact with either nAChR beta-2 or nAChR beta-4 to form a functional receptor. Mutations in this gene cause nocturnal frontal lobe epilepsy type 1. Polymorphisms in this gene that provide protection against nicotine addiction have been described. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Feb 2012]\", \"label\": \"cholinergic receptor nicotinic alpha 4 subunit\", \"cname\": \"CHRNA4\", \"id\": [\"Protein\", \"HGNC\", \"CHRNA4\"]}, {\"function\": \"Abundance\", \"namespace\": \"CHEBI\", \"name\": \"gamma-aminobutyric acid\", \"cname\": \"gamma-aminobutyric acid\", \"id\": [\"Abundance\", \"CHEBI\", \"gamma-aminobutyric acid\"]}, {\"function\": \"Abundance\", \"namespace\": \"CHEBI\", \"name\": \"glutamate(1-)\", \"cname\": \"glutamate(1-)\", \"id\": [\"Abundance\", \"CHEBI\", \"glutamate(1-)\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CHRNB2\", \"description\": \"Neuronal acetylcholine receptors are homo- or heteropentameric complexes composed of homologous alpha and beta subunits. They belong to a superfamily of ligand-gated ion channels which allow the flow of sodium and potassium across the plasma membrane in response to ligands such as acetylcholine and nicotine. This gene encodes one of several beta subunits. Mutations in this gene are associated with autosomal dominant nocturnal frontal lobe epilepsy. [provided by RefSeq, Jul 2008]\", \"label\": \"cholinergic receptor nicotinic beta 2 subunit\", \"cname\": \"CHRNB2\", \"id\": [\"Protein\", \"HGNC\", \"CHRNB2\"]}, {\"function\": \"BiologicalProcess\", \"namespace\": \"GOBP\", \"name\": \"regulation of neuronal synaptic plasticity\", \"cname\": \"regulation of neuronal synaptic plasticity\", \"id\": [\"BiologicalProcess\", \"GOBP\", \"regulation of neuronal synaptic plasticity\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CHRNA2\", \"description\": \"Nicotinic acetylcholine receptors (nAChRs) are ligand-gated ion channels formed by a pentameric arrangement of alpha and beta subunits to create distinct muscle and neuronal receptors. Neuronal receptors are found throughout the peripheral and central nervous system where they are involved in fast synaptic transmission. This gene encodes an alpha subunit that is widely expressed in the brain. The proposed structure for nAChR subunits is a conserved N-terminal extracellular domain followed by three conserved transmembrane domains, a variable cytoplasmic loop, a fourth conserved transmembrane domain, and a short C-terminal extracellular region. Mutations in this gene cause autosomal dominant nocturnal frontal lobe epilepsy type 4. Single nucleotide polymorphisms (SNPs) in this gene have been associated with nicotine dependence. [provided by RefSeq, Nov 2009]\", \"label\": \"cholinergic receptor nicotinic alpha 2 subunit\", \"cname\": \"CHRNA2\", \"id\": [\"Protein\", \"HGNC\", \"CHRNA2\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CHRNA3\", \"description\": \"This locus encodes a member of the nicotinic acetylcholine receptor family of proteins. Members of this family of proteins form pentameric complexes comprised of both alpha and beta subunits. This locus encodes an alpha-type subunit, as it contains characteristic adjacent cysteine residues. The encoded protein is a ligand-gated ion channel that likely plays a role in neurotransmission. Polymorphisms in this gene have been associated with an increased risk of smoking initiation and an increased susceptibility to lung cancer. Alternatively spliced transcript variants have been described. [provided by RefSeq, Nov 2009]\", \"label\": \"cholinergic receptor nicotinic alpha 3 subunit\", \"cname\": \"CHRNA3\", \"id\": [\"Protein\", \"HGNC\", \"CHRNA3\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CHRNA5\", \"description\": \"The protein encoded by this gene is a nicotinic acetylcholine receptor subunit and a member of a superfamily of ligand-gated ion channels that mediate fast signal transmission at synapses. These receptors are thought to be heteropentamers composed of separate but similar subunits. Defects in this gene have been linked to susceptibility to lung cancer type 2 (LNCR2).[provided by RefSeq, Jun 2010]\", \"label\": \"cholinergic receptor nicotinic alpha 5 subunit\", \"cname\": \"CHRNA5\", \"id\": [\"Protein\", \"HGNC\", \"CHRNA5\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CHRNA6\", \"description\": \"This gene encodes an alpha subunit of neuronal nicotinic acetylcholine receptors. These receptors consist of five subunits and function as ion channels involved in neurotransmission. The encoded protein is a subunit of neuronal nicotinic acetylcholine receptors that mediate dopaminergic neurotransmission and are activated by acetylcholine and exogenous nicotine. Alternatively spliced transcript variants have been observed for this gene. Single nucleotide polymorphisms in this gene have been associated with both nicotine and alcohol dependence. [provided by RefSeq, Dec 2010]\", \"label\": \"cholinergic receptor nicotinic alpha 6 subunit\", \"cname\": \"CHRNA6\", \"id\": [\"Protein\", \"HGNC\", \"CHRNA6\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CHRNA7\", \"description\": \"The nicotinic acetylcholine receptors (nAChRs) are members of a superfamily of ligand-gated ion channels that mediate fast signal transmission at synapses. The nAChRs are thought to be hetero-pentamers composed of homologous subunits. The proposed structure for each subunit is a conserved N-terminal extracellular domain followed by three conserved transmembrane domains, a variable cytoplasmic loop, a fourth conserved transmembrane domain, and a short C-terminal extracellular region. The protein encoded by this gene forms a homo-oligomeric channel, displays marked permeability to calcium ions and is a major component of brain nicotinic receptors that are blocked by, and highly sensitive to, alpha-bungarotoxin. Once this receptor binds acetylcholine, it undergoes an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. This gene is located in a region identified as a major susceptibility locus for juvenile myoclonic epilepsy and a chromosomal location involved in the genetic transmission of schizophrenia. An evolutionarily recent partial duplication event in this region results in a hybrid containing sequence from this gene and a novel FAM7A gene. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Feb 2012]\", \"label\": \"cholinergic receptor nicotinic alpha 7 subunit\", \"cname\": \"CHRNA7\", \"id\": [\"Protein\", \"HGNC\", \"CHRNA7\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CHRNA9\", \"description\": \"This gene is a member of the ligand-gated ionic channel family and nicotinic acetylcholine receptor gene superfamily. It encodes a plasma membrane protein that forms homo- or hetero-oligomeric divalent cation channels. This protein is involved in cochlea hair cell development and is also expressed in the outer hair cells (OHCs) of the adult cochlea. [provided by RefSeq, Feb 2012]\", \"label\": \"cholinergic receptor nicotinic alpha 9 subunit\", \"cname\": \"CHRNA9\", \"id\": [\"Protein\", \"HGNC\", \"CHRNA9\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CHRNA10\", \"description\": null, \"label\": \"cholinergic receptor nicotinic alpha 10 subunit\", \"cname\": \"CHRNA10\", \"id\": [\"Protein\", \"HGNC\", \"CHRNA10\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CHRNB3\", \"description\": \"The nicotinic acetylcholine receptors (nAChRs) are members of a superfamily of ligand-gated ion channels that mediate fast signal transmission at synapses. The nAChRs are (hetero)pentamers composed of homologous subunits. The subunits that make up the muscle and neuronal forms of nAChRs are encoded by separate genes and have different primary structure. There are several subtypes of neuronal nAChRs that vary based on which homologous subunits are arranged around the central channel. They are classified as alpha-subunits if, like muscle alpha-1 (MIM 100690), they have a pair of adjacent cysteines as part of the presumed acetylcholine binding site. Subunits lacking these cysteine residues are classified as beta-subunits (Groot Kormelink and Luyten, 1997 [PubMed 9009220]). Elliott et al. (1996) [PubMed 8906617] stated that the proposed structure for each subunit is a conserved N-terminal extracellular domain followed by 3 conserved transmembrane domains, a variable cytoplasmic loop, a fourth conserved transmembrane domain, and a short C-terminal extracellular region.[supplied by OMIM, Apr 2010]\", \"label\": \"cholinergic receptor nicotinic beta 3 subunit\", \"cname\": \"CHRNB3\", \"id\": [\"Protein\", \"HGNC\", \"CHRNB3\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CHRNB4\", \"description\": null, \"label\": \"cholinergic receptor nicotinic beta 4 subunit\", \"cname\": \"CHRNB4\", \"id\": [\"Protein\", \"HGNC\", \"CHRNB4\"]}, {\"function\": \"Abundance\", \"namespace\": \"CHEBI\", \"name\": \"galanthamine\", \"cname\": \"galanthamine\", \"id\": [\"Abundance\", \"CHEBI\", \"galanthamine\"]}, {\"function\": \"Abundance\", \"namespace\": \"CHEBI\", \"name\": \"1-(3-chlorophenyl)piperazine\", \"cname\": \"1-(3-chlorophenyl)piperazine\", \"id\": [\"Abundance\", \"CHEBI\", \"1-(3-chlorophenyl)piperazine\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GABBR2\", \"description\": \"The multi-pass membrane protein encoded by this gene belongs to the G-protein coupled receptor 3 family and GABA-B receptor subfamily. The GABA-B receptors inhibit neuronal activity through G protein-coupled second-messenger systems, which regulate the release of neurotransmitters, and the activity of ion channels and adenylyl cyclase. This receptor subunit forms an active heterodimeric complex with GABA-B receptor subunit 1, neither of which is effective on its own. Allelic variants of this gene have been associated with nicotine dependence.[provided by RefSeq, Jan 2010]\", \"label\": \"gamma-aminobutyric acid type B receptor subunit 2\", \"cname\": \"GABBR2\", \"id\": [\"Protein\", \"HGNC\", \"GABBR2\"]}, {\"function\": \"BiologicalProcess\", \"namespace\": \"GOBP\", \"name\": \"cAMP catabolic process\", \"cname\": \"cAMP catabolic process\", \"id\": [\"BiologicalProcess\", \"GOBP\", \"cAMP catabolic process\"]}, {\"function\": \"Abundance\", \"namespace\": \"CHEBI\", \"name\": \"nefiracetam\", \"cname\": \"nefiracetam\", \"id\": [\"Abundance\", \"CHEBI\", \"nefiracetam\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"PRKCA\", \"description\": \"Protein kinase C (PKC) is a family of serine- and threonine-specific protein kinases that can be activated by calcium and the second messenger diacylglycerol. PKC family members phosphorylate a wide variety of protein targets and are known to be involved in diverse cellular signaling pathways. PKC family members also serve as major receptors for phorbol esters, a class of tumor promoters. Each member of the PKC family has a specific expression profile and is believed to play a distinct role in cells. The protein encoded by this gene is one of the PKC family members. This kinase has been reported to play roles in many different cellular processes, such as cell adhesion, cell transformation, cell cycle checkpoint, and cell volume control. Knockout studies in mice suggest that this kinase may be a fundamental regulator of cardiac contractility and Ca(2+) handling in myocytes. [provided by RefSeq, Jul 2008]\", \"label\": \"protein kinase C alpha\", \"cname\": \"PRKCA\", \"id\": [\"Protein\", \"HGNC\", \"PRKCA\"]}, {\"function\": \"BiologicalProcess\", \"namespace\": \"GOBP\", \"name\": \"protein kinase A signaling\", \"cname\": \"protein kinase A signaling\", \"id\": [\"BiologicalProcess\", \"GOBP\", \"protein kinase A signaling\"]}, {\"function\": \"Abundance\", \"namespace\": \"CHEBI\", \"name\": \"EC 3.1.1.7 (acetylcholinesterase) inhibitor\", \"cname\": \"EC 3.1.1.7 (acetylcholinesterase) inhibitor\", \"id\": [\"Abundance\", \"CHEBI\", \"EC 3.1.1.7 (acetylcholinesterase) inhibitor\"]}, {\"function\": \"BiologicalProcess\", \"namespace\": \"GOBP\", \"name\": \"long-term synaptic potentiation\", \"cname\": \"long-term synaptic potentiation\", \"id\": [\"BiologicalProcess\", \"GOBP\", \"long-term synaptic potentiation\"]}, {\"function\": \"Complex\", \"namespace\": \"SCOMP\", \"name\": \"CAMK2 Complex\", \"cname\": \"CAMK2 Complex\", \"id\": [\"Complex\", \"SCOMP\", \"CAMK2 Complex\"]}, {\"function\": \"Complex\", \"cname\": \"complex(a(CHEBI:nefiracetam), p(HGNC:PRKCA))\", \"id\": [\"Complex\", [\"Abundance\", \"CHEBI\", \"nefiracetam\"], [\"Protein\", \"HGNC\", \"PRKCA\"]]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GRIA1\", \"variants\": [{\"kind\": \"pmod\", \"identifier\": {\"namespace\": \"bel\", \"name\": \"Ph\"}, \"code\": \"Ser\", \"pos\": 831}], \"description\": \"Glutamate receptors are the predominant excitatory neurotransmitter receptors in the mammalian brain and are activated in a variety of normal neurophysiologic processes. These receptors are heteromeric protein complexes with multiple subunits, each possessing transmembrane regions, and all arranged to form a ligand-gated ion channel. The classification of glutamate receptors is based on their activation by different pharmacologic agonists. This gene belongs to a family of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) receptors. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]\", \"label\": \"glutamate ionotropic receptor AMPA type subunit 1\", \"cname\": \"p(HGNC:GRIA1, pmod(Ph, Ser, 831))\", \"id\": [\"Protein\", \"HGNC\", \"GRIA1\", [\"pmod\", [\"bel\", \"Ph\"], \"Ser\", 831]]}, {\"function\": \"Complex\", \"namespace\": \"GOCC\", \"name\": \"proteasome complex\", \"cname\": \"proteasome complex\", \"id\": [\"Complex\", \"GOCC\", \"proteasome complex\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GPHN\", \"description\": \"This gene encodes a neuronal assembly protein that anchors inhibitory neurotransmitter receptors to the postsynaptic cytoskeleton via high affinity binding to a receptor subunit domain and tubulin dimers. In nonneuronal tissues, the encoded protein is also required for molybdenum cofactor biosynthesis. Mutations in this gene may be associated with the neurological condition hyperplexia and also lead to molybdenum cofactor deficiency. Numerous alternatively spliced transcript variants encoding different isoforms have been described; however, the full-length nature of all transcript variants is not currently known. [provided by RefSeq, Jul 2008]\", \"label\": \"gephyrin\", \"cname\": \"GPHN\", \"id\": [\"Protein\", \"HGNC\", \"GPHN\"]}, {\"function\": \"Pathology\", \"namespace\": \"MESHD\", \"name\": \"Glaucoma\", \"cname\": \"Glaucoma\", \"id\": [\"Pathology\", \"MESHD\", \"Glaucoma\"]}, {\"function\": \"Complex\", \"cname\": \"complex(p(HGNC:EGR1), p(HGNC:PSEN2))\", \"id\": [\"Complex\", [\"Protein\", \"HGNC\", \"EGR1\"], [\"Protein\", \"HGNC\", \"PSEN2\"]]}, {\"function\": \"Abundance\", \"namespace\": \"CHEBI\", \"name\": \"estradiol\", \"cname\": \"estradiol\", \"id\": [\"Abundance\", \"CHEBI\", \"estradiol\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"GABRA4\", \"description\": \"Gamma-aminobutyric acid (GABA) is the major inhibitory neurotransmitter in the mammalian brain where it acts at GABA-A receptors, which are ligand-gated chloride channels. Chloride conductance of these channels can be modulated by agents such as benzodiazepines that bind to the GABA-A receptor. At least 16 distinct subunits of GABA-A receptors have been identified. This gene encodes subunit alpha-4, which is involved in the etiology of autism and eventually increases autism risk through interaction with another subunit, gamma-aminobutyric acid receptor beta-1 (GABRB1). Alternatively spliced transcript variants encoding different isoforms have been found in this gene.[provided by RefSeq, Feb 2011]\", \"label\": \"gamma-aminobutyric acid type A receptor alpha4 subunit\", \"cname\": \"GABRA4\", \"id\": [\"RNA\", \"HGNC\", \"GABRA4\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"GABRA3\", \"description\": \"GABA is the major inhibitory neurotransmitter in the mammalian brain where it acts at GABA-A receptors, which are ligand-gated chloride channels. Chloride conductance of these channels can be modulated by agents such as benzodiazepines that bind to the GABA-A receptor. At least 16 distinct subunits of GABA-A receptors have been identified. [provided by RefSeq, Jul 2008]\", \"label\": \"gamma-aminobutyric acid type A receptor alpha3 subunit\", \"cname\": \"GABRA3\", \"id\": [\"RNA\", \"HGNC\", \"GABRA3\"]}, {\"function\": \"Abundance\", \"namespace\": \"CHEBI\", \"name\": \"Midazolam\", \"cname\": \"Midazolam\", \"id\": [\"Abundance\", \"CHEBI\", \"Midazolam\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GRIA1\", \"description\": \"Glutamate receptors are the predominant excitatory neurotransmitter receptors in the mammalian brain and are activated in a variety of normal neurophysiologic processes. These receptors are heteromeric protein complexes with multiple subunits, each possessing transmembrane regions, and all arranged to form a ligand-gated ion channel. The classification of glutamate receptors is based on their activation by different pharmacologic agonists. This gene belongs to a family of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) receptors. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]\", \"label\": \"glutamate ionotropic receptor AMPA type subunit 1\", \"cname\": \"GRIA1\", \"id\": [\"Protein\", \"HGNC\", \"GRIA1\"]}], \"links\": [{\"relation\": \"negativeCorrelation\", \"evidence\": \"Further, EGR1 levels were negatively correlated with hippocampal amyloid- plaque burden.This study presents global gene expression profiles associated with GA immunization in a glaucoma rat model.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Investigative ophthalmology &amp; visual science\", \"reference\": \"21969301\", \"authors\": [\"Bakalash S\", \"Pham M\", \"Koronyo Y\", \"Salumbides BC\", \"Kramerov A\", \"Seidenberg H\", \"Berel D\", \"Black KL\", \"Koronyo-Hamaoui M\"], \"date\": \"2011-11-21\", \"title\": \"Egr1 expression is induced following glatiramer acetate immunotherapy in rodent models of glaucoma and Alzheimer's disease.\", \"lastauthor\": \"Koronyo-Hamaoui M\", \"volume\": \"52\", \"issue\": \"12\", \"pages\": \"9033-46\", \"firstauthor\": \"Bakalash S\"}, \"line\": 17223, \"annotations\": {\"Disease\": \"Alzheimer's disease\", \"Species\": \"10116\", \"MeSHDisease\": \"Glaucoma\", \"MeSHAnatomy\": \"Hippocampus\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 0, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"In AD-Tg mice, a significant increase in hippocampal EGR1 protein levels was also found in response to GA immunization.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Investigative ophthalmology &amp; visual science\", \"reference\": \"21969301\", \"authors\": [\"Bakalash S\", \"Pham M\", \"Koronyo Y\", \"Salumbides BC\", \"Kramerov A\", \"Seidenberg H\", \"Berel D\", \"Black KL\", \"Koronyo-Hamaoui M\"], \"date\": \"2011-11-21\", \"title\": \"Egr1 expression is induced following glatiramer acetate immunotherapy in rodent models of glaucoma and Alzheimer's disease.\", \"lastauthor\": \"Koronyo-Hamaoui M\", \"volume\": \"52\", \"issue\": \"12\", \"pages\": \"9033-46\", \"firstauthor\": \"Bakalash S\"}, \"line\": 17211, \"annotations\": {\"Disease\": \"Alzheimer's disease\", \"MeSHAnatomy\": \"Hippocampus\", \"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 4, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Egr-1 upregulates the Alzheimer's disease presenilin-2 gene in neuronal cells.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Gene\", \"reference\": \"14585504\", \"authors\": [\"Renbaum P\", \"Beeri R\", \"Gabai E\", \"Amiel M\", \"Gal M\", \"Ehrengruber MU\", \"Levy-Lahad E\"], \"date\": \"2003-10-30\", \"title\": \"Egr-1 upregulates the Alzheimer's disease presenilin-2 gene in neuronal cells.\", \"lastauthor\": \"Levy-Lahad E\", \"volume\": \"318\", \"issue\": \"\", \"pages\": \"113-24\", \"firstauthor\": \"Renbaum P\"}, \"line\": 17249, \"annotations\": {\"Disease\": \"Alzheimer's disease\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 4, \"key\": 1}, {\"relation\": \"association\", \"evidence\": \"Most forms of neuronal plasticity are associated with the induction of the transcription factor zif268 (egr1).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17148, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 35, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17154, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 8, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17155, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 9, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17156, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 10, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17157, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 11, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17158, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 12, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17159, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 13, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17160, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 14, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17161, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 15, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17162, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 16, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17163, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 17, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17164, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 18, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17165, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 19, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17166, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 20, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17167, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 21, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17168, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 22, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17169, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 23, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17170, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 25, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Induction of zif268 in neurons leads to altered expression of proteasome subunit and proteasome-regulatory genes, thereby changing the capacity of the neuron to degrade synaptic proteins, including receptors and receptor subunits.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17177, \"annotations\": {\"MeSHAnatomy\": \"Neurons\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 57, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"In addition, zif268 alters the transcription of genes associated with GABA(A)R expression and trafficking, such as ubiquilin and gephyrin.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17182, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 58, \"key\": 0}, {\"relation\": \"negativeCorrelation\", \"evidence\": \"Further, EGR1 levels were negatively correlated with hippocampal amyloid- plaque burden.This study presents global gene expression profiles associated with GA immunization in a glaucoma rat model.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Investigative ophthalmology &amp; visual science\", \"reference\": \"21969301\", \"authors\": [\"Bakalash S\", \"Pham M\", \"Koronyo Y\", \"Salumbides BC\", \"Kramerov A\", \"Seidenberg H\", \"Berel D\", \"Black KL\", \"Koronyo-Hamaoui M\"], \"date\": \"2011-11-21\", \"title\": \"Egr1 expression is induced following glatiramer acetate immunotherapy in rodent models of glaucoma and Alzheimer's disease.\", \"lastauthor\": \"Koronyo-Hamaoui M\", \"volume\": \"52\", \"issue\": \"12\", \"pages\": \"9033-46\", \"firstauthor\": \"Bakalash S\"}, \"line\": 17223, \"annotations\": {\"Disease\": \"Alzheimer's disease\", \"Species\": \"10116\", \"MeSHDisease\": \"Glaucoma\", \"MeSHAnatomy\": \"Hippocampus\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 0, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Further, EGR1 levels were negatively correlated with hippocampal amyloid- plaque burden.This study presents global gene expression profiles associated with GA immunization in a glaucoma rat model.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Investigative ophthalmology &amp; visual science\", \"reference\": \"21969301\", \"authors\": [\"Bakalash S\", \"Pham M\", \"Koronyo Y\", \"Salumbides BC\", \"Kramerov A\", \"Seidenberg H\", \"Berel D\", \"Black KL\", \"Koronyo-Hamaoui M\"], \"date\": \"2011-11-21\", \"title\": \"Egr1 expression is induced following glatiramer acetate immunotherapy in rodent models of glaucoma and Alzheimer's disease.\", \"lastauthor\": \"Koronyo-Hamaoui M\", \"volume\": \"52\", \"issue\": \"12\", \"pages\": \"9033-46\", \"firstauthor\": \"Bakalash S\"}, \"line\": 17224, \"annotations\": {\"Disease\": \"Alzheimer's disease\", \"Species\": \"10116\", \"MeSHDisease\": \"Glaucoma\", \"MeSHAnatomy\": \"Hippocampus\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 59, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Egr-1 upregulates the Alzheimer's disease presenilin-2 gene in neuronal cells.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Gene\", \"reference\": \"14585504\", \"authors\": [\"Renbaum P\", \"Beeri R\", \"Gabai E\", \"Amiel M\", \"Gal M\", \"Ehrengruber MU\", \"Levy-Lahad E\"], \"date\": \"2003-10-30\", \"title\": \"Egr-1 upregulates the Alzheimer's disease presenilin-2 gene in neuronal cells.\", \"lastauthor\": \"Levy-Lahad E\", \"volume\": \"318\", \"issue\": \"\", \"pages\": \"113-24\", \"firstauthor\": \"Renbaum P\"}, \"line\": 17248, \"annotations\": {\"Disease\": \"Alzheimer's disease\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 1, \"target\": 6, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"In immunoblotting analysis, nefiracetam treatment increased the PKCalpha activity with a bell-shaped dose-response relationship peaking at 10 nM, thereby increasing phosphorylation of PKC substrate and NMDA receptor. Nefiracetam treatment did not affect the PKA activity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Molecular pharmacology\", \"reference\": \"17095583\", \"authors\": [\"Moriguchi S\", \"Shioda N\", \"Maejima H\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2007-02-01\", \"title\": \"Nefiracetam potentiates N-methyl-D-aspartate (NMDA) receptor function via protein kinase C activation and reduces magnesium block of NMDA receptor.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"71\", \"issue\": \"2\", \"pages\": \"580-7\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14364, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 2, \"target\": 3, \"key\": 0}, {\"relation\": \"hasVariant\", \"annotations\": {}, \"source\": 2, \"target\": 0, \"key\": -4}, {\"relation\": \"decreases\", \"evidence\": \"The nefiracetam-induced increase in the frequency of mEPSCs and mIPSCs over and above the level achieved by ACh alone would contribute to the therapeutic effect of nefiracetam as the cholinergic system is known to be downregulated in the brain of Alzheimer's disease patients.The therapeutic effects of galantamine are ascribed to the modest potentiation of nACh receptor and NMDA receptor activities in addition to the modest inhibition of acetylcholinesterase.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14418, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 4, \"target\": 5, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"In AD-Tg mice, a significant increase in hippocampal EGR1 protein levels was also found in response to GA immunization.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Investigative ophthalmology &amp; visual science\", \"reference\": \"21969301\", \"authors\": [\"Bakalash S\", \"Pham M\", \"Koronyo Y\", \"Salumbides BC\", \"Kramerov A\", \"Seidenberg H\", \"Berel D\", \"Black KL\", \"Koronyo-Hamaoui M\"], \"date\": \"2011-11-21\", \"title\": \"Egr1 expression is induced following glatiramer acetate immunotherapy in rodent models of glaucoma and Alzheimer's disease.\", \"lastauthor\": \"Koronyo-Hamaoui M\", \"volume\": \"52\", \"issue\": \"12\", \"pages\": \"9033-46\", \"firstauthor\": \"Bakalash S\"}, \"line\": 17211, \"annotations\": {\"Disease\": \"Alzheimer's disease\", \"MeSHAnatomy\": \"Hippocampus\", \"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 4, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Egr-1 upregulates the Alzheimer's disease presenilin-2 gene in neuronal cells.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Gene\", \"reference\": \"14585504\", \"authors\": [\"Renbaum P\", \"Beeri R\", \"Gabai E\", \"Amiel M\", \"Gal M\", \"Ehrengruber MU\", \"Levy-Lahad E\"], \"date\": \"2003-10-30\", \"title\": \"Egr-1 upregulates the Alzheimer's disease presenilin-2 gene in neuronal cells.\", \"lastauthor\": \"Levy-Lahad E\", \"volume\": \"318\", \"issue\": \"\", \"pages\": \"113-24\", \"firstauthor\": \"Renbaum P\"}, \"line\": 17249, \"annotations\": {\"Disease\": \"Alzheimer's disease\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 4, \"target\": 1, \"key\": 1}, {\"relation\": \"association\", \"evidence\": \"Egr-1 upregulates the Alzheimer's disease presenilin-2 gene in neuronal cells.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Gene\", \"reference\": \"14585504\", \"authors\": [\"Renbaum P\", \"Beeri R\", \"Gabai E\", \"Amiel M\", \"Gal M\", \"Ehrengruber MU\", \"Levy-Lahad E\"], \"date\": \"2003-10-30\", \"title\": \"Egr-1 upregulates the Alzheimer's disease presenilin-2 gene in neuronal cells.\", \"lastauthor\": \"Levy-Lahad E\", \"volume\": \"318\", \"issue\": \"\", \"pages\": \"113-24\", \"firstauthor\": \"Renbaum P\"}, \"line\": 17250, \"annotations\": {\"Disease\": \"Alzheimer's disease\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 4, \"target\": 6, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Egr-1 upregulates the Alzheimer's disease presenilin-2 gene in neuronal cells.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Gene\", \"reference\": \"14585504\", \"authors\": [\"Renbaum P\", \"Beeri R\", \"Gabai E\", \"Amiel M\", \"Gal M\", \"Ehrengruber MU\", \"Levy-Lahad E\"], \"date\": \"2003-10-30\", \"title\": \"Egr-1 upregulates the Alzheimer's disease presenilin-2 gene in neuronal cells.\", \"lastauthor\": \"Levy-Lahad E\", \"volume\": \"318\", \"issue\": \"\", \"pages\": \"113-24\", \"firstauthor\": \"Renbaum P\"}, \"line\": 17250, \"annotations\": {\"Disease\": \"Alzheimer's disease\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 6, \"target\": 4, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF-  can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators of inflammation\", \"reference\": \"24966471\", \"authors\": [\"Olmos G\", \"Llad J\"], \"date\": \"2014-01-01\", \"title\": \"Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity.\", \"lastauthor\": \"Llad J\", \"volume\": \"2014\", \"issue\": \"\", \"pages\": \"861231\", \"firstauthor\": \"Olmos G\"}, \"line\": 21557, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 8, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF-  can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators of inflammation\", \"reference\": \"24966471\", \"authors\": [\"Olmos G\", \"Llad J\"], \"date\": \"2014-01-01\", \"title\": \"Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity.\", \"lastauthor\": \"Llad J\", \"volume\": \"2014\", \"issue\": \"\", \"pages\": \"861231\", \"firstauthor\": \"Olmos G\"}, \"line\": 21558, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 9, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF-  can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators of inflammation\", \"reference\": \"24966471\", \"authors\": [\"Olmos G\", \"Llad J\"], \"date\": \"2014-01-01\", \"title\": \"Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity.\", \"lastauthor\": \"Llad J\", \"volume\": \"2014\", \"issue\": \"\", \"pages\": \"861231\", \"firstauthor\": \"Olmos G\"}, \"line\": 21559, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 10, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF-  can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators of inflammation\", \"reference\": \"24966471\", \"authors\": [\"Olmos G\", \"Llad J\"], \"date\": \"2014-01-01\", \"title\": \"Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity.\", \"lastauthor\": \"Llad J\", \"volume\": \"2014\", \"issue\": \"\", \"pages\": \"861231\", \"firstauthor\": \"Olmos G\"}, \"line\": 21560, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 11, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF-  can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators of inflammation\", \"reference\": \"24966471\", \"authors\": [\"Olmos G\", \"Llad J\"], \"date\": \"2014-01-01\", \"title\": \"Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity.\", \"lastauthor\": \"Llad J\", \"volume\": \"2014\", \"issue\": \"\", \"pages\": \"861231\", \"firstauthor\": \"Olmos G\"}, \"line\": 21561, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 12, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF-  can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators of inflammation\", \"reference\": \"24966471\", \"authors\": [\"Olmos G\", \"Llad J\"], \"date\": \"2014-01-01\", \"title\": \"Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity.\", \"lastauthor\": \"Llad J\", \"volume\": \"2014\", \"issue\": \"\", \"pages\": \"861231\", \"firstauthor\": \"Olmos G\"}, \"line\": 21562, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 13, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF-  can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators of inflammation\", \"reference\": \"24966471\", \"authors\": [\"Olmos G\", \"Llad J\"], \"date\": \"2014-01-01\", \"title\": \"Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity.\", \"lastauthor\": \"Llad J\", \"volume\": \"2014\", \"issue\": \"\", \"pages\": \"861231\", \"firstauthor\": \"Olmos G\"}, \"line\": 21563, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 14, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF-  can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators of inflammation\", \"reference\": \"24966471\", \"authors\": [\"Olmos G\", \"Llad J\"], \"date\": \"2014-01-01\", \"title\": \"Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity.\", \"lastauthor\": \"Llad J\", \"volume\": \"2014\", \"issue\": \"\", \"pages\": \"861231\", \"firstauthor\": \"Olmos G\"}, \"line\": 21564, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 15, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF-  can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators of inflammation\", \"reference\": \"24966471\", \"authors\": [\"Olmos G\", \"Llad J\"], \"date\": \"2014-01-01\", \"title\": \"Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity.\", \"lastauthor\": \"Llad J\", \"volume\": \"2014\", \"issue\": \"\", \"pages\": \"861231\", \"firstauthor\": \"Olmos G\"}, \"line\": 21565, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 16, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF-  can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators of inflammation\", \"reference\": \"24966471\", \"authors\": [\"Olmos G\", \"Llad J\"], \"date\": \"2014-01-01\", \"title\": \"Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity.\", \"lastauthor\": \"Llad J\", \"volume\": \"2014\", \"issue\": \"\", \"pages\": \"861231\", \"firstauthor\": \"Olmos G\"}, \"line\": 21566, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 17, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF-  can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators of inflammation\", \"reference\": \"24966471\", \"authors\": [\"Olmos G\", \"Llad J\"], \"date\": \"2014-01-01\", \"title\": \"Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity.\", \"lastauthor\": \"Llad J\", \"volume\": \"2014\", \"issue\": \"\", \"pages\": \"861231\", \"firstauthor\": \"Olmos G\"}, \"line\": 21567, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 18, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF-  can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators of inflammation\", \"reference\": \"24966471\", \"authors\": [\"Olmos G\", \"Llad J\"], \"date\": \"2014-01-01\", \"title\": \"Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity.\", \"lastauthor\": \"Llad J\", \"volume\": \"2014\", \"issue\": \"\", \"pages\": \"861231\", \"firstauthor\": \"Olmos G\"}, \"line\": 21568, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 19, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF-  can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators of inflammation\", \"reference\": \"24966471\", \"authors\": [\"Olmos G\", \"Llad J\"], \"date\": \"2014-01-01\", \"title\": \"Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity.\", \"lastauthor\": \"Llad J\", \"volume\": \"2014\", \"issue\": \"\", \"pages\": \"861231\", \"firstauthor\": \"Olmos G\"}, \"line\": 21569, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 20, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF-  can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators of inflammation\", \"reference\": \"24966471\", \"authors\": [\"Olmos G\", \"Llad J\"], \"date\": \"2014-01-01\", \"title\": \"Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity.\", \"lastauthor\": \"Llad J\", \"volume\": \"2014\", \"issue\": \"\", \"pages\": \"861231\", \"firstauthor\": \"Olmos G\"}, \"line\": 21570, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 21, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF-  can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators of inflammation\", \"reference\": \"24966471\", \"authors\": [\"Olmos G\", \"Llad J\"], \"date\": \"2014-01-01\", \"title\": \"Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity.\", \"lastauthor\": \"Llad J\", \"volume\": \"2014\", \"issue\": \"\", \"pages\": \"861231\", \"firstauthor\": \"Olmos G\"}, \"line\": 21571, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 22, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF-  can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators of inflammation\", \"reference\": \"24966471\", \"authors\": [\"Olmos G\", \"Llad J\"], \"date\": \"2014-01-01\", \"title\": \"Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity.\", \"lastauthor\": \"Llad J\", \"volume\": \"2014\", \"issue\": \"\", \"pages\": \"861231\", \"firstauthor\": \"Olmos G\"}, \"line\": 21572, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 23, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"In addition, TNF-  can potentiate glutamate-mediated cytotoxicity by two complementary mechanisms: indirectly, by inhibiting glutamate transport on astrocytes, and directly, by rapidly triggering the surface expression of Ca+2 permeable-AMPA receptors and NMDA receptors, while decreasing inhibitory GABAA receptors on neurons.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Mediators of inflammation\", \"reference\": \"24966471\", \"authors\": [\"Olmos G\", \"Llad J\"], \"date\": \"2014-01-01\", \"title\": \"Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity.\", \"lastauthor\": \"Llad J\", \"volume\": \"2014\", \"issue\": \"\", \"pages\": \"861231\", \"firstauthor\": \"Olmos G\"}, \"line\": 21573, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 7, \"target\": 24, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17128, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 8, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17154, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 8, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"1-(3-chlorophenyl)piperazine affects the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein co-treated with GABBR2 protein co-treated with GABRG2 protein]]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neurotoxicology\", \"reference\": \"21729720\", \"authors\": [\"Hondebrink L\", \"Meulenbelt J\", \"van Kleef RG\", \"van den Berg M\", \"Westerink RH\"], \"date\": \"2011-12-01\", \"title\": \"Modulation of human GABAA receptor function: a novel mode of action of drugs of abuse.\", \"lastauthor\": \"Westerink RH\", \"volume\": \"32\", \"issue\": \"6\", \"pages\": \"823-7\", \"firstauthor\": \"Hondebrink L\"}, \"line\": 46705, \"annotations\": {\"Species\": \"9606\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 8, \"target\": 46, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17129, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 9, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17155, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 9, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17130, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 10, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17156, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 10, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17131, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 11, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17157, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 11, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17132, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 12, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17158, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 12, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17133, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 13, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17159, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 13, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17134, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 14, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17160, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 14, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17135, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 15, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17161, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 15, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17136, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 16, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17162, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 16, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17137, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 17, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17163, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 17, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17138, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 18, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17164, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 18, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17139, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 19, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17165, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 19, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17140, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 20, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17166, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 20, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17141, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 21, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17167, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 21, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17142, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 22, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17168, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 22, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17143, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 23, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17169, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 23, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17144, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 25, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Hence, it is predicted that zif268 may regulate transcription of genes associated with glutamate receptors and/or GABA(A)Rs.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17170, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 25, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17128, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 8, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17129, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 9, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17130, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 10, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17131, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 11, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17132, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 12, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17133, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 13, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17134, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 14, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17135, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 15, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17136, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 16, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17137, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 17, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17138, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 18, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17139, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 19, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17140, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 20, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17141, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 21, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17142, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 22, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17143, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 23, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"The regulation of synaptic glutamate receptor and GABA(A)R (gamma-aminobutyric acid subtype A receptor) levels is a key component of synaptic plasticity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17144, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 26, \"target\": 25, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"In conclusion, nefiracetam enhances NMDA-receptor function through stimulation of its glycine binding site and nefiracetam-induced CaMKII activation likely contributes to improvement of cognition, learning, and memory.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of pharmacological sciences\", \"reference\": \"21821968\", \"authors\": [\"Moriguchi S\"], \"date\": \"2011-01-01\", \"title\": \"Pharmacological study on Alzheimer's drugs targeting calcium/calmodulin-dependent protein kinase II.\", \"lastauthor\": \"Moriguchi S\", \"volume\": \"117\", \"issue\": \"1\", \"pages\": \"6-11\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14460, \"annotations\": {\"Species\": \"10116\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 27, \"target\": 28, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"In conclusion, nefiracetam enhances NMDA-receptor function through stimulation of its glycine binding site and nefiracetam-induced CaMKII activation likely contributes to improvement of cognition, learning, and memory.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of pharmacological sciences\", \"reference\": \"21821968\", \"authors\": [\"Moriguchi S\"], \"date\": \"2011-01-01\", \"title\": \"Pharmacological study on Alzheimer's drugs targeting calcium/calmodulin-dependent protein kinase II.\", \"lastauthor\": \"Moriguchi S\", \"volume\": \"117\", \"issue\": \"1\", \"pages\": \"6-11\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14461, \"annotations\": {\"Species\": \"10116\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 27, \"target\": 29, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"In conclusion, nefiracetam enhances NMDA-receptor function through stimulation of its glycine binding site and nefiracetam-induced CaMKII activation likely contributes to improvement of cognition, learning, and memory.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of pharmacological sciences\", \"reference\": \"21821968\", \"authors\": [\"Moriguchi S\"], \"date\": \"2011-01-01\", \"title\": \"Pharmacological study on Alzheimer's drugs targeting calcium/calmodulin-dependent protein kinase II.\", \"lastauthor\": \"Moriguchi S\", \"volume\": \"117\", \"issue\": \"1\", \"pages\": \"6-11\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14462, \"annotations\": {\"Species\": \"10116\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 27, \"target\": 30, \"key\": 0}, {\"relation\": \"hasVariant\", \"annotations\": {}, \"source\": 27, \"target\": 3, \"key\": -4}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14391, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 31, \"target\": 32, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14402, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 31, \"target\": 33, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14397, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 34, \"target\": 33, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14408, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 34, \"target\": 33, \"key\": 1}, {\"relation\": \"association\", \"evidence\": \"Most forms of neuronal plasticity are associated with the induction of the transcription factor zif268 (egr1).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17148, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 35, \"target\": 1, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14389, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 36, \"target\": 32, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14400, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 36, \"target\": 33, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14390, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 37, \"target\": 32, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14401, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 37, \"target\": 33, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14392, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 38, \"target\": 32, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14403, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 38, \"target\": 33, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14393, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 39, \"target\": 32, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14404, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 39, \"target\": 33, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14394, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 40, \"target\": 32, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14405, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 40, \"target\": 33, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14395, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 41, \"target\": 32, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14406, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 41, \"target\": 33, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14396, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 42, \"target\": 32, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14407, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 42, \"target\": 33, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14398, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 43, \"target\": 33, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14409, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 43, \"target\": 33, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14399, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 44, \"target\": 33, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14410, \"subject\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 44, \"target\": 33, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14378, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 45, \"target\": 36, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14379, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 45, \"target\": 37, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14380, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 45, \"target\": 31, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14381, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 45, \"target\": 38, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14382, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 45, \"target\": 39, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14383, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 45, \"target\": 40, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14384, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 45, \"target\": 41, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14385, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 45, \"target\": 42, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14386, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 45, \"target\": 34, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14387, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 45, \"target\": 43, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14388, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 45, \"target\": 44, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"1-(3-chlorophenyl)piperazine affects the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein co-treated with GABBR2 protein co-treated with GABRG2 protein]]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neurotoxicology\", \"reference\": \"21729720\", \"authors\": [\"Hondebrink L\", \"Meulenbelt J\", \"van Kleef RG\", \"van den Berg M\", \"Westerink RH\"], \"date\": \"2011-12-01\", \"title\": \"Modulation of human GABAA receptor function: a novel mode of action of drugs of abuse.\", \"lastauthor\": \"Westerink RH\", \"volume\": \"32\", \"issue\": \"6\", \"pages\": \"823-7\", \"firstauthor\": \"Hondebrink L\"}, \"line\": 46705, \"annotations\": {\"Species\": \"9606\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 46, \"target\": 8, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"In this work, we describe a novel non-coding (nc) RNA (named 17A) RNA polymerase (pol) III-dependent embedded in the human G-protein-coupled receptor 51 gene (GPR51, GABA B2 receptor). The stable expression of 17A in SHSY5Y neuroblastoma cells induces the synthesis of an alternative splicing isoform that abolish GABA B2 intracellular signaling (i.e., inhibition of cAMP accumulation and activation of K(+) channels). Indeed, 17A is expressed in human brain, and we report that it is upregulated in cerebral tissues derived from Alzheimer disease patients. We demonstrate that 17A expression in neuroblastoma cells enhances the secretion of amyloid  peptide (Abeta) and the Abeta x-42/ x-40 peptide ratio and that its synthesis is induced in response to inflammatory stimuli.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neurobiology of disease\", \"reference\": \"20888417\", \"authors\": [\"Massone S\", \"Vassallo I\", \"Fiorino G\", \"Castelnuovo M\", \"Barbieri F\", \"Borghi R\", \"Tabaton M\", \"Robello M\", \"Gatta E\", \"Russo C\", \"Florio T\", \"Dieci G\", \"Cancedda R\", \"Pagano A\"], \"date\": \"2011-02-01\", \"title\": \"17A, a novel non-coding RNA, regulates GABA B alternative splicing and signaling in response to inflammatory stimuli and in Alzheimer disease.\", \"lastauthor\": \"Pagano A\", \"volume\": \"41\", \"issue\": \"2\", \"pages\": \"308-17\", \"firstauthor\": \"Massone S\"}, \"line\": 33227, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 47, \"target\": 48, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Nefiracetam is undergoing preclinical and clinical tests as a cognition-enhancing drug in Alzheimer's disease (AD).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Psychopharmacology\", \"reference\": \"9201800\", \"authors\": [\"Woodruff-Pak DS\", \"Hinchliffe RM\"], \"date\": \"1997-05-01\", \"title\": \"Mecamylamine- or scopolamine-induced learning impairment: ameliorated by nefiracetam.\", \"lastauthor\": \"Hinchliffe RM\", \"volume\": \"131\", \"issue\": \"2\", \"pages\": \"130-9\", \"firstauthor\": \"Woodruff-Pak DS\"}, \"line\": 14320, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 28, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The nootropic compound nefiracetam was evaluated in 88 older rabbits in a 750-ms delay paradigm of eyeblink classical conditioning (EBCC). Nefiracetam facilitated acquisition of EBCC in older rabbits. EBCC is performed poorly by older humans and is seriously impaired in Alzheimer's disease. These preclinical data in an animal model with clear parallels in humans suggest that nefiracetam may prove effective as a cognition enhancer in clinical trials.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Psychopharmacology\", \"reference\": \"7838908\", \"authors\": [\"Woodruff-Pak DS\", \"Li YT\"], \"date\": \"1994-03-01\", \"title\": \"Nefiracetam (DM-9384): effect on eyeblink classical conditioning in older rabbits.\", \"lastauthor\": \"Li YT\", \"volume\": \"114\", \"issue\": \"2\", \"pages\": \"200-8\", \"firstauthor\": \"Woodruff-Pak DS\"}, \"line\": 14332, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 28, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain research. Molecular brain research\", \"reference\": \"11039729\", \"authors\": [\"Nishizaki T\", \"Nomura T\", \"Matuoka T\", \"Kondoh T\", \"Enikolopov G\", \"Sumikawa K\", \"Watabe S\", \"Shiotani T\", \"Yoshii M\"], \"date\": \"2000-08-14\", \"title\": \"The anti-dementia drug nefiracetam facilitates hippocampal synaptic transmission by functionally targeting presynaptic nicotinic ACh receptors.\", \"lastauthor\": \"Yoshii M\", \"volume\": \"80\", \"issue\": \"1\", \"pages\": \"53-62\", \"firstauthor\": \"Nishizaki T\"}, \"line\": 14492, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 28, \"key\": 2}, {\"relation\": \"increases\", \"evidence\": \"We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Molecular pharmacology\", \"reference\": \"17095583\", \"authors\": [\"Moriguchi S\", \"Shioda N\", \"Maejima H\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2007-02-01\", \"title\": \"Nefiracetam potentiates N-methyl-D-aspartate (NMDA) receptor function via protein kinase C activation and reduces magnesium block of NMDA receptor.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"71\", \"issue\": \"2\", \"pages\": \"580-7\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14346, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 27, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"In conclusion, nefiracetam enhances NMDA-receptor function through stimulation of its glycine binding site and nefiracetam-induced CaMKII activation likely contributes to improvement of cognition, learning, and memory.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of pharmacological sciences\", \"reference\": \"21821968\", \"authors\": [\"Moriguchi S\"], \"date\": \"2011-01-01\", \"title\": \"Pharmacological study on Alzheimer's drugs targeting calcium/calmodulin-dependent protein kinase II.\", \"lastauthor\": \"Moriguchi S\", \"volume\": \"117\", \"issue\": \"1\", \"pages\": \"6-11\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14458, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10116\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 27, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Molecular pharmacology\", \"reference\": \"17095583\", \"authors\": [\"Moriguchi S\", \"Shioda N\", \"Maejima H\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2007-02-01\", \"title\": \"Nefiracetam potentiates N-methyl-D-aspartate (NMDA) receptor function via protein kinase C activation and reduces magnesium block of NMDA receptor.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"71\", \"issue\": \"2\", \"pages\": \"580-7\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14347, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 36, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Molecular pharmacology\", \"reference\": \"17095583\", \"authors\": [\"Moriguchi S\", \"Shioda N\", \"Maejima H\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2007-02-01\", \"title\": \"Nefiracetam potentiates N-methyl-D-aspartate (NMDA) receptor function via protein kinase C activation and reduces magnesium block of NMDA receptor.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"71\", \"issue\": \"2\", \"pages\": \"580-7\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14348, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 37, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Molecular pharmacology\", \"reference\": \"17095583\", \"authors\": [\"Moriguchi S\", \"Shioda N\", \"Maejima H\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2007-02-01\", \"title\": \"Nefiracetam potentiates N-methyl-D-aspartate (NMDA) receptor function via protein kinase C activation and reduces magnesium block of NMDA receptor.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"71\", \"issue\": \"2\", \"pages\": \"580-7\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14349, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 31, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Molecular pharmacology\", \"reference\": \"17095583\", \"authors\": [\"Moriguchi S\", \"Shioda N\", \"Maejima H\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2007-02-01\", \"title\": \"Nefiracetam potentiates N-methyl-D-aspartate (NMDA) receptor function via protein kinase C activation and reduces magnesium block of NMDA receptor.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"71\", \"issue\": \"2\", \"pages\": \"580-7\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14350, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 38, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Molecular pharmacology\", \"reference\": \"17095583\", \"authors\": [\"Moriguchi S\", \"Shioda N\", \"Maejima H\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2007-02-01\", \"title\": \"Nefiracetam potentiates N-methyl-D-aspartate (NMDA) receptor function via protein kinase C activation and reduces magnesium block of NMDA receptor.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"71\", \"issue\": \"2\", \"pages\": \"580-7\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14351, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 39, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Molecular pharmacology\", \"reference\": \"17095583\", \"authors\": [\"Moriguchi S\", \"Shioda N\", \"Maejima H\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2007-02-01\", \"title\": \"Nefiracetam potentiates N-methyl-D-aspartate (NMDA) receptor function via protein kinase C activation and reduces magnesium block of NMDA receptor.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"71\", \"issue\": \"2\", \"pages\": \"580-7\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14352, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 40, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Molecular pharmacology\", \"reference\": \"17095583\", \"authors\": [\"Moriguchi S\", \"Shioda N\", \"Maejima H\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2007-02-01\", \"title\": \"Nefiracetam potentiates N-methyl-D-aspartate (NMDA) receptor function via protein kinase C activation and reduces magnesium block of NMDA receptor.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"71\", \"issue\": \"2\", \"pages\": \"580-7\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14353, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 41, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Molecular pharmacology\", \"reference\": \"17095583\", \"authors\": [\"Moriguchi S\", \"Shioda N\", \"Maejima H\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2007-02-01\", \"title\": \"Nefiracetam potentiates N-methyl-D-aspartate (NMDA) receptor function via protein kinase C activation and reduces magnesium block of NMDA receptor.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"71\", \"issue\": \"2\", \"pages\": \"580-7\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14354, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 42, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Molecular pharmacology\", \"reference\": \"17095583\", \"authors\": [\"Moriguchi S\", \"Shioda N\", \"Maejima H\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2007-02-01\", \"title\": \"Nefiracetam potentiates N-methyl-D-aspartate (NMDA) receptor function via protein kinase C activation and reduces magnesium block of NMDA receptor.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"71\", \"issue\": \"2\", \"pages\": \"580-7\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14355, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 34, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Molecular pharmacology\", \"reference\": \"17095583\", \"authors\": [\"Moriguchi S\", \"Shioda N\", \"Maejima H\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2007-02-01\", \"title\": \"Nefiracetam potentiates N-methyl-D-aspartate (NMDA) receptor function via protein kinase C activation and reduces magnesium block of NMDA receptor.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"71\", \"issue\": \"2\", \"pages\": \"580-7\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14356, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 43, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"In immunoblotting analysis, nefiracetam treatment increased the PKCalpha activity with a bell-shaped dose-response relationship peaking at 10 nM, thereby increasing phosphorylation of PKC substrate and NMDA receptor. Nefiracetam treatment did not affect the PKA activity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Molecular pharmacology\", \"reference\": \"17095583\", \"authors\": [\"Moriguchi S\", \"Shioda N\", \"Maejima H\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2007-02-01\", \"title\": \"Nefiracetam potentiates N-methyl-D-aspartate (NMDA) receptor function via protein kinase C activation and reduces magnesium block of NMDA receptor.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"71\", \"issue\": \"2\", \"pages\": \"580-7\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14363, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 50, \"key\": 0}, {\"relation\": \"causesNoChange\", \"evidence\": \"In immunoblotting analysis, nefiracetam treatment increased the PKCalpha activity with a bell-shaped dose-response relationship peaking at 10 nM, thereby increasing phosphorylation of PKC substrate and NMDA receptor. Nefiracetam treatment did not affect the PKA activity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Molecular pharmacology\", \"reference\": \"17095583\", \"authors\": [\"Moriguchi S\", \"Shioda N\", \"Maejima H\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2007-02-01\", \"title\": \"Nefiracetam potentiates N-methyl-D-aspartate (NMDA) receptor function via protein kinase C activation and reduces magnesium block of NMDA receptor.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"71\", \"issue\": \"2\", \"pages\": \"580-7\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14365, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 51, \"key\": 0}, {\"relation\": \"isA\", \"evidence\": \"The nefiracetam-induced increase in the frequency of mEPSCs and mIPSCs over and above the level achieved by ACh alone would contribute to the therapeutic effect of nefiracetam as the cholinergic system is known to be downregulated in the brain of Alzheimer's disease patients.The therapeutic effects of galantamine are ascribed to the modest potentiation of nACh receptor and NMDA receptor activities in addition to the modest inhibition of acetylcholinesterase.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience\", \"reference\": \"19272425\", \"authors\": [\"Moriguchi S\", \"Zhao X\", \"Marszalec W\", \"Yeh JZ\", \"Fukunaga K\", \"Narahashi T\"], \"date\": \"2009-05-05\", \"title\": \"Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.\", \"lastauthor\": \"Narahashi T\", \"volume\": \"160\", \"issue\": \"2\", \"pages\": \"484-91\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14419, \"annotations\": {\"Species\": \"10090\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 52, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Nefiracetam treatment significantly enhanced long-term potentiation (LTP) with the same bell-shaped dose-response curve. Furthermore, nefiracetam-induced LTP enhancement was closely associated with calcium/calmodulin-dependent protein kinase II (CaMKII) activation with increase in phosphorylation of AMPA-type glutamate receptor subunit 1 (GluA1) (Ser-831) as a postsynaptic CaMKII substrate. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of pharmacological sciences\", \"reference\": \"21821968\", \"authors\": [\"Moriguchi S\"], \"date\": \"2011-01-01\", \"title\": \"Pharmacological study on Alzheimer's drugs targeting calcium/calmodulin-dependent protein kinase II.\", \"lastauthor\": \"Moriguchi S\", \"volume\": \"117\", \"issue\": \"1\", \"pages\": \"6-11\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14450, \"annotations\": {\"Species\": \"10116\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 53, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Nefiracetam treatment significantly enhanced long-term potentiation (LTP) with the same bell-shaped dose-response curve. Furthermore, nefiracetam-induced LTP enhancement was closely associated with calcium/calmodulin-dependent protein kinase II (CaMKII) activation with increase in phosphorylation of AMPA-type glutamate receptor subunit 1 (GluA1) (Ser-831) as a postsynaptic CaMKII substrate. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of pharmacological sciences\", \"reference\": \"21821968\", \"authors\": [\"Moriguchi S\"], \"date\": \"2011-01-01\", \"title\": \"Pharmacological study on Alzheimer's drugs targeting calcium/calmodulin-dependent protein kinase II.\", \"lastauthor\": \"Moriguchi S\", \"volume\": \"117\", \"issue\": \"1\", \"pages\": \"6-11\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14451, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10116\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 54, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"In conclusion, nefiracetam enhances NMDA-receptor function through stimulation of its glycine binding site and nefiracetam-induced CaMKII activation likely contributes to improvement of cognition, learning, and memory.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of pharmacological sciences\", \"reference\": \"21821968\", \"authors\": [\"Moriguchi S\"], \"date\": \"2011-01-01\", \"title\": \"Pharmacological study on Alzheimer's drugs targeting calcium/calmodulin-dependent protein kinase II.\", \"lastauthor\": \"Moriguchi S\", \"volume\": \"117\", \"issue\": \"1\", \"pages\": \"6-11\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14459, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Species\": \"10116\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 54, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain research. Molecular brain research\", \"reference\": \"11039729\", \"authors\": [\"Nishizaki T\", \"Nomura T\", \"Matuoka T\", \"Kondoh T\", \"Enikolopov G\", \"Sumikawa K\", \"Watabe S\", \"Shiotani T\", \"Yoshii M\"], \"date\": \"2000-08-14\", \"title\": \"The anti-dementia drug nefiracetam facilitates hippocampal synaptic transmission by functionally targeting presynaptic nicotinic ACh receptors.\", \"lastauthor\": \"Yoshii M\", \"volume\": \"80\", \"issue\": \"1\", \"pages\": \"53-62\", \"firstauthor\": \"Nishizaki T\"}, \"line\": 14480, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 49, \"target\": 55, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Nefiracetam treatment significantly enhanced long-term potentiation (LTP) with the same bell-shaped dose-response curve. Furthermore, nefiracetam-induced LTP enhancement was closely associated with calcium/calmodulin-dependent protein kinase II (CaMKII) activation with increase in phosphorylation of AMPA-type glutamate receptor subunit 1 (GluA1) (Ser-831) as a postsynaptic CaMKII substrate. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of pharmacological sciences\", \"reference\": \"21821968\", \"authors\": [\"Moriguchi S\"], \"date\": \"2011-01-01\", \"title\": \"Pharmacological study on Alzheimer's drugs targeting calcium/calmodulin-dependent protein kinase II.\", \"lastauthor\": \"Moriguchi S\", \"volume\": \"117\", \"issue\": \"1\", \"pages\": \"6-11\", \"firstauthor\": \"Moriguchi S\"}, \"line\": 14452, \"annotations\": {\"Species\": \"10116\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 54, \"target\": 56, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain research. Molecular brain research\", \"reference\": \"11039729\", \"authors\": [\"Nishizaki T\", \"Nomura T\", \"Matuoka T\", \"Kondoh T\", \"Enikolopov G\", \"Sumikawa K\", \"Watabe S\", \"Shiotani T\", \"Yoshii M\"], \"date\": \"2000-08-14\", \"title\": \"The anti-dementia drug nefiracetam facilitates hippocampal synaptic transmission by functionally targeting presynaptic nicotinic ACh receptors.\", \"lastauthor\": \"Yoshii M\", \"volume\": \"80\", \"issue\": \"1\", \"pages\": \"53-62\", \"firstauthor\": \"Nishizaki T\"}, \"line\": 14481, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 55, \"target\": 36, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain research. Molecular brain research\", \"reference\": \"11039729\", \"authors\": [\"Nishizaki T\", \"Nomura T\", \"Matuoka T\", \"Kondoh T\", \"Enikolopov G\", \"Sumikawa K\", \"Watabe S\", \"Shiotani T\", \"Yoshii M\"], \"date\": \"2000-08-14\", \"title\": \"The anti-dementia drug nefiracetam facilitates hippocampal synaptic transmission by functionally targeting presynaptic nicotinic ACh receptors.\", \"lastauthor\": \"Yoshii M\", \"volume\": \"80\", \"issue\": \"1\", \"pages\": \"53-62\", \"firstauthor\": \"Nishizaki T\"}, \"line\": 14482, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 55, \"target\": 37, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain research. Molecular brain research\", \"reference\": \"11039729\", \"authors\": [\"Nishizaki T\", \"Nomura T\", \"Matuoka T\", \"Kondoh T\", \"Enikolopov G\", \"Sumikawa K\", \"Watabe S\", \"Shiotani T\", \"Yoshii M\"], \"date\": \"2000-08-14\", \"title\": \"The anti-dementia drug nefiracetam facilitates hippocampal synaptic transmission by functionally targeting presynaptic nicotinic ACh receptors.\", \"lastauthor\": \"Yoshii M\", \"volume\": \"80\", \"issue\": \"1\", \"pages\": \"53-62\", \"firstauthor\": \"Nishizaki T\"}, \"line\": 14483, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 55, \"target\": 31, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain research. Molecular brain research\", \"reference\": \"11039729\", \"authors\": [\"Nishizaki T\", \"Nomura T\", \"Matuoka T\", \"Kondoh T\", \"Enikolopov G\", \"Sumikawa K\", \"Watabe S\", \"Shiotani T\", \"Yoshii M\"], \"date\": \"2000-08-14\", \"title\": \"The anti-dementia drug nefiracetam facilitates hippocampal synaptic transmission by functionally targeting presynaptic nicotinic ACh receptors.\", \"lastauthor\": \"Yoshii M\", \"volume\": \"80\", \"issue\": \"1\", \"pages\": \"53-62\", \"firstauthor\": \"Nishizaki T\"}, \"line\": 14484, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 55, \"target\": 38, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain research. Molecular brain research\", \"reference\": \"11039729\", \"authors\": [\"Nishizaki T\", \"Nomura T\", \"Matuoka T\", \"Kondoh T\", \"Enikolopov G\", \"Sumikawa K\", \"Watabe S\", \"Shiotani T\", \"Yoshii M\"], \"date\": \"2000-08-14\", \"title\": \"The anti-dementia drug nefiracetam facilitates hippocampal synaptic transmission by functionally targeting presynaptic nicotinic ACh receptors.\", \"lastauthor\": \"Yoshii M\", \"volume\": \"80\", \"issue\": \"1\", \"pages\": \"53-62\", \"firstauthor\": \"Nishizaki T\"}, \"line\": 14485, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 55, \"target\": 39, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain research. Molecular brain research\", \"reference\": \"11039729\", \"authors\": [\"Nishizaki T\", \"Nomura T\", \"Matuoka T\", \"Kondoh T\", \"Enikolopov G\", \"Sumikawa K\", \"Watabe S\", \"Shiotani T\", \"Yoshii M\"], \"date\": \"2000-08-14\", \"title\": \"The anti-dementia drug nefiracetam facilitates hippocampal synaptic transmission by functionally targeting presynaptic nicotinic ACh receptors.\", \"lastauthor\": \"Yoshii M\", \"volume\": \"80\", \"issue\": \"1\", \"pages\": \"53-62\", \"firstauthor\": \"Nishizaki T\"}, \"line\": 14486, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 55, \"target\": 40, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain research. Molecular brain research\", \"reference\": \"11039729\", \"authors\": [\"Nishizaki T\", \"Nomura T\", \"Matuoka T\", \"Kondoh T\", \"Enikolopov G\", \"Sumikawa K\", \"Watabe S\", \"Shiotani T\", \"Yoshii M\"], \"date\": \"2000-08-14\", \"title\": \"The anti-dementia drug nefiracetam facilitates hippocampal synaptic transmission by functionally targeting presynaptic nicotinic ACh receptors.\", \"lastauthor\": \"Yoshii M\", \"volume\": \"80\", \"issue\": \"1\", \"pages\": \"53-62\", \"firstauthor\": \"Nishizaki T\"}, \"line\": 14487, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 55, \"target\": 41, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain research. Molecular brain research\", \"reference\": \"11039729\", \"authors\": [\"Nishizaki T\", \"Nomura T\", \"Matuoka T\", \"Kondoh T\", \"Enikolopov G\", \"Sumikawa K\", \"Watabe S\", \"Shiotani T\", \"Yoshii M\"], \"date\": \"2000-08-14\", \"title\": \"The anti-dementia drug nefiracetam facilitates hippocampal synaptic transmission by functionally targeting presynaptic nicotinic ACh receptors.\", \"lastauthor\": \"Yoshii M\", \"volume\": \"80\", \"issue\": \"1\", \"pages\": \"53-62\", \"firstauthor\": \"Nishizaki T\"}, \"line\": 14488, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 55, \"target\": 42, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain research. Molecular brain research\", \"reference\": \"11039729\", \"authors\": [\"Nishizaki T\", \"Nomura T\", \"Matuoka T\", \"Kondoh T\", \"Enikolopov G\", \"Sumikawa K\", \"Watabe S\", \"Shiotani T\", \"Yoshii M\"], \"date\": \"2000-08-14\", \"title\": \"The anti-dementia drug nefiracetam facilitates hippocampal synaptic transmission by functionally targeting presynaptic nicotinic ACh receptors.\", \"lastauthor\": \"Yoshii M\", \"volume\": \"80\", \"issue\": \"1\", \"pages\": \"53-62\", \"firstauthor\": \"Nishizaki T\"}, \"line\": 14489, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 55, \"target\": 34, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain research. Molecular brain research\", \"reference\": \"11039729\", \"authors\": [\"Nishizaki T\", \"Nomura T\", \"Matuoka T\", \"Kondoh T\", \"Enikolopov G\", \"Sumikawa K\", \"Watabe S\", \"Shiotani T\", \"Yoshii M\"], \"date\": \"2000-08-14\", \"title\": \"The anti-dementia drug nefiracetam facilitates hippocampal synaptic transmission by functionally targeting presynaptic nicotinic ACh receptors.\", \"lastauthor\": \"Yoshii M\", \"volume\": \"80\", \"issue\": \"1\", \"pages\": \"53-62\", \"firstauthor\": \"Nishizaki T\"}, \"line\": 14490, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 55, \"target\": 43, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain research. Molecular brain research\", \"reference\": \"11039729\", \"authors\": [\"Nishizaki T\", \"Nomura T\", \"Matuoka T\", \"Kondoh T\", \"Enikolopov G\", \"Sumikawa K\", \"Watabe S\", \"Shiotani T\", \"Yoshii M\"], \"date\": \"2000-08-14\", \"title\": \"The anti-dementia drug nefiracetam facilitates hippocampal synaptic transmission by functionally targeting presynaptic nicotinic ACh receptors.\", \"lastauthor\": \"Yoshii M\", \"volume\": \"80\", \"issue\": \"1\", \"pages\": \"53-62\", \"firstauthor\": \"Nishizaki T\"}, \"line\": 14491, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 55, \"target\": 44, \"key\": 0}, {\"relation\": \"hasComponent\", \"annotations\": {}, \"source\": 55, \"target\": 49, \"key\": -3}, {\"relation\": \"hasComponent\", \"annotations\": {}, \"source\": 55, \"target\": 50, \"key\": -3}, {\"relation\": \"association\", \"evidence\": \"Induction of zif268 in neurons leads to altered expression of proteasome subunit and proteasome-regulatory genes, thereby changing the capacity of the neuron to degrade synaptic proteins, including receptors and receptor subunits.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17177, \"annotations\": {\"MeSHAnatomy\": \"Neurons\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 57, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"In addition, zif268 alters the transcription of genes associated with GABA(A)R expression and trafficking, such as ubiquilin and gephyrin.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Biochemical Society transactions\", \"reference\": \"19909279\", \"authors\": [\"McDade DM\", \"Conway AM\", \"James AB\", \"Morris BJ\"], \"date\": \"2009-12-01\", \"title\": \"Activity-dependent gene transcription as a long-term influence on receptor signalling.\", \"lastauthor\": \"Morris BJ\", \"volume\": \"37\", \"issue\": \"Pt 6\", \"pages\": \"1375-7\", \"firstauthor\": \"McDade DM\"}, \"line\": 17182, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 58, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Further, EGR1 levels were negatively correlated with hippocampal amyloid- plaque burden.This study presents global gene expression profiles associated with GA immunization in a glaucoma rat model.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Investigative ophthalmology &amp; visual science\", \"reference\": \"21969301\", \"authors\": [\"Bakalash S\", \"Pham M\", \"Koronyo Y\", \"Salumbides BC\", \"Kramerov A\", \"Seidenberg H\", \"Berel D\", \"Black KL\", \"Koronyo-Hamaoui M\"], \"date\": \"2011-11-21\", \"title\": \"Egr1 expression is induced following glatiramer acetate immunotherapy in rodent models of glaucoma and Alzheimer's disease.\", \"lastauthor\": \"Koronyo-Hamaoui M\", \"volume\": \"52\", \"issue\": \"12\", \"pages\": \"9033-46\", \"firstauthor\": \"Bakalash S\"}, \"line\": 17224, \"annotations\": {\"Disease\": \"Alzheimer's disease\", \"Species\": \"10116\", \"MeSHDisease\": \"Glaucoma\", \"MeSHAnatomy\": \"Hippocampus\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 59, \"target\": 1, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We show that Egr-1 binds to PSEN-P2, and that PSEN-P2 activity is increased threefold by overexpression of Egr-1, and by 12-O-tetradecanoylphorbol-13-acetate (TPA), which induces physiological Egr-1 levels.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Gene\", \"reference\": \"14585504\", \"authors\": [\"Renbaum P\", \"Beeri R\", \"Gabai E\", \"Amiel M\", \"Gal M\", \"Ehrengruber MU\", \"Levy-Lahad E\"], \"date\": \"2003-10-30\", \"title\": \"Egr-1 upregulates the Alzheimer's disease presenilin-2 gene in neuronal cells.\", \"lastauthor\": \"Levy-Lahad E\", \"volume\": \"318\", \"issue\": \"\", \"pages\": \"113-24\", \"firstauthor\": \"Renbaum P\"}, \"line\": 17256, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Disease\": \"Alzheimer's disease\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 60, \"target\": 6, \"key\": 0}, {\"relation\": \"hasComponent\", \"annotations\": {}, \"source\": 60, \"target\": 6, \"key\": -3}, {\"relation\": \"hasComponent\", \"annotations\": {}, \"source\": 60, \"target\": 1, \"key\": -3}, {\"relation\": \"association\", \"evidence\": \"Estradiol affects the expression of GABRA4 mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain research. Molecular brain research\", \"reference\": \"16000229\", \"authors\": [\"Pierson RC\", \"Lyons AM\", \"Greenfield LJ Jr\"], \"date\": \"2005-08-18\", \"title\": \"Gonadal steroids regulate GABAA receptor subunit mRNA expression in NT2-N neurons.\", \"lastauthor\": \"Greenfield LJ Jr\", \"volume\": \"138\", \"issue\": \"2\", \"pages\": \"105-15\", \"firstauthor\": \"Pierson RC\"}, \"line\": 46602, \"annotations\": {\"Species\": \"9606\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 61, \"target\": 62, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Estradiol results in increased expression of GABRA3 mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain research. Molecular brain research\", \"reference\": \"16000229\", \"authors\": [\"Pierson RC\", \"Lyons AM\", \"Greenfield LJ Jr\"], \"date\": \"2005-08-18\", \"title\": \"Gonadal steroids regulate GABAA receptor subunit mRNA expression in NT2-N neurons.\", \"lastauthor\": \"Greenfield LJ Jr\", \"volume\": \"138\", \"issue\": \"2\", \"pages\": \"105-15\", \"firstauthor\": \"Pierson RC\"}, \"line\": 47285, \"annotations\": {\"Subgraph\": \"GABA subgraph\"}, \"source\": 61, \"target\": 63, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Estradiol affects the expression of GABRA4 mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Brain research. Molecular brain research\", \"reference\": \"16000229\", \"authors\": [\"Pierson RC\", \"Lyons AM\", \"Greenfield LJ Jr\"], \"date\": \"2005-08-18\", \"title\": \"Gonadal steroids regulate GABAA receptor subunit mRNA expression in NT2-N neurons.\", \"lastauthor\": \"Greenfield LJ Jr\", \"volume\": \"138\", \"issue\": \"2\", \"pages\": \"105-15\", \"firstauthor\": \"Pierson RC\"}, \"line\": 46602, \"annotations\": {\"Species\": \"9606\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 62, \"target\": 61, \"key\": 0}, {\"relation\": \"translatedTo\", \"annotations\": {}, \"source\": 62, \"target\": 11, \"key\": -6}, {\"relation\": \"translatedTo\", \"annotations\": {}, \"source\": 63, \"target\": 10, \"key\": -6}, {\"relation\": \"decreases\", \"evidence\": \"GABRA6 protein mutant form results in decreased susceptibility to Midazolam\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of clinical anesthesia\", \"reference\": \"12031754\", \"authors\": [\"Hoffman WE\", \"Balyasnikova IV\", \"Mahay H\", \"Danilov SM\", \"Baughman VL\"], \"date\": \"2002-05-01\", \"title\": \"GABA alpha6 receptors mediate midazolam-induced anxiolysis.\", \"lastauthor\": \"Baughman VL\", \"volume\": \"14\", \"issue\": \"3\", \"pages\": \"206-9\", \"firstauthor\": \"Hoffman WE\"}, \"line\": 48542, \"annotations\": {\"Species\": \"9606\", \"Subgraph\": \"GABA subgraph\"}, \"source\": 64, \"target\": 13, \"key\": 0}, {\"relation\": \"hasVariant\", \"annotations\": {}, \"source\": 65, \"target\": 56, \"key\": -4}]};\n",
       "        const color_map = {'Protein': '#1F77B4', 'Pathology': '#FF7F0E', 'BiologicalProcess': '#2CA02C', 'miRNA': '#D62728', 'Complex': '#9467bd', 'Composite': '#9467bd', 'Reaction': '#8c564b', 'Gene': '#e377c2', 'Abundance': '#bcbd22', 'RNA': '#17becf'};\n",
       "    \n",
       "        require.config({\n",
       "          paths: {\n",
       "              d3: '//cdnjs.cloudflare.com/ajax/libs/d3/4.5.0/d3.min'\n",
       "          }\n",
       "        });\n",
       "\n",
       "        var elementInnerHTML = \"<div id='\" + chart + \"'></div>\";\n",
       "\n",
       "        element.append(elementInnerHTML);\n",
       "\n",
       "        var chartQualified = \"#\" + chart;\n",
       "\n",
       "        require(['d3'], function(d3) {\n",
       "            return init_d3_force(d3, graph, chartQualified, width, height, color_map);\n",
       "        });\n",
       "    "
      ],
      "text/plain": [
       "<IPython.core.display.Javascript object>"
      ]
     },
     "execution_count": 19,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "to_jupyter(subgraph)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "The concept of expansion then contraction is commonly called \"opening\" in the domain of image processing. Inference of the central dogma then removal of leaf genes and RNAs is such a standard operation that both steps can be run by [pbt.mutation.opening_on_central_dogma](http://pybel-tools.readthedocs.io/en/latest/mutation.html#pybel_tools.mutation.opening_on_central_dogma).\n",
    "\n",
    "### Further Consideration\n",
    "\n",
    "The fact that a subgraph contains more than one connected component probably means that there were errors in the original BEL script. There is an entire module devoted to analyzing the errors produced during compilation called `pbt.summary.error_summary`\n",
    "\n",
    "However, it's also possible that the connections are due to lack of knowledge in the literature. In the curation process for the NeuroMMSig Database, many entitity types were not considered. We've developed an algorithm for inferring additional members of a subgraph, including chemicals that occur as intermediates in biochemical processes, and higher level entities such as biological processes. The set of tools for running the algorithm are avaliable in the `pbt.mutations.subgraph_expansion` submodule (see [pbt.mutation.fill_subgraph](http://pybel-tools.readthedocs.io/en/latest/mutation.html#pybel_tools.mutation.fill_subgraph)). "
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Expanding on the Periphery\n",
    "\n",
    "In this example, we'll look at the Estrogen Subgraph. The subgraph is enriched with unqualified edges and opened with the central dogma."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": [
    "example_subgraph_name = 'Estrogen subgraph'"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Nodes: 25\n",
      "Edges: 39\n",
      "Citations: 10\n",
      "Authors: 50\n",
      "Network density: 0.065\n",
      "Components: 5\n",
      "Average degree: 1.56\n"
     ]
    }
   ],
   "source": [
    "subgraph = pbt.selection.get_subgraph_by_annotation_value(graph, annotation='Subgraph', value=example_subgraph_name)\n",
    "\n",
    "pbt.mutation.enrich_unqualified(graph, subgraph)\n",
    "pbt.mutation.opening_on_central_dogma(subgraph)\n",
    "\n",
    "pbt.summary.print_summary(subgraph)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/javascript": [
       "function init_d3_force(d3, graph, chart, width, height, function_colors) {\n",
       "    var focus_node = null;\n",
       "    var highlight_node = null;\n",
       "\n",
       "    // Highlight color variables\n",
       "\n",
       "    // Highlight color of the node boundering\n",
       "    const highlight_node_boundering = \"#4EB2D4\";\n",
       "\n",
       "    // Highlight color of the edge\n",
       "    const highlighted_link_color = \"#4EB2D4\";\n",
       "\n",
       "    // Text highlight color\n",
       "    const highlight_text = \"#4EB2D4\";\n",
       "\n",
       "    // Size when zooming scale\n",
       "    var size = d3.scalePow().exponent(1)\n",
       "        .domain([1, 100])\n",
       "        .range([8, 24]);\n",
       "\n",
       "    // Simulation parameters\n",
       "    const linkDistance = 100;\n",
       "    const fCharge = -1000;\n",
       "    const linkStrength = 0.7;\n",
       "    const collideStrength = 1;\n",
       "\n",
       "    // Simulation defined with variables\n",
       "    var simulation = d3.forceSimulation()\n",
       "        .force(\"link\", d3.forceLink()\n",
       "            .distance(linkDistance)\n",
       "            .strength(linkStrength)\n",
       "        )\n",
       "        .force(\"collide\", d3.forceCollide()\n",
       "            .radius(function (d) {\n",
       "                return d.r + 10\n",
       "            })\n",
       "            .strength(collideStrength)\n",
       "        )\n",
       "        .force(\"charge\", d3.forceManyBody()\n",
       "            .strength(fCharge)\n",
       "        )\n",
       "        .force(\"center\", d3.forceCenter(width / 2, height / 2))\n",
       "        .force(\"y\", d3.forceY(0))\n",
       "        .force(\"x\", d3.forceX(0));\n",
       "\n",
       "    // Pin down functionality\n",
       "    var node_drag = d3.drag()\n",
       "        .on(\"start\", dragstarted)\n",
       "        .on(\"drag\", dragged)\n",
       "        .on(\"end\", dragended);\n",
       "\n",
       "    function dragstarted(d) {\n",
       "        if (!d3.event.active) simulation.alphaTarget(0.3).restart();\n",
       "        d.fx = d.x;\n",
       "        d.fy = d.y;\n",
       "    }\n",
       "\n",
       "    function dragged(d) {\n",
       "        d.fx = d3.event.x;\n",
       "        d.fy = d3.event.y;\n",
       "    }\n",
       "\n",
       "    function dragended(d) {\n",
       "        if (!d3.event.active) simulation.alphaTarget(0);\n",
       "    }\n",
       "\n",
       "    function releasenode(d) {\n",
       "        d.fx = null;\n",
       "        d.fy = null;\n",
       "    }\n",
       "\n",
       "    //END Pin down functionality\n",
       "\n",
       "    const color_circunferencia = \"black\";\n",
       "    const default_link_color = \"#AAAAAA\";\n",
       "    const nominal_base_node_size = 8;\n",
       "\n",
       "    // Normal and highlighted stroke of the links (double the width of the link when highlighted)\n",
       "    const nominal_stroke = 1.5;\n",
       "\n",
       "    // Zoom variables\n",
       "    const min_zoom = 0.1;\n",
       "    const max_zoom = 10;\n",
       "    const border = 1;\n",
       "    const bordercolor = 'black';\n",
       "\n",
       "    var svg = d3.select(chart).append(\"svg\")\n",
       "        .attr(\"width\", width)\n",
       "        .attr(\"height\", height);\n",
       "\n",
       "    // // Create definition for arrowhead.\n",
       "    svg.append(\"defs\").append(\"marker\")\n",
       "        .attr(\"id\", \"arrowhead\")\n",
       "        .attr(\"viewBox\", \"0 -5 10 10\")\n",
       "        .attr(\"refX\", 20)\n",
       "        .attr(\"refY\", 0)\n",
       "        .attr(\"markerUnits\", \"strokeWidth\")\n",
       "        .attr(\"markerWidth\", 6)\n",
       "        .attr(\"markerHeight\", 6)\n",
       "        .attr(\"orient\", \"auto\")\n",
       "        .append(\"path\")\n",
       "        .attr(\"d\", \"M0,-5L10,0L0,5\");\n",
       "\n",
       "    // // Create definition for stub.\n",
       "    svg.append(\"defs\").append(\"marker\")\n",
       "        .attr(\"id\", \"stub\")\n",
       "        .attr(\"viewBox\", \"-1 -5 2 10\")\n",
       "        .attr(\"refX\", 15)\n",
       "        .attr(\"refY\", 0)\n",
       "        .attr(\"markerUnits\", \"strokeWidth\")\n",
       "        .attr(\"markerWidth\", 6)\n",
       "        .attr(\"markerHeight\", 6)\n",
       "        .attr(\"orient\", \"auto\")\n",
       "        .append(\"path\")\n",
       "        .attr(\"d\", \"M 0,0 m -1,-5 L 1,-5 L 1,5 L -1,5 Z\");\n",
       "\n",
       "    // Background\n",
       "    svg.append(\"rect\")\n",
       "        .attr(\"width\", \"100%\")\n",
       "        .attr(\"height\", \"100%\")\n",
       "        .attr(\"fill\", \"#ffffff\")\n",
       "        .style(\"pointer-events\", \"all\")\n",
       "        // Zoom + panning functionality\n",
       "        .call(d3.zoom()\n",
       "            .scaleExtent([min_zoom, max_zoom])\n",
       "            .on(\"zoom\", zoomed))\n",
       "        .on(\"dblclick.zoom\", null);\n",
       "\n",
       "\n",
       "    function zoomed() {\n",
       "        g.attr(\"transform\", d3.event.transform);\n",
       "    }\n",
       "\n",
       "    // g = svg object where the graph will be appended\n",
       "    var g = svg.append(\"g\");\n",
       "\n",
       "    var linkedByIndex = {};\n",
       "    graph.links.forEach(function (d) {\n",
       "        linkedByIndex[d.source + \",\" + d.target] = true;\n",
       "    });\n",
       "\n",
       "    function isConnected(a, b) {\n",
       "        return linkedByIndex[a.index + \",\" + b.index] || linkedByIndex[b.index + \",\" + a.index] || a.index == b.index;\n",
       "    }\n",
       "\n",
       "    function ticked() {\n",
       "        link.attr(\"x1\", function (d) {\n",
       "            return d.source.x;\n",
       "        })\n",
       "            .attr(\"y1\", function (d) {\n",
       "                return d.source.y;\n",
       "            })\n",
       "            .attr(\"x2\", function (d) {\n",
       "                return d.target.x;\n",
       "            })\n",
       "            .attr(\"y2\", function (d) {\n",
       "                return d.target.y;\n",
       "            });\n",
       "\n",
       "        node\n",
       "            .attr(\"transform\", function (d) {\n",
       "                return \"translate(\" + d.x + \", \" + d.y + \")\";\n",
       "            });\n",
       "    }\n",
       "\n",
       "\n",
       "    simulation\n",
       "        .nodes(graph.nodes)\n",
       "        .on(\"tick\", ticked);\n",
       "\n",
       "    simulation.force(\"link\")\n",
       "        .links(graph.links);\n",
       "\n",
       "    // Definition of links nodes text...\n",
       "\n",
       "    var link = g.selectAll(\".link\")\n",
       "        .data(graph.links)\n",
       "        .enter().append(\"line\")\n",
       "        .style(\"stroke-width\", nominal_stroke)\n",
       "        .style(\"stroke\", default_link_color)\n",
       "        .style(\"stroke-dasharray\", function (d) {\n",
       "            if (['decreases', 'directlyDecreases', 'increases', 'directlyIncreases', 'negativeCorrelation',\n",
       "                    'positiveCorrelation'].indexOf(d.relation) >= 0) {\n",
       "                return \"none\"\n",
       "            } else {\n",
       "                return \"4, 4\"\n",
       "            }\n",
       "        })\n",
       "        .attr(\"marker-start\", function (d) {\n",
       "            if ('positiveCorrelation' == d.relation) {\n",
       "                return \"url(#arrowhead)\"\n",
       "            }\n",
       "            else if ('negativeCorrelation' == d.relation) {\n",
       "                return \"url(#stub)\"\n",
       "            }\n",
       "            else {\n",
       "                return \"\"\n",
       "            }\n",
       "        })\n",
       "        .attr(\"marker-end\", function (d) {\n",
       "            if (['increases', 'directlyIncreases', 'positiveCorrelation'].indexOf(d.relation) >= 0) {\n",
       "                return \"url(#arrowhead)\"\n",
       "            } else if (['decreases', 'directlyDecreases', 'negativeCorrelation'].indexOf(d.relation) >= 0) {\n",
       "                return \"url(#stub)\"\n",
       "            } else {\n",
       "                return \"\"\n",
       "            }\n",
       "        });\n",
       "\n",
       "    var node = g.selectAll(\".nodes\")\n",
       "        .data(graph.nodes)\n",
       "        .enter().append(\"g\")\n",
       "        .attr(\"class\", \"node\")\n",
       "        // Next two lines -> Pin down functionality\n",
       "        .on('dblclick', releasenode)\n",
       "        .call(node_drag);\n",
       "\n",
       "    var circle = node.append(\"path\")\n",
       "        .attr(\"d\", d3.symbol()\n",
       "            .size(function (d) {\n",
       "                return Math.PI * Math.pow(size(d.size) || nominal_base_node_size, 2);\n",
       "            })\n",
       "        )\n",
       "        .attr(\"class\", function (d) {\n",
       "            return d.function\n",
       "        })\n",
       "        .style('fill', function (d) {\n",
       "            return function_colors[d.function]\n",
       "        })\n",
       "        .style(\"stroke-width\", nominal_stroke)\n",
       "        .style(\"stroke\", color_circunferencia);\n",
       "\n",
       "    var text = node.append(\"text\")\n",
       "        .attr(\"class\", \"node-name\")\n",
       "        // .attr(\"id\", nodehashes[d])\n",
       "        .attr(\"fill\", \"black\")\n",
       "        .attr(\"dx\", 12)\n",
       "        .attr(\"dy\", \".35em\")\n",
       "        .text(function (d) {\n",
       "            return d.cname\n",
       "        });\n",
       "\n",
       "    // Highlight on mouseenter and back to normal on mouseout\n",
       "    node.on(\"mouseenter\", function (d) {\n",
       "        set_highlight(d);\n",
       "    })\n",
       "        .on(\"mousedown\", function () {\n",
       "            d3.event.stopPropagation();\n",
       "        }).on(\"mouseout\", function () {\n",
       "        exit_highlight();\n",
       "    });\n",
       "\n",
       "    function exit_highlight() {\n",
       "        highlight_node = null;\n",
       "        if (focus_node === null) {\n",
       "            if (highlight_node_boundering != color_circunferencia) {\n",
       "                circle.style(\"stroke\", color_circunferencia);\n",
       "                text.style(\"fill\", \"black\");\n",
       "                link.style(\"stroke\", default_link_color);\n",
       "            }\n",
       "        }\n",
       "    }\n",
       "\n",
       "    function set_highlight(d) {\n",
       "        if (focus_node !== null) d = focus_node;\n",
       "        highlight_node = d;\n",
       "\n",
       "        if (highlight_node_boundering != color_circunferencia) {\n",
       "            circle.style(\"stroke\", function (o) {\n",
       "                return isConnected(d, o) ? highlight_node_boundering : color_circunferencia;\n",
       "            });\n",
       "            text.style(\"fill\", function (o) {\n",
       "                return isConnected(d, o) ? highlight_text : \"black\";\n",
       "            });\n",
       "            link.style(\"stroke\", function (o) {\n",
       "                return o.source.index == d.index || o.target.index == d.index ? highlighted_link_color : default_link_color;\n",
       "            });\n",
       "        }\n",
       "    }\n",
       "\n",
       "\n",
       "    // Freeze the graph when space is pressed\n",
       "    function freezeGraph() {\n",
       "        // Space button Triggers STOP\n",
       "        if (d3.event.keyCode == 32) {\n",
       "            simulation.stop();\n",
       "        }\n",
       "    }\n",
       "\n",
       "    // Call freezeGraph when a key is pressed, freezeGraph checks whether this key is \"Space\" that triggers the freeze\n",
       "    d3.select(window).on(\"keydown\", freezeGraph);\n",
       "}\n",
       "        var chart = \"cugyjsrzoepqfbxh\";\n",
       "        var width = 1000;\n",
       "        var height = 650;\n",
       "        var graph = {\"directed\": true, \"multigraph\": true, \"graph\": {\"document_metadata\": {}, \"pybel_version\": \"0.7.2\", \"namespace_url\": {}, \"namespace_owl\": {}, \"namespace_pattern\": {}, \"annotation_url\": {}, \"annotation_owl\": {}, \"annotation_pattern\": {}, \"annotation_list\": {}}, \"nodes\": [{\"function\": \"Pathology\", \"namespace\": \"MESHD\", \"name\": \"Alzheimer Disease\", \"cname\": \"Alzheimer Disease\", \"id\": [\"Pathology\", \"MESHD\", \"Alzheimer Disease\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"ESR1\", \"description\": \"This gene encodes an estrogen receptor, a ligand-activated transcription factor composed of several domains important for hormone binding, DNA binding, and activation of transcription. The protein localizes to the nucleus where it may form a homodimer or a heterodimer with estrogen receptor 2. Estrogen and its receptors are essential for sexual development and reproductive function, but also play a role in other tissues such as bone. Estrogen receptors are also involved in pathological processes including breast cancer, endometrial cancer, and osteoporosis. Alternative promoter usage and alternative splicing result in dozens of transcript variants, but the full-length nature of many of these variants has not been determined. [provided by RefSeq, Mar 2014]\", \"label\": \"estrogen receptor 1\", \"cname\": \"ESR1\", \"id\": [\"Protein\", \"HGNC\", \"ESR1\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GSK3B\", \"description\": \"The protein encoded by this gene is a serine-threonine kinase, belonging to the glycogen synthase kinase subfamily. It is involved in energy metabolism, neuronal cell development, and body pattern formation. Polymorphisms in this gene have been implicated in modifying risk of Parkinson disease, and studies in mice show that overexpression of this gene may be relevant to the pathogenesis of Alzheimer disease. Alternatively spliced transcript variants encoding different isoforms have been found for this gene.[provided by RefSeq, Sep 2009]\", \"label\": \"glycogen synthase kinase 3 beta\", \"cname\": \"GSK3B\", \"id\": [\"Protein\", \"HGNC\", \"GSK3B\"]}, {\"function\": \"Abundance\", \"namespace\": \"CHEBI\", \"name\": \"17beta-estradiol\", \"cname\": \"17beta-estradiol\", \"id\": [\"Abundance\", \"CHEBI\", \"17beta-estradiol\"]}, {\"function\": \"Pathology\", \"namespace\": \"MESHD\", \"name\": \"Parkinson Disease\", \"cname\": \"Parkinson Disease\", \"id\": [\"Pathology\", \"MESHD\", \"Parkinson Disease\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GSK3B\", \"variants\": [{\"kind\": \"pmod\", \"identifier\": {\"namespace\": \"bel\", \"name\": \"Ph\"}, \"code\": \"Ser\", \"pos\": 9}], \"description\": \"The protein encoded by this gene is a serine-threonine kinase, belonging to the glycogen synthase kinase subfamily. It is involved in energy metabolism, neuronal cell development, and body pattern formation. Polymorphisms in this gene have been implicated in modifying risk of Parkinson disease, and studies in mice show that overexpression of this gene may be relevant to the pathogenesis of Alzheimer disease. Alternatively spliced transcript variants encoding different isoforms have been found for this gene.[provided by RefSeq, Sep 2009]\", \"label\": \"glycogen synthase kinase 3 beta\", \"cname\": \"p(HGNC:GSK3B, pmod(Ph, Ser, 9))\", \"id\": [\"Protein\", \"HGNC\", \"GSK3B\", [\"pmod\", [\"bel\", \"Ph\"], \"Ser\", 9]]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CYP3A4\", \"description\": \"This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases that catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and its expression is induced by glucocorticoids and some pharmacological agents. This enzyme is involved in the metabolism of approximately half the drugs in use today, including acetaminophen, codeine, cyclosporin A, diazepam and erythromycin. The enzyme also metabolizes some steroids and carcinogens. This gene is part of a cluster of cytochrome P450 genes on chromosome 7q21.1. Previously another CYP3A gene, CYP3A3, was thought to exist; however, it is now thought that this sequence represents a transcript variant of CYP3A4. Alternatively spliced transcript variants encoding different isoforms have been identified. [provided by RefSeq, Feb 2011]\", \"label\": \"cytochrome P450 family 3 subfamily A member 4\", \"cname\": \"CYP3A4\", \"id\": [\"Protein\", \"HGNC\", \"CYP3A4\"]}, {\"function\": \"BiologicalProcess\", \"namespace\": \"GOBP\", \"name\": \"metabolic process\", \"cname\": \"metabolic process\", \"id\": [\"BiologicalProcess\", \"GOBP\", \"metabolic process\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"MAPT\", \"variants\": [{\"kind\": \"pmod\", \"identifier\": {\"namespace\": \"bel\", \"name\": \"Ph\"}, \"code\": \"Thr\", \"pos\": 231}], \"description\": \"This gene encodes the microtubule-associated protein tau (MAPT) whose transcript undergoes complex, regulated alternative splicing, giving rise to several mRNA species. MAPT transcripts are differentially expressed in the nervous system, depending on stage of neuronal maturation and neuron type. MAPT gene mutations have been associated with several neurodegenerative disorders such as Alzheimer's disease, Pick's disease, frontotemporal dementia, cortico-basal degeneration and progressive supranuclear palsy. [provided by RefSeq, Jul 2008]\", \"label\": \"microtubule associated protein tau\", \"cname\": \"p(HGNC:MAPT, pmod(Ph, Thr, 231))\", \"id\": [\"Protein\", \"HGNC\", \"MAPT\", [\"pmod\", [\"bel\", \"Ph\"], \"Thr\", 231]]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"MAPT\", \"variants\": [{\"kind\": \"pmod\", \"identifier\": {\"namespace\": \"bel\", \"name\": \"Ph\"}, \"code\": \"Thr\", \"pos\": 205}], \"description\": \"This gene encodes the microtubule-associated protein tau (MAPT) whose transcript undergoes complex, regulated alternative splicing, giving rise to several mRNA species. MAPT transcripts are differentially expressed in the nervous system, depending on stage of neuronal maturation and neuron type. MAPT gene mutations have been associated with several neurodegenerative disorders such as Alzheimer's disease, Pick's disease, frontotemporal dementia, cortico-basal degeneration and progressive supranuclear palsy. [provided by RefSeq, Jul 2008]\", \"label\": \"microtubule associated protein tau\", \"cname\": \"p(HGNC:MAPT, pmod(Ph, Thr, 205))\", \"id\": [\"Protein\", \"HGNC\", \"MAPT\", [\"pmod\", [\"bel\", \"Ph\"], \"Thr\", 205]]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"MAPT\", \"variants\": [{\"kind\": \"pmod\", \"identifier\": {\"namespace\": \"bel\", \"name\": \"Ph\"}, \"code\": \"Ser\", \"pos\": 396}], \"description\": \"This gene encodes the microtubule-associated protein tau (MAPT) whose transcript undergoes complex, regulated alternative splicing, giving rise to several mRNA species. MAPT transcripts are differentially expressed in the nervous system, depending on stage of neuronal maturation and neuron type. MAPT gene mutations have been associated with several neurodegenerative disorders such as Alzheimer's disease, Pick's disease, frontotemporal dementia, cortico-basal degeneration and progressive supranuclear palsy. [provided by RefSeq, Jul 2008]\", \"label\": \"microtubule associated protein tau\", \"cname\": \"p(HGNC:MAPT, pmod(Ph, Ser, 396))\", \"id\": [\"Protein\", \"HGNC\", \"MAPT\", [\"pmod\", [\"bel\", \"Ph\"], \"Ser\", 396]]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"MAPT\", \"variants\": [{\"kind\": \"pmod\", \"identifier\": {\"namespace\": \"bel\", \"name\": \"Ph\"}, \"code\": \"Ser\", \"pos\": 404}], \"description\": \"This gene encodes the microtubule-associated protein tau (MAPT) whose transcript undergoes complex, regulated alternative splicing, giving rise to several mRNA species. MAPT transcripts are differentially expressed in the nervous system, depending on stage of neuronal maturation and neuron type. MAPT gene mutations have been associated with several neurodegenerative disorders such as Alzheimer's disease, Pick's disease, frontotemporal dementia, cortico-basal degeneration and progressive supranuclear palsy. [provided by RefSeq, Jul 2008]\", \"label\": \"microtubule associated protein tau\", \"cname\": \"p(HGNC:MAPT, pmod(Ph, Ser, 404))\", \"id\": [\"Protein\", \"HGNC\", \"MAPT\", [\"pmod\", [\"bel\", \"Ph\"], \"Ser\", 404]]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"MAPT\", \"variants\": [{\"kind\": \"pmod\", \"identifier\": {\"namespace\": \"bel\", \"name\": \"Ph\"}, \"code\": \"Ser\", \"pos\": 199}], \"description\": \"This gene encodes the microtubule-associated protein tau (MAPT) whose transcript undergoes complex, regulated alternative splicing, giving rise to several mRNA species. MAPT transcripts are differentially expressed in the nervous system, depending on stage of neuronal maturation and neuron type. MAPT gene mutations have been associated with several neurodegenerative disorders such as Alzheimer's disease, Pick's disease, frontotemporal dementia, cortico-basal degeneration and progressive supranuclear palsy. [provided by RefSeq, Jul 2008]\", \"label\": \"microtubule associated protein tau\", \"cname\": \"p(HGNC:MAPT, pmod(Ph, Ser, 199))\", \"id\": [\"Protein\", \"HGNC\", \"MAPT\", [\"pmod\", [\"bel\", \"Ph\"], \"Ser\", 199]]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"MAPT\", \"variants\": [{\"kind\": \"pmod\", \"identifier\": {\"namespace\": \"bel\", \"name\": \"Ph\"}, \"code\": \"Ser\", \"pos\": 202}], \"description\": \"This gene encodes the microtubule-associated protein tau (MAPT) whose transcript undergoes complex, regulated alternative splicing, giving rise to several mRNA species. MAPT transcripts are differentially expressed in the nervous system, depending on stage of neuronal maturation and neuron type. MAPT gene mutations have been associated with several neurodegenerative disorders such as Alzheimer's disease, Pick's disease, frontotemporal dementia, cortico-basal degeneration and progressive supranuclear palsy. [provided by RefSeq, Jul 2008]\", \"label\": \"microtubule associated protein tau\", \"cname\": \"p(HGNC:MAPT, pmod(Ph, Ser, 202))\", \"id\": [\"Protein\", \"HGNC\", \"MAPT\", [\"pmod\", [\"bel\", \"Ph\"], \"Ser\", 202]]}, {\"function\": \"Abundance\", \"namespace\": \"CHEBI\", \"name\": \"estradiol\", \"cname\": \"estradiol\", \"id\": [\"Abundance\", \"CHEBI\", \"estradiol\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"S100A9\", \"description\": \"The protein encoded by this gene is a member of the S100 family of proteins containing 2 EF-hand calcium-binding motifs. S100 proteins are localized in the cytoplasm and/or nucleus of a wide range of cells, and involved in the regulation of a number of cellular processes such as cell cycle progression and differentiation. S100 genes include at least 13 members which are located as a cluster on chromosome 1q21. This protein may function in the inhibition of casein kinase and altered expression of this protein is associated with the disease cystic fibrosis. This antimicrobial protein exhibits antifungal and antibacterial activity. [provided by RefSeq, Nov 2014]\", \"label\": \"S100 calcium binding protein A9\", \"cname\": \"S100A9\", \"id\": [\"Protein\", \"HGNC\", \"S100A9\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"PPARG\", \"description\": \"This gene encodes a member of the peroxisome proliferator-activated receptor (PPAR) subfamily of nuclear receptors. PPARs form heterodimers with retinoid X receptors (RXRs) and these heterodimers regulate transcription of various genes. Three subtypes of PPARs are known: PPAR-alpha, PPAR-delta, and PPAR-gamma. The protein encoded by this gene is PPAR-gamma and is a regulator of adipocyte differentiation. Additionally, PPAR-gamma has been implicated in the pathology of numerous diseases including obesity, diabetes, atherosclerosis and cancer. Alternatively spliced transcript variants that encode different isoforms have been described. [provided by RefSeq, Jul 2008]\", \"label\": \"peroxisome proliferator activated receptor gamma\", \"cname\": \"PPARG\", \"id\": [\"Protein\", \"HGNC\", \"PPARG\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"TFF1\", \"description\": \"Members of the trefoil family are characterized by having at least one copy of the trefoil motif, a 40-amino acid domain that contains three conserved disulfides. They are stable secretory proteins expressed in gastrointestinal mucosa. Their functions are not defined, but they may protect the mucosa from insults, stabilize the mucus layer, and affect healing of the epithelium. This gene, which is expressed in the gastric mucosa, has also been studied because of its expression in human tumors. This gene and two other related trefoil family member genes are found in a cluster on chromosome 21. [provided by RefSeq, Jul 2008]\", \"label\": \"trefoil factor 1\", \"cname\": \"TFF1\", \"id\": [\"RNA\", \"HGNC\", \"TFF1\"]}, {\"function\": \"Abundance\", \"namespace\": \"CHEBI\", \"name\": \"resveratrol\", \"cname\": \"resveratrol\", \"id\": [\"Abundance\", \"CHEBI\", \"resveratrol\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"ESR2\", \"description\": \"This gene encodes a member of the family of estrogen receptors and superfamily of nuclear receptor transcription factors. The gene product contains an N-terminal DNA binding domain and C-terminal ligand binding domain and is localized to the nucleus, cytoplasm, and mitochondria. Upon binding to 17beta-estradiol or related ligands, the encoded protein forms homo- or hetero-dimers that interact with specific DNA sequences to activate transcription. Some isoforms dominantly inhibit the activity of other estrogen receptor family members. Several alternatively spliced transcript variants of this gene have been described, but the full-length nature of some of these variants has not been fully characterized. [provided by RefSeq, Jul 2008]\", \"label\": \"estrogen receptor 2\", \"cname\": \"ESR2\", \"id\": [\"Protein\", \"HGNC\", \"ESR2\"]}, {\"function\": \"Complex\", \"cname\": \"complex(a(CHEBI:\\\"24-hydroxycholesterol\\\"), p(HGNC:ESR2))\", \"id\": [\"Complex\", [\"Abundance\", \"CHEBI\", \"24-hydroxycholesterol\"], [\"Protein\", \"HGNC\", \"ESR2\"]]}, {\"function\": \"Complex\", \"cname\": \"complex(a(CHEBI:\\\"medroxyprogesterone acetate\\\"), p(HGNC:ESR2))\", \"id\": [\"Complex\", [\"Abundance\", \"CHEBI\", \"medroxyprogesterone acetate\"], [\"Protein\", \"HGNC\", \"ESR2\"]]}, {\"function\": \"Abundance\", \"namespace\": \"CHEBI\", \"name\": \"24-hydroxycholesterol\", \"cname\": \"24-hydroxycholesterol\", \"id\": [\"Abundance\", \"CHEBI\", \"24-hydroxycholesterol\"]}, {\"function\": \"Abundance\", \"namespace\": \"CHEBI\", \"name\": \"medroxyprogesterone acetate\", \"cname\": \"medroxyprogesterone acetate\", \"id\": [\"Abundance\", \"CHEBI\", \"medroxyprogesterone acetate\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"MAPT\", \"description\": \"This gene encodes the microtubule-associated protein tau (MAPT) whose transcript undergoes complex, regulated alternative splicing, giving rise to several mRNA species. MAPT transcripts are differentially expressed in the nervous system, depending on stage of neuronal maturation and neuron type. MAPT gene mutations have been associated with several neurodegenerative disorders such as Alzheimer's disease, Pick's disease, frontotemporal dementia, cortico-basal degeneration and progressive supranuclear palsy. [provided by RefSeq, Jul 2008]\", \"label\": \"microtubule associated protein tau\", \"cname\": \"MAPT\", \"id\": [\"Protein\", \"HGNC\", \"MAPT\"]}], \"links\": [{\"relation\": \"association\", \"evidence\": \"Herein, we conducted a meta-analysis to clarify the association between ESR1 polymorphisms and the occurrence of AD.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience letters\", \"reference\": \"24857745\", \"authors\": [\"Wang T\"], \"date\": \"2014-06-27\", \"title\": \"Meta-analysis of PvuII, XbaI variants in ESR1 gene and the risk of Alzheimer's disease: the regional European difference.\", \"lastauthor\": \"Wang T\", \"volume\": \"574\", \"issue\": \"\", \"pages\": \"41-6\", \"firstauthor\": \"Wang T\"}, \"line\": 18507, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 0, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Herein, we conducted a meta-analysis to clarify the association between ESR1 polymorphisms and the occurrence of AD.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience letters\", \"reference\": \"24857745\", \"authors\": [\"Wang T\"], \"date\": \"2014-06-27\", \"title\": \"Meta-analysis of PvuII, XbaI variants in ESR1 gene and the risk of Alzheimer's disease: the regional European difference.\", \"lastauthor\": \"Wang T\", \"volume\": \"574\", \"issue\": \"\", \"pages\": \"41-6\", \"firstauthor\": \"Wang T\"}, \"line\": 18507, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 1, \"target\": 0, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Positive association between an estrogen receptor gene polymorphism and Parkinson's disease with dementia.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"European journal of neurology\", \"reference\": \"10362895\", \"authors\": [\"Isoe-Wada K\", \"Maeda M\", \"Yong J\", \"Adachi Y\", \"Harada H\", \"Urakami K\", \"Nakashima K\"], \"date\": \"1999-07-01\", \"title\": \"Positive association between an estrogen receptor gene polymorphism and Parkinson's disease with dementia.\", \"lastauthor\": \"Nakashima K\", \"volume\": \"6\", \"issue\": \"4\", \"pages\": \"431-5\", \"firstauthor\": \"Isoe-Wada K\"}, \"line\": 18525, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\", \"Species\": \"9606\", \"MeSHDisease\": \"Parkinson Disease\"}, \"source\": 1, \"target\": 4, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Positive association between an estrogen receptor gene polymorphism and Parkinson's disease with dementia.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"European journal of neurology\", \"reference\": \"10362895\", \"authors\": [\"Isoe-Wada K\", \"Maeda M\", \"Yong J\", \"Adachi Y\", \"Harada H\", \"Urakami K\", \"Nakashima K\"], \"date\": \"1999-07-01\", \"title\": \"Positive association between an estrogen receptor gene polymorphism and Parkinson's disease with dementia.\", \"lastauthor\": \"Nakashima K\", \"volume\": \"6\", \"issue\": \"4\", \"pages\": \"431-5\", \"firstauthor\": \"Isoe-Wada K\"}, \"line\": 18525, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\", \"Species\": \"9606\", \"MeSHDisease\": \"Dementia\"}, \"source\": 1, \"target\": 4, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"We found that betaE2 could attenuate tau hyperphosphorylation at multiple AD-related sites, including Ser396/404, Thr231, Thr205, and Ser199/202, induced by Wort/GFX or transient overexpression of GSK-3beta. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of neural transmission (Vienna, Austria : 1996)\", \"reference\": \"18217188\", \"authors\": [\"Shi HR\", \"Zhu LQ\", \"Wang SH\", \"Liu XA\", \"Tian Q\", \"Zhang Q\", \"Wang Q\", \"Wang JZ\"], \"date\": \"2008-06-01\", \"title\": \"17beta-estradiol attenuates glycogen synthase kinase-3beta activation and tau hyperphosphorylation in Akt-independent manner.\", \"lastauthor\": \"Wang JZ\", \"volume\": \"115\", \"issue\": \"6\", \"pages\": \"879-88\", \"firstauthor\": \"Shi HR\"}, \"line\": 32069, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 2, \"target\": 3, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We found that betaE2 could attenuate tau hyperphosphorylation at multiple AD-related sites, including Ser396/404, Thr231, Thr205, and Ser199/202, induced by Wort/GFX or transient overexpression of GSK-3beta. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of neural transmission (Vienna, Austria : 1996)\", \"reference\": \"18217188\", \"authors\": [\"Shi HR\", \"Zhu LQ\", \"Wang SH\", \"Liu XA\", \"Tian Q\", \"Zhang Q\", \"Wang Q\", \"Wang JZ\"], \"date\": \"2008-06-01\", \"title\": \"17beta-estradiol attenuates glycogen synthase kinase-3beta activation and tau hyperphosphorylation in Akt-independent manner.\", \"lastauthor\": \"Wang JZ\", \"volume\": \"115\", \"issue\": \"6\", \"pages\": \"879-88\", \"firstauthor\": \"Shi HR\"}, \"line\": 32071, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 2, \"target\": 3, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"We found that betaE2 could attenuate tau hyperphosphorylation at multiple AD-related sites, including Ser396/404, Thr231, Thr205, and Ser199/202, induced by Wort/GFX or transient overexpression of GSK-3beta. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of neural transmission (Vienna, Austria : 1996)\", \"reference\": \"18217188\", \"authors\": [\"Shi HR\", \"Zhu LQ\", \"Wang SH\", \"Liu XA\", \"Tian Q\", \"Zhang Q\", \"Wang Q\", \"Wang JZ\"], \"date\": \"2008-06-01\", \"title\": \"17beta-estradiol attenuates glycogen synthase kinase-3beta activation and tau hyperphosphorylation in Akt-independent manner.\", \"lastauthor\": \"Wang JZ\", \"volume\": \"115\", \"issue\": \"6\", \"pages\": \"879-88\", \"firstauthor\": \"Shi HR\"}, \"line\": 32073, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 2, \"target\": 3, \"key\": 2}, {\"relation\": \"increases\", \"evidence\": \"We found that betaE2 could attenuate tau hyperphosphorylation at multiple AD-related sites, including Ser396/404, Thr231, Thr205, and Ser199/202, induced by Wort/GFX or transient overexpression of GSK-3beta. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of neural transmission (Vienna, Austria : 1996)\", \"reference\": \"18217188\", \"authors\": [\"Shi HR\", \"Zhu LQ\", \"Wang SH\", \"Liu XA\", \"Tian Q\", \"Zhang Q\", \"Wang Q\", \"Wang JZ\"], \"date\": \"2008-06-01\", \"title\": \"17beta-estradiol attenuates glycogen synthase kinase-3beta activation and tau hyperphosphorylation in Akt-independent manner.\", \"lastauthor\": \"Wang JZ\", \"volume\": \"115\", \"issue\": \"6\", \"pages\": \"879-88\", \"firstauthor\": \"Shi HR\"}, \"line\": 32075, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 2, \"target\": 3, \"key\": 3}, {\"relation\": \"increases\", \"evidence\": \"We found that betaE2 could attenuate tau hyperphosphorylation at multiple AD-related sites, including Ser396/404, Thr231, Thr205, and Ser199/202, induced by Wort/GFX or transient overexpression of GSK-3beta. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of neural transmission (Vienna, Austria : 1996)\", \"reference\": \"18217188\", \"authors\": [\"Shi HR\", \"Zhu LQ\", \"Wang SH\", \"Liu XA\", \"Tian Q\", \"Zhang Q\", \"Wang Q\", \"Wang JZ\"], \"date\": \"2008-06-01\", \"title\": \"17beta-estradiol attenuates glycogen synthase kinase-3beta activation and tau hyperphosphorylation in Akt-independent manner.\", \"lastauthor\": \"Wang JZ\", \"volume\": \"115\", \"issue\": \"6\", \"pages\": \"879-88\", \"firstauthor\": \"Shi HR\"}, \"line\": 32077, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 2, \"target\": 3, \"key\": 4}, {\"relation\": \"increases\", \"evidence\": \"We found that betaE2 could attenuate tau hyperphosphorylation at multiple AD-related sites, including Ser396/404, Thr231, Thr205, and Ser199/202, induced by Wort/GFX or transient overexpression of GSK-3beta. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of neural transmission (Vienna, Austria : 1996)\", \"reference\": \"18217188\", \"authors\": [\"Shi HR\", \"Zhu LQ\", \"Wang SH\", \"Liu XA\", \"Tian Q\", \"Zhang Q\", \"Wang Q\", \"Wang JZ\"], \"date\": \"2008-06-01\", \"title\": \"17beta-estradiol attenuates glycogen synthase kinase-3beta activation and tau hyperphosphorylation in Akt-independent manner.\", \"lastauthor\": \"Wang JZ\", \"volume\": \"115\", \"issue\": \"6\", \"pages\": \"879-88\", \"firstauthor\": \"Shi HR\"}, \"line\": 32079, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 2, \"target\": 3, \"key\": 5}, {\"relation\": \"hasVariant\", \"annotations\": {}, \"source\": 2, \"target\": 5, \"key\": -4}, {\"relation\": \"decreases\", \"evidence\": \"We found that betaE2 could attenuate tau hyperphosphorylation at multiple AD-related sites, including Ser396/404, Thr231, Thr205, and Ser199/202, induced by Wort/GFX or transient overexpression of GSK-3beta. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of neural transmission (Vienna, Austria : 1996)\", \"reference\": \"18217188\", \"authors\": [\"Shi HR\", \"Zhu LQ\", \"Wang SH\", \"Liu XA\", \"Tian Q\", \"Zhang Q\", \"Wang Q\", \"Wang JZ\"], \"date\": \"2008-06-01\", \"title\": \"17beta-estradiol attenuates glycogen synthase kinase-3beta activation and tau hyperphosphorylation in Akt-independent manner.\", \"lastauthor\": \"Wang JZ\", \"volume\": \"115\", \"issue\": \"6\", \"pages\": \"879-88\", \"firstauthor\": \"Shi HR\"}, \"line\": 32070, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 3, \"target\": 8, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"We found that betaE2 could attenuate tau hyperphosphorylation at multiple AD-related sites, including Ser396/404, Thr231, Thr205, and Ser199/202, induced by Wort/GFX or transient overexpression of GSK-3beta. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of neural transmission (Vienna, Austria : 1996)\", \"reference\": \"18217188\", \"authors\": [\"Shi HR\", \"Zhu LQ\", \"Wang SH\", \"Liu XA\", \"Tian Q\", \"Zhang Q\", \"Wang Q\", \"Wang JZ\"], \"date\": \"2008-06-01\", \"title\": \"17beta-estradiol attenuates glycogen synthase kinase-3beta activation and tau hyperphosphorylation in Akt-independent manner.\", \"lastauthor\": \"Wang JZ\", \"volume\": \"115\", \"issue\": \"6\", \"pages\": \"879-88\", \"firstauthor\": \"Shi HR\"}, \"line\": 32072, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 3, \"target\": 9, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"We found that betaE2 could attenuate tau hyperphosphorylation at multiple AD-related sites, including Ser396/404, Thr231, Thr205, and Ser199/202, induced by Wort/GFX or transient overexpression of GSK-3beta. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of neural transmission (Vienna, Austria : 1996)\", \"reference\": \"18217188\", \"authors\": [\"Shi HR\", \"Zhu LQ\", \"Wang SH\", \"Liu XA\", \"Tian Q\", \"Zhang Q\", \"Wang Q\", \"Wang JZ\"], \"date\": \"2008-06-01\", \"title\": \"17beta-estradiol attenuates glycogen synthase kinase-3beta activation and tau hyperphosphorylation in Akt-independent manner.\", \"lastauthor\": \"Wang JZ\", \"volume\": \"115\", \"issue\": \"6\", \"pages\": \"879-88\", \"firstauthor\": \"Shi HR\"}, \"line\": 32074, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 3, \"target\": 10, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"We found that betaE2 could attenuate tau hyperphosphorylation at multiple AD-related sites, including Ser396/404, Thr231, Thr205, and Ser199/202, induced by Wort/GFX or transient overexpression of GSK-3beta. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of neural transmission (Vienna, Austria : 1996)\", \"reference\": \"18217188\", \"authors\": [\"Shi HR\", \"Zhu LQ\", \"Wang SH\", \"Liu XA\", \"Tian Q\", \"Zhang Q\", \"Wang Q\", \"Wang JZ\"], \"date\": \"2008-06-01\", \"title\": \"17beta-estradiol attenuates glycogen synthase kinase-3beta activation and tau hyperphosphorylation in Akt-independent manner.\", \"lastauthor\": \"Wang JZ\", \"volume\": \"115\", \"issue\": \"6\", \"pages\": \"879-88\", \"firstauthor\": \"Shi HR\"}, \"line\": 32076, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 3, \"target\": 11, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"We found that betaE2 could attenuate tau hyperphosphorylation at multiple AD-related sites, including Ser396/404, Thr231, Thr205, and Ser199/202, induced by Wort/GFX or transient overexpression of GSK-3beta. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of neural transmission (Vienna, Austria : 1996)\", \"reference\": \"18217188\", \"authors\": [\"Shi HR\", \"Zhu LQ\", \"Wang SH\", \"Liu XA\", \"Tian Q\", \"Zhang Q\", \"Wang Q\", \"Wang JZ\"], \"date\": \"2008-06-01\", \"title\": \"17beta-estradiol attenuates glycogen synthase kinase-3beta activation and tau hyperphosphorylation in Akt-independent manner.\", \"lastauthor\": \"Wang JZ\", \"volume\": \"115\", \"issue\": \"6\", \"pages\": \"879-88\", \"firstauthor\": \"Shi HR\"}, \"line\": 32078, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 3, \"target\": 12, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"We found that betaE2 could attenuate tau hyperphosphorylation at multiple AD-related sites, including Ser396/404, Thr231, Thr205, and Ser199/202, induced by Wort/GFX or transient overexpression of GSK-3beta. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of neural transmission (Vienna, Austria : 1996)\", \"reference\": \"18217188\", \"authors\": [\"Shi HR\", \"Zhu LQ\", \"Wang SH\", \"Liu XA\", \"Tian Q\", \"Zhang Q\", \"Wang Q\", \"Wang JZ\"], \"date\": \"2008-06-01\", \"title\": \"17beta-estradiol attenuates glycogen synthase kinase-3beta activation and tau hyperphosphorylation in Akt-independent manner.\", \"lastauthor\": \"Wang JZ\", \"volume\": \"115\", \"issue\": \"6\", \"pages\": \"879-88\", \"firstauthor\": \"Shi HR\"}, \"line\": 32080, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 3, \"target\": 13, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Simultaneously, it increased the level of Ser9-phosphorylated (inactive) GSK-3beta\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of neural transmission (Vienna, Austria : 1996)\", \"reference\": \"18217188\", \"authors\": [\"Shi HR\", \"Zhu LQ\", \"Wang SH\", \"Liu XA\", \"Tian Q\", \"Zhang Q\", \"Wang Q\", \"Wang JZ\"], \"date\": \"2008-06-01\", \"title\": \"17beta-estradiol attenuates glycogen synthase kinase-3beta activation and tau hyperphosphorylation in Akt-independent manner.\", \"lastauthor\": \"Wang JZ\", \"volume\": \"115\", \"issue\": \"6\", \"pages\": \"879-88\", \"firstauthor\": \"Shi HR\"}, \"line\": 32084, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 3, \"target\": 5, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Positive association between an estrogen receptor gene polymorphism and Parkinson's disease with dementia.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"European journal of neurology\", \"reference\": \"10362895\", \"authors\": [\"Isoe-Wada K\", \"Maeda M\", \"Yong J\", \"Adachi Y\", \"Harada H\", \"Urakami K\", \"Nakashima K\"], \"date\": \"1999-07-01\", \"title\": \"Positive association between an estrogen receptor gene polymorphism and Parkinson's disease with dementia.\", \"lastauthor\": \"Nakashima K\", \"volume\": \"6\", \"issue\": \"4\", \"pages\": \"431-5\", \"firstauthor\": \"Isoe-Wada K\"}, \"line\": 18525, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\", \"Species\": \"9606\", \"MeSHDisease\": \"Parkinson Disease\"}, \"source\": 4, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Positive association between an estrogen receptor gene polymorphism and Parkinson's disease with dementia.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"European journal of neurology\", \"reference\": \"10362895\", \"authors\": [\"Isoe-Wada K\", \"Maeda M\", \"Yong J\", \"Adachi Y\", \"Harada H\", \"Urakami K\", \"Nakashima K\"], \"date\": \"1999-07-01\", \"title\": \"Positive association between an estrogen receptor gene polymorphism and Parkinson's disease with dementia.\", \"lastauthor\": \"Nakashima K\", \"volume\": \"6\", \"issue\": \"4\", \"pages\": \"431-5\", \"firstauthor\": \"Isoe-Wada K\"}, \"line\": 18525, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\", \"Species\": \"9606\", \"MeSHDisease\": \"Dementia\"}, \"source\": 4, \"target\": 1, \"key\": 1}, {\"relation\": \"decreases\", \"evidence\": \"Simultaneously, it increased the level of Ser9-phosphorylated (inactive) GSK-3beta\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of neural transmission (Vienna, Austria : 1996)\", \"reference\": \"18217188\", \"authors\": [\"Shi HR\", \"Zhu LQ\", \"Wang SH\", \"Liu XA\", \"Tian Q\", \"Zhang Q\", \"Wang Q\", \"Wang JZ\"], \"date\": \"2008-06-01\", \"title\": \"17beta-estradiol attenuates glycogen synthase kinase-3beta activation and tau hyperphosphorylation in Akt-independent manner.\", \"lastauthor\": \"Wang JZ\", \"volume\": \"115\", \"issue\": \"6\", \"pages\": \"879-88\", \"firstauthor\": \"Shi HR\"}, \"line\": 32085, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 5, \"target\": 2, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Donepezil is metabolized via CYP-related enzymes, especially CYP2D6, CYP3A4, and CYP1A2.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuropsychiatric disease and treatment\", \"reference\": \"19300564\", \"authors\": [\"Cacabelos R\"], \"date\": \"2007-06-01\", \"title\": \"Donepezil in Alzheimer's disease: From conventional trials to pharmacogenetics.\", \"lastauthor\": \"Cacabelos R\", \"volume\": \"3\", \"issue\": \"3\", \"pages\": \"303-33\", \"firstauthor\": \"Cacabelos R\"}, \"line\": 15668, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 6, \"target\": 7, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"[Estradiol co-treated with Tetrachlorodibenzodioxin] results in decreased expression of S100A9 mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Molecular reproduction and development\", \"reference\": \"19484750\", \"authors\": [\"Deroo BJ\", \"Hewitt SC\", \"Collins JB\", \"Grissom SF\", \"Hamilton KJ\", \"Korach KS\"], \"date\": \"2009-08-01\", \"title\": \"Profile of estrogen-responsive genes in an estrogen-specific mammary gland outgrowth model.\", \"lastauthor\": \"Korach KS\", \"volume\": \"76\", \"issue\": \"8\", \"pages\": \"733-50\", \"firstauthor\": \"Deroo BJ\"}, \"line\": 41867, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 14, \"target\": 15, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Estradiol results in increased expression of PPARG protein\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Toxicology in vitro : an international journal published in association with BIBRA\", \"reference\": \"15964169\", \"authors\": [\"Ibabe A\", \"Herrero A\", \"Cajaraville MP\"], \"date\": \"2005-09-01\", \"title\": \"Modulation of peroxisome proliferator-activated receptors (PPARs) by PPAR(alpha)- and PPAR(gamma)-specific ligands and by 17beta-estradiol in isolated zebrafish hepatocytes.\", \"lastauthor\": \"Cajaraville MP\", \"volume\": \"19\", \"issue\": \"6\", \"pages\": \"725-35\", \"firstauthor\": \"Ibabe A\"}, \"line\": 42336, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 14, \"target\": 16, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of TFF1 mRNA]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Human reproduction (Oxford, England)\", \"reference\": \"11331657\", \"authors\": [\"Leffers H\", \"Naesby M\", \"Vendelbo B\", \"Skakkebaek NE\", \"Jrgensen M\"], \"date\": \"2001-05-01\", \"title\": \"Oestrogenic potencies of Zeranol, oestradiol, diethylstilboestrol, Bisphenol-A and genistein: implications for exposure assessment of potential endocrine disrupters.\", \"lastauthor\": \"Jrgensen M\", \"volume\": \"16\", \"issue\": \"5\", \"pages\": \"1037-45\", \"firstauthor\": \"Leffers H\"}, \"line\": 46189, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 14, \"target\": 17, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"resveratrol inhibits the reaction [ESR2 protein binds to CAV1 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"FASEB journal : official publication of the Federation of American Societies for Experimental Biology\", \"reference\": \"18296501\", \"authors\": [\"Klinge CM\", \"Wickramasinghe NS\", \"Ivanova MM\", \"Dougherty SM\"], \"date\": \"2008-07-01\", \"title\": \"Resveratrol stimulates nitric oxide production by increasing estrogen receptor alpha-Src-caveolin-1 interaction and phosphorylation in human umbilical vein endothelial cells.\", \"lastauthor\": \"Dougherty SM\", \"volume\": \"22\", \"issue\": \"7\", \"pages\": \"2185-97\", \"firstauthor\": \"Klinge CM\"}, \"line\": 49702, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 18, \"target\": 19, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"resveratrol inhibits the reaction [ESR2 protein binds to CAV1 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"FASEB journal : official publication of the Federation of American Societies for Experimental Biology\", \"reference\": \"18296501\", \"authors\": [\"Klinge CM\", \"Wickramasinghe NS\", \"Ivanova MM\", \"Dougherty SM\"], \"date\": \"2008-07-01\", \"title\": \"Resveratrol stimulates nitric oxide production by increasing estrogen receptor alpha-Src-caveolin-1 interaction and phosphorylation in human umbilical vein endothelial cells.\", \"lastauthor\": \"Dougherty SM\", \"volume\": \"22\", \"issue\": \"7\", \"pages\": \"2185-97\", \"firstauthor\": \"Klinge CM\"}, \"line\": 49702, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 19, \"target\": 18, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"24-hydroxycholesterol binds to and results in decreased activity of ESR2 protein\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Nature medicine\", \"reference\": \"17873880\", \"authors\": [\"Umetani M\", \"Domoto H\", \"Gormley AK\", \"Yuhanna IS\", \"Cummins CL\", \"Javitt NB\", \"Korach KS\", \"Shaul PW\", \"Mangelsdorf DJ\"], \"date\": \"2007-10-01\", \"title\": \"27-Hydroxycholesterol is an endogenous SERM that inhibits the cardiovascular effects of estrogen.\", \"lastauthor\": \"Mangelsdorf DJ\", \"volume\": \"13\", \"issue\": \"10\", \"pages\": \"1185-92\", \"firstauthor\": \"Umetani M\"}, \"line\": 49640, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 20, \"target\": 19, \"key\": 0}, {\"relation\": \"hasComponent\", \"annotations\": {}, \"source\": 20, \"target\": 19, \"key\": -3}, {\"relation\": \"hasComponent\", \"annotations\": {}, \"source\": 20, \"target\": 22, \"key\": -3}, {\"relation\": \"increases\", \"evidence\": \"Activation;Binding;Medroxyprogesterone acetate intracellular binds to and activates ESR2 .\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of medicinal chemistry\", \"reference\": \"9464360\", \"authors\": [\"Zhi L\", \"Tegley CM\", \"Kallel EA\", \"Marschke KB\", \"Mais DE\", \"Gottardis MM\", \"Jones TK\"], \"date\": \"1998-01-29\", \"title\": \"5-Aryl-1,2-dihydrochromeno[3,4-f]quinolines: a novel class of nonsteroidal human progesterone receptor agonists.\", \"lastauthor\": \"Jones TK\", \"volume\": \"41\", \"issue\": \"3\", \"pages\": \"291-302\", \"firstauthor\": \"Zhi L\"}, \"line\": 49712, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 21, \"target\": 19, \"key\": 0}, {\"relation\": \"hasComponent\", \"annotations\": {}, \"source\": 21, \"target\": 19, \"key\": -3}, {\"relation\": \"hasComponent\", \"annotations\": {}, \"source\": 21, \"target\": 23, \"key\": -3}, {\"relation\": \"hasVariant\", \"annotations\": {}, \"source\": 24, \"target\": 8, \"key\": -4}, {\"relation\": \"hasVariant\", \"annotations\": {}, \"source\": 24, \"target\": 9, \"key\": -4}, {\"relation\": \"hasVariant\", \"annotations\": {}, \"source\": 24, \"target\": 10, \"key\": -4}, {\"relation\": \"hasVariant\", \"annotations\": {}, \"source\": 24, \"target\": 11, \"key\": -4}, {\"relation\": \"hasVariant\", \"annotations\": {}, \"source\": 24, \"target\": 12, \"key\": -4}, {\"relation\": \"hasVariant\", \"annotations\": {}, \"source\": 24, \"target\": 13, \"key\": -4}]};\n",
       "        const color_map = {'Protein': '#1F77B4', 'Pathology': '#FF7F0E', 'BiologicalProcess': '#2CA02C', 'miRNA': '#D62728', 'Complex': '#9467bd', 'Composite': '#9467bd', 'Reaction': '#8c564b', 'Gene': '#e377c2', 'Abundance': '#bcbd22', 'RNA': '#17becf'};\n",
       "    \n",
       "        require.config({\n",
       "          paths: {\n",
       "              d3: '//cdnjs.cloudflare.com/ajax/libs/d3/4.5.0/d3.min'\n",
       "          }\n",
       "        });\n",
       "\n",
       "        var elementInnerHTML = \"<div id='\" + chart + \"'></div>\";\n",
       "\n",
       "        element.append(elementInnerHTML);\n",
       "\n",
       "        var chartQualified = \"#\" + chart;\n",
       "\n",
       "        require(['d3'], function(d3) {\n",
       "            return init_d3_force(d3, graph, chartQualified, width, height, color_map);\n",
       "        });\n",
       "    "
      ],
      "text/plain": [
       "<IPython.core.display.Javascript object>"
      ]
     },
     "execution_count": 22,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "to_jupyter(subgraph)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "The nodes along the periphery of this subgraph can be investigated with [pbt.mutation.get_subgraph_peripheral_nodes](). Below, it is used to output which nodes which aren't already in the Estrogen Subgraph, and how many in- and out-edges they have to it."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": [
    "pnd = pbt.mutation.get_subgraph_peripheral_nodes(graph, subgraph, node_filters=pbt.filters.exclude_pathology_filter)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "('Protein', 'HGNC', 'APP', ('frag', (672, 713))) 7 2 7\n",
      "('Protein', 'HGNC', 'MAPT', ('pmod', ('bel', 'Glyco'))) 1 5 6\n"
     ]
    }
   ],
   "source": [
    "for node in sorted(pnd, key=lambda k: len(set(pnd[k]['successor']) | set(pnd[k]['predecessor'])), reverse=True):\n",
    "    pred_d = pnd[node]['predecessor']\n",
    "    succ_d = pnd[node]['successor']\n",
    "\n",
    "    if 0 == len(pred_d) or 0 == len(succ_d):\n",
    "        continue\n",
    "    \n",
    "    periphery = set(pred_d) | set(succ_d)\n",
    "    \n",
    "    if 4 > len(periphery):\n",
    "        continue\n",
    "    \n",
    "    print(node, len(pred_d), len(succ_d), len(periphery))"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "The function [pbt.mutation.expand_periphery](http://pybel-tools.readthedocs.io/en/latest/mutation.html#pybel_tools.mutation.expand_periphery) automatically handles these calcuations and allows for the specification of a threshold for how \"confident\" it should be to add a node to the subgraph. Filters to exclude pathologies (which have many connections to everything). The inferred edges are limited to only causal edges, to avoid adding many low confidence relations. Luckily, the Estrogen Subgraph is small and doesn't become unmanagable after expanding along the periphery. Other, larger subgraphs might have this issue. If the subgraph becomes too complicated, it might be useful to extract the causal subgraph using  [pbt.selection.get_causal_subgraph](http://pybel-tools.readthedocs.io/en/latest/selection.html#pybel_tools.selection.get_causal_subgraph)."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Nodes: 33\n",
      "Edges: 139\n",
      "Citations: 34\n",
      "Authors: 181\n",
      "Network density: 0.13162878787878787\n",
      "Components: 2\n",
      "Average degree: 4.212121212121212\n"
     ]
    }
   ],
   "source": [
    "pbt.mutation.expand_periphery(\n",
    "    graph, \n",
    "    subgraph, \n",
    "    node_filters=pbt.filters.exclude_pathology_filter, \n",
    "    threshold=3)\n",
    "\n",
    "pbt.summary.print_summary(subgraph)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/javascript": [
       "function init_d3_force(d3, graph, chart, width, height, function_colors) {\n",
       "    var focus_node = null;\n",
       "    var highlight_node = null;\n",
       "\n",
       "    // Highlight color variables\n",
       "\n",
       "    // Highlight color of the node boundering\n",
       "    const highlight_node_boundering = \"#4EB2D4\";\n",
       "\n",
       "    // Highlight color of the edge\n",
       "    const highlighted_link_color = \"#4EB2D4\";\n",
       "\n",
       "    // Text highlight color\n",
       "    const highlight_text = \"#4EB2D4\";\n",
       "\n",
       "    // Size when zooming scale\n",
       "    var size = d3.scalePow().exponent(1)\n",
       "        .domain([1, 100])\n",
       "        .range([8, 24]);\n",
       "\n",
       "    // Simulation parameters\n",
       "    const linkDistance = 100;\n",
       "    const fCharge = -1000;\n",
       "    const linkStrength = 0.7;\n",
       "    const collideStrength = 1;\n",
       "\n",
       "    // Simulation defined with variables\n",
       "    var simulation = d3.forceSimulation()\n",
       "        .force(\"link\", d3.forceLink()\n",
       "            .distance(linkDistance)\n",
       "            .strength(linkStrength)\n",
       "        )\n",
       "        .force(\"collide\", d3.forceCollide()\n",
       "            .radius(function (d) {\n",
       "                return d.r + 10\n",
       "            })\n",
       "            .strength(collideStrength)\n",
       "        )\n",
       "        .force(\"charge\", d3.forceManyBody()\n",
       "            .strength(fCharge)\n",
       "        )\n",
       "        .force(\"center\", d3.forceCenter(width / 2, height / 2))\n",
       "        .force(\"y\", d3.forceY(0))\n",
       "        .force(\"x\", d3.forceX(0));\n",
       "\n",
       "    // Pin down functionality\n",
       "    var node_drag = d3.drag()\n",
       "        .on(\"start\", dragstarted)\n",
       "        .on(\"drag\", dragged)\n",
       "        .on(\"end\", dragended);\n",
       "\n",
       "    function dragstarted(d) {\n",
       "        if (!d3.event.active) simulation.alphaTarget(0.3).restart();\n",
       "        d.fx = d.x;\n",
       "        d.fy = d.y;\n",
       "    }\n",
       "\n",
       "    function dragged(d) {\n",
       "        d.fx = d3.event.x;\n",
       "        d.fy = d3.event.y;\n",
       "    }\n",
       "\n",
       "    function dragended(d) {\n",
       "        if (!d3.event.active) simulation.alphaTarget(0);\n",
       "    }\n",
       "\n",
       "    function releasenode(d) {\n",
       "        d.fx = null;\n",
       "        d.fy = null;\n",
       "    }\n",
       "\n",
       "    //END Pin down functionality\n",
       "\n",
       "    const color_circunferencia = \"black\";\n",
       "    const default_link_color = \"#AAAAAA\";\n",
       "    const nominal_base_node_size = 8;\n",
       "\n",
       "    // Normal and highlighted stroke of the links (double the width of the link when highlighted)\n",
       "    const nominal_stroke = 1.5;\n",
       "\n",
       "    // Zoom variables\n",
       "    const min_zoom = 0.1;\n",
       "    const max_zoom = 10;\n",
       "    const border = 1;\n",
       "    const bordercolor = 'black';\n",
       "\n",
       "    var svg = d3.select(chart).append(\"svg\")\n",
       "        .attr(\"width\", width)\n",
       "        .attr(\"height\", height);\n",
       "\n",
       "    // // Create definition for arrowhead.\n",
       "    svg.append(\"defs\").append(\"marker\")\n",
       "        .attr(\"id\", \"arrowhead\")\n",
       "        .attr(\"viewBox\", \"0 -5 10 10\")\n",
       "        .attr(\"refX\", 20)\n",
       "        .attr(\"refY\", 0)\n",
       "        .attr(\"markerUnits\", \"strokeWidth\")\n",
       "        .attr(\"markerWidth\", 6)\n",
       "        .attr(\"markerHeight\", 6)\n",
       "        .attr(\"orient\", \"auto\")\n",
       "        .append(\"path\")\n",
       "        .attr(\"d\", \"M0,-5L10,0L0,5\");\n",
       "\n",
       "    // // Create definition for stub.\n",
       "    svg.append(\"defs\").append(\"marker\")\n",
       "        .attr(\"id\", \"stub\")\n",
       "        .attr(\"viewBox\", \"-1 -5 2 10\")\n",
       "        .attr(\"refX\", 15)\n",
       "        .attr(\"refY\", 0)\n",
       "        .attr(\"markerUnits\", \"strokeWidth\")\n",
       "        .attr(\"markerWidth\", 6)\n",
       "        .attr(\"markerHeight\", 6)\n",
       "        .attr(\"orient\", \"auto\")\n",
       "        .append(\"path\")\n",
       "        .attr(\"d\", \"M 0,0 m -1,-5 L 1,-5 L 1,5 L -1,5 Z\");\n",
       "\n",
       "    // Background\n",
       "    svg.append(\"rect\")\n",
       "        .attr(\"width\", \"100%\")\n",
       "        .attr(\"height\", \"100%\")\n",
       "        .attr(\"fill\", \"#ffffff\")\n",
       "        .style(\"pointer-events\", \"all\")\n",
       "        // Zoom + panning functionality\n",
       "        .call(d3.zoom()\n",
       "            .scaleExtent([min_zoom, max_zoom])\n",
       "            .on(\"zoom\", zoomed))\n",
       "        .on(\"dblclick.zoom\", null);\n",
       "\n",
       "\n",
       "    function zoomed() {\n",
       "        g.attr(\"transform\", d3.event.transform);\n",
       "    }\n",
       "\n",
       "    // g = svg object where the graph will be appended\n",
       "    var g = svg.append(\"g\");\n",
       "\n",
       "    var linkedByIndex = {};\n",
       "    graph.links.forEach(function (d) {\n",
       "        linkedByIndex[d.source + \",\" + d.target] = true;\n",
       "    });\n",
       "\n",
       "    function isConnected(a, b) {\n",
       "        return linkedByIndex[a.index + \",\" + b.index] || linkedByIndex[b.index + \",\" + a.index] || a.index == b.index;\n",
       "    }\n",
       "\n",
       "    function ticked() {\n",
       "        link.attr(\"x1\", function (d) {\n",
       "            return d.source.x;\n",
       "        })\n",
       "            .attr(\"y1\", function (d) {\n",
       "                return d.source.y;\n",
       "            })\n",
       "            .attr(\"x2\", function (d) {\n",
       "                return d.target.x;\n",
       "            })\n",
       "            .attr(\"y2\", function (d) {\n",
       "                return d.target.y;\n",
       "            });\n",
       "\n",
       "        node\n",
       "            .attr(\"transform\", function (d) {\n",
       "                return \"translate(\" + d.x + \", \" + d.y + \")\";\n",
       "            });\n",
       "    }\n",
       "\n",
       "\n",
       "    simulation\n",
       "        .nodes(graph.nodes)\n",
       "        .on(\"tick\", ticked);\n",
       "\n",
       "    simulation.force(\"link\")\n",
       "        .links(graph.links);\n",
       "\n",
       "    // Definition of links nodes text...\n",
       "\n",
       "    var link = g.selectAll(\".link\")\n",
       "        .data(graph.links)\n",
       "        .enter().append(\"line\")\n",
       "        .style(\"stroke-width\", nominal_stroke)\n",
       "        .style(\"stroke\", default_link_color)\n",
       "        .style(\"stroke-dasharray\", function (d) {\n",
       "            if (['decreases', 'directlyDecreases', 'increases', 'directlyIncreases', 'negativeCorrelation',\n",
       "                    'positiveCorrelation'].indexOf(d.relation) >= 0) {\n",
       "                return \"none\"\n",
       "            } else {\n",
       "                return \"4, 4\"\n",
       "            }\n",
       "        })\n",
       "        .attr(\"marker-start\", function (d) {\n",
       "            if ('positiveCorrelation' == d.relation) {\n",
       "                return \"url(#arrowhead)\"\n",
       "            }\n",
       "            else if ('negativeCorrelation' == d.relation) {\n",
       "                return \"url(#stub)\"\n",
       "            }\n",
       "            else {\n",
       "                return \"\"\n",
       "            }\n",
       "        })\n",
       "        .attr(\"marker-end\", function (d) {\n",
       "            if (['increases', 'directlyIncreases', 'positiveCorrelation'].indexOf(d.relation) >= 0) {\n",
       "                return \"url(#arrowhead)\"\n",
       "            } else if (['decreases', 'directlyDecreases', 'negativeCorrelation'].indexOf(d.relation) >= 0) {\n",
       "                return \"url(#stub)\"\n",
       "            } else {\n",
       "                return \"\"\n",
       "            }\n",
       "        });\n",
       "\n",
       "    var node = g.selectAll(\".nodes\")\n",
       "        .data(graph.nodes)\n",
       "        .enter().append(\"g\")\n",
       "        .attr(\"class\", \"node\")\n",
       "        // Next two lines -> Pin down functionality\n",
       "        .on('dblclick', releasenode)\n",
       "        .call(node_drag);\n",
       "\n",
       "    var circle = node.append(\"path\")\n",
       "        .attr(\"d\", d3.symbol()\n",
       "            .size(function (d) {\n",
       "                return Math.PI * Math.pow(size(d.size) || nominal_base_node_size, 2);\n",
       "            })\n",
       "        )\n",
       "        .attr(\"class\", function (d) {\n",
       "            return d.function\n",
       "        })\n",
       "        .style('fill', function (d) {\n",
       "            return function_colors[d.function]\n",
       "        })\n",
       "        .style(\"stroke-width\", nominal_stroke)\n",
       "        .style(\"stroke\", color_circunferencia);\n",
       "\n",
       "    var text = node.append(\"text\")\n",
       "        .attr(\"class\", \"node-name\")\n",
       "        // .attr(\"id\", nodehashes[d])\n",
       "        .attr(\"fill\", \"black\")\n",
       "        .attr(\"dx\", 12)\n",
       "        .attr(\"dy\", \".35em\")\n",
       "        .text(function (d) {\n",
       "            return d.cname\n",
       "        });\n",
       "\n",
       "    // Highlight on mouseenter and back to normal on mouseout\n",
       "    node.on(\"mouseenter\", function (d) {\n",
       "        set_highlight(d);\n",
       "    })\n",
       "        .on(\"mousedown\", function () {\n",
       "            d3.event.stopPropagation();\n",
       "        }).on(\"mouseout\", function () {\n",
       "        exit_highlight();\n",
       "    });\n",
       "\n",
       "    function exit_highlight() {\n",
       "        highlight_node = null;\n",
       "        if (focus_node === null) {\n",
       "            if (highlight_node_boundering != color_circunferencia) {\n",
       "                circle.style(\"stroke\", color_circunferencia);\n",
       "                text.style(\"fill\", \"black\");\n",
       "                link.style(\"stroke\", default_link_color);\n",
       "            }\n",
       "        }\n",
       "    }\n",
       "\n",
       "    function set_highlight(d) {\n",
       "        if (focus_node !== null) d = focus_node;\n",
       "        highlight_node = d;\n",
       "\n",
       "        if (highlight_node_boundering != color_circunferencia) {\n",
       "            circle.style(\"stroke\", function (o) {\n",
       "                return isConnected(d, o) ? highlight_node_boundering : color_circunferencia;\n",
       "            });\n",
       "            text.style(\"fill\", function (o) {\n",
       "                return isConnected(d, o) ? highlight_text : \"black\";\n",
       "            });\n",
       "            link.style(\"stroke\", function (o) {\n",
       "                return o.source.index == d.index || o.target.index == d.index ? highlighted_link_color : default_link_color;\n",
       "            });\n",
       "        }\n",
       "    }\n",
       "\n",
       "\n",
       "    // Freeze the graph when space is pressed\n",
       "    function freezeGraph() {\n",
       "        // Space button Triggers STOP\n",
       "        if (d3.event.keyCode == 32) {\n",
       "            simulation.stop();\n",
       "        }\n",
       "    }\n",
       "\n",
       "    // Call freezeGraph when a key is pressed, freezeGraph checks whether this key is \"Space\" that triggers the freeze\n",
       "    d3.select(window).on(\"keydown\", freezeGraph);\n",
       "}\n",
       "        var chart = \"xftzrmsgvyjcqdou\";\n",
       "        var width = 1000;\n",
       "        var height = 650;\n",
       "        var graph = {\"directed\": true, \"multigraph\": true, \"graph\": {\"document_metadata\": {}, \"pybel_version\": \"0.7.2\", \"namespace_url\": {}, \"namespace_owl\": {}, \"namespace_pattern\": {}, \"annotation_url\": {}, \"annotation_owl\": {}, \"annotation_pattern\": {}, \"annotation_list\": {}}, \"nodes\": [{\"function\": \"Pathology\", \"namespace\": \"MESHD\", \"name\": \"Alzheimer Disease\", \"cname\": \"Alzheimer Disease\", \"id\": [\"Pathology\", \"MESHD\", \"Alzheimer Disease\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"ESR1\", \"description\": \"This gene encodes an estrogen receptor, a ligand-activated transcription factor composed of several domains important for hormone binding, DNA binding, and activation of transcription. The protein localizes to the nucleus where it may form a homodimer or a heterodimer with estrogen receptor 2. Estrogen and its receptors are essential for sexual development and reproductive function, but also play a role in other tissues such as bone. Estrogen receptors are also involved in pathological processes including breast cancer, endometrial cancer, and osteoporosis. Alternative promoter usage and alternative splicing result in dozens of transcript variants, but the full-length nature of many of these variants has not been determined. [provided by RefSeq, Mar 2014]\", \"label\": \"estrogen receptor 1\", \"cname\": \"ESR1\", \"id\": [\"Protein\", \"HGNC\", \"ESR1\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GSK3B\", \"description\": \"The protein encoded by this gene is a serine-threonine kinase, belonging to the glycogen synthase kinase subfamily. It is involved in energy metabolism, neuronal cell development, and body pattern formation. Polymorphisms in this gene have been implicated in modifying risk of Parkinson disease, and studies in mice show that overexpression of this gene may be relevant to the pathogenesis of Alzheimer disease. Alternatively spliced transcript variants encoding different isoforms have been found for this gene.[provided by RefSeq, Sep 2009]\", \"label\": \"glycogen synthase kinase 3 beta\", \"cname\": \"GSK3B\", \"id\": [\"Protein\", \"HGNC\", \"GSK3B\"]}, {\"function\": \"Abundance\", \"namespace\": \"CHEBI\", \"name\": \"17beta-estradiol\", \"cname\": \"17beta-estradiol\", \"id\": [\"Abundance\", \"CHEBI\", \"17beta-estradiol\"]}, {\"function\": \"Pathology\", \"namespace\": \"MESHD\", \"name\": \"Parkinson Disease\", \"cname\": \"Parkinson Disease\", \"id\": [\"Pathology\", \"MESHD\", \"Parkinson Disease\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"GSK3B\", \"variants\": [{\"kind\": \"pmod\", \"identifier\": {\"namespace\": \"bel\", \"name\": \"Ph\"}, \"code\": \"Ser\", \"pos\": 9}], \"description\": \"The protein encoded by this gene is a serine-threonine kinase, belonging to the glycogen synthase kinase subfamily. It is involved in energy metabolism, neuronal cell development, and body pattern formation. Polymorphisms in this gene have been implicated in modifying risk of Parkinson disease, and studies in mice show that overexpression of this gene may be relevant to the pathogenesis of Alzheimer disease. Alternatively spliced transcript variants encoding different isoforms have been found for this gene.[provided by RefSeq, Sep 2009]\", \"label\": \"glycogen synthase kinase 3 beta\", \"cname\": \"p(HGNC:GSK3B, pmod(Ph, Ser, 9))\", \"id\": [\"Protein\", \"HGNC\", \"GSK3B\", [\"pmod\", [\"bel\", \"Ph\"], \"Ser\", 9]]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CYP3A4\", \"description\": \"This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases that catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and its expression is induced by glucocorticoids and some pharmacological agents. This enzyme is involved in the metabolism of approximately half the drugs in use today, including acetaminophen, codeine, cyclosporin A, diazepam and erythromycin. The enzyme also metabolizes some steroids and carcinogens. This gene is part of a cluster of cytochrome P450 genes on chromosome 7q21.1. Previously another CYP3A gene, CYP3A3, was thought to exist; however, it is now thought that this sequence represents a transcript variant of CYP3A4. Alternatively spliced transcript variants encoding different isoforms have been identified. [provided by RefSeq, Feb 2011]\", \"label\": \"cytochrome P450 family 3 subfamily A member 4\", \"cname\": \"CYP3A4\", \"id\": [\"Protein\", \"HGNC\", \"CYP3A4\"]}, {\"function\": \"BiologicalProcess\", \"namespace\": \"GOBP\", \"name\": \"metabolic process\", \"cname\": \"metabolic process\", \"id\": [\"BiologicalProcess\", \"GOBP\", \"metabolic process\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"MAPT\", \"variants\": [{\"kind\": \"pmod\", \"identifier\": {\"namespace\": \"bel\", \"name\": \"Ph\"}, \"code\": \"Thr\", \"pos\": 231}], \"description\": \"This gene encodes the microtubule-associated protein tau (MAPT) whose transcript undergoes complex, regulated alternative splicing, giving rise to several mRNA species. MAPT transcripts are differentially expressed in the nervous system, depending on stage of neuronal maturation and neuron type. MAPT gene mutations have been associated with several neurodegenerative disorders such as Alzheimer's disease, Pick's disease, frontotemporal dementia, cortico-basal degeneration and progressive supranuclear palsy. [provided by RefSeq, Jul 2008]\", \"label\": \"microtubule associated protein tau\", \"cname\": \"p(HGNC:MAPT, pmod(Ph, Thr, 231))\", \"id\": [\"Protein\", \"HGNC\", \"MAPT\", [\"pmod\", [\"bel\", \"Ph\"], \"Thr\", 231]]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"MAPT\", \"variants\": [{\"kind\": \"pmod\", \"identifier\": {\"namespace\": \"bel\", \"name\": \"Ph\"}, \"code\": \"Thr\", \"pos\": 205}], \"description\": \"This gene encodes the microtubule-associated protein tau (MAPT) whose transcript undergoes complex, regulated alternative splicing, giving rise to several mRNA species. MAPT transcripts are differentially expressed in the nervous system, depending on stage of neuronal maturation and neuron type. MAPT gene mutations have been associated with several neurodegenerative disorders such as Alzheimer's disease, Pick's disease, frontotemporal dementia, cortico-basal degeneration and progressive supranuclear palsy. [provided by RefSeq, Jul 2008]\", \"label\": \"microtubule associated protein tau\", \"cname\": \"p(HGNC:MAPT, pmod(Ph, Thr, 205))\", \"id\": [\"Protein\", \"HGNC\", \"MAPT\", [\"pmod\", [\"bel\", \"Ph\"], \"Thr\", 205]]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"MAPT\", \"variants\": [{\"kind\": \"pmod\", \"identifier\": {\"namespace\": \"bel\", \"name\": \"Ph\"}, \"code\": \"Ser\", \"pos\": 396}], \"description\": \"This gene encodes the microtubule-associated protein tau (MAPT) whose transcript undergoes complex, regulated alternative splicing, giving rise to several mRNA species. MAPT transcripts are differentially expressed in the nervous system, depending on stage of neuronal maturation and neuron type. MAPT gene mutations have been associated with several neurodegenerative disorders such as Alzheimer's disease, Pick's disease, frontotemporal dementia, cortico-basal degeneration and progressive supranuclear palsy. [provided by RefSeq, Jul 2008]\", \"label\": \"microtubule associated protein tau\", \"cname\": \"p(HGNC:MAPT, pmod(Ph, Ser, 396))\", \"id\": [\"Protein\", \"HGNC\", \"MAPT\", [\"pmod\", [\"bel\", \"Ph\"], \"Ser\", 396]]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"MAPT\", \"variants\": [{\"kind\": \"pmod\", \"identifier\": {\"namespace\": \"bel\", \"name\": \"Ph\"}, \"code\": \"Ser\", \"pos\": 404}], \"description\": \"This gene encodes the microtubule-associated protein tau (MAPT) whose transcript undergoes complex, regulated alternative splicing, giving rise to several mRNA species. MAPT transcripts are differentially expressed in the nervous system, depending on stage of neuronal maturation and neuron type. MAPT gene mutations have been associated with several neurodegenerative disorders such as Alzheimer's disease, Pick's disease, frontotemporal dementia, cortico-basal degeneration and progressive supranuclear palsy. [provided by RefSeq, Jul 2008]\", \"label\": \"microtubule associated protein tau\", \"cname\": \"p(HGNC:MAPT, pmod(Ph, Ser, 404))\", \"id\": [\"Protein\", \"HGNC\", \"MAPT\", [\"pmod\", [\"bel\", \"Ph\"], \"Ser\", 404]]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"MAPT\", \"variants\": [{\"kind\": \"pmod\", \"identifier\": {\"namespace\": \"bel\", \"name\": \"Ph\"}, \"code\": \"Ser\", \"pos\": 199}], \"description\": \"This gene encodes the microtubule-associated protein tau (MAPT) whose transcript undergoes complex, regulated alternative splicing, giving rise to several mRNA species. MAPT transcripts are differentially expressed in the nervous system, depending on stage of neuronal maturation and neuron type. MAPT gene mutations have been associated with several neurodegenerative disorders such as Alzheimer's disease, Pick's disease, frontotemporal dementia, cortico-basal degeneration and progressive supranuclear palsy. [provided by RefSeq, Jul 2008]\", \"label\": \"microtubule associated protein tau\", \"cname\": \"p(HGNC:MAPT, pmod(Ph, Ser, 199))\", \"id\": [\"Protein\", \"HGNC\", \"MAPT\", [\"pmod\", [\"bel\", \"Ph\"], \"Ser\", 199]]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"MAPT\", \"variants\": [{\"kind\": \"pmod\", \"identifier\": {\"namespace\": \"bel\", \"name\": \"Ph\"}, \"code\": \"Ser\", \"pos\": 202}], \"description\": \"This gene encodes the microtubule-associated protein tau (MAPT) whose transcript undergoes complex, regulated alternative splicing, giving rise to several mRNA species. MAPT transcripts are differentially expressed in the nervous system, depending on stage of neuronal maturation and neuron type. MAPT gene mutations have been associated with several neurodegenerative disorders such as Alzheimer's disease, Pick's disease, frontotemporal dementia, cortico-basal degeneration and progressive supranuclear palsy. [provided by RefSeq, Jul 2008]\", \"label\": \"microtubule associated protein tau\", \"cname\": \"p(HGNC:MAPT, pmod(Ph, Ser, 202))\", \"id\": [\"Protein\", \"HGNC\", \"MAPT\", [\"pmod\", [\"bel\", \"Ph\"], \"Ser\", 202]]}, {\"function\": \"Abundance\", \"namespace\": \"CHEBI\", \"name\": \"estradiol\", \"cname\": \"estradiol\", \"id\": [\"Abundance\", \"CHEBI\", \"estradiol\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"S100A9\", \"description\": \"The protein encoded by this gene is a member of the S100 family of proteins containing 2 EF-hand calcium-binding motifs. S100 proteins are localized in the cytoplasm and/or nucleus of a wide range of cells, and involved in the regulation of a number of cellular processes such as cell cycle progression and differentiation. S100 genes include at least 13 members which are located as a cluster on chromosome 1q21. This protein may function in the inhibition of casein kinase and altered expression of this protein is associated with the disease cystic fibrosis. This antimicrobial protein exhibits antifungal and antibacterial activity. [provided by RefSeq, Nov 2014]\", \"label\": \"S100 calcium binding protein A9\", \"cname\": \"S100A9\", \"id\": [\"Protein\", \"HGNC\", \"S100A9\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"PPARG\", \"description\": \"This gene encodes a member of the peroxisome proliferator-activated receptor (PPAR) subfamily of nuclear receptors. PPARs form heterodimers with retinoid X receptors (RXRs) and these heterodimers regulate transcription of various genes. Three subtypes of PPARs are known: PPAR-alpha, PPAR-delta, and PPAR-gamma. The protein encoded by this gene is PPAR-gamma and is a regulator of adipocyte differentiation. Additionally, PPAR-gamma has been implicated in the pathology of numerous diseases including obesity, diabetes, atherosclerosis and cancer. Alternatively spliced transcript variants that encode different isoforms have been described. [provided by RefSeq, Jul 2008]\", \"label\": \"peroxisome proliferator activated receptor gamma\", \"cname\": \"PPARG\", \"id\": [\"Protein\", \"HGNC\", \"PPARG\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"TFF1\", \"description\": \"Members of the trefoil family are characterized by having at least one copy of the trefoil motif, a 40-amino acid domain that contains three conserved disulfides. They are stable secretory proteins expressed in gastrointestinal mucosa. Their functions are not defined, but they may protect the mucosa from insults, stabilize the mucus layer, and affect healing of the epithelium. This gene, which is expressed in the gastric mucosa, has also been studied because of its expression in human tumors. This gene and two other related trefoil family member genes are found in a cluster on chromosome 21. [provided by RefSeq, Jul 2008]\", \"label\": \"trefoil factor 1\", \"cname\": \"TFF1\", \"id\": [\"RNA\", \"HGNC\", \"TFF1\"]}, {\"function\": \"Abundance\", \"namespace\": \"CHEBI\", \"name\": \"resveratrol\", \"cname\": \"resveratrol\", \"id\": [\"Abundance\", \"CHEBI\", \"resveratrol\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"ESR2\", \"description\": \"This gene encodes a member of the family of estrogen receptors and superfamily of nuclear receptor transcription factors. The gene product contains an N-terminal DNA binding domain and C-terminal ligand binding domain and is localized to the nucleus, cytoplasm, and mitochondria. Upon binding to 17beta-estradiol or related ligands, the encoded protein forms homo- or hetero-dimers that interact with specific DNA sequences to activate transcription. Some isoforms dominantly inhibit the activity of other estrogen receptor family members. Several alternatively spliced transcript variants of this gene have been described, but the full-length nature of some of these variants has not been fully characterized. [provided by RefSeq, Jul 2008]\", \"label\": \"estrogen receptor 2\", \"cname\": \"ESR2\", \"id\": [\"Protein\", \"HGNC\", \"ESR2\"]}, {\"function\": \"Complex\", \"cname\": \"complex(a(CHEBI:\\\"24-hydroxycholesterol\\\"), p(HGNC:ESR2))\", \"id\": [\"Complex\", [\"Abundance\", \"CHEBI\", \"24-hydroxycholesterol\"], [\"Protein\", \"HGNC\", \"ESR2\"]]}, {\"function\": \"Complex\", \"cname\": \"complex(a(CHEBI:\\\"medroxyprogesterone acetate\\\"), p(HGNC:ESR2))\", \"id\": [\"Complex\", [\"Abundance\", \"CHEBI\", \"medroxyprogesterone acetate\"], [\"Protein\", \"HGNC\", \"ESR2\"]]}, {\"function\": \"Abundance\", \"namespace\": \"CHEBI\", \"name\": \"24-hydroxycholesterol\", \"cname\": \"24-hydroxycholesterol\", \"id\": [\"Abundance\", \"CHEBI\", \"24-hydroxycholesterol\"]}, {\"function\": \"Abundance\", \"namespace\": \"CHEBI\", \"name\": \"medroxyprogesterone acetate\", \"cname\": \"medroxyprogesterone acetate\", \"id\": [\"Abundance\", \"CHEBI\", \"medroxyprogesterone acetate\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"MAPT\", \"description\": \"This gene encodes the microtubule-associated protein tau (MAPT) whose transcript undergoes complex, regulated alternative splicing, giving rise to several mRNA species. MAPT transcripts are differentially expressed in the nervous system, depending on stage of neuronal maturation and neuron type. MAPT gene mutations have been associated with several neurodegenerative disorders such as Alzheimer's disease, Pick's disease, frontotemporal dementia, cortico-basal degeneration and progressive supranuclear palsy. [provided by RefSeq, Jul 2008]\", \"label\": \"microtubule associated protein tau\", \"cname\": \"MAPT\", \"id\": [\"Protein\", \"HGNC\", \"MAPT\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"APP\", \"variants\": [{\"kind\": \"frag\", \"start\": 672, \"stop\": 713}], \"description\": \"This gene encodes a cell surface receptor and transmembrane precursor protein that is cleaved by secretases to form a number of peptides. Some of these peptides are secreted and can bind to the acetyltransferase complex APBB1/TIP60 to promote transcriptional activation, while others form the protein basis of the amyloid plaques found in the brains of patients with Alzheimer disease. In addition, two of the peptides are antimicrobial peptides, having been shown to have bacteriocidal and antifungal activities. Mutations in this gene have been implicated in autosomal dominant Alzheimer disease and cerebroarterial amyloidosis (cerebral amyloid angiopathy). Multiple transcript variants encoding several different isoforms have been found for this gene. [provided by RefSeq, Aug 2014]\", \"label\": \"amyloid beta precursor protein\", \"cname\": \"p(HGNC:APP, frag(672_713))\", \"id\": [\"Protein\", \"HGNC\", \"APP\", [\"frag\", [672, 713]]]}, {\"function\": \"Abundance\", \"namespace\": \"CHEBI\", \"name\": \"donepezil\", \"cname\": \"donepezil\", \"id\": [\"Abundance\", \"CHEBI\", \"donepezil\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"APP\", \"description\": \"This gene encodes a cell surface receptor and transmembrane precursor protein that is cleaved by secretases to form a number of peptides. Some of these peptides are secreted and can bind to the acetyltransferase complex APBB1/TIP60 to promote transcriptional activation, while others form the protein basis of the amyloid plaques found in the brains of patients with Alzheimer disease. In addition, two of the peptides are antimicrobial peptides, having been shown to have bacteriocidal and antifungal activities. Mutations in this gene have been implicated in autosomal dominant Alzheimer disease and cerebroarterial amyloidosis (cerebral amyloid angiopathy). Multiple transcript variants encoding several different isoforms have been found for this gene. [provided by RefSeq, Aug 2014]\", \"label\": \"amyloid beta precursor protein\", \"cname\": \"APP\", \"id\": [\"Protein\", \"HGNC\", \"APP\"]}, {\"function\": \"RNA\", \"namespace\": \"HGNC\", \"name\": \"TIMP3\", \"description\": \"This gene belongs to the TIMP gene family. The proteins encoded by this gene family are inhibitors of the matrix metalloproteinases, a group of peptidases involved in degradation of the extracellular matrix (ECM). Expression of this gene is induced in response to mitogenic stimulation and this netrin domain-containing protein is localized to the ECM. Mutations in this gene have been associated with the autosomal dominant disorder Sorsby's fundus dystrophy. [provided by RefSeq, Jul 2008]\", \"label\": \"TIMP metallopeptidase inhibitor 3\", \"cname\": \"TIMP3\", \"id\": [\"RNA\", \"HGNC\", \"TIMP3\"]}, {\"function\": \"Protein\", \"namespace\": \"ADO\", \"name\": \"Amyloid Beta\", \"cname\": \"Amyloid Beta\", \"id\": [\"Protein\", \"ADO\", \"Amyloid Beta\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"MAPT\", \"variants\": [{\"kind\": \"pmod\", \"identifier\": {\"namespace\": \"bel\", \"name\": \"Glyco\"}}], \"description\": \"This gene encodes the microtubule-associated protein tau (MAPT) whose transcript undergoes complex, regulated alternative splicing, giving rise to several mRNA species. MAPT transcripts are differentially expressed in the nervous system, depending on stage of neuronal maturation and neuron type. MAPT gene mutations have been associated with several neurodegenerative disorders such as Alzheimer's disease, Pick's disease, frontotemporal dementia, cortico-basal degeneration and progressive supranuclear palsy. [provided by RefSeq, Jul 2008]\", \"label\": \"microtubule associated protein tau\", \"cname\": \"p(HGNC:MAPT, pmod(Glyco))\", \"id\": [\"Protein\", \"HGNC\", \"MAPT\", [\"pmod\", [\"bel\", \"Glyco\"]]]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"CDK5\", \"description\": \"This gene encodes a proline-directed serine/threonine kinase that is a member of the cyclin-dependent kinase family of proteins. Unlike other members of the family, the protein encoded by this gene does not directly control cell cycle regulation. Instead the protein, which is predominantly expressed at high levels in mammalian postmitotic central nervous system neurons, functions in diverse processes such as synaptic plasticity and neuronal migration through phosphorylation of proteins required for cytoskeletal organization, endocytosis and exocytosis, and apoptosis. In humans, an allelic variant of the gene that results in undetectable levels of the protein has been associated with lethal autosomal recessive lissencephaly-7. Alternative splicing results in multiple transcript variants. [provided by RefSeq, May 2015]\", \"label\": \"cyclin dependent kinase 5\", \"cname\": \"CDK5\", \"id\": [\"Protein\", \"HGNC\", \"CDK5\"]}, {\"function\": \"Protein\", \"namespace\": \"HGNC\", \"name\": \"MAPK14\", \"description\": \"The protein encoded by this gene is a member of the MAP kinase family. MAP kinases act as an integration point for multiple biochemical signals, and are involved in a wide variety of cellular processes such as proliferation, differentiation, transcription regulation and development. This kinase is activated by various environmental stresses and proinflammatory cytokines. The activation requires its phosphorylation by MAP kinase kinases (MKKs), or its autophosphorylation triggered by the interaction of MAP3K7IP1/TAB1 protein with this kinase. The substrates of this kinase include transcription regulator ATF2, MEF2C, and MAX, cell cycle regulator CDC25B, and tumor suppressor p53, which suggest the roles of this kinase in stress related transcription and cell cycle regulation, as well as in genotoxic stress response. Four alternatively spliced transcript variants of this gene encoding distinct isoforms have been reported. [provided by RefSeq, Jul 2008]\", \"label\": \"mitogen-activated protein kinase 14\", \"cname\": \"MAPK14\", \"id\": [\"Protein\", \"HGNC\", \"MAPK14\"]}], \"links\": [{\"relation\": \"association\", \"evidence\": \"Herein, we conducted a meta-analysis to clarify the association between ESR1 polymorphisms and the occurrence of AD.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience letters\", \"reference\": \"24857745\", \"authors\": [\"Wang T\"], \"date\": \"2014-06-27\", \"title\": \"Meta-analysis of PvuII, XbaI variants in ESR1 gene and the risk of Alzheimer's disease: the regional European difference.\", \"lastauthor\": \"Wang T\", \"volume\": \"574\", \"issue\": \"\", \"pages\": \"41-6\", \"firstauthor\": \"Wang T\"}, \"line\": 18507, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 0, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Herein, we conducted a meta-analysis to clarify the association between ESR1 polymorphisms and the occurrence of AD.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuroscience letters\", \"reference\": \"24857745\", \"authors\": [\"Wang T\"], \"date\": \"2014-06-27\", \"title\": \"Meta-analysis of PvuII, XbaI variants in ESR1 gene and the risk of Alzheimer's disease: the regional European difference.\", \"lastauthor\": \"Wang T\", \"volume\": \"574\", \"issue\": \"\", \"pages\": \"41-6\", \"firstauthor\": \"Wang T\"}, \"line\": 18507, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 1, \"target\": 0, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Positive association between an estrogen receptor gene polymorphism and Parkinson's disease with dementia.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"European journal of neurology\", \"reference\": \"10362895\", \"authors\": [\"Isoe-Wada K\", \"Maeda M\", \"Yong J\", \"Adachi Y\", \"Harada H\", \"Urakami K\", \"Nakashima K\"], \"date\": \"1999-07-01\", \"title\": \"Positive association between an estrogen receptor gene polymorphism and Parkinson's disease with dementia.\", \"lastauthor\": \"Nakashima K\", \"volume\": \"6\", \"issue\": \"4\", \"pages\": \"431-5\", \"firstauthor\": \"Isoe-Wada K\"}, \"line\": 18525, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\", \"Species\": \"9606\", \"MeSHDisease\": \"Parkinson Disease\"}, \"source\": 1, \"target\": 4, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Positive association between an estrogen receptor gene polymorphism and Parkinson's disease with dementia.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"European journal of neurology\", \"reference\": \"10362895\", \"authors\": [\"Isoe-Wada K\", \"Maeda M\", \"Yong J\", \"Adachi Y\", \"Harada H\", \"Urakami K\", \"Nakashima K\"], \"date\": \"1999-07-01\", \"title\": \"Positive association between an estrogen receptor gene polymorphism and Parkinson's disease with dementia.\", \"lastauthor\": \"Nakashima K\", \"volume\": \"6\", \"issue\": \"4\", \"pages\": \"431-5\", \"firstauthor\": \"Isoe-Wada K\"}, \"line\": 18525, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\", \"Species\": \"9606\", \"MeSHDisease\": \"Dementia\"}, \"source\": 1, \"target\": 4, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"We found that betaE2 could attenuate tau hyperphosphorylation at multiple AD-related sites, including Ser396/404, Thr231, Thr205, and Ser199/202, induced by Wort/GFX or transient overexpression of GSK-3beta. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of neural transmission (Vienna, Austria : 1996)\", \"reference\": \"18217188\", \"authors\": [\"Shi HR\", \"Zhu LQ\", \"Wang SH\", \"Liu XA\", \"Tian Q\", \"Zhang Q\", \"Wang Q\", \"Wang JZ\"], \"date\": \"2008-06-01\", \"title\": \"17beta-estradiol attenuates glycogen synthase kinase-3beta activation and tau hyperphosphorylation in Akt-independent manner.\", \"lastauthor\": \"Wang JZ\", \"volume\": \"115\", \"issue\": \"6\", \"pages\": \"879-88\", \"firstauthor\": \"Shi HR\"}, \"line\": 32069, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 2, \"target\": 3, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We found that betaE2 could attenuate tau hyperphosphorylation at multiple AD-related sites, including Ser396/404, Thr231, Thr205, and Ser199/202, induced by Wort/GFX or transient overexpression of GSK-3beta. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of neural transmission (Vienna, Austria : 1996)\", \"reference\": \"18217188\", \"authors\": [\"Shi HR\", \"Zhu LQ\", \"Wang SH\", \"Liu XA\", \"Tian Q\", \"Zhang Q\", \"Wang Q\", \"Wang JZ\"], \"date\": \"2008-06-01\", \"title\": \"17beta-estradiol attenuates glycogen synthase kinase-3beta activation and tau hyperphosphorylation in Akt-independent manner.\", \"lastauthor\": \"Wang JZ\", \"volume\": \"115\", \"issue\": \"6\", \"pages\": \"879-88\", \"firstauthor\": \"Shi HR\"}, \"line\": 32071, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 2, \"target\": 3, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"We found that betaE2 could attenuate tau hyperphosphorylation at multiple AD-related sites, including Ser396/404, Thr231, Thr205, and Ser199/202, induced by Wort/GFX or transient overexpression of GSK-3beta. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of neural transmission (Vienna, Austria : 1996)\", \"reference\": \"18217188\", \"authors\": [\"Shi HR\", \"Zhu LQ\", \"Wang SH\", \"Liu XA\", \"Tian Q\", \"Zhang Q\", \"Wang Q\", \"Wang JZ\"], \"date\": \"2008-06-01\", \"title\": \"17beta-estradiol attenuates glycogen synthase kinase-3beta activation and tau hyperphosphorylation in Akt-independent manner.\", \"lastauthor\": \"Wang JZ\", \"volume\": \"115\", \"issue\": \"6\", \"pages\": \"879-88\", \"firstauthor\": \"Shi HR\"}, \"line\": 32073, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 2, \"target\": 3, \"key\": 2}, {\"relation\": \"increases\", \"evidence\": \"We found that betaE2 could attenuate tau hyperphosphorylation at multiple AD-related sites, including Ser396/404, Thr231, Thr205, and Ser199/202, induced by Wort/GFX or transient overexpression of GSK-3beta. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of neural transmission (Vienna, Austria : 1996)\", \"reference\": \"18217188\", \"authors\": [\"Shi HR\", \"Zhu LQ\", \"Wang SH\", \"Liu XA\", \"Tian Q\", \"Zhang Q\", \"Wang Q\", \"Wang JZ\"], \"date\": \"2008-06-01\", \"title\": \"17beta-estradiol attenuates glycogen synthase kinase-3beta activation and tau hyperphosphorylation in Akt-independent manner.\", \"lastauthor\": \"Wang JZ\", \"volume\": \"115\", \"issue\": \"6\", \"pages\": \"879-88\", \"firstauthor\": \"Shi HR\"}, \"line\": 32075, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 2, \"target\": 3, \"key\": 3}, {\"relation\": \"increases\", \"evidence\": \"We found that betaE2 could attenuate tau hyperphosphorylation at multiple AD-related sites, including Ser396/404, Thr231, Thr205, and Ser199/202, induced by Wort/GFX or transient overexpression of GSK-3beta. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of neural transmission (Vienna, Austria : 1996)\", \"reference\": \"18217188\", \"authors\": [\"Shi HR\", \"Zhu LQ\", \"Wang SH\", \"Liu XA\", \"Tian Q\", \"Zhang Q\", \"Wang Q\", \"Wang JZ\"], \"date\": \"2008-06-01\", \"title\": \"17beta-estradiol attenuates glycogen synthase kinase-3beta activation and tau hyperphosphorylation in Akt-independent manner.\", \"lastauthor\": \"Wang JZ\", \"volume\": \"115\", \"issue\": \"6\", \"pages\": \"879-88\", \"firstauthor\": \"Shi HR\"}, \"line\": 32077, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 2, \"target\": 3, \"key\": 4}, {\"relation\": \"increases\", \"evidence\": \"We found that betaE2 could attenuate tau hyperphosphorylation at multiple AD-related sites, including Ser396/404, Thr231, Thr205, and Ser199/202, induced by Wort/GFX or transient overexpression of GSK-3beta. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of neural transmission (Vienna, Austria : 1996)\", \"reference\": \"18217188\", \"authors\": [\"Shi HR\", \"Zhu LQ\", \"Wang SH\", \"Liu XA\", \"Tian Q\", \"Zhang Q\", \"Wang Q\", \"Wang JZ\"], \"date\": \"2008-06-01\", \"title\": \"17beta-estradiol attenuates glycogen synthase kinase-3beta activation and tau hyperphosphorylation in Akt-independent manner.\", \"lastauthor\": \"Wang JZ\", \"volume\": \"115\", \"issue\": \"6\", \"pages\": \"879-88\", \"firstauthor\": \"Shi HR\"}, \"line\": 32079, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 2, \"target\": 3, \"key\": 5}, {\"relation\": \"hasVariant\", \"annotations\": {}, \"source\": 2, \"target\": 5, \"key\": -4}, {\"relation\": \"decreases\", \"evidence\": \"The inhibition of this kinase can prevent the aggregation of -amyloid (Abeta) and hyperphosphorylation of tau protein.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reviews in the neurosciences\", \"reference\": \"22718609\", \"authors\": [\"Gao C\", \"Hlscher C\", \"Liu Y\", \"Li L\"], \"date\": \"2011-12-21\", \"title\": \"GSK3: a key target for the development of novel treatments for type 2 diabetes mellitus and Alzheimer disease.\", \"lastauthor\": \"Li L\", \"volume\": \"23\", \"issue\": \"1\", \"pages\": \"1-11\", \"firstauthor\": \"Gao C\"}, \"line\": 11904, \"subject\": {\"modifier\": \"Degradation\"}, \"annotations\": {\"Subgraph\": \"GSK3 subgraph\"}, \"source\": 2, \"target\": 25, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"The inhibition of this kinase can prevent the aggregation of -amyloid (Abeta) and hyperphosphorylation of tau protein.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Reviews in the neurosciences\", \"reference\": \"22718609\", \"authors\": [\"Gao C\", \"Hlscher C\", \"Liu Y\", \"Li L\"], \"date\": \"2011-12-21\", \"title\": \"GSK3: a key target for the development of novel treatments for type 2 diabetes mellitus and Alzheimer disease.\", \"lastauthor\": \"Li L\", \"volume\": \"23\", \"issue\": \"1\", \"pages\": \"1-11\", \"firstauthor\": \"Gao C\"}, \"line\": 11904, \"subject\": {\"modifier\": \"Degradation\"}, \"annotations\": {\"Subgraph\": \"Non-amyloidogenic subgraph\"}, \"source\": 2, \"target\": 25, \"key\": 1}, {\"relation\": \"decreases\", \"evidence\": \"We found that betaE2 could attenuate tau hyperphosphorylation at multiple AD-related sites, including Ser396/404, Thr231, Thr205, and Ser199/202, induced by Wort/GFX or transient overexpression of GSK-3beta. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of neural transmission (Vienna, Austria : 1996)\", \"reference\": \"18217188\", \"authors\": [\"Shi HR\", \"Zhu LQ\", \"Wang SH\", \"Liu XA\", \"Tian Q\", \"Zhang Q\", \"Wang Q\", \"Wang JZ\"], \"date\": \"2008-06-01\", \"title\": \"17beta-estradiol attenuates glycogen synthase kinase-3beta activation and tau hyperphosphorylation in Akt-independent manner.\", \"lastauthor\": \"Wang JZ\", \"volume\": \"115\", \"issue\": \"6\", \"pages\": \"879-88\", \"firstauthor\": \"Shi HR\"}, \"line\": 32070, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 3, \"target\": 8, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"We found that betaE2 could attenuate tau hyperphosphorylation at multiple AD-related sites, including Ser396/404, Thr231, Thr205, and Ser199/202, induced by Wort/GFX or transient overexpression of GSK-3beta. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of neural transmission (Vienna, Austria : 1996)\", \"reference\": \"18217188\", \"authors\": [\"Shi HR\", \"Zhu LQ\", \"Wang SH\", \"Liu XA\", \"Tian Q\", \"Zhang Q\", \"Wang Q\", \"Wang JZ\"], \"date\": \"2008-06-01\", \"title\": \"17beta-estradiol attenuates glycogen synthase kinase-3beta activation and tau hyperphosphorylation in Akt-independent manner.\", \"lastauthor\": \"Wang JZ\", \"volume\": \"115\", \"issue\": \"6\", \"pages\": \"879-88\", \"firstauthor\": \"Shi HR\"}, \"line\": 32072, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 3, \"target\": 9, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"We found that betaE2 could attenuate tau hyperphosphorylation at multiple AD-related sites, including Ser396/404, Thr231, Thr205, and Ser199/202, induced by Wort/GFX or transient overexpression of GSK-3beta. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of neural transmission (Vienna, Austria : 1996)\", \"reference\": \"18217188\", \"authors\": [\"Shi HR\", \"Zhu LQ\", \"Wang SH\", \"Liu XA\", \"Tian Q\", \"Zhang Q\", \"Wang Q\", \"Wang JZ\"], \"date\": \"2008-06-01\", \"title\": \"17beta-estradiol attenuates glycogen synthase kinase-3beta activation and tau hyperphosphorylation in Akt-independent manner.\", \"lastauthor\": \"Wang JZ\", \"volume\": \"115\", \"issue\": \"6\", \"pages\": \"879-88\", \"firstauthor\": \"Shi HR\"}, \"line\": 32074, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 3, \"target\": 10, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"We found that betaE2 could attenuate tau hyperphosphorylation at multiple AD-related sites, including Ser396/404, Thr231, Thr205, and Ser199/202, induced by Wort/GFX or transient overexpression of GSK-3beta. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of neural transmission (Vienna, Austria : 1996)\", \"reference\": \"18217188\", \"authors\": [\"Shi HR\", \"Zhu LQ\", \"Wang SH\", \"Liu XA\", \"Tian Q\", \"Zhang Q\", \"Wang Q\", \"Wang JZ\"], \"date\": \"2008-06-01\", \"title\": \"17beta-estradiol attenuates glycogen synthase kinase-3beta activation and tau hyperphosphorylation in Akt-independent manner.\", \"lastauthor\": \"Wang JZ\", \"volume\": \"115\", \"issue\": \"6\", \"pages\": \"879-88\", \"firstauthor\": \"Shi HR\"}, \"line\": 32076, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 3, \"target\": 11, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"We found that betaE2 could attenuate tau hyperphosphorylation at multiple AD-related sites, including Ser396/404, Thr231, Thr205, and Ser199/202, induced by Wort/GFX or transient overexpression of GSK-3beta. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of neural transmission (Vienna, Austria : 1996)\", \"reference\": \"18217188\", \"authors\": [\"Shi HR\", \"Zhu LQ\", \"Wang SH\", \"Liu XA\", \"Tian Q\", \"Zhang Q\", \"Wang Q\", \"Wang JZ\"], \"date\": \"2008-06-01\", \"title\": \"17beta-estradiol attenuates glycogen synthase kinase-3beta activation and tau hyperphosphorylation in Akt-independent manner.\", \"lastauthor\": \"Wang JZ\", \"volume\": \"115\", \"issue\": \"6\", \"pages\": \"879-88\", \"firstauthor\": \"Shi HR\"}, \"line\": 32078, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 3, \"target\": 12, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"We found that betaE2 could attenuate tau hyperphosphorylation at multiple AD-related sites, including Ser396/404, Thr231, Thr205, and Ser199/202, induced by Wort/GFX or transient overexpression of GSK-3beta. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of neural transmission (Vienna, Austria : 1996)\", \"reference\": \"18217188\", \"authors\": [\"Shi HR\", \"Zhu LQ\", \"Wang SH\", \"Liu XA\", \"Tian Q\", \"Zhang Q\", \"Wang Q\", \"Wang JZ\"], \"date\": \"2008-06-01\", \"title\": \"17beta-estradiol attenuates glycogen synthase kinase-3beta activation and tau hyperphosphorylation in Akt-independent manner.\", \"lastauthor\": \"Wang JZ\", \"volume\": \"115\", \"issue\": \"6\", \"pages\": \"879-88\", \"firstauthor\": \"Shi HR\"}, \"line\": 32080, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 3, \"target\": 13, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Simultaneously, it increased the level of Ser9-phosphorylated (inactive) GSK-3beta\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of neural transmission (Vienna, Austria : 1996)\", \"reference\": \"18217188\", \"authors\": [\"Shi HR\", \"Zhu LQ\", \"Wang SH\", \"Liu XA\", \"Tian Q\", \"Zhang Q\", \"Wang Q\", \"Wang JZ\"], \"date\": \"2008-06-01\", \"title\": \"17beta-estradiol attenuates glycogen synthase kinase-3beta activation and tau hyperphosphorylation in Akt-independent manner.\", \"lastauthor\": \"Wang JZ\", \"volume\": \"115\", \"issue\": \"6\", \"pages\": \"879-88\", \"firstauthor\": \"Shi HR\"}, \"line\": 32084, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 3, \"target\": 5, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Positive association between an estrogen receptor gene polymorphism and Parkinson's disease with dementia.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"European journal of neurology\", \"reference\": \"10362895\", \"authors\": [\"Isoe-Wada K\", \"Maeda M\", \"Yong J\", \"Adachi Y\", \"Harada H\", \"Urakami K\", \"Nakashima K\"], \"date\": \"1999-07-01\", \"title\": \"Positive association between an estrogen receptor gene polymorphism and Parkinson's disease with dementia.\", \"lastauthor\": \"Nakashima K\", \"volume\": \"6\", \"issue\": \"4\", \"pages\": \"431-5\", \"firstauthor\": \"Isoe-Wada K\"}, \"line\": 18525, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\", \"Species\": \"9606\", \"MeSHDisease\": \"Parkinson Disease\"}, \"source\": 4, \"target\": 1, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Positive association between an estrogen receptor gene polymorphism and Parkinson's disease with dementia.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"European journal of neurology\", \"reference\": \"10362895\", \"authors\": [\"Isoe-Wada K\", \"Maeda M\", \"Yong J\", \"Adachi Y\", \"Harada H\", \"Urakami K\", \"Nakashima K\"], \"date\": \"1999-07-01\", \"title\": \"Positive association between an estrogen receptor gene polymorphism and Parkinson's disease with dementia.\", \"lastauthor\": \"Nakashima K\", \"volume\": \"6\", \"issue\": \"4\", \"pages\": \"431-5\", \"firstauthor\": \"Isoe-Wada K\"}, \"line\": 18525, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\", \"Species\": \"9606\", \"MeSHDisease\": \"Dementia\"}, \"source\": 4, \"target\": 1, \"key\": 1}, {\"relation\": \"decreases\", \"evidence\": \"Simultaneously, it increased the level of Ser9-phosphorylated (inactive) GSK-3beta\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of neural transmission (Vienna, Austria : 1996)\", \"reference\": \"18217188\", \"authors\": [\"Shi HR\", \"Zhu LQ\", \"Wang SH\", \"Liu XA\", \"Tian Q\", \"Zhang Q\", \"Wang Q\", \"Wang JZ\"], \"date\": \"2008-06-01\", \"title\": \"17beta-estradiol attenuates glycogen synthase kinase-3beta activation and tau hyperphosphorylation in Akt-independent manner.\", \"lastauthor\": \"Wang JZ\", \"volume\": \"115\", \"issue\": \"6\", \"pages\": \"879-88\", \"firstauthor\": \"Shi HR\"}, \"line\": 32085, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 5, \"target\": 2, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Donepezil is metabolized via CYP-related enzymes, especially CYP2D6, CYP3A4, and CYP1A2.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuropsychiatric disease and treatment\", \"reference\": \"19300564\", \"authors\": [\"Cacabelos R\"], \"date\": \"2007-06-01\", \"title\": \"Donepezil in Alzheimer's disease: From conventional trials to pharmacogenetics.\", \"lastauthor\": \"Cacabelos R\", \"volume\": \"3\", \"issue\": \"3\", \"pages\": \"303-33\", \"firstauthor\": \"Cacabelos R\"}, \"line\": 15668, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 6, \"target\": 7, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Some cholinesterase inhibitors (tacrine, donepezil, galantamine) are metabolized via CYP-related enzymes, especially CYP2D6, CYP3A4, and CYP1A2.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Current Alzheimer research\", \"reference\": \"17908053\", \"authors\": [\"Cacabelos R\", \"Llovo R\", \"Fraile C\", \"Fernndez-Novoa L\"], \"date\": \"2007-09-01\", \"title\": \"Pharmacogenetic aspects of therapy with cholinesterase inhibitors: the role of CYP2D6 in Alzheimer's disease pharmacogenetics.\", \"lastauthor\": \"Fernndez-Novoa L\", \"volume\": \"4\", \"issue\": \"4\", \"pages\": \"479-500\", \"firstauthor\": \"Cacabelos R\"}, \"line\": 18762, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"Cholesterol metabolism subgraph\"}, \"source\": 6, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Donepezil is metabolized via CYP-related enzymes, especially CYP2D6, CYP3A4, and CYP1A2.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuropsychiatric disease and treatment\", \"reference\": \"19300564\", \"authors\": [\"Cacabelos R\"], \"date\": \"2007-06-01\", \"title\": \"Donepezil in Alzheimer's disease: From conventional trials to pharmacogenetics.\", \"lastauthor\": \"Cacabelos R\", \"volume\": \"3\", \"issue\": \"3\", \"pages\": \"303-33\", \"firstauthor\": \"Cacabelos R\"}, \"line\": 15671, \"annotations\": {\"Subgraph\": \"Cholesterol metabolism subgraph\"}, \"source\": 7, \"target\": 26, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Cytochrome P450 (CYP) 2D6 enzyme is the major responsible for the metabolism of donepezil, an inhibitor of acetyl cholinesterase currently used for the symptomatic treatment of mild-to-moderate Alzheimer's disease (AD).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Pharmacogenetics and genomics\", \"reference\": \"20859244\", \"authors\": [\"Seripa D\", \"Bizzarro A\", \"Pilotto A\", \"D'onofrio G\", \"Vecchione G\", \"Gallo AP\", \"Cascavilla L\", \"Paris F\", \"Grandone E\", \"Mecocci P\", \"Santini SA\", \"Masullo C\", \"Pilotto A\"], \"date\": \"2011-04-01\", \"title\": \"Role of cytochrome P4502D6 functional polymorphisms in the efficacy of donepezil in patients with Alzheimer's disease.\", \"lastauthor\": \"Pilotto A\", \"volume\": \"21\", \"issue\": \"4\", \"pages\": \"225-30\", \"firstauthor\": \"Seripa D\"}, \"line\": 18358, \"annotations\": {\"Disease\": \"Alzheimer's disease\", \"Subgraph\": \"Paroxetine subgraph\"}, \"source\": 7, \"target\": 26, \"key\": 1}, {\"relation\": \"association\", \"evidence\": \"Over the last several years a number of reports have emerged suggesting that at least some ChEI might take part in betaAPP metabolism, influencing its secretion and Abeta differential cleavage. Moreover, we (Sob6w and Kloszewska 2005) and others (Basun et al. 2002, Zimmermann et al. 2005) have shown that the treatment with ChEI might influence BAPP metabolism in AD patients as measured by changes in plasma (including platelet-derived) metabolites. In our previous pilot study we have demonstrated that short-term treatment with ChEI rivastigmine exhibits a significant effect on plasma concentrations of Abeta-42 (mean increase after treatment reached 7.8  8.4 pg/ml) with a negative correlation to patients age, while no changes in Abeta-40 levels were detected.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Acta neurobiologiae experimentalis\", \"reference\": \"17691220\", \"authors\": [\"Sobow T\", \"Flirski M\", \"Liberski P\", \"Kloszewska I\"], \"date\": \"2007-01-01\", \"title\": \"Plasma Abeta levels as predictors of response to rivastigmine treatment in Alzheimer's disease.\", \"lastauthor\": \"Kloszewska I\", \"volume\": \"67\", \"issue\": \"2\", \"pages\": \"131-9\", \"firstauthor\": \"Sobow T\"}, \"line\": 22588, \"annotations\": {\"Species\": \"10116\", \"Subgraph\": \"Amyloidogenic subgraph\"}, \"source\": 7, \"target\": 27, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Rivastigmine treatment induced an elevation in both metabolic activity and APP secretion, and differentially impacted two isoforms of sAPP. In our cultures, low molecular weight sAPP corresponded closely to neuronal viability, and high molecular weight sAPP corresponded with glial proliferation. Our results suggest that within the mixed culture system used, neurons are the primary source of sAPP, and rivastigmine's actions are mediated principally through neuronal, rather than glial, targets. Importantly, rivastigmine was found to increase the neurotrophic sAPP and decrease Abeta secretion, suggesting a mechanism for the previously observed neuropreservation effects.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"PloS one\", \"reference\": \"21799757\", \"authors\": [\"Bailey JA\", \"Ray B\", \"Greig NH\", \"Lahiri DK\"], \"date\": \"2011-01-01\", \"title\": \"Rivastigmine lowers A and increases sAPP levels, which parallel elevated synaptic markers and metabolic activity in degenerating primary rat neurons.\", \"lastauthor\": \"Lahiri DK\", \"volume\": \"6\", \"issue\": \"7\", \"pages\": \"e21954\", \"firstauthor\": \"Bailey JA\"}, \"line\": 22643, \"annotations\": {\"Species\": \"10116\", \"MeSHAnatomy\": \"Brain\", \"Subgraph\": \"Non-amyloidogenic subgraph\"}, \"source\": 7, \"target\": 27, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"AMP-activated protein kinase (AMPK), a master regulator of cellular energy homeostasis and a central player in glucose and lipid metabolism, is potentially implicated in the pathogenesis of Alzheimer's disease (AD). AMPK activity decreases in AD brain, indicating decreased mitochondrial biogenesis and function. Emerging evidence demonstrates that AMPK activation is a potential target for improving perturbed brain energy metabolism that is involved in the pathogenesis of AD. The roles of AMPK in the pathogenesis of AD include Abeta-amyloid protein (Abeta) generation and tau phosphorylation. In particular, AMPK may regulate Abeta generation through modulating neuronal cholesterol and sphingomyelin levels and through regulating APP distribution in the lipid rafts. AMPK is activated by phosphorylation of Thr-172 by LKB1 complex in response to increase in the AMP/ATP ratio and by calmodulin-dependent protein kinase kinase-beta in response to elevated Ca(2+) levels, which contributes to regulating Abeta generation. AMPK is a physiological tau kinase and can increase the phosphorylation of tau at Ser-262. AMPK can also directly phosphorylate tau at Thr-231 and Ser-396/404. Furthermore, AMPK activation decreases mTOR signaling activity to facilitate autophagy and promotes lysosomal degradation of Abeta. However, AMPK activation has non-neuroprotective property and may lead to detrimental outcomes, including Abeta generation and tau phosphorylation. Therefore, it is still unclear whether AMPK could serve a potential therapeutic target for AD, and hence, further studies will be needed to clarify the role of AMPK in AD.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuromolecular medicine\", \"reference\": \"22367557\", \"authors\": [\"Cai Z\", \"Yan LJ\", \"Li K\", \"Quazi SH\", \"Zhao B\"], \"date\": \"2012-03-01\", \"title\": \"Roles of AMP-activated protein kinase in Alzheimer's disease.\", \"lastauthor\": \"Zhao B\", \"volume\": \"14\", \"issue\": \"1\", \"pages\": \"1-14\", \"firstauthor\": \"Cai Z\"}, \"line\": 3135, \"annotations\": {\"Disease\": \"Alzheimer's disease\", \"Subgraph\": \"Cholesterol metabolism subgraph\"}, \"source\": 8, \"target\": 25, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"AMP-activated protein kinase (AMPK), a master regulator of cellular energy homeostasis and a central player in glucose and lipid metabolism, is potentially implicated in the pathogenesis of Alzheimer's disease (AD). AMPK activity decreases in AD brain, indicating decreased mitochondrial biogenesis and function. Emerging evidence demonstrates that AMPK activation is a potential target for improving perturbed brain energy metabolism that is involved in the pathogenesis of AD. The roles of AMPK in the pathogenesis of AD include Abeta-amyloid protein (Abeta) generation and tau phosphorylation. In particular, AMPK may regulate Abeta generation through modulating neuronal cholesterol and sphingomyelin levels and through regulating APP distribution in the lipid rafts. AMPK is activated by phosphorylation of Thr-172 by LKB1 complex in response to increase in the AMP/ATP ratio and by calmodulin-dependent protein kinase kinase-beta in response to elevated Ca(2+) levels, which contributes to regulating Abeta generation. AMPK is a physiological tau kinase and can increase the phosphorylation of tau at Ser-262. AMPK can also directly phosphorylate tau at Thr-231 and Ser-396/404. Furthermore, AMPK activation decreases mTOR signaling activity to facilitate autophagy and promotes lysosomal degradation of Abeta. However, AMPK activation has non-neuroprotective property and may lead to detrimental outcomes, including Abeta generation and tau phosphorylation. Therefore, it is still unclear whether AMPK could serve a potential therapeutic target for AD, and hence, further studies will be needed to clarify the role of AMPK in AD.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuromolecular medicine\", \"reference\": \"22367557\", \"authors\": [\"Cai Z\", \"Yan LJ\", \"Li K\", \"Quazi SH\", \"Zhao B\"], \"date\": \"2012-03-01\", \"title\": \"Roles of AMP-activated protein kinase in Alzheimer's disease.\", \"lastauthor\": \"Zhao B\", \"volume\": \"14\", \"issue\": \"1\", \"pages\": \"1-14\", \"firstauthor\": \"Cai Z\"}, \"line\": 3135, \"annotations\": {\"Disease\": \"Alzheimer's disease\", \"Subgraph\": \"Akt subgraph\"}, \"source\": 8, \"target\": 25, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"AMP-activated protein kinase (AMPK), a master regulator of cellular energy homeostasis and a central player in glucose and lipid metabolism, is potentially implicated in the pathogenesis of Alzheimer's disease (AD). AMPK activity decreases in AD brain, indicating decreased mitochondrial biogenesis and function. Emerging evidence demonstrates that AMPK activation is a potential target for improving perturbed brain energy metabolism that is involved in the pathogenesis of AD. The roles of AMPK in the pathogenesis of AD include Abeta-amyloid protein (Abeta) generation and tau phosphorylation. In particular, AMPK may regulate Abeta generation through modulating neuronal cholesterol and sphingomyelin levels and through regulating APP distribution in the lipid rafts. AMPK is activated by phosphorylation of Thr-172 by LKB1 complex in response to increase in the AMP/ATP ratio and by calmodulin-dependent protein kinase kinase-beta in response to elevated Ca(2+) levels, which contributes to regulating Abeta generation. AMPK is a physiological tau kinase and can increase the phosphorylation of tau at Ser-262. AMPK can also directly phosphorylate tau at Thr-231 and Ser-396/404. Furthermore, AMPK activation decreases mTOR signaling activity to facilitate autophagy and promotes lysosomal degradation of Abeta. However, AMPK activation has non-neuroprotective property and may lead to detrimental outcomes, including Abeta generation and tau phosphorylation. Therefore, it is still unclear whether AMPK could serve a potential therapeutic target for AD, and hence, further studies will be needed to clarify the role of AMPK in AD.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuromolecular medicine\", \"reference\": \"22367557\", \"authors\": [\"Cai Z\", \"Yan LJ\", \"Li K\", \"Quazi SH\", \"Zhao B\"], \"date\": \"2012-03-01\", \"title\": \"Roles of AMP-activated protein kinase in Alzheimer's disease.\", \"lastauthor\": \"Zhao B\", \"volume\": \"14\", \"issue\": \"1\", \"pages\": \"1-14\", \"firstauthor\": \"Cai Z\"}, \"line\": 3135, \"annotations\": {\"Disease\": \"Alzheimer's disease\", \"Subgraph\": \"Sphingolipid metabolic subgraph\"}, \"source\": 8, \"target\": 25, \"key\": 2}, {\"relation\": \"increases\", \"evidence\": \"AMP-activated protein kinase (AMPK), a master regulator of cellular energy homeostasis and a central player in glucose and lipid metabolism, is potentially implicated in the pathogenesis of Alzheimer's disease (AD). AMPK activity decreases in AD brain, indicating decreased mitochondrial biogenesis and function. Emerging evidence demonstrates that AMPK activation is a potential target for improving perturbed brain energy metabolism that is involved in the pathogenesis of AD. The roles of AMPK in the pathogenesis of AD include Abeta-amyloid protein (Abeta) generation and tau phosphorylation. In particular, AMPK may regulate Abeta generation through modulating neuronal cholesterol and sphingomyelin levels and through regulating APP distribution in the lipid rafts. AMPK is activated by phosphorylation of Thr-172 by LKB1 complex in response to increase in the AMP/ATP ratio and by calmodulin-dependent protein kinase kinase-beta in response to elevated Ca(2+) levels, which contributes to regulating Abeta generation. AMPK is a physiological tau kinase and can increase the phosphorylation of tau at Ser-262. AMPK can also directly phosphorylate tau at Thr-231 and Ser-396/404. Furthermore, AMPK activation decreases mTOR signaling activity to facilitate autophagy and promotes lysosomal degradation of Abeta. However, AMPK activation has non-neuroprotective property and may lead to detrimental outcomes, including Abeta generation and tau phosphorylation. Therefore, it is still unclear whether AMPK could serve a potential therapeutic target for AD, and hence, further studies will be needed to clarify the role of AMPK in AD.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuromolecular medicine\", \"reference\": \"22367557\", \"authors\": [\"Cai Z\", \"Yan LJ\", \"Li K\", \"Quazi SH\", \"Zhao B\"], \"date\": \"2012-03-01\", \"title\": \"Roles of AMP-activated protein kinase in Alzheimer's disease.\", \"lastauthor\": \"Zhao B\", \"volume\": \"14\", \"issue\": \"1\", \"pages\": \"1-14\", \"firstauthor\": \"Cai Z\"}, \"line\": 3137, \"annotations\": {\"Disease\": \"Alzheimer's disease\", \"Subgraph\": \"Cholesterol metabolism subgraph\"}, \"source\": 10, \"target\": 25, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"AMP-activated protein kinase (AMPK), a master regulator of cellular energy homeostasis and a central player in glucose and lipid metabolism, is potentially implicated in the pathogenesis of Alzheimer's disease (AD). AMPK activity decreases in AD brain, indicating decreased mitochondrial biogenesis and function. Emerging evidence demonstrates that AMPK activation is a potential target for improving perturbed brain energy metabolism that is involved in the pathogenesis of AD. The roles of AMPK in the pathogenesis of AD include Abeta-amyloid protein (Abeta) generation and tau phosphorylation. In particular, AMPK may regulate Abeta generation through modulating neuronal cholesterol and sphingomyelin levels and through regulating APP distribution in the lipid rafts. AMPK is activated by phosphorylation of Thr-172 by LKB1 complex in response to increase in the AMP/ATP ratio and by calmodulin-dependent protein kinase kinase-beta in response to elevated Ca(2+) levels, which contributes to regulating Abeta generation. AMPK is a physiological tau kinase and can increase the phosphorylation of tau at Ser-262. AMPK can also directly phosphorylate tau at Thr-231 and Ser-396/404. Furthermore, AMPK activation decreases mTOR signaling activity to facilitate autophagy and promotes lysosomal degradation of Abeta. However, AMPK activation has non-neuroprotective property and may lead to detrimental outcomes, including Abeta generation and tau phosphorylation. Therefore, it is still unclear whether AMPK could serve a potential therapeutic target for AD, and hence, further studies will be needed to clarify the role of AMPK in AD.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuromolecular medicine\", \"reference\": \"22367557\", \"authors\": [\"Cai Z\", \"Yan LJ\", \"Li K\", \"Quazi SH\", \"Zhao B\"], \"date\": \"2012-03-01\", \"title\": \"Roles of AMP-activated protein kinase in Alzheimer's disease.\", \"lastauthor\": \"Zhao B\", \"volume\": \"14\", \"issue\": \"1\", \"pages\": \"1-14\", \"firstauthor\": \"Cai Z\"}, \"line\": 3137, \"annotations\": {\"Disease\": \"Alzheimer's disease\", \"Subgraph\": \"Akt subgraph\"}, \"source\": 10, \"target\": 25, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"AMP-activated protein kinase (AMPK), a master regulator of cellular energy homeostasis and a central player in glucose and lipid metabolism, is potentially implicated in the pathogenesis of Alzheimer's disease (AD). AMPK activity decreases in AD brain, indicating decreased mitochondrial biogenesis and function. Emerging evidence demonstrates that AMPK activation is a potential target for improving perturbed brain energy metabolism that is involved in the pathogenesis of AD. The roles of AMPK in the pathogenesis of AD include Abeta-amyloid protein (Abeta) generation and tau phosphorylation. In particular, AMPK may regulate Abeta generation through modulating neuronal cholesterol and sphingomyelin levels and through regulating APP distribution in the lipid rafts. AMPK is activated by phosphorylation of Thr-172 by LKB1 complex in response to increase in the AMP/ATP ratio and by calmodulin-dependent protein kinase kinase-beta in response to elevated Ca(2+) levels, which contributes to regulating Abeta generation. AMPK is a physiological tau kinase and can increase the phosphorylation of tau at Ser-262. AMPK can also directly phosphorylate tau at Thr-231 and Ser-396/404. Furthermore, AMPK activation decreases mTOR signaling activity to facilitate autophagy and promotes lysosomal degradation of Abeta. However, AMPK activation has non-neuroprotective property and may lead to detrimental outcomes, including Abeta generation and tau phosphorylation. Therefore, it is still unclear whether AMPK could serve a potential therapeutic target for AD, and hence, further studies will be needed to clarify the role of AMPK in AD.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuromolecular medicine\", \"reference\": \"22367557\", \"authors\": [\"Cai Z\", \"Yan LJ\", \"Li K\", \"Quazi SH\", \"Zhao B\"], \"date\": \"2012-03-01\", \"title\": \"Roles of AMP-activated protein kinase in Alzheimer's disease.\", \"lastauthor\": \"Zhao B\", \"volume\": \"14\", \"issue\": \"1\", \"pages\": \"1-14\", \"firstauthor\": \"Cai Z\"}, \"line\": 3137, \"annotations\": {\"Disease\": \"Alzheimer's disease\", \"Subgraph\": \"Sphingolipid metabolic subgraph\"}, \"source\": 10, \"target\": 25, \"key\": 2}, {\"relation\": \"increases\", \"evidence\": \"AMP-activated protein kinase (AMPK), a master regulator of cellular energy homeostasis and a central player in glucose and lipid metabolism, is potentially implicated in the pathogenesis of Alzheimer's disease (AD). AMPK activity decreases in AD brain, indicating decreased mitochondrial biogenesis and function. Emerging evidence demonstrates that AMPK activation is a potential target for improving perturbed brain energy metabolism that is involved in the pathogenesis of AD. The roles of AMPK in the pathogenesis of AD include Abeta-amyloid protein (Abeta) generation and tau phosphorylation. In particular, AMPK may regulate Abeta generation through modulating neuronal cholesterol and sphingomyelin levels and through regulating APP distribution in the lipid rafts. AMPK is activated by phosphorylation of Thr-172 by LKB1 complex in response to increase in the AMP/ATP ratio and by calmodulin-dependent protein kinase kinase-beta in response to elevated Ca(2+) levels, which contributes to regulating Abeta generation. AMPK is a physiological tau kinase and can increase the phosphorylation of tau at Ser-262. AMPK can also directly phosphorylate tau at Thr-231 and Ser-396/404. Furthermore, AMPK activation decreases mTOR signaling activity to facilitate autophagy and promotes lysosomal degradation of Abeta. However, AMPK activation has non-neuroprotective property and may lead to detrimental outcomes, including Abeta generation and tau phosphorylation. Therefore, it is still unclear whether AMPK could serve a potential therapeutic target for AD, and hence, further studies will be needed to clarify the role of AMPK in AD.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuromolecular medicine\", \"reference\": \"22367557\", \"authors\": [\"Cai Z\", \"Yan LJ\", \"Li K\", \"Quazi SH\", \"Zhao B\"], \"date\": \"2012-03-01\", \"title\": \"Roles of AMP-activated protein kinase in Alzheimer's disease.\", \"lastauthor\": \"Zhao B\", \"volume\": \"14\", \"issue\": \"1\", \"pages\": \"1-14\", \"firstauthor\": \"Cai Z\"}, \"line\": 3139, \"annotations\": {\"Disease\": \"Alzheimer's disease\", \"Subgraph\": \"Cholesterol metabolism subgraph\"}, \"source\": 11, \"target\": 25, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"AMP-activated protein kinase (AMPK), a master regulator of cellular energy homeostasis and a central player in glucose and lipid metabolism, is potentially implicated in the pathogenesis of Alzheimer's disease (AD). AMPK activity decreases in AD brain, indicating decreased mitochondrial biogenesis and function. Emerging evidence demonstrates that AMPK activation is a potential target for improving perturbed brain energy metabolism that is involved in the pathogenesis of AD. The roles of AMPK in the pathogenesis of AD include Abeta-amyloid protein (Abeta) generation and tau phosphorylation. In particular, AMPK may regulate Abeta generation through modulating neuronal cholesterol and sphingomyelin levels and through regulating APP distribution in the lipid rafts. AMPK is activated by phosphorylation of Thr-172 by LKB1 complex in response to increase in the AMP/ATP ratio and by calmodulin-dependent protein kinase kinase-beta in response to elevated Ca(2+) levels, which contributes to regulating Abeta generation. AMPK is a physiological tau kinase and can increase the phosphorylation of tau at Ser-262. AMPK can also directly phosphorylate tau at Thr-231 and Ser-396/404. Furthermore, AMPK activation decreases mTOR signaling activity to facilitate autophagy and promotes lysosomal degradation of Abeta. However, AMPK activation has non-neuroprotective property and may lead to detrimental outcomes, including Abeta generation and tau phosphorylation. Therefore, it is still unclear whether AMPK could serve a potential therapeutic target for AD, and hence, further studies will be needed to clarify the role of AMPK in AD.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuromolecular medicine\", \"reference\": \"22367557\", \"authors\": [\"Cai Z\", \"Yan LJ\", \"Li K\", \"Quazi SH\", \"Zhao B\"], \"date\": \"2012-03-01\", \"title\": \"Roles of AMP-activated protein kinase in Alzheimer's disease.\", \"lastauthor\": \"Zhao B\", \"volume\": \"14\", \"issue\": \"1\", \"pages\": \"1-14\", \"firstauthor\": \"Cai Z\"}, \"line\": 3139, \"annotations\": {\"Disease\": \"Alzheimer's disease\", \"Subgraph\": \"Akt subgraph\"}, \"source\": 11, \"target\": 25, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"AMP-activated protein kinase (AMPK), a master regulator of cellular energy homeostasis and a central player in glucose and lipid metabolism, is potentially implicated in the pathogenesis of Alzheimer's disease (AD). AMPK activity decreases in AD brain, indicating decreased mitochondrial biogenesis and function. Emerging evidence demonstrates that AMPK activation is a potential target for improving perturbed brain energy metabolism that is involved in the pathogenesis of AD. The roles of AMPK in the pathogenesis of AD include Abeta-amyloid protein (Abeta) generation and tau phosphorylation. In particular, AMPK may regulate Abeta generation through modulating neuronal cholesterol and sphingomyelin levels and through regulating APP distribution in the lipid rafts. AMPK is activated by phosphorylation of Thr-172 by LKB1 complex in response to increase in the AMP/ATP ratio and by calmodulin-dependent protein kinase kinase-beta in response to elevated Ca(2+) levels, which contributes to regulating Abeta generation. AMPK is a physiological tau kinase and can increase the phosphorylation of tau at Ser-262. AMPK can also directly phosphorylate tau at Thr-231 and Ser-396/404. Furthermore, AMPK activation decreases mTOR signaling activity to facilitate autophagy and promotes lysosomal degradation of Abeta. However, AMPK activation has non-neuroprotective property and may lead to detrimental outcomes, including Abeta generation and tau phosphorylation. Therefore, it is still unclear whether AMPK could serve a potential therapeutic target for AD, and hence, further studies will be needed to clarify the role of AMPK in AD.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuromolecular medicine\", \"reference\": \"22367557\", \"authors\": [\"Cai Z\", \"Yan LJ\", \"Li K\", \"Quazi SH\", \"Zhao B\"], \"date\": \"2012-03-01\", \"title\": \"Roles of AMP-activated protein kinase in Alzheimer's disease.\", \"lastauthor\": \"Zhao B\", \"volume\": \"14\", \"issue\": \"1\", \"pages\": \"1-14\", \"firstauthor\": \"Cai Z\"}, \"line\": 3139, \"annotations\": {\"Disease\": \"Alzheimer's disease\", \"Subgraph\": \"Sphingolipid metabolic subgraph\"}, \"source\": 11, \"target\": 25, \"key\": 2}, {\"relation\": \"decreases\", \"evidence\": \"[Estradiol co-treated with Tetrachlorodibenzodioxin] results in decreased expression of S100A9 mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Molecular reproduction and development\", \"reference\": \"19484750\", \"authors\": [\"Deroo BJ\", \"Hewitt SC\", \"Collins JB\", \"Grissom SF\", \"Hamilton KJ\", \"Korach KS\"], \"date\": \"2009-08-01\", \"title\": \"Profile of estrogen-responsive genes in an estrogen-specific mammary gland outgrowth model.\", \"lastauthor\": \"Korach KS\", \"volume\": \"76\", \"issue\": \"8\", \"pages\": \"733-50\", \"firstauthor\": \"Deroo BJ\"}, \"line\": 41867, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 14, \"target\": 15, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Estradiol results in increased expression of PPARG protein\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Toxicology in vitro : an international journal published in association with BIBRA\", \"reference\": \"15964169\", \"authors\": [\"Ibabe A\", \"Herrero A\", \"Cajaraville MP\"], \"date\": \"2005-09-01\", \"title\": \"Modulation of peroxisome proliferator-activated receptors (PPARs) by PPAR(alpha)- and PPAR(gamma)-specific ligands and by 17beta-estradiol in isolated zebrafish hepatocytes.\", \"lastauthor\": \"Cajaraville MP\", \"volume\": \"19\", \"issue\": \"6\", \"pages\": \"725-35\", \"firstauthor\": \"Ibabe A\"}, \"line\": 42336, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 14, \"target\": 16, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased expression of TFF1 mRNA]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Human reproduction (Oxford, England)\", \"reference\": \"11331657\", \"authors\": [\"Leffers H\", \"Naesby M\", \"Vendelbo B\", \"Skakkebaek NE\", \"Jrgensen M\"], \"date\": \"2001-05-01\", \"title\": \"Oestrogenic potencies of Zeranol, oestradiol, diethylstilboestrol, Bisphenol-A and genistein: implications for exposure assessment of potential endocrine disrupters.\", \"lastauthor\": \"Jrgensen M\", \"volume\": \"16\", \"issue\": \"5\", \"pages\": \"1037-45\", \"firstauthor\": \"Leffers H\"}, \"line\": 46189, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 14, \"target\": 17, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"[Estradiol binds to ESR2 protein] which results in increased expression of TIMP3 mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Carcinogenesis\", \"reference\": \"16474171\", \"authors\": [\"Buterin T\", \"Koch C\", \"Naegeli H\"], \"date\": \"2006-08-01\", \"title\": \"Convergent transcriptional profiles induced by endogenous estrogen and distinct xenoestrogens in breast cancer cells.\", \"lastauthor\": \"Naegeli H\", \"volume\": \"27\", \"issue\": \"8\", \"pages\": \"1567-78\", \"firstauthor\": \"Buterin T\"}, \"line\": 48192, \"annotations\": {\"Species\": \"9606\"}, \"source\": 14, \"target\": 28, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"In CAA, and probably in AD, corticosteroid treatment suppresses the secondarily induced vascular inflammation (Chang et al., 2012, Kloppenborg et al., 2010 and Machida et al., 2012) and the activation of S100A9/Mrp14 (Gebhardt et al., 2002 and Kametani and Ikeda, 2013). Recently, it has been reported that anti-Abeta autoantibodies were progressively reduced in the cerebrospinal fluid of a patient with CAA-related inflammation, following intravenous steroid administration (Piazza et al., 2013). Reduction of S100A9/Mrp14 might induce suppression of amyloid fibril formation (Zhang et al., 2012) and increase phagocytosis of fibrillar Abeta in microglia cells (Kummer et al., 2012), resulting in reduced Abeta amyloid fibril deposition.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neurobiology of aging\", \"reference\": \"24262203\", \"authors\": [\"Kametani F\"], \"date\": \"2014-04-01\", \"title\": \"Corticosteroid treatment of Alzheimer's disease: is S100A9/Mrp14 a key target?\", \"lastauthor\": \"Kametani F\", \"volume\": \"35\", \"issue\": \"4\", \"pages\": \"e11-2\", \"firstauthor\": \"Kametani F\"}, \"line\": 41785, \"annotations\": {\"Subgraph\": \"Inflammatory response subgraph\"}, \"source\": 15, \"target\": 25, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"In CAA, and probably in AD, corticosteroid treatment suppresses the secondarily induced vascular inflammation (Chang et al., 2012, Kloppenborg et al., 2010 and Machida et al., 2012) and the activation of S100A9/Mrp14 (Gebhardt et al., 2002 and Kametani and Ikeda, 2013). Recently, it has been reported that anti-Abeta autoantibodies were progressively reduced in the cerebrospinal fluid of a patient with CAA-related inflammation, following intravenous steroid administration (Piazza et al., 2013). Reduction of S100A9/Mrp14 might induce suppression of amyloid fibril formation (Zhang et al., 2012) and increase phagocytosis of fibrillar Abeta in microglia cells (Kummer et al., 2012), resulting in reduced Abeta amyloid fibril deposition.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neurobiology of aging\", \"reference\": \"24262203\", \"authors\": [\"Kametani F\"], \"date\": \"2014-04-01\", \"title\": \"Corticosteroid treatment of Alzheimer's disease: is S100A9/Mrp14 a key target?\", \"lastauthor\": \"Kametani F\", \"volume\": \"35\", \"issue\": \"4\", \"pages\": \"e11-2\", \"firstauthor\": \"Kametani F\"}, \"line\": 41785, \"annotations\": {\"Subgraph\": \"Metabolism of steroid hormones subgraph\"}, \"source\": 15, \"target\": 25, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"Pro-inflammatory S100A9 protein is increasingly recognized as an important contributor to inflammation-related neurodegeneration. Here, we provide insights into S100A9 specific mechanisms of action in Alzheimer's disease (AD). Due to its inherent amyloidogenicity S100A9 contributes to amyloid plaque formation together with Abeta.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Acta neuropathologica\", \"reference\": \"24240735\", \"authors\": [\"Wang C\", \"Klechikov AG\", \"Gharibyan AL\", \"Wrmlnder SK\", \"Jarvet J\", \"Zhao L\", \"Jia X\", \"Narayana VK\", \"Shankar SK\", \"Olofsson A\", \"Brnnstrm T\", \"Mu Y\", \"Grslund A\", \"Morozova-Roche LA\"], \"date\": \"2014-04-01\", \"title\": \"The role of pro-inflammatory S100A9 in Alzheimer's disease amyloid-neuroinflammatory cascade.\", \"lastauthor\": \"Morozova-Roche LA\", \"volume\": \"127\", \"issue\": \"4\", \"pages\": \"507-22\", \"firstauthor\": \"Wang C\"}, \"line\": 41809, \"annotations\": {\"Subgraph\": \"Toll like receptor subgraph\"}, \"source\": 15, \"target\": 25, \"key\": 2}, {\"relation\": \"increases\", \"evidence\": \"Pro-inflammatory S100A9 protein is increasingly recognized as an important contributor to inflammation-related neurodegeneration. Here, we provide insights into S100A9 specific mechanisms of action in Alzheimer's disease (AD). Due to its inherent amyloidogenicity S100A9 contributes to amyloid plaque formation together with Abeta.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Acta neuropathologica\", \"reference\": \"24240735\", \"authors\": [\"Wang C\", \"Klechikov AG\", \"Gharibyan AL\", \"Wrmlnder SK\", \"Jarvet J\", \"Zhao L\", \"Jia X\", \"Narayana VK\", \"Shankar SK\", \"Olofsson A\", \"Brnnstrm T\", \"Mu Y\", \"Grslund A\", \"Morozova-Roche LA\"], \"date\": \"2014-04-01\", \"title\": \"The role of pro-inflammatory S100A9 in Alzheimer's disease amyloid-neuroinflammatory cascade.\", \"lastauthor\": \"Morozova-Roche LA\", \"volume\": \"127\", \"issue\": \"4\", \"pages\": \"507-22\", \"firstauthor\": \"Wang C\"}, \"line\": 41809, \"annotations\": {\"Subgraph\": \"Amyloidogenic subgraph\"}, \"source\": 15, \"target\": 25, \"key\": 3}, {\"relation\": \"increases\", \"evidence\": \"We therefore conclude that Mrp14 promotes APP processing and Abeta accumulation under neuroinflammatory conditions.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"The Journal of neuroscience : the official journal of the Society for Neuroscience\", \"reference\": \"23223301\", \"authors\": [\"Kummer MP\", \"Vogl T\", \"Axt D\", \"Griep A\", \"Vieira-Saecker A\", \"Jessen F\", \"Gelpi E\", \"Roth J\", \"Heneka MT\"], \"date\": \"2012-12-05\", \"title\": \"Mrp14 deficiency ameliorates amyloid  burden by increasing microglial phagocytosis and modulation of amyloid precursor protein processing.\", \"lastauthor\": \"Heneka MT\", \"volume\": \"32\", \"issue\": \"49\", \"pages\": \"17824-9\", \"firstauthor\": \"Kummer MP\"}, \"line\": 41849, \"annotations\": {\"Subgraph\": \"Toll like receptor subgraph\"}, \"source\": 15, \"target\": 25, \"key\": 4}, {\"relation\": \"increases\", \"evidence\": \"We therefore conclude that Mrp14 promotes APP processing and Abeta accumulation under neuroinflammatory conditions.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"The Journal of neuroscience : the official journal of the Society for Neuroscience\", \"reference\": \"23223301\", \"authors\": [\"Kummer MP\", \"Vogl T\", \"Axt D\", \"Griep A\", \"Vieira-Saecker A\", \"Jessen F\", \"Gelpi E\", \"Roth J\", \"Heneka MT\"], \"date\": \"2012-12-05\", \"title\": \"Mrp14 deficiency ameliorates amyloid  burden by increasing microglial phagocytosis and modulation of amyloid precursor protein processing.\", \"lastauthor\": \"Heneka MT\", \"volume\": \"32\", \"issue\": \"49\", \"pages\": \"17824-9\", \"firstauthor\": \"Kummer MP\"}, \"line\": 41849, \"annotations\": {\"Subgraph\": \"Amyloidogenic subgraph\"}, \"source\": 15, \"target\": 25, \"key\": 5}, {\"relation\": \"decreases\", \"evidence\": \"The peroxisome proliferator-activated receptor- (PPAR-) is a ligand-inducible transcription factor that suppresses microglial inflammatory responses and inhibits amyloid beta (Abeta) production through promoting cholesterol efflux from glial cells. PPAR- agonists have been advanced as a new disease altering approach to Alzheimer's disease (AD), with rosiglitazone therapy having improved cognition in those AD patients that did not possess an Apolipoprotein E (APOE) 4 allele\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neurobiology of aging\", \"reference\": \"19660836\", \"authors\": [\"Combarros O\", \"Rodrguez-Rodrguez E\", \"Mateo I\", \"Vzquez-Higuera JL\", \"Infante J\", \"Berciano J\", \"Snchez-Juan P\"], \"date\": \"2011-03-01\", \"title\": \"APOE dependent-association of PPAR- genetic variants with Alzheimer's disease risk.\", \"lastauthor\": \"Snchez-Juan P\", \"volume\": \"32\", \"issue\": \"3\", \"pages\": \"547.e1-6\", \"firstauthor\": \"Combarros O\"}, \"line\": 5010, \"annotations\": {\"Disease\": \"Alzheimer's disease\", \"Subgraph\": \"Peroxisome proliferator activated receptor subgraph\"}, \"source\": 16, \"target\": 25, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"The peroxisome proliferator-activated receptor- (PPAR-) is a ligand-inducible transcription factor that suppresses microglial inflammatory responses and inhibits amyloid beta (Abeta) production through promoting cholesterol efflux from glial cells. PPAR- agonists have been advanced as a new disease altering approach to Alzheimer's disease (AD), with rosiglitazone therapy having improved cognition in those AD patients that did not possess an Apolipoprotein E (APOE) 4 allele\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neurobiology of aging\", \"reference\": \"19660836\", \"authors\": [\"Combarros O\", \"Rodrguez-Rodrguez E\", \"Mateo I\", \"Vzquez-Higuera JL\", \"Infante J\", \"Berciano J\", \"Snchez-Juan P\"], \"date\": \"2011-03-01\", \"title\": \"APOE dependent-association of PPAR- genetic variants with Alzheimer's disease risk.\", \"lastauthor\": \"Snchez-Juan P\", \"volume\": \"32\", \"issue\": \"3\", \"pages\": \"547.e1-6\", \"firstauthor\": \"Combarros O\"}, \"line\": 5010, \"annotations\": {\"Disease\": \"Alzheimer's disease\", \"Subgraph\": \"Non-amyloidogenic subgraph\"}, \"source\": 16, \"target\": 25, \"key\": 1}, {\"relation\": \"decreases\", \"evidence\": \"PPARgamma activity decreases Abeta production by promoting harmless catabolism of amyloid precursor protein while blocking the up-regulatory impact of cytokines on beta-secretase expression.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Medical hypotheses\", \"reference\": \"16828233\", \"authors\": [\"McCarty MF\"], \"date\": \"2006-01-01\", \"title\": \"Toward prevention of Alzheimers disease--potential nutraceutical strategies for suppressing the production of amyloid beta peptides.\", \"lastauthor\": \"McCarty MF\", \"volume\": \"67\", \"issue\": \"4\", \"pages\": \"682-97\", \"firstauthor\": \"McCarty MF\"}, \"line\": 32001, \"annotations\": {\"Subgraph\": \"Peroxisome proliferator activated receptor subgraph\"}, \"source\": 16, \"target\": 25, \"key\": 2}, {\"relation\": \"decreases\", \"evidence\": \"PPARgamma activity decreases Abeta production by promoting harmless catabolism of amyloid precursor protein while blocking the up-regulatory impact of cytokines on beta-secretase expression.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Medical hypotheses\", \"reference\": \"16828233\", \"authors\": [\"McCarty MF\"], \"date\": \"2006-01-01\", \"title\": \"Toward prevention of Alzheimers disease--potential nutraceutical strategies for suppressing the production of amyloid beta peptides.\", \"lastauthor\": \"McCarty MF\", \"volume\": \"67\", \"issue\": \"4\", \"pages\": \"682-97\", \"firstauthor\": \"McCarty MF\"}, \"line\": 32001, \"annotations\": {\"Subgraph\": \"Non-amyloidogenic subgraph\"}, \"source\": 16, \"target\": 25, \"key\": 3}, {\"relation\": \"decreases\", \"evidence\": \"The peroxisome proliferator-activated receptor- (PPAR-) is a ligand-inducible transcription factor that suppresses microglial inflammatory responses and inhibits amyloid beta (Abeta) production through promoting cholesterol efflux from glial cells. PPAR- agonists have been advanced as a new disease altering approach to Alzheimer's disease (AD), with rosiglitazone therapy having improved cognition in those AD patients that did not possess an Apolipoprotein E (APOE) 4 allele\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neurobiology of aging\", \"reference\": \"19660836\", \"authors\": [\"Combarros O\", \"Rodrguez-Rodrguez E\", \"Mateo I\", \"Vzquez-Higuera JL\", \"Infante J\", \"Berciano J\", \"Snchez-Juan P\"], \"date\": \"2011-03-01\", \"title\": \"APOE dependent-association of PPAR- genetic variants with Alzheimer's disease risk.\", \"lastauthor\": \"Snchez-Juan P\", \"volume\": \"32\", \"issue\": \"3\", \"pages\": \"547.e1-6\", \"firstauthor\": \"Combarros O\"}, \"line\": 42010, \"annotations\": {\"Subgraph\": \"Peroxisome proliferator activated receptor subgraph\"}, \"source\": 16, \"target\": 25, \"key\": 4}, {\"relation\": \"decreases\", \"evidence\": \"The peroxisome proliferator-activated receptor- (PPAR-) is a ligand-inducible transcription factor that suppresses microglial inflammatory responses and inhibits amyloid beta (Abeta) production through promoting cholesterol efflux from glial cells. PPAR- agonists have been advanced as a new disease altering approach to Alzheimer's disease (AD), with rosiglitazone therapy having improved cognition in those AD patients that did not possess an Apolipoprotein E (APOE) 4 allele\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neurobiology of aging\", \"reference\": \"19660836\", \"authors\": [\"Combarros O\", \"Rodrguez-Rodrguez E\", \"Mateo I\", \"Vzquez-Higuera JL\", \"Infante J\", \"Berciano J\", \"Snchez-Juan P\"], \"date\": \"2011-03-01\", \"title\": \"APOE dependent-association of PPAR- genetic variants with Alzheimer's disease risk.\", \"lastauthor\": \"Snchez-Juan P\", \"volume\": \"32\", \"issue\": \"3\", \"pages\": \"547.e1-6\", \"firstauthor\": \"Combarros O\"}, \"line\": 42010, \"annotations\": {\"Subgraph\": \"Non-amyloidogenic subgraph\"}, \"source\": 16, \"target\": 25, \"key\": 5}, {\"relation\": \"decreases\", \"evidence\": \"PPARgamma activity decreases Abeta production by promoting harmless catabolism of amyloid precursor protein while blocking the up-regulatory impact of cytokines on beta-secretase expression.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Medical hypotheses\", \"reference\": \"16828233\", \"authors\": [\"McCarty MF\"], \"date\": \"2006-01-01\", \"title\": \"Toward prevention of Alzheimers disease--potential nutraceutical strategies for suppressing the production of amyloid beta peptides.\", \"lastauthor\": \"McCarty MF\", \"volume\": \"67\", \"issue\": \"4\", \"pages\": \"682-97\", \"firstauthor\": \"McCarty MF\"}, \"line\": 42229, \"annotations\": {\"Subgraph\": \"Peroxisome proliferator activated receptor subgraph\"}, \"source\": 16, \"target\": 25, \"key\": 6}, {\"relation\": \"decreases\", \"evidence\": \"PPARgamma activity decreases Abeta production by promoting harmless catabolism of amyloid precursor protein while blocking the up-regulatory impact of cytokines on beta-secretase expression.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Medical hypotheses\", \"reference\": \"16828233\", \"authors\": [\"McCarty MF\"], \"date\": \"2006-01-01\", \"title\": \"Toward prevention of Alzheimers disease--potential nutraceutical strategies for suppressing the production of amyloid beta peptides.\", \"lastauthor\": \"McCarty MF\", \"volume\": \"67\", \"issue\": \"4\", \"pages\": \"682-97\", \"firstauthor\": \"McCarty MF\"}, \"line\": 42229, \"annotations\": {\"Subgraph\": \"Non-amyloidogenic subgraph\"}, \"source\": 16, \"target\": 25, \"key\": 7}, {\"relation\": \"decreases\", \"evidence\": \"these findings suggest the existence of a down-regulation of PPAR under inflammatory conditions, which would result in an increase in BACE1 transcription and Abeta generation. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of neuroinflammation\", \"reference\": \"18564425\", \"authors\": [\"Sastre M\", \"Walter J\", \"Gentleman SM\"], \"date\": \"2008-06-18\", \"title\": \"Interactions between APP secretases and inflammatory mediators.\", \"lastauthor\": \"Gentleman SM\", \"volume\": \"5\", \"issue\": \"\", \"pages\": \"25\", \"firstauthor\": \"Sastre M\"}, \"line\": 36761, \"annotations\": {\"Subgraph\": \"Beta secretase subgraph\"}, \"source\": 16, \"target\": 29, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"these findings suggest the existence of a down-regulation of PPAR under inflammatory conditions, which would result in an increase in BACE1 transcription and Abeta generation. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of neuroinflammation\", \"reference\": \"18564425\", \"authors\": [\"Sastre M\", \"Walter J\", \"Gentleman SM\"], \"date\": \"2008-06-18\", \"title\": \"Interactions between APP secretases and inflammatory mediators.\", \"lastauthor\": \"Gentleman SM\", \"volume\": \"5\", \"issue\": \"\", \"pages\": \"25\", \"firstauthor\": \"Sastre M\"}, \"line\": 36761, \"annotations\": {\"Subgraph\": \"Peroxisome proliferator activated receptor subgraph\"}, \"source\": 16, \"target\": 29, \"key\": 1}, {\"relation\": \"decreases\", \"evidence\": \"these findings suggest the existence of a down-regulation of PPAR under inflammatory conditions, which would result in an increase in BACE1 transcription and Abeta generation. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of neuroinflammation\", \"reference\": \"18564425\", \"authors\": [\"Sastre M\", \"Walter J\", \"Gentleman SM\"], \"date\": \"2008-06-18\", \"title\": \"Interactions between APP secretases and inflammatory mediators.\", \"lastauthor\": \"Gentleman SM\", \"volume\": \"5\", \"issue\": \"\", \"pages\": \"25\", \"firstauthor\": \"Sastre M\"}, \"line\": 42320, \"annotations\": {\"Subgraph\": \"Peroxisome proliferator activated receptor subgraph\"}, \"source\": 16, \"target\": 29, \"key\": 2}, {\"relation\": \"decreases\", \"evidence\": \"these findings suggest the existence of a down-regulation of PPAR under inflammatory conditions, which would result in an increase in BACE1 transcription and Abeta generation. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of neuroinflammation\", \"reference\": \"18564425\", \"authors\": [\"Sastre M\", \"Walter J\", \"Gentleman SM\"], \"date\": \"2008-06-18\", \"title\": \"Interactions between APP secretases and inflammatory mediators.\", \"lastauthor\": \"Gentleman SM\", \"volume\": \"5\", \"issue\": \"\", \"pages\": \"25\", \"firstauthor\": \"Sastre M\"}, \"line\": 42320, \"annotations\": {\"Subgraph\": \"Non-amyloidogenic subgraph\"}, \"source\": 16, \"target\": 29, \"key\": 3}, {\"relation\": \"association\", \"evidence\": \"resveratrol inhibits the reaction [ESR2 protein binds to CAV1 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"FASEB journal : official publication of the Federation of American Societies for Experimental Biology\", \"reference\": \"18296501\", \"authors\": [\"Klinge CM\", \"Wickramasinghe NS\", \"Ivanova MM\", \"Dougherty SM\"], \"date\": \"2008-07-01\", \"title\": \"Resveratrol stimulates nitric oxide production by increasing estrogen receptor alpha-Src-caveolin-1 interaction and phosphorylation in human umbilical vein endothelial cells.\", \"lastauthor\": \"Dougherty SM\", \"volume\": \"22\", \"issue\": \"7\", \"pages\": \"2185-97\", \"firstauthor\": \"Klinge CM\"}, \"line\": 49702, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 18, \"target\": 19, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"[Coumestrol co-treated with resveratrol] results in decreased expression of TIMP3 mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association\", \"reference\": \"19167446\", \"authors\": [\"Dip R\", \"Lenz S\", \"Gmuender H\", \"Naegeli H\"], \"date\": \"2009-04-01\", \"title\": \"Pleiotropic combinatorial transcriptomes of human breast cancer cells exposed to mixtures of dietary phytoestrogens.\", \"lastauthor\": \"Naegeli H\", \"volume\": \"47\", \"issue\": \"4\", \"pages\": \"787-95\", \"firstauthor\": \"Dip R\"}, \"line\": 48224, \"annotations\": {}, \"source\": 18, \"target\": 28, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"resveratrol inhibits the reaction [ESR2 protein binds to CAV1 protein]\", \"citation\": {\"type\": \"PubMed\", \"name\": \"FASEB journal : official publication of the Federation of American Societies for Experimental Biology\", \"reference\": \"18296501\", \"authors\": [\"Klinge CM\", \"Wickramasinghe NS\", \"Ivanova MM\", \"Dougherty SM\"], \"date\": \"2008-07-01\", \"title\": \"Resveratrol stimulates nitric oxide production by increasing estrogen receptor alpha-Src-caveolin-1 interaction and phosphorylation in human umbilical vein endothelial cells.\", \"lastauthor\": \"Dougherty SM\", \"volume\": \"22\", \"issue\": \"7\", \"pages\": \"2185-97\", \"firstauthor\": \"Klinge CM\"}, \"line\": 49702, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 19, \"target\": 18, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"24-hydroxycholesterol binds to and results in decreased activity of ESR2 protein\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Nature medicine\", \"reference\": \"17873880\", \"authors\": [\"Umetani M\", \"Domoto H\", \"Gormley AK\", \"Yuhanna IS\", \"Cummins CL\", \"Javitt NB\", \"Korach KS\", \"Shaul PW\", \"Mangelsdorf DJ\"], \"date\": \"2007-10-01\", \"title\": \"27-Hydroxycholesterol is an endogenous SERM that inhibits the cardiovascular effects of estrogen.\", \"lastauthor\": \"Mangelsdorf DJ\", \"volume\": \"13\", \"issue\": \"10\", \"pages\": \"1185-92\", \"firstauthor\": \"Umetani M\"}, \"line\": 49640, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 20, \"target\": 19, \"key\": 0}, {\"relation\": \"hasComponent\", \"annotations\": {}, \"source\": 20, \"target\": 19, \"key\": -3}, {\"relation\": \"hasComponent\", \"annotations\": {}, \"source\": 20, \"target\": 22, \"key\": -3}, {\"relation\": \"increases\", \"evidence\": \"Activation;Binding;Medroxyprogesterone acetate intracellular binds to and activates ESR2 .\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of medicinal chemistry\", \"reference\": \"9464360\", \"authors\": [\"Zhi L\", \"Tegley CM\", \"Kallel EA\", \"Marschke KB\", \"Mais DE\", \"Gottardis MM\", \"Jones TK\"], \"date\": \"1998-01-29\", \"title\": \"5-Aryl-1,2-dihydrochromeno[3,4-f]quinolines: a novel class of nonsteroidal human progesterone receptor agonists.\", \"lastauthor\": \"Jones TK\", \"volume\": \"41\", \"issue\": \"3\", \"pages\": \"291-302\", \"firstauthor\": \"Zhi L\"}, \"line\": 49712, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"Estrogen subgraph\"}, \"source\": 21, \"target\": 19, \"key\": 0}, {\"relation\": \"hasComponent\", \"annotations\": {}, \"source\": 21, \"target\": 19, \"key\": -3}, {\"relation\": \"hasComponent\", \"annotations\": {}, \"source\": 21, \"target\": 23, \"key\": -3}, {\"relation\": \"decreases\", \"evidence\": \"Medroxyprogesterone Acetate results in decreased expression of TIMP3 mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"The Journal of clinical endocrinology and metabolism\", \"reference\": \"20843944\", \"authors\": [\"Cordeaux Y\", \"Tattersall M\", \"Charnock-Jones DS\", \"Smith GC\"], \"date\": \"2010-12-01\", \"title\": \"Effects of medroxyprogesterone acetate on gene expression in myometrial explants from pregnant women.\", \"lastauthor\": \"Smith GC\", \"volume\": \"95\", \"issue\": \"12\", \"pages\": \"E437-47\", \"firstauthor\": \"Cordeaux Y\"}, \"line\": 48214, \"annotations\": {\"Species\": \"9606\"}, \"source\": 23, \"target\": 28, \"key\": 0}, {\"relation\": \"hasVariant\", \"annotations\": {}, \"source\": 24, \"target\": 8, \"key\": -4}, {\"relation\": \"hasVariant\", \"annotations\": {}, \"source\": 24, \"target\": 9, \"key\": -4}, {\"relation\": \"hasVariant\", \"annotations\": {}, \"source\": 24, \"target\": 10, \"key\": -4}, {\"relation\": \"hasVariant\", \"annotations\": {}, \"source\": 24, \"target\": 11, \"key\": -4}, {\"relation\": \"hasVariant\", \"annotations\": {}, \"source\": 24, \"target\": 12, \"key\": -4}, {\"relation\": \"hasVariant\", \"annotations\": {}, \"source\": 24, \"target\": 13, \"key\": -4}, {\"relation\": \"association\", \"evidence\": \"Compared to vehicle, Abeta increased GSK3 activity, and was associated with elevations in levels of ptau, caspase-3, the tau kinase phospho-c-jun N-terminal kinase (pJNK), neuronal DNA fragmentation, and gliosis.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neurobiology of disease\", \"reference\": \"19038340\", \"authors\": [\"Hu S\", \"Begum AN\", \"Jones MR\", \"Oh MS\", \"Beech WK\", \"Beech BH\", \"Yang F\", \"Chen P\", \"Ubeda OJ\", \"Kim PC\", \"Davies P\", \"Ma Q\", \"Cole GM\", \"Frautschy SA\"], \"date\": \"2009-02-01\", \"title\": \"GSK3 inhibitors show benefits in an Alzheimer's disease (AD) model of neurodegeneration but adverse effects in control animals.\", \"lastauthor\": \"Frautschy SA\", \"volume\": \"33\", \"issue\": \"2\", \"pages\": \"193-206\", \"firstauthor\": \"Hu S\"}, \"line\": 31860, \"annotations\": {\"Subgraph\": \"Tau protein subgraph\"}, \"source\": 24, \"target\": 25, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Compared to vehicle, Abeta increased GSK3 activity, and was associated with elevations in levels of ptau, caspase-3, the tau kinase phospho-c-jun N-terminal kinase (pJNK), neuronal DNA fragmentation, and gliosis.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neurobiology of disease\", \"reference\": \"19038340\", \"authors\": [\"Hu S\", \"Begum AN\", \"Jones MR\", \"Oh MS\", \"Beech WK\", \"Beech BH\", \"Yang F\", \"Chen P\", \"Ubeda OJ\", \"Kim PC\", \"Davies P\", \"Ma Q\", \"Cole GM\", \"Frautschy SA\"], \"date\": \"2009-02-01\", \"title\": \"GSK3 inhibitors show benefits in an Alzheimer's disease (AD) model of neurodegeneration but adverse effects in control animals.\", \"lastauthor\": \"Frautschy SA\", \"volume\": \"33\", \"issue\": \"2\", \"pages\": \"193-206\", \"firstauthor\": \"Hu S\"}, \"line\": 31860, \"annotations\": {\"Subgraph\": \"Amyloidogenic subgraph\"}, \"source\": 24, \"target\": 25, \"key\": 1}, {\"relation\": \"hasVariant\", \"annotations\": {}, \"source\": 24, \"target\": 30, \"key\": -4}, {\"relation\": \"increases\", \"evidence\": \"Abeta-Amyloid (Abeta) plaques in Alzheimer (AD) brains are surrounded by severe dendritic and axonal changes, including local spine loss, axonal swellings and distorted neurite trajectories. Whether and how plaques induce these neuropil abnormalities remains unknown. We tested the hypothesis that oligomeric assemblies of Abeta, seen in the periphery of plaques, mediate the neurodegenerative phenotype of AD by triggering activation of the enzyme GSK-3Abeta, which in turn appears to inhibit a transcriptional program mediated by CREB. We detect increased activity of GSK-3Abeta after exposure to oligomeric Abeta in neurons in culture, in the brain of double transgenic APP/tau mice and in AD brains. Activation of GSK-3Abeta, even in the absence of Abeta, is sufficient to produce a phenocopy of Abeta-induced dendritic spine loss in neurons in culture, while pharmacological inhibition of GSK-3Abeta prevents spine loss and increases expression of CREB-target genes like BDNF. Of note, in transgenic mice GSK-3Abeta inhibition ameliorated plaque-related neuritic changes and increased CREB-mediated gene expression. Moreover, GSK-3Abeta inhibition robustly decreased the oligomeric Abeta load in the mouse brain. All these findings support the idea that GSK3Abeta is aberrantly activated by the presence of Abeta, and contributes, at least in part, to the neuronal anatomical derangement associated with Abeta plaques in AD brains and to Abeta pathology itself.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neurobiology of disease\", \"reference\": \"21945540\", \"authors\": [\"DaRocha-Souto B\", \"Coma M\", \"Prez-Nievas BG\", \"Scotton TC\", \"Siao M\", \"Snchez-Ferrer P\", \"Hashimoto T\", \"Fan Z\", \"Hudry E\", \"Barroeta I\", \"Seren L\", \"Rodrguez M\", \"Snchez MB\", \"Hyman BT\", \"Gmez-Isla T\"], \"date\": \"2012-01-01\", \"title\": \"Activation of glycogen synthase kinase-3 beta mediates -amyloid induced neuritic damage in Alzheimer's disease.\", \"lastauthor\": \"Gmez-Isla T\", \"volume\": \"45\", \"issue\": \"1\", \"pages\": \"425-37\", \"firstauthor\": \"DaRocha-Souto B\"}, \"line\": 2742, \"object\": {\"modifier\": \"Activity\", \"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}}, \"annotations\": {\"Disease\": \"Alzheimer's disease\", \"Subgraph\": \"GSK3 subgraph\"}, \"source\": 25, \"target\": 2, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Abeta-Amyloid (Abeta) plaques in Alzheimer (AD) brains are surrounded by severe dendritic and axonal changes, including local spine loss, axonal swellings and distorted neurite trajectories. Whether and how plaques induce these neuropil abnormalities remains unknown. We tested the hypothesis that oligomeric assemblies of Abeta, seen in the periphery of plaques, mediate the neurodegenerative phenotype of AD by triggering activation of the enzyme GSK-3Abeta, which in turn appears to inhibit a transcriptional program mediated by CREB. We detect increased activity of GSK-3Abeta after exposure to oligomeric Abeta in neurons in culture, in the brain of double transgenic APP/tau mice and in AD brains. Activation of GSK-3Abeta, even in the absence of Abeta, is sufficient to produce a phenocopy of Abeta-induced dendritic spine loss in neurons in culture, while pharmacological inhibition of GSK-3Abeta prevents spine loss and increases expression of CREB-target genes like BDNF. Of note, in transgenic mice GSK-3Abeta inhibition ameliorated plaque-related neuritic changes and increased CREB-mediated gene expression. Moreover, GSK-3Abeta inhibition robustly decreased the oligomeric Abeta load in the mouse brain. All these findings support the idea that GSK3Abeta is aberrantly activated by the presence of Abeta, and contributes, at least in part, to the neuronal anatomical derangement associated with Abeta plaques in AD brains and to Abeta pathology itself.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neurobiology of disease\", \"reference\": \"21945540\", \"authors\": [\"DaRocha-Souto B\", \"Coma M\", \"Prez-Nievas BG\", \"Scotton TC\", \"Siao M\", \"Snchez-Ferrer P\", \"Hashimoto T\", \"Fan Z\", \"Hudry E\", \"Barroeta I\", \"Seren L\", \"Rodrguez M\", \"Snchez MB\", \"Hyman BT\", \"Gmez-Isla T\"], \"date\": \"2012-01-01\", \"title\": \"Activation of glycogen synthase kinase-3 beta mediates -amyloid induced neuritic damage in Alzheimer's disease.\", \"lastauthor\": \"Gmez-Isla T\", \"volume\": \"45\", \"issue\": \"1\", \"pages\": \"425-37\", \"firstauthor\": \"DaRocha-Souto B\"}, \"line\": 2742, \"object\": {\"modifier\": \"Activity\", \"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}}, \"annotations\": {\"Disease\": \"Alzheimer's disease\", \"Subgraph\": \"Amyloidogenic subgraph\"}, \"source\": 25, \"target\": 2, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"Abeta-Amyloid (Abeta) plaques in Alzheimer (AD) brains are surrounded by severe dendritic and axonal changes, including local spine loss, axonal swellings and distorted neurite trajectories. Whether and how plaques induce these neuropil abnormalities remains unknown. We tested the hypothesis that oligomeric assemblies of Abeta, seen in the periphery of plaques, mediate the neurodegenerative phenotype of AD by triggering activation of the enzyme GSK-3Abeta, which in turn appears to inhibit a transcriptional program mediated by CREB. We detect increased activity of GSK-3Abeta after exposure to oligomeric Abeta in neurons in culture, in the brain of double transgenic APP/tau mice and in AD brains. Activation of GSK-3Abeta, even in the absence of Abeta, is sufficient to produce a phenocopy of Abeta-induced dendritic spine loss in neurons in culture, while pharmacological inhibition of GSK-3Abeta prevents spine loss and increases expression of CREB-target genes like BDNF. Of note, in transgenic mice GSK-3Abeta inhibition ameliorated plaque-related neuritic changes and increased CREB-mediated gene expression. Moreover, GSK-3Abeta inhibition robustly decreased the oligomeric Abeta load in the mouse brain. All these findings support the idea that GSK3Abeta is aberrantly activated by the presence of Abeta, and contributes, at least in part, to the neuronal anatomical derangement associated with Abeta plaques in AD brains and to Abeta pathology itself.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neurobiology of disease\", \"reference\": \"21945540\", \"authors\": [\"DaRocha-Souto B\", \"Coma M\", \"Prez-Nievas BG\", \"Scotton TC\", \"Siao M\", \"Snchez-Ferrer P\", \"Hashimoto T\", \"Fan Z\", \"Hudry E\", \"Barroeta I\", \"Seren L\", \"Rodrguez M\", \"Snchez MB\", \"Hyman BT\", \"Gmez-Isla T\"], \"date\": \"2012-01-01\", \"title\": \"Activation of glycogen synthase kinase-3 beta mediates -amyloid induced neuritic damage in Alzheimer's disease.\", \"lastauthor\": \"Gmez-Isla T\", \"volume\": \"45\", \"issue\": \"1\", \"pages\": \"425-37\", \"firstauthor\": \"DaRocha-Souto B\"}, \"line\": 2745, \"object\": {\"modifier\": \"Activity\", \"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}}, \"annotations\": {\"Disease\": \"Alzheimer's disease\", \"Subgraph\": \"GSK3 subgraph\"}, \"source\": 25, \"target\": 2, \"key\": 2}, {\"relation\": \"increases\", \"evidence\": \"Abeta-Amyloid (Abeta) plaques in Alzheimer (AD) brains are surrounded by severe dendritic and axonal changes, including local spine loss, axonal swellings and distorted neurite trajectories. Whether and how plaques induce these neuropil abnormalities remains unknown. We tested the hypothesis that oligomeric assemblies of Abeta, seen in the periphery of plaques, mediate the neurodegenerative phenotype of AD by triggering activation of the enzyme GSK-3Abeta, which in turn appears to inhibit a transcriptional program mediated by CREB. We detect increased activity of GSK-3Abeta after exposure to oligomeric Abeta in neurons in culture, in the brain of double transgenic APP/tau mice and in AD brains. Activation of GSK-3Abeta, even in the absence of Abeta, is sufficient to produce a phenocopy of Abeta-induced dendritic spine loss in neurons in culture, while pharmacological inhibition of GSK-3Abeta prevents spine loss and increases expression of CREB-target genes like BDNF. Of note, in transgenic mice GSK-3Abeta inhibition ameliorated plaque-related neuritic changes and increased CREB-mediated gene expression. Moreover, GSK-3Abeta inhibition robustly decreased the oligomeric Abeta load in the mouse brain. All these findings support the idea that GSK3Abeta is aberrantly activated by the presence of Abeta, and contributes, at least in part, to the neuronal anatomical derangement associated with Abeta plaques in AD brains and to Abeta pathology itself.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neurobiology of disease\", \"reference\": \"21945540\", \"authors\": [\"DaRocha-Souto B\", \"Coma M\", \"Prez-Nievas BG\", \"Scotton TC\", \"Siao M\", \"Snchez-Ferrer P\", \"Hashimoto T\", \"Fan Z\", \"Hudry E\", \"Barroeta I\", \"Seren L\", \"Rodrguez M\", \"Snchez MB\", \"Hyman BT\", \"Gmez-Isla T\"], \"date\": \"2012-01-01\", \"title\": \"Activation of glycogen synthase kinase-3 beta mediates -amyloid induced neuritic damage in Alzheimer's disease.\", \"lastauthor\": \"Gmez-Isla T\", \"volume\": \"45\", \"issue\": \"1\", \"pages\": \"425-37\", \"firstauthor\": \"DaRocha-Souto B\"}, \"line\": 2745, \"object\": {\"modifier\": \"Activity\", \"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}}, \"annotations\": {\"Disease\": \"Alzheimer's disease\", \"Subgraph\": \"Amyloidogenic subgraph\"}, \"source\": 25, \"target\": 2, \"key\": 3}, {\"relation\": \"increases\", \"evidence\": \"In the present review, we discuss our initial in vitro results and additional investigations showing that Abeta activates GSK-3beta through impairment of phosphatidylinositol-3 (PI3)/Akt signaling; that Abeta-activated GSK-3beta induces hyperphosphorylation of tau, NFT formation, neuronal death, and synaptic loss (all found in the AD brain); that GSK-3beta can induce memory deficits in vivo; and that inhibition of GSK-3alpha (an isoform of GSK-3beta) reduces Abeta production.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of Alzheimer's disease : JAD\", \"reference\": \"16914869\", \"authors\": [\"Takashima A\"], \"date\": \"2006-01-01\", \"title\": \"GSK-3 is essential in the pathogenesis of Alzheimer's disease.\", \"lastauthor\": \"Takashima A\", \"volume\": \"9\", \"issue\": \"3 Suppl\", \"pages\": \"309-17\", \"firstauthor\": \"Takashima A\"}, \"line\": 31435, \"object\": {\"modifier\": \"Activity\", \"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}}, \"annotations\": {\"Subgraph\": \"GSK3 subgraph\"}, \"source\": 25, \"target\": 2, \"key\": 4}, {\"relation\": \"increases\", \"evidence\": \"In the present review, we discuss our initial in vitro results and additional investigations showing that Abeta activates GSK-3beta through impairment of phosphatidylinositol-3 (PI3)/Akt signaling; that Abeta-activated GSK-3beta induces hyperphosphorylation of tau, NFT formation, neuronal death, and synaptic loss (all found in the AD brain); that GSK-3beta can induce memory deficits in vivo; and that inhibition of GSK-3alpha (an isoform of GSK-3beta) reduces Abeta production.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of Alzheimer's disease : JAD\", \"reference\": \"16914869\", \"authors\": [\"Takashima A\"], \"date\": \"2006-01-01\", \"title\": \"GSK-3 is essential in the pathogenesis of Alzheimer's disease.\", \"lastauthor\": \"Takashima A\", \"volume\": \"9\", \"issue\": \"3 Suppl\", \"pages\": \"309-17\", \"firstauthor\": \"Takashima A\"}, \"line\": 31435, \"object\": {\"modifier\": \"Activity\", \"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}}, \"annotations\": {\"Subgraph\": \"Tau protein subgraph\"}, \"source\": 25, \"target\": 2, \"key\": 5}, {\"relation\": \"increases\", \"evidence\": \"In the present review, we discuss our initial in vitro results and additional investigations showing that Abeta activates GSK-3beta through impairment of phosphatidylinositol-3 (PI3)/Akt signaling; that Abeta-activated GSK-3beta induces hyperphosphorylation of tau, NFT formation, neuronal death, and synaptic loss (all found in the AD brain); that GSK-3beta can induce memory deficits in vivo; and that inhibition of GSK-3alpha (an isoform of GSK-3beta) reduces Abeta production.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of Alzheimer's disease : JAD\", \"reference\": \"16914869\", \"authors\": [\"Takashima A\"], \"date\": \"2006-01-01\", \"title\": \"GSK-3 is essential in the pathogenesis of Alzheimer's disease.\", \"lastauthor\": \"Takashima A\", \"volume\": \"9\", \"issue\": \"3 Suppl\", \"pages\": \"309-17\", \"firstauthor\": \"Takashima A\"}, \"line\": 31435, \"object\": {\"modifier\": \"Activity\", \"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}}, \"annotations\": {\"Subgraph\": \"Amyloidogenic subgraph\"}, \"source\": 25, \"target\": 2, \"key\": 6}, {\"relation\": \"association\", \"evidence\": \"Compared to vehicle, Abeta increased GSK3 activity, and was associated with elevations in levels of ptau, caspase-3, the tau kinase phospho-c-jun N-terminal kinase (pJNK), neuronal DNA fragmentation, and gliosis.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neurobiology of disease\", \"reference\": \"19038340\", \"authors\": [\"Hu S\", \"Begum AN\", \"Jones MR\", \"Oh MS\", \"Beech WK\", \"Beech BH\", \"Yang F\", \"Chen P\", \"Ubeda OJ\", \"Kim PC\", \"Davies P\", \"Ma Q\", \"Cole GM\", \"Frautschy SA\"], \"date\": \"2009-02-01\", \"title\": \"GSK3 inhibitors show benefits in an Alzheimer's disease (AD) model of neurodegeneration but adverse effects in control animals.\", \"lastauthor\": \"Frautschy SA\", \"volume\": \"33\", \"issue\": \"2\", \"pages\": \"193-206\", \"firstauthor\": \"Hu S\"}, \"line\": 31860, \"annotations\": {\"Subgraph\": \"Tau protein subgraph\"}, \"source\": 25, \"target\": 24, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Compared to vehicle, Abeta increased GSK3 activity, and was associated with elevations in levels of ptau, caspase-3, the tau kinase phospho-c-jun N-terminal kinase (pJNK), neuronal DNA fragmentation, and gliosis.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neurobiology of disease\", \"reference\": \"19038340\", \"authors\": [\"Hu S\", \"Begum AN\", \"Jones MR\", \"Oh MS\", \"Beech WK\", \"Beech BH\", \"Yang F\", \"Chen P\", \"Ubeda OJ\", \"Kim PC\", \"Davies P\", \"Ma Q\", \"Cole GM\", \"Frautschy SA\"], \"date\": \"2009-02-01\", \"title\": \"GSK3 inhibitors show benefits in an Alzheimer's disease (AD) model of neurodegeneration but adverse effects in control animals.\", \"lastauthor\": \"Frautschy SA\", \"volume\": \"33\", \"issue\": \"2\", \"pages\": \"193-206\", \"firstauthor\": \"Hu S\"}, \"line\": 31860, \"annotations\": {\"Subgraph\": \"Amyloidogenic subgraph\"}, \"source\": 25, \"target\": 24, \"key\": 1}, {\"relation\": \"decreases\", \"evidence\": \"Taken together, our results suggest that the neuroprotective effects of donepezil against Abeta42-induced neurotoxicity are mediated through activation of PP2A, but its additional mechanisms including regulation of GSK-3beta and nAChRs activity would partially contribute to its effects. This observation led us to assume that additional mechanisms of donepezil, including its inhibitory effect on GSK-3beta activity and/or the activation role of nicotinic acetylcholine receptors (nAChRs), might be involved. Donepezil increased neuronal viability with reduced p-tau by enhancing PP2A activity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of neurochemistry\", \"reference\": \"23711227\", \"authors\": [\"Noh MY\", \"Koh SH\", \"Kim SM\", \"Maurice T\", \"Ku SK\", \"Kim SH\"], \"date\": \"2013-11-01\", \"title\": \"Neuroprotective effects of donepezil against A42-induced neuronal toxicity are mediated through not only enhancing PP2A activity but also regulating GSK-3 and nAChRs activity.\", \"lastauthor\": \"Kim SH\", \"volume\": \"127\", \"issue\": \"4\", \"pages\": \"562-74\", \"firstauthor\": \"Noh MY\"}, \"line\": 12899, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GSK3 subgraph\"}, \"source\": 26, \"target\": 2, \"key\": 0}, {\"relation\": \"decreases\", \"evidence\": \"Taken together, our results suggest that the neuroprotective effects of donepezil against Abeta42-induced neurotoxicity are mediated through activation of PP2A, but its additional mechanisms including regulation of GSK-3beta and nAChRs activity would partially contribute to its effects. This observation led us to assume that additional mechanisms of donepezil, including its inhibitory effect on GSK-3beta activity and/or the activation role of nicotinic acetylcholine receptors (nAChRs), might be involved. Donepezil increased neuronal viability with reduced p-tau by enhancing PP2A activity.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of neurochemistry\", \"reference\": \"23711227\", \"authors\": [\"Noh MY\", \"Koh SH\", \"Kim SM\", \"Maurice T\", \"Ku SK\", \"Kim SH\"], \"date\": \"2013-11-01\", \"title\": \"Neuroprotective effects of donepezil against A42-induced neuronal toxicity are mediated through not only enhancing PP2A activity but also regulating GSK-3 and nAChRs activity.\", \"lastauthor\": \"Kim SH\", \"volume\": \"127\", \"issue\": \"4\", \"pages\": \"562-74\", \"firstauthor\": \"Noh MY\"}, \"line\": 12899, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"Acetylcholine signaling subgraph\"}, \"source\": 26, \"target\": 2, \"key\": 1}, {\"relation\": \"association\", \"evidence\": \"Donepezil is metabolized via CYP-related enzymes, especially CYP2D6, CYP3A4, and CYP1A2.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neuropsychiatric disease and treatment\", \"reference\": \"19300564\", \"authors\": [\"Cacabelos R\"], \"date\": \"2007-06-01\", \"title\": \"Donepezil in Alzheimer's disease: From conventional trials to pharmacogenetics.\", \"lastauthor\": \"Cacabelos R\", \"volume\": \"3\", \"issue\": \"3\", \"pages\": \"303-33\", \"firstauthor\": \"Cacabelos R\"}, \"line\": 15671, \"annotations\": {\"Subgraph\": \"Cholesterol metabolism subgraph\"}, \"source\": 26, \"target\": 7, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Cytochrome P450 (CYP) 2D6 enzyme is the major responsible for the metabolism of donepezil, an inhibitor of acetyl cholinesterase currently used for the symptomatic treatment of mild-to-moderate Alzheimer's disease (AD).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Pharmacogenetics and genomics\", \"reference\": \"20859244\", \"authors\": [\"Seripa D\", \"Bizzarro A\", \"Pilotto A\", \"D'onofrio G\", \"Vecchione G\", \"Gallo AP\", \"Cascavilla L\", \"Paris F\", \"Grandone E\", \"Mecocci P\", \"Santini SA\", \"Masullo C\", \"Pilotto A\"], \"date\": \"2011-04-01\", \"title\": \"Role of cytochrome P4502D6 functional polymorphisms in the efficacy of donepezil in patients with Alzheimer's disease.\", \"lastauthor\": \"Pilotto A\", \"volume\": \"21\", \"issue\": \"4\", \"pages\": \"225-30\", \"firstauthor\": \"Seripa D\"}, \"line\": 18358, \"annotations\": {\"Disease\": \"Alzheimer's disease\", \"Subgraph\": \"Paroxetine subgraph\"}, \"source\": 26, \"target\": 7, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"Although the role of AICD as a gene transcription inducer is still controversial, several targets of AICD- or APP-mediated transcriptional activation are reportedly regulated by APP nuclear signaling, including APP itself, BACE, Tip60, GSK-3, p53, Mn-SOD, KAI1, Neprilysin, transgelin, a2actin, S100a9, and other genes\", \"citation\": {\"type\": \"PubMed\", \"name\": \"BMB reports\", \"reference\": \"21034527\", \"authors\": [\"Chang KA\", \"Suh YH\"], \"date\": \"2010-10-01\", \"title\": \"Possible roles of amyloid intracellular domain of amyloid precursor protein.\", \"lastauthor\": \"Suh YH\", \"volume\": \"43\", \"issue\": \"10\", \"pages\": \"656-63\", \"firstauthor\": \"Chang KA\"}, \"line\": 36343, \"subject\": {\"modifier\": \"Activity\", \"effect\": {\"name\": \"tscript\", \"namespace\": \"bel\"}}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GSK3 subgraph\"}, \"source\": 27, \"target\": 2, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Over the last several years a number of reports have emerged suggesting that at least some ChEI might take part in betaAPP metabolism, influencing its secretion and Abeta differential cleavage. Moreover, we (Sob6w and Kloszewska 2005) and others (Basun et al. 2002, Zimmermann et al. 2005) have shown that the treatment with ChEI might influence BAPP metabolism in AD patients as measured by changes in plasma (including platelet-derived) metabolites. In our previous pilot study we have demonstrated that short-term treatment with ChEI rivastigmine exhibits a significant effect on plasma concentrations of Abeta-42 (mean increase after treatment reached 7.8  8.4 pg/ml) with a negative correlation to patients age, while no changes in Abeta-40 levels were detected.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Acta neurobiologiae experimentalis\", \"reference\": \"17691220\", \"authors\": [\"Sobow T\", \"Flirski M\", \"Liberski P\", \"Kloszewska I\"], \"date\": \"2007-01-01\", \"title\": \"Plasma Abeta levels as predictors of response to rivastigmine treatment in Alzheimer's disease.\", \"lastauthor\": \"Kloszewska I\", \"volume\": \"67\", \"issue\": \"2\", \"pages\": \"131-9\", \"firstauthor\": \"Sobow T\"}, \"line\": 22588, \"annotations\": {\"Species\": \"10116\", \"Subgraph\": \"Amyloidogenic subgraph\"}, \"source\": 27, \"target\": 7, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"Rivastigmine treatment induced an elevation in both metabolic activity and APP secretion, and differentially impacted two isoforms of sAPP. In our cultures, low molecular weight sAPP corresponded closely to neuronal viability, and high molecular weight sAPP corresponded with glial proliferation. Our results suggest that within the mixed culture system used, neurons are the primary source of sAPP, and rivastigmine's actions are mediated principally through neuronal, rather than glial, targets. Importantly, rivastigmine was found to increase the neurotrophic sAPP and decrease Abeta secretion, suggesting a mechanism for the previously observed neuropreservation effects.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"PloS one\", \"reference\": \"21799757\", \"authors\": [\"Bailey JA\", \"Ray B\", \"Greig NH\", \"Lahiri DK\"], \"date\": \"2011-01-01\", \"title\": \"Rivastigmine lowers A and increases sAPP levels, which parallel elevated synaptic markers and metabolic activity in degenerating primary rat neurons.\", \"lastauthor\": \"Lahiri DK\", \"volume\": \"6\", \"issue\": \"7\", \"pages\": \"e21954\", \"firstauthor\": \"Bailey JA\"}, \"line\": 22643, \"annotations\": {\"Species\": \"10116\", \"MeSHAnatomy\": \"Brain\", \"Subgraph\": \"Non-amyloidogenic subgraph\"}, \"source\": 27, \"target\": 7, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"Although the role of AICD as a gene transcription inducer is still controversial, several targets of AICD- or APP-mediated transcriptional activation are reportedly regulated by APP nuclear signaling, including APP itself, BACE, Tip60, GSK-3, p53, Mn-SOD, KAI1, Neprilysin, transgelin, a2actin, S100a9, and other genes\", \"citation\": {\"type\": \"PubMed\", \"name\": \"BMB reports\", \"reference\": \"21034527\", \"authors\": [\"Chang KA\", \"Suh YH\"], \"date\": \"2010-10-01\", \"title\": \"Possible roles of amyloid intracellular domain of amyloid precursor protein.\", \"lastauthor\": \"Suh YH\", \"volume\": \"43\", \"issue\": \"10\", \"pages\": \"656-63\", \"firstauthor\": \"Chang KA\"}, \"line\": 36358, \"subject\": {\"modifier\": \"Activity\", \"effect\": {\"name\": \"tscript\", \"namespace\": \"bel\"}}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {}, \"source\": 27, \"target\": 15, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Although the role of AICD as a gene transcription inducer is still controversial, several targets of AICD- or APP-mediated transcriptional activation are reportedly regulated by APP nuclear signaling, including APP itself, BACE, Tip60, GSK-3, p53, Mn-SOD, KAI1, Neprilysin, transgelin, a2actin, S100a9, and other genes\", \"citation\": {\"type\": \"PubMed\", \"name\": \"BMB reports\", \"reference\": \"21034527\", \"authors\": [\"Chang KA\", \"Suh YH\"], \"date\": \"2010-10-01\", \"title\": \"Possible roles of amyloid intracellular domain of amyloid precursor protein.\", \"lastauthor\": \"Suh YH\", \"volume\": \"43\", \"issue\": \"10\", \"pages\": \"656-63\", \"firstauthor\": \"Chang KA\"}, \"line\": 41859, \"subject\": {\"modifier\": \"Activity\", \"effect\": {\"name\": \"tscript\", \"namespace\": \"bel\"}}, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {}, \"source\": 27, \"target\": 15, \"key\": 1}, {\"relation\": \"association\", \"evidence\": \"[Estradiol binds to ESR2 protein] which results in increased expression of TIMP3 mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Carcinogenesis\", \"reference\": \"16474171\", \"authors\": [\"Buterin T\", \"Koch C\", \"Naegeli H\"], \"date\": \"2006-08-01\", \"title\": \"Convergent transcriptional profiles induced by endogenous estrogen and distinct xenoestrogens in breast cancer cells.\", \"lastauthor\": \"Naegeli H\", \"volume\": \"27\", \"issue\": \"8\", \"pages\": \"1567-78\", \"firstauthor\": \"Buterin T\"}, \"line\": 48192, \"annotations\": {\"Species\": \"9606\"}, \"source\": 28, \"target\": 14, \"key\": 0}, {\"relation\": \"association\", \"evidence\": \"[Coumestrol co-treated with resveratrol] results in decreased expression of TIMP3 mRNA\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association\", \"reference\": \"19167446\", \"authors\": [\"Dip R\", \"Lenz S\", \"Gmuender H\", \"Naegeli H\"], \"date\": \"2009-04-01\", \"title\": \"Pleiotropic combinatorial transcriptomes of human breast cancer cells exposed to mixtures of dietary phytoestrogens.\", \"lastauthor\": \"Naegeli H\", \"volume\": \"47\", \"issue\": \"4\", \"pages\": \"787-95\", \"firstauthor\": \"Dip R\"}, \"line\": 48224, \"annotations\": {}, \"source\": 28, \"target\": 18, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Abeta-Amyloid (Abeta) plaques in Alzheimer (AD) brains are surrounded by severe dendritic and axonal changes, including local spine loss, axonal swellings and distorted neurite trajectories. Whether and how plaques induce these neuropil abnormalities remains unknown. We tested the hypothesis that oligomeric assemblies of Abeta, seen in the periphery of plaques, mediate the neurodegenerative phenotype of AD by triggering activation of the enzyme GSK-3Abeta, which in turn appears to inhibit a transcriptional program mediated by CREB. We detect increased activity of GSK-3Abeta after exposure to oligomeric Abeta in neurons in culture, in the brain of double transgenic APP/tau mice and in AD brains. Activation of GSK-3Abeta, even in the absence of Abeta, is sufficient to produce a phenocopy of Abeta-induced dendritic spine loss in neurons in culture, while pharmacological inhibition of GSK-3Abeta prevents spine loss and increases expression of CREB-target genes like BDNF. Of note, in transgenic mice GSK-3Abeta inhibition ameliorated plaque-related neuritic changes and increased CREB-mediated gene expression. Moreover, GSK-3Abeta inhibition robustly decreased the oligomeric Abeta load in the mouse brain. All these findings support the idea that GSK3Abeta is aberrantly activated by the presence of Abeta, and contributes, at least in part, to the neuronal anatomical derangement associated with Abeta plaques in AD brains and to Abeta pathology itself.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neurobiology of disease\", \"reference\": \"21945540\", \"authors\": [\"DaRocha-Souto B\", \"Coma M\", \"Prez-Nievas BG\", \"Scotton TC\", \"Siao M\", \"Snchez-Ferrer P\", \"Hashimoto T\", \"Fan Z\", \"Hudry E\", \"Barroeta I\", \"Seren L\", \"Rodrguez M\", \"Snchez MB\", \"Hyman BT\", \"Gmez-Isla T\"], \"date\": \"2012-01-01\", \"title\": \"Activation of glycogen synthase kinase-3 beta mediates -amyloid induced neuritic damage in Alzheimer's disease.\", \"lastauthor\": \"Gmez-Isla T\", \"volume\": \"45\", \"issue\": \"1\", \"pages\": \"425-37\", \"firstauthor\": \"DaRocha-Souto B\"}, \"line\": 33961, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GSK3 subgraph\"}, \"source\": 29, \"target\": 2, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Abeta-Amyloid (Abeta) plaques in Alzheimer (AD) brains are surrounded by severe dendritic and axonal changes, including local spine loss, axonal swellings and distorted neurite trajectories. Whether and how plaques induce these neuropil abnormalities remains unknown. We tested the hypothesis that oligomeric assemblies of Abeta, seen in the periphery of plaques, mediate the neurodegenerative phenotype of AD by triggering activation of the enzyme GSK-3Abeta, which in turn appears to inhibit a transcriptional program mediated by CREB. We detect increased activity of GSK-3Abeta after exposure to oligomeric Abeta in neurons in culture, in the brain of double transgenic APP/tau mice and in AD brains. Activation of GSK-3Abeta, even in the absence of Abeta, is sufficient to produce a phenocopy of Abeta-induced dendritic spine loss in neurons in culture, while pharmacological inhibition of GSK-3Abeta prevents spine loss and increases expression of CREB-target genes like BDNF. Of note, in transgenic mice GSK-3Abeta inhibition ameliorated plaque-related neuritic changes and increased CREB-mediated gene expression. Moreover, GSK-3Abeta inhibition robustly decreased the oligomeric Abeta load in the mouse brain. All these findings support the idea that GSK3Abeta is aberrantly activated by the presence of Abeta, and contributes, at least in part, to the neuronal anatomical derangement associated with Abeta plaques in AD brains and to Abeta pathology itself.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Neurobiology of disease\", \"reference\": \"21945540\", \"authors\": [\"DaRocha-Souto B\", \"Coma M\", \"Prez-Nievas BG\", \"Scotton TC\", \"Siao M\", \"Snchez-Ferrer P\", \"Hashimoto T\", \"Fan Z\", \"Hudry E\", \"Barroeta I\", \"Seren L\", \"Rodrguez M\", \"Snchez MB\", \"Hyman BT\", \"Gmez-Isla T\"], \"date\": \"2012-01-01\", \"title\": \"Activation of glycogen synthase kinase-3 beta mediates -amyloid induced neuritic damage in Alzheimer's disease.\", \"lastauthor\": \"Gmez-Isla T\", \"volume\": \"45\", \"issue\": \"1\", \"pages\": \"425-37\", \"firstauthor\": \"DaRocha-Souto B\"}, \"line\": 33967, \"object\": {\"modifier\": \"Activity\"}, \"annotations\": {\"Subgraph\": \"GSK3 subgraph\"}, \"source\": 29, \"target\": 2, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"The PI3K/Akt signaling: PI3K, a membrane-associated second messenger protein, and its downstream kinase, Akt, are associated with neuronal survival [111] and plasticity [112] via activation of transcription pathways and protein synthesis. PI3K pathway, which required the activation of IGF-1/insulin receptors, is the most convincing prosurvival effect of ABeta42 monomers. The PI3K signaling pathway is important in the transmission of survival signals in many cell types including neurons [113, 114]. The PI3K-Akt signaling cascade, initiated by IRS, is phosphorylated by stimulated insulin- andIGF-receptor tyrosine kinases [115]. One of the kinases known to lie downstream of PI3K is Akt, which can be directly activated by products of PI3K [116] by promoting its phosphorylation at Ser473 and Thr308 [117]. Activated Akt, in turn, phosphorylates a wide range of substrates activating anti-apoptotic (survival) factors and inactivating pro-apoptotic factors [114, 117]. Certain proapoptotic mediators, such as the transcription factor forkhead (FOXO), the tau kinase GSK-3, and the Bcl2 antagonist BAD proteins, are inactivated by Akt [118, 119]. Akt downregulates the activities of GSK-3a and GSK-3 by phosphorylating the former at Ser21 and the latter at Ser9 [118]. Phosphorylation/inactivation of GSK-3, suppresses GSK-3-dependent phosphorylation of tau at residues overphosphorylated in AD and prevents apoptosis of confluent cells. Treatment of cortical neurons with ABeta42 monomers increased Ser9 phosphorylation (inhibition) of the Akt substrate, GSK- 3 [97]. Inhibition of GSK-3 promotes cell survival through a variety of mechanisms including a reduced degradation of -catenin, which then translocates into the nucleus and activates the transcription of protective genes [126].\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of Alzheimer's disease : JAD\", \"reference\": \"20847424\", \"authors\": [\"Parihar MS\", \"Brewer GJ\"], \"date\": \"2010-01-01\", \"title\": \"Amyloid- as a modulator of synaptic plasticity.\", \"lastauthor\": \"Brewer GJ\", \"volume\": \"22\", \"issue\": \"3\", \"pages\": \"741-63\", \"firstauthor\": \"Parihar MS\"}, \"line\": 35213, \"annotations\": {\"Subgraph\": \"GSK3 subgraph\"}, \"source\": 29, \"target\": 5, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"The PI3K/Akt signaling: PI3K, a membrane-associated second messenger protein, and its downstream kinase, Akt, are associated with neuronal survival [111] and plasticity [112] via activation of transcription pathways and protein synthesis. PI3K pathway, which required the activation of IGF-1/insulin receptors, is the most convincing prosurvival effect of ABeta42 monomers. The PI3K signaling pathway is important in the transmission of survival signals in many cell types including neurons [113, 114]. The PI3K-Akt signaling cascade, initiated by IRS, is phosphorylated by stimulated insulin- andIGF-receptor tyrosine kinases [115]. One of the kinases known to lie downstream of PI3K is Akt, which can be directly activated by products of PI3K [116] by promoting its phosphorylation at Ser473 and Thr308 [117]. Activated Akt, in turn, phosphorylates a wide range of substrates activating anti-apoptotic (survival) factors and inactivating pro-apoptotic factors [114, 117]. Certain proapoptotic mediators, such as the transcription factor forkhead (FOXO), the tau kinase GSK-3, and the Bcl2 antagonist BAD proteins, are inactivated by Akt [118, 119]. Akt downregulates the activities of GSK-3a and GSK-3 by phosphorylating the former at Ser21 and the latter at Ser9 [118]. Phosphorylation/inactivation of GSK-3, suppresses GSK-3-dependent phosphorylation of tau at residues overphosphorylated in AD and prevents apoptosis of confluent cells. Treatment of cortical neurons with ABeta42 monomers increased Ser9 phosphorylation (inhibition) of the Akt substrate, GSK- 3 [97]. Inhibition of GSK-3 promotes cell survival through a variety of mechanisms including a reduced degradation of -catenin, which then translocates into the nucleus and activates the transcription of protective genes [126].\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of Alzheimer's disease : JAD\", \"reference\": \"20847424\", \"authors\": [\"Parihar MS\", \"Brewer GJ\"], \"date\": \"2010-01-01\", \"title\": \"Amyloid- as a modulator of synaptic plasticity.\", \"lastauthor\": \"Brewer GJ\", \"volume\": \"22\", \"issue\": \"3\", \"pages\": \"741-63\", \"firstauthor\": \"Parihar MS\"}, \"line\": 35213, \"annotations\": {\"Subgraph\": \"Amyloidogenic subgraph\"}, \"source\": 29, \"target\": 5, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"These data suggest that aberrant glycosylation of tau in AD might be involved in neurofibrillary degeneration by promoting abnormal hyperphosphorylation by cdk5 and GSK-3beta.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"FEBS letters\", \"reference\": \"12387894\", \"authors\": [\"Liu F\", \"Iqbal K\", \"Grundke-Iqbal I\", \"Gong CX\"], \"date\": \"2002-10-23\", \"title\": \"Involvement of aberrant glycosylation in phosphorylation of tau by cdk5 and GSK-3beta.\", \"lastauthor\": \"Gong CX\", \"volume\": \"530\", \"issue\": \"1-3\", \"pages\": \"209-14\", \"firstauthor\": \"Liu F\"}, \"line\": 28119, \"object\": {\"modifier\": \"Activity\", \"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}}, \"annotations\": {\"Subgraph\": \"GSK3 subgraph\"}, \"source\": 30, \"target\": 2, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"These data suggest that aberrant glycosylation of tau in AD might be involved in neurofibrillary degeneration by promoting abnormal hyperphosphorylation by cdk5 and GSK-3beta.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"FEBS letters\", \"reference\": \"12387894\", \"authors\": [\"Liu F\", \"Iqbal K\", \"Grundke-Iqbal I\", \"Gong CX\"], \"date\": \"2002-10-23\", \"title\": \"Involvement of aberrant glycosylation in phosphorylation of tau by cdk5 and GSK-3beta.\", \"lastauthor\": \"Gong CX\", \"volume\": \"530\", \"issue\": \"1-3\", \"pages\": \"209-14\", \"firstauthor\": \"Liu F\"}, \"line\": 28119, \"object\": {\"modifier\": \"Activity\", \"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}}, \"annotations\": {\"Subgraph\": \"Tau protein subgraph\"}, \"source\": 30, \"target\": 2, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"Deglycosylation by glycosidases depressed the subsequent phosphorylation of AD-tau (i) with cdk5 at Thr-181, Ser-199, Ser-202, Thr-205, and Ser-404, but not at Thr-212; and (ii) with GSK-3beta at Thr-181, Ser-202, Thr-205, Ser-217, and Ser-404, but not at Ser-199, Thr-212, Thr-231, or Ser-396. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"FEBS letters\", \"reference\": \"12387894\", \"authors\": [\"Liu F\", \"Iqbal K\", \"Grundke-Iqbal I\", \"Gong CX\"], \"date\": \"2002-10-23\", \"title\": \"Involvement of aberrant glycosylation in phosphorylation of tau by cdk5 and GSK-3beta.\", \"lastauthor\": \"Gong CX\", \"volume\": \"530\", \"issue\": \"1-3\", \"pages\": \"209-14\", \"firstauthor\": \"Liu F\"}, \"line\": 28109, \"annotations\": {\"Subgraph\": \"Tau protein subgraph\"}, \"source\": 30, \"target\": 9, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Deglycosylation by glycosidases depressed the subsequent phosphorylation of AD-tau (i) with cdk5 at Thr-181, Ser-199, Ser-202, Thr-205, and Ser-404, but not at Thr-212; and (ii) with GSK-3beta at Thr-181, Ser-202, Thr-205, Ser-217, and Ser-404, but not at Ser-199, Thr-212, Thr-231, or Ser-396. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"FEBS letters\", \"reference\": \"12387894\", \"authors\": [\"Liu F\", \"Iqbal K\", \"Grundke-Iqbal I\", \"Gong CX\"], \"date\": \"2002-10-23\", \"title\": \"Involvement of aberrant glycosylation in phosphorylation of tau by cdk5 and GSK-3beta.\", \"lastauthor\": \"Gong CX\", \"volume\": \"530\", \"issue\": \"1-3\", \"pages\": \"209-14\", \"firstauthor\": \"Liu F\"}, \"line\": 28109, \"annotations\": {\"Subgraph\": \"Cyclin-CDK subgraph\"}, \"source\": 30, \"target\": 9, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"Deglycosylation by glycosidases depressed the subsequent phosphorylation of AD-tau (i) with cdk5 at Thr-181, Ser-199, Ser-202, Thr-205, and Ser-404, but not at Thr-212; and (ii) with GSK-3beta at Thr-181, Ser-202, Thr-205, Ser-217, and Ser-404, but not at Ser-199, Thr-212, Thr-231, or Ser-396. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"FEBS letters\", \"reference\": \"12387894\", \"authors\": [\"Liu F\", \"Iqbal K\", \"Grundke-Iqbal I\", \"Gong CX\"], \"date\": \"2002-10-23\", \"title\": \"Involvement of aberrant glycosylation in phosphorylation of tau by cdk5 and GSK-3beta.\", \"lastauthor\": \"Gong CX\", \"volume\": \"530\", \"issue\": \"1-3\", \"pages\": \"209-14\", \"firstauthor\": \"Liu F\"}, \"line\": 28110, \"annotations\": {\"Subgraph\": \"Tau protein subgraph\"}, \"source\": 30, \"target\": 11, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Deglycosylation by glycosidases depressed the subsequent phosphorylation of AD-tau (i) with cdk5 at Thr-181, Ser-199, Ser-202, Thr-205, and Ser-404, but not at Thr-212; and (ii) with GSK-3beta at Thr-181, Ser-202, Thr-205, Ser-217, and Ser-404, but not at Ser-199, Thr-212, Thr-231, or Ser-396. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"FEBS letters\", \"reference\": \"12387894\", \"authors\": [\"Liu F\", \"Iqbal K\", \"Grundke-Iqbal I\", \"Gong CX\"], \"date\": \"2002-10-23\", \"title\": \"Involvement of aberrant glycosylation in phosphorylation of tau by cdk5 and GSK-3beta.\", \"lastauthor\": \"Gong CX\", \"volume\": \"530\", \"issue\": \"1-3\", \"pages\": \"209-14\", \"firstauthor\": \"Liu F\"}, \"line\": 28110, \"annotations\": {\"Subgraph\": \"Cyclin-CDK subgraph\"}, \"source\": 30, \"target\": 11, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"Deglycosylation by glycosidases depressed the subsequent phosphorylation of AD-tau (i) with cdk5 at Thr-181, Ser-199, Ser-202, Thr-205, and Ser-404, but not at Thr-212; and (ii) with GSK-3beta at Thr-181, Ser-202, Thr-205, Ser-217, and Ser-404, but not at Ser-199, Thr-212, Thr-231, or Ser-396. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"FEBS letters\", \"reference\": \"12387894\", \"authors\": [\"Liu F\", \"Iqbal K\", \"Grundke-Iqbal I\", \"Gong CX\"], \"date\": \"2002-10-23\", \"title\": \"Involvement of aberrant glycosylation in phosphorylation of tau by cdk5 and GSK-3beta.\", \"lastauthor\": \"Gong CX\", \"volume\": \"530\", \"issue\": \"1-3\", \"pages\": \"209-14\", \"firstauthor\": \"Liu F\"}, \"line\": 28112, \"annotations\": {\"Subgraph\": \"Tau protein subgraph\"}, \"source\": 30, \"target\": 11, \"key\": 2}, {\"relation\": \"increases\", \"evidence\": \"Deglycosylation by glycosidases depressed the subsequent phosphorylation of AD-tau (i) with cdk5 at Thr-181, Ser-199, Ser-202, Thr-205, and Ser-404, but not at Thr-212; and (ii) with GSK-3beta at Thr-181, Ser-202, Thr-205, Ser-217, and Ser-404, but not at Ser-199, Thr-212, Thr-231, or Ser-396. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"FEBS letters\", \"reference\": \"12387894\", \"authors\": [\"Liu F\", \"Iqbal K\", \"Grundke-Iqbal I\", \"Gong CX\"], \"date\": \"2002-10-23\", \"title\": \"Involvement of aberrant glycosylation in phosphorylation of tau by cdk5 and GSK-3beta.\", \"lastauthor\": \"Gong CX\", \"volume\": \"530\", \"issue\": \"1-3\", \"pages\": \"209-14\", \"firstauthor\": \"Liu F\"}, \"line\": 28112, \"annotations\": {\"Subgraph\": \"Cyclin-CDK subgraph\"}, \"source\": 30, \"target\": 11, \"key\": 3}, {\"relation\": \"increases\", \"evidence\": \"Deglycosylation by glycosidases depressed the subsequent phosphorylation of AD-tau (i) with cdk5 at Thr-181, Ser-199, Ser-202, Thr-205, and Ser-404, but not at Thr-212; and (ii) with GSK-3beta at Thr-181, Ser-202, Thr-205, Ser-217, and Ser-404, but not at Ser-199, Thr-212, Thr-231, or Ser-396. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"FEBS letters\", \"reference\": \"12387894\", \"authors\": [\"Liu F\", \"Iqbal K\", \"Grundke-Iqbal I\", \"Gong CX\"], \"date\": \"2002-10-23\", \"title\": \"Involvement of aberrant glycosylation in phosphorylation of tau by cdk5 and GSK-3beta.\", \"lastauthor\": \"Gong CX\", \"volume\": \"530\", \"issue\": \"1-3\", \"pages\": \"209-14\", \"firstauthor\": \"Liu F\"}, \"line\": 28106, \"annotations\": {\"Subgraph\": \"Tau protein subgraph\"}, \"source\": 30, \"target\": 12, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Deglycosylation by glycosidases depressed the subsequent phosphorylation of AD-tau (i) with cdk5 at Thr-181, Ser-199, Ser-202, Thr-205, and Ser-404, but not at Thr-212; and (ii) with GSK-3beta at Thr-181, Ser-202, Thr-205, Ser-217, and Ser-404, but not at Ser-199, Thr-212, Thr-231, or Ser-396. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"FEBS letters\", \"reference\": \"12387894\", \"authors\": [\"Liu F\", \"Iqbal K\", \"Grundke-Iqbal I\", \"Gong CX\"], \"date\": \"2002-10-23\", \"title\": \"Involvement of aberrant glycosylation in phosphorylation of tau by cdk5 and GSK-3beta.\", \"lastauthor\": \"Gong CX\", \"volume\": \"530\", \"issue\": \"1-3\", \"pages\": \"209-14\", \"firstauthor\": \"Liu F\"}, \"line\": 28106, \"annotations\": {\"Subgraph\": \"Cyclin-CDK subgraph\"}, \"source\": 30, \"target\": 12, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"Deglycosylation by glycosidases depressed the subsequent phosphorylation of AD-tau (i) with cdk5 at Thr-181, Ser-199, Ser-202, Thr-205, and Ser-404, but not at Thr-212; and (ii) with GSK-3beta at Thr-181, Ser-202, Thr-205, Ser-217, and Ser-404, but not at Ser-199, Thr-212, Thr-231, or Ser-396. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"FEBS letters\", \"reference\": \"12387894\", \"authors\": [\"Liu F\", \"Iqbal K\", \"Grundke-Iqbal I\", \"Gong CX\"], \"date\": \"2002-10-23\", \"title\": \"Involvement of aberrant glycosylation in phosphorylation of tau by cdk5 and GSK-3beta.\", \"lastauthor\": \"Gong CX\", \"volume\": \"530\", \"issue\": \"1-3\", \"pages\": \"209-14\", \"firstauthor\": \"Liu F\"}, \"line\": 28108, \"annotations\": {\"Subgraph\": \"Tau protein subgraph\"}, \"source\": 30, \"target\": 13, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Deglycosylation by glycosidases depressed the subsequent phosphorylation of AD-tau (i) with cdk5 at Thr-181, Ser-199, Ser-202, Thr-205, and Ser-404, but not at Thr-212; and (ii) with GSK-3beta at Thr-181, Ser-202, Thr-205, Ser-217, and Ser-404, but not at Ser-199, Thr-212, Thr-231, or Ser-396. \", \"citation\": {\"type\": \"PubMed\", \"name\": \"FEBS letters\", \"reference\": \"12387894\", \"authors\": [\"Liu F\", \"Iqbal K\", \"Grundke-Iqbal I\", \"Gong CX\"], \"date\": \"2002-10-23\", \"title\": \"Involvement of aberrant glycosylation in phosphorylation of tau by cdk5 and GSK-3beta.\", \"lastauthor\": \"Gong CX\", \"volume\": \"530\", \"issue\": \"1-3\", \"pages\": \"209-14\", \"firstauthor\": \"Liu F\"}, \"line\": 28108, \"annotations\": {\"Subgraph\": \"Cyclin-CDK subgraph\"}, \"source\": 30, \"target\": 13, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"We found that cdk5 phosphorylated tau(441) at Thr-181, Ser-199, Ser-202, Thr-205, Thr-212, Ser-214, Thr-217, Thr-231, Ser-235, Ser-396, and Ser-404, but not at Ser-262, Ser-400, Thr-403, Ser-409, Ser-413, or Ser-422.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"FEBS letters\", \"reference\": \"12387894\", \"authors\": [\"Liu F\", \"Iqbal K\", \"Grundke-Iqbal I\", \"Gong CX\"], \"date\": \"2002-10-23\", \"title\": \"Involvement of aberrant glycosylation in phosphorylation of tau by cdk5 and GSK-3beta.\", \"lastauthor\": \"Gong CX\", \"volume\": \"530\", \"issue\": \"1-3\", \"pages\": \"209-14\", \"firstauthor\": \"Liu F\"}, \"line\": 28101, \"subject\": {\"modifier\": \"Activity\", \"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}}, \"annotations\": {\"Subgraph\": \"Tau protein subgraph\"}, \"source\": 31, \"target\": 8, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We found that cdk5 phosphorylated tau(441) at Thr-181, Ser-199, Ser-202, Thr-205, Thr-212, Ser-214, Thr-217, Thr-231, Ser-235, Ser-396, and Ser-404, but not at Ser-262, Ser-400, Thr-403, Ser-409, Ser-413, or Ser-422.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"FEBS letters\", \"reference\": \"12387894\", \"authors\": [\"Liu F\", \"Iqbal K\", \"Grundke-Iqbal I\", \"Gong CX\"], \"date\": \"2002-10-23\", \"title\": \"Involvement of aberrant glycosylation in phosphorylation of tau by cdk5 and GSK-3beta.\", \"lastauthor\": \"Gong CX\", \"volume\": \"530\", \"issue\": \"1-3\", \"pages\": \"209-14\", \"firstauthor\": \"Liu F\"}, \"line\": 28101, \"subject\": {\"modifier\": \"Activity\", \"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}}, \"annotations\": {\"Subgraph\": \"Cyclin-CDK subgraph\"}, \"source\": 31, \"target\": 8, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"We found that cdk5 phosphorylated tau(441) at Thr-181, Ser-199, Ser-202, Thr-205, Thr-212, Ser-214, Thr-217, Thr-231, Ser-235, Ser-396, and Ser-404, but not at Ser-262, Ser-400, Thr-403, Ser-409, Ser-413, or Ser-422.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"FEBS letters\", \"reference\": \"12387894\", \"authors\": [\"Liu F\", \"Iqbal K\", \"Grundke-Iqbal I\", \"Gong CX\"], \"date\": \"2002-10-23\", \"title\": \"Involvement of aberrant glycosylation in phosphorylation of tau by cdk5 and GSK-3beta.\", \"lastauthor\": \"Gong CX\", \"volume\": \"530\", \"issue\": \"1-3\", \"pages\": \"209-14\", \"firstauthor\": \"Liu F\"}, \"line\": 28098, \"subject\": {\"modifier\": \"Activity\", \"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}}, \"annotations\": {\"Subgraph\": \"Tau protein subgraph\"}, \"source\": 31, \"target\": 9, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We found that cdk5 phosphorylated tau(441) at Thr-181, Ser-199, Ser-202, Thr-205, Thr-212, Ser-214, Thr-217, Thr-231, Ser-235, Ser-396, and Ser-404, but not at Ser-262, Ser-400, Thr-403, Ser-409, Ser-413, or Ser-422.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"FEBS letters\", \"reference\": \"12387894\", \"authors\": [\"Liu F\", \"Iqbal K\", \"Grundke-Iqbal I\", \"Gong CX\"], \"date\": \"2002-10-23\", \"title\": \"Involvement of aberrant glycosylation in phosphorylation of tau by cdk5 and GSK-3beta.\", \"lastauthor\": \"Gong CX\", \"volume\": \"530\", \"issue\": \"1-3\", \"pages\": \"209-14\", \"firstauthor\": \"Liu F\"}, \"line\": 28098, \"subject\": {\"modifier\": \"Activity\", \"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}}, \"annotations\": {\"Subgraph\": \"Cyclin-CDK subgraph\"}, \"source\": 31, \"target\": 9, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"we conclude that tau protein kinase II (cdk5/p20) can phosphorylate human tau at Thr(181), Thr(205), Thr(212), Thr(217), Ser(396) and Ser(404).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of neurochemistry\", \"reference\": \"11181841\", \"authors\": [\"Lund ET\", \"McKenna R\", \"Evans DB\", \"Sharma SK\", \"Mathews WR\"], \"date\": \"2001-02-01\", \"title\": \"Characterization of the in vitro phosphorylation of human tau by tau protein kinase II (cdk5/p20) using mass spectrometry.\", \"lastauthor\": \"Mathews WR\", \"volume\": \"76\", \"issue\": \"4\", \"pages\": \"1221-32\", \"firstauthor\": \"Lund ET\"}, \"line\": 28308, \"subject\": {\"modifier\": \"Activity\", \"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}}, \"annotations\": {\"Subgraph\": \"Tau protein subgraph\"}, \"source\": 31, \"target\": 9, \"key\": 2}, {\"relation\": \"increases\", \"evidence\": \"we conclude that tau protein kinase II (cdk5/p20) can phosphorylate human tau at Thr(181), Thr(205), Thr(212), Thr(217), Ser(396) and Ser(404).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of neurochemistry\", \"reference\": \"11181841\", \"authors\": [\"Lund ET\", \"McKenna R\", \"Evans DB\", \"Sharma SK\", \"Mathews WR\"], \"date\": \"2001-02-01\", \"title\": \"Characterization of the in vitro phosphorylation of human tau by tau protein kinase II (cdk5/p20) using mass spectrometry.\", \"lastauthor\": \"Mathews WR\", \"volume\": \"76\", \"issue\": \"4\", \"pages\": \"1221-32\", \"firstauthor\": \"Lund ET\"}, \"line\": 28308, \"subject\": {\"modifier\": \"Activity\", \"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}}, \"annotations\": {\"Subgraph\": \"Cyclin-CDK subgraph\"}, \"source\": 31, \"target\": 9, \"key\": 3}, {\"relation\": \"increases\", \"evidence\": \"We found that cdk5 phosphorylated tau(441) at Thr-181, Ser-199, Ser-202, Thr-205, Thr-212, Ser-214, Thr-217, Thr-231, Ser-235, Ser-396, and Ser-404, but not at Ser-262, Ser-400, Thr-403, Ser-409, Ser-413, or Ser-422.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"FEBS letters\", \"reference\": \"12387894\", \"authors\": [\"Liu F\", \"Iqbal K\", \"Grundke-Iqbal I\", \"Gong CX\"], \"date\": \"2002-10-23\", \"title\": \"Involvement of aberrant glycosylation in phosphorylation of tau by cdk5 and GSK-3beta.\", \"lastauthor\": \"Gong CX\", \"volume\": \"530\", \"issue\": \"1-3\", \"pages\": \"209-14\", \"firstauthor\": \"Liu F\"}, \"line\": 28095, \"subject\": {\"modifier\": \"Activity\", \"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}}, \"annotations\": {\"Subgraph\": \"Tau protein subgraph\"}, \"source\": 31, \"target\": 10, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We found that cdk5 phosphorylated tau(441) at Thr-181, Ser-199, Ser-202, Thr-205, Thr-212, Ser-214, Thr-217, Thr-231, Ser-235, Ser-396, and Ser-404, but not at Ser-262, Ser-400, Thr-403, Ser-409, Ser-413, or Ser-422.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"FEBS letters\", \"reference\": \"12387894\", \"authors\": [\"Liu F\", \"Iqbal K\", \"Grundke-Iqbal I\", \"Gong CX\"], \"date\": \"2002-10-23\", \"title\": \"Involvement of aberrant glycosylation in phosphorylation of tau by cdk5 and GSK-3beta.\", \"lastauthor\": \"Gong CX\", \"volume\": \"530\", \"issue\": \"1-3\", \"pages\": \"209-14\", \"firstauthor\": \"Liu F\"}, \"line\": 28095, \"subject\": {\"modifier\": \"Activity\", \"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}}, \"annotations\": {\"Subgraph\": \"Cyclin-CDK subgraph\"}, \"source\": 31, \"target\": 10, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"we conclude that tau protein kinase II (cdk5/p20) can phosphorylate human tau at Thr(181), Thr(205), Thr(212), Thr(217), Ser(396) and Ser(404).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of neurochemistry\", \"reference\": \"11181841\", \"authors\": [\"Lund ET\", \"McKenna R\", \"Evans DB\", \"Sharma SK\", \"Mathews WR\"], \"date\": \"2001-02-01\", \"title\": \"Characterization of the in vitro phosphorylation of human tau by tau protein kinase II (cdk5/p20) using mass spectrometry.\", \"lastauthor\": \"Mathews WR\", \"volume\": \"76\", \"issue\": \"4\", \"pages\": \"1221-32\", \"firstauthor\": \"Lund ET\"}, \"line\": 28305, \"subject\": {\"modifier\": \"Activity\", \"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}}, \"annotations\": {\"Subgraph\": \"Tau protein subgraph\"}, \"source\": 31, \"target\": 10, \"key\": 2}, {\"relation\": \"increases\", \"evidence\": \"we conclude that tau protein kinase II (cdk5/p20) can phosphorylate human tau at Thr(181), Thr(205), Thr(212), Thr(217), Ser(396) and Ser(404).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of neurochemistry\", \"reference\": \"11181841\", \"authors\": [\"Lund ET\", \"McKenna R\", \"Evans DB\", \"Sharma SK\", \"Mathews WR\"], \"date\": \"2001-02-01\", \"title\": \"Characterization of the in vitro phosphorylation of human tau by tau protein kinase II (cdk5/p20) using mass spectrometry.\", \"lastauthor\": \"Mathews WR\", \"volume\": \"76\", \"issue\": \"4\", \"pages\": \"1221-32\", \"firstauthor\": \"Lund ET\"}, \"line\": 28305, \"subject\": {\"modifier\": \"Activity\", \"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}}, \"annotations\": {\"Subgraph\": \"Cyclin-CDK subgraph\"}, \"source\": 31, \"target\": 10, \"key\": 3}, {\"relation\": \"increases\", \"evidence\": \"We found that cdk5 phosphorylated tau(441) at Thr-181, Ser-199, Ser-202, Thr-205, Thr-212, Ser-214, Thr-217, Thr-231, Ser-235, Ser-396, and Ser-404, but not at Ser-262, Ser-400, Thr-403, Ser-409, Ser-413, or Ser-422.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"FEBS letters\", \"reference\": \"12387894\", \"authors\": [\"Liu F\", \"Iqbal K\", \"Grundke-Iqbal I\", \"Gong CX\"], \"date\": \"2002-10-23\", \"title\": \"Involvement of aberrant glycosylation in phosphorylation of tau by cdk5 and GSK-3beta.\", \"lastauthor\": \"Gong CX\", \"volume\": \"530\", \"issue\": \"1-3\", \"pages\": \"209-14\", \"firstauthor\": \"Liu F\"}, \"line\": 28096, \"subject\": {\"modifier\": \"Activity\", \"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}}, \"annotations\": {\"Subgraph\": \"Tau protein subgraph\"}, \"source\": 31, \"target\": 11, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We found that cdk5 phosphorylated tau(441) at Thr-181, Ser-199, Ser-202, Thr-205, Thr-212, Ser-214, Thr-217, Thr-231, Ser-235, Ser-396, and Ser-404, but not at Ser-262, Ser-400, Thr-403, Ser-409, Ser-413, or Ser-422.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"FEBS letters\", \"reference\": \"12387894\", \"authors\": [\"Liu F\", \"Iqbal K\", \"Grundke-Iqbal I\", \"Gong CX\"], \"date\": \"2002-10-23\", \"title\": \"Involvement of aberrant glycosylation in phosphorylation of tau by cdk5 and GSK-3beta.\", \"lastauthor\": \"Gong CX\", \"volume\": \"530\", \"issue\": \"1-3\", \"pages\": \"209-14\", \"firstauthor\": \"Liu F\"}, \"line\": 28096, \"subject\": {\"modifier\": \"Activity\", \"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}}, \"annotations\": {\"Subgraph\": \"Cyclin-CDK subgraph\"}, \"source\": 31, \"target\": 11, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"we conclude that tau protein kinase II (cdk5/p20) can phosphorylate human tau at Thr(181), Thr(205), Thr(212), Thr(217), Ser(396) and Ser(404).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of neurochemistry\", \"reference\": \"11181841\", \"authors\": [\"Lund ET\", \"McKenna R\", \"Evans DB\", \"Sharma SK\", \"Mathews WR\"], \"date\": \"2001-02-01\", \"title\": \"Characterization of the in vitro phosphorylation of human tau by tau protein kinase II (cdk5/p20) using mass spectrometry.\", \"lastauthor\": \"Mathews WR\", \"volume\": \"76\", \"issue\": \"4\", \"pages\": \"1221-32\", \"firstauthor\": \"Lund ET\"}, \"line\": 28306, \"subject\": {\"modifier\": \"Activity\", \"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}}, \"annotations\": {\"Subgraph\": \"Tau protein subgraph\"}, \"source\": 31, \"target\": 11, \"key\": 2}, {\"relation\": \"increases\", \"evidence\": \"we conclude that tau protein kinase II (cdk5/p20) can phosphorylate human tau at Thr(181), Thr(205), Thr(212), Thr(217), Ser(396) and Ser(404).\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of neurochemistry\", \"reference\": \"11181841\", \"authors\": [\"Lund ET\", \"McKenna R\", \"Evans DB\", \"Sharma SK\", \"Mathews WR\"], \"date\": \"2001-02-01\", \"title\": \"Characterization of the in vitro phosphorylation of human tau by tau protein kinase II (cdk5/p20) using mass spectrometry.\", \"lastauthor\": \"Mathews WR\", \"volume\": \"76\", \"issue\": \"4\", \"pages\": \"1221-32\", \"firstauthor\": \"Lund ET\"}, \"line\": 28306, \"subject\": {\"modifier\": \"Activity\", \"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}}, \"annotations\": {\"Subgraph\": \"Cyclin-CDK subgraph\"}, \"source\": 31, \"target\": 11, \"key\": 3}, {\"relation\": \"increases\", \"evidence\": \"We found that cdk5 phosphorylated tau(441) at Thr-181, Ser-199, Ser-202, Thr-205, Thr-212, Ser-214, Thr-217, Thr-231, Ser-235, Ser-396, and Ser-404, but not at Ser-262, Ser-400, Thr-403, Ser-409, Ser-413, or Ser-422.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"FEBS letters\", \"reference\": \"12387894\", \"authors\": [\"Liu F\", \"Iqbal K\", \"Grundke-Iqbal I\", \"Gong CX\"], \"date\": \"2002-10-23\", \"title\": \"Involvement of aberrant glycosylation in phosphorylation of tau by cdk5 and GSK-3beta.\", \"lastauthor\": \"Gong CX\", \"volume\": \"530\", \"issue\": \"1-3\", \"pages\": \"209-14\", \"firstauthor\": \"Liu F\"}, \"line\": 28091, \"subject\": {\"modifier\": \"Activity\", \"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}}, \"annotations\": {\"Subgraph\": \"Tau protein subgraph\"}, \"source\": 31, \"target\": 12, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We found that cdk5 phosphorylated tau(441) at Thr-181, Ser-199, Ser-202, Thr-205, Thr-212, Ser-214, Thr-217, Thr-231, Ser-235, Ser-396, and Ser-404, but not at Ser-262, Ser-400, Thr-403, Ser-409, Ser-413, or Ser-422.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"FEBS letters\", \"reference\": \"12387894\", \"authors\": [\"Liu F\", \"Iqbal K\", \"Grundke-Iqbal I\", \"Gong CX\"], \"date\": \"2002-10-23\", \"title\": \"Involvement of aberrant glycosylation in phosphorylation of tau by cdk5 and GSK-3beta.\", \"lastauthor\": \"Gong CX\", \"volume\": \"530\", \"issue\": \"1-3\", \"pages\": \"209-14\", \"firstauthor\": \"Liu F\"}, \"line\": 28091, \"subject\": {\"modifier\": \"Activity\", \"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}}, \"annotations\": {\"Subgraph\": \"Cyclin-CDK subgraph\"}, \"source\": 31, \"target\": 12, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"We found that cdk5 phosphorylated tau(441) at Thr-181, Ser-199, Ser-202, Thr-205, Thr-212, Ser-214, Thr-217, Thr-231, Ser-235, Ser-396, and Ser-404, but not at Ser-262, Ser-400, Thr-403, Ser-409, Ser-413, or Ser-422.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"FEBS letters\", \"reference\": \"12387894\", \"authors\": [\"Liu F\", \"Iqbal K\", \"Grundke-Iqbal I\", \"Gong CX\"], \"date\": \"2002-10-23\", \"title\": \"Involvement of aberrant glycosylation in phosphorylation of tau by cdk5 and GSK-3beta.\", \"lastauthor\": \"Gong CX\", \"volume\": \"530\", \"issue\": \"1-3\", \"pages\": \"209-14\", \"firstauthor\": \"Liu F\"}, \"line\": 28092, \"subject\": {\"modifier\": \"Activity\", \"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}}, \"annotations\": {\"Subgraph\": \"Tau protein subgraph\"}, \"source\": 31, \"target\": 13, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"We found that cdk5 phosphorylated tau(441) at Thr-181, Ser-199, Ser-202, Thr-205, Thr-212, Ser-214, Thr-217, Thr-231, Ser-235, Ser-396, and Ser-404, but not at Ser-262, Ser-400, Thr-403, Ser-409, Ser-413, or Ser-422.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"FEBS letters\", \"reference\": \"12387894\", \"authors\": [\"Liu F\", \"Iqbal K\", \"Grundke-Iqbal I\", \"Gong CX\"], \"date\": \"2002-10-23\", \"title\": \"Involvement of aberrant glycosylation in phosphorylation of tau by cdk5 and GSK-3beta.\", \"lastauthor\": \"Gong CX\", \"volume\": \"530\", \"issue\": \"1-3\", \"pages\": \"209-14\", \"firstauthor\": \"Liu F\"}, \"line\": 28092, \"subject\": {\"modifier\": \"Activity\", \"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}}, \"annotations\": {\"Subgraph\": \"Cyclin-CDK subgraph\"}, \"source\": 31, \"target\": 13, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"Western blots with phosphorylation-sensitive antibodies showed that p38, like ERK2 and SAP kinase-beta/JNK, phosphorylated tau at sites found phosphorylated physiologically (Thr181, Ser202, Thr205, and Ser396) and also at Ser422, which is phosphorylated in neurofibrillary tangles but not in normal adult or foetal brain.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of neurochemistry\", \"reference\": \"9202310\", \"authors\": [\"Reynolds CH\", \"Nebreda AR\", \"Gibb GM\", \"Utton MA\", \"Anderton BH\"], \"date\": \"1997-07-01\", \"title\": \"Reactivating kinase/p38 phosphorylates tau protein in vitro.\", \"lastauthor\": \"Anderton BH\", \"volume\": \"69\", \"issue\": \"1\", \"pages\": \"191-8\", \"firstauthor\": \"Reynolds CH\"}, \"line\": 31152, \"subject\": {\"modifier\": \"Activity\", \"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}}, \"annotations\": {\"Subgraph\": \"MAPK-JNK subgraph\"}, \"source\": 32, \"target\": 9, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Western blots with phosphorylation-sensitive antibodies showed that p38, like ERK2 and SAP kinase-beta/JNK, phosphorylated tau at sites found phosphorylated physiologically (Thr181, Ser202, Thr205, and Ser396) and also at Ser422, which is phosphorylated in neurofibrillary tangles but not in normal adult or foetal brain.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of neurochemistry\", \"reference\": \"9202310\", \"authors\": [\"Reynolds CH\", \"Nebreda AR\", \"Gibb GM\", \"Utton MA\", \"Anderton BH\"], \"date\": \"1997-07-01\", \"title\": \"Reactivating kinase/p38 phosphorylates tau protein in vitro.\", \"lastauthor\": \"Anderton BH\", \"volume\": \"69\", \"issue\": \"1\", \"pages\": \"191-8\", \"firstauthor\": \"Reynolds CH\"}, \"line\": 31152, \"subject\": {\"modifier\": \"Activity\", \"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}}, \"annotations\": {\"Subgraph\": \"Tau protein subgraph\"}, \"source\": 32, \"target\": 9, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"Western blots with phosphorylation-sensitive antibodies showed that p38, like ERK2 and SAP kinase-beta/JNK, phosphorylated tau at sites found phosphorylated physiologically (Thr181, Ser202, Thr205, and Ser396) and also at Ser422, which is phosphorylated in neurofibrillary tangles but not in normal adult or foetal brain.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of neurochemistry\", \"reference\": \"9202310\", \"authors\": [\"Reynolds CH\", \"Nebreda AR\", \"Gibb GM\", \"Utton MA\", \"Anderton BH\"], \"date\": \"1997-07-01\", \"title\": \"Reactivating kinase/p38 phosphorylates tau protein in vitro.\", \"lastauthor\": \"Anderton BH\", \"volume\": \"69\", \"issue\": \"1\", \"pages\": \"191-8\", \"firstauthor\": \"Reynolds CH\"}, \"line\": 31154, \"subject\": {\"modifier\": \"Activity\", \"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}}, \"annotations\": {\"Subgraph\": \"MAPK-JNK subgraph\"}, \"source\": 32, \"target\": 10, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Western blots with phosphorylation-sensitive antibodies showed that p38, like ERK2 and SAP kinase-beta/JNK, phosphorylated tau at sites found phosphorylated physiologically (Thr181, Ser202, Thr205, and Ser396) and also at Ser422, which is phosphorylated in neurofibrillary tangles but not in normal adult or foetal brain.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of neurochemistry\", \"reference\": \"9202310\", \"authors\": [\"Reynolds CH\", \"Nebreda AR\", \"Gibb GM\", \"Utton MA\", \"Anderton BH\"], \"date\": \"1997-07-01\", \"title\": \"Reactivating kinase/p38 phosphorylates tau protein in vitro.\", \"lastauthor\": \"Anderton BH\", \"volume\": \"69\", \"issue\": \"1\", \"pages\": \"191-8\", \"firstauthor\": \"Reynolds CH\"}, \"line\": 31154, \"subject\": {\"modifier\": \"Activity\", \"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}}, \"annotations\": {\"Subgraph\": \"Tau protein subgraph\"}, \"source\": 32, \"target\": 10, \"key\": 1}, {\"relation\": \"increases\", \"evidence\": \"Western blots with phosphorylation-sensitive antibodies showed that p38, like ERK2 and SAP kinase-beta/JNK, phosphorylated tau at sites found phosphorylated physiologically (Thr181, Ser202, Thr205, and Ser396) and also at Ser422, which is phosphorylated in neurofibrillary tangles but not in normal adult or foetal brain.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of neurochemistry\", \"reference\": \"9202310\", \"authors\": [\"Reynolds CH\", \"Nebreda AR\", \"Gibb GM\", \"Utton MA\", \"Anderton BH\"], \"date\": \"1997-07-01\", \"title\": \"Reactivating kinase/p38 phosphorylates tau protein in vitro.\", \"lastauthor\": \"Anderton BH\", \"volume\": \"69\", \"issue\": \"1\", \"pages\": \"191-8\", \"firstauthor\": \"Reynolds CH\"}, \"line\": 31153, \"subject\": {\"modifier\": \"Activity\", \"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}}, \"annotations\": {\"Subgraph\": \"MAPK-JNK subgraph\"}, \"source\": 32, \"target\": 13, \"key\": 0}, {\"relation\": \"increases\", \"evidence\": \"Western blots with phosphorylation-sensitive antibodies showed that p38, like ERK2 and SAP kinase-beta/JNK, phosphorylated tau at sites found phosphorylated physiologically (Thr181, Ser202, Thr205, and Ser396) and also at Ser422, which is phosphorylated in neurofibrillary tangles but not in normal adult or foetal brain.\", \"citation\": {\"type\": \"PubMed\", \"name\": \"Journal of neurochemistry\", \"reference\": \"9202310\", \"authors\": [\"Reynolds CH\", \"Nebreda AR\", \"Gibb GM\", \"Utton MA\", \"Anderton BH\"], \"date\": \"1997-07-01\", \"title\": \"Reactivating kinase/p38 phosphorylates tau protein in vitro.\", \"lastauthor\": \"Anderton BH\", \"volume\": \"69\", \"issue\": \"1\", \"pages\": \"191-8\", \"firstauthor\": \"Reynolds CH\"}, \"line\": 31153, \"subject\": {\"modifier\": \"Activity\", \"effect\": {\"name\": \"kin\", \"namespace\": \"bel\"}}, \"annotations\": {\"Subgraph\": \"Tau protein subgraph\"}, \"source\": 32, \"target\": 13, \"key\": 1}]};\n",
       "        const color_map = {'Protein': '#1F77B4', 'Pathology': '#FF7F0E', 'BiologicalProcess': '#2CA02C', 'miRNA': '#D62728', 'Complex': '#9467bd', 'Composite': '#9467bd', 'Reaction': '#8c564b', 'Gene': '#e377c2', 'Abundance': '#bcbd22', 'RNA': '#17becf'};\n",
       "    \n",
       "        require.config({\n",
       "          paths: {\n",
       "              d3: '//cdnjs.cloudflare.com/ajax/libs/d3/4.5.0/d3.min'\n",
       "          }\n",
       "        });\n",
       "\n",
       "        var elementInnerHTML = \"<div id='\" + chart + \"'></div>\";\n",
       "\n",
       "        element.append(elementInnerHTML);\n",
       "\n",
       "        var chartQualified = \"#\" + chart;\n",
       "\n",
       "        require(['d3'], function(d3) {\n",
       "            return init_d3_force(d3, graph, chartQualified, width, height, color_map);\n",
       "        });\n",
       "    "
      ],
      "text/plain": [
       "<IPython.core.display.Javascript object>"
      ]
     },
     "execution_count": 26,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "to_jupyter(subgraph)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "In this case, we were able to infer connections that not only gave the Estrogen subgraph more context, but also connected the individual components"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Conclusions\n",
    "\n",
    "A final touch to the subgraph might be to infer connections between nodes that have just been added. This can be done with [pbt.mutation.expand_internal](http://pybel-tools.readthedocs.io/en/latest/mutation.html#pybel_tools.mutation.expand_internal) which allows for specification of edge filters, or with [pbt.mutation.expand_internal_causal](http://pybel-tools.readthedocs.io/en/latest/mutation.html#pybel_tools.mutation.expand_internal_causal) that is a thin wrapper, giving the edge filter [pbt.filters.keep_causal_edges](http://pybel-tools.readthedocs.io/en/latest/filters.html#pybel_tools.filters.edge_filters.keep_causal_edges). Again, expansion on unqualified edges and opening with the central dogma can make this expanded subgraph easier to interpret.\n",
    "\n",
    "Further, an unbiased expansion method could allow for annotations of entities to subgraphs such as chemicals and bioprocesses, and allow for more exotic enrichment algorithms to be implemented similar to NeuroMMSigDB."
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.6.2"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
